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                                                             Abstract 
Hypoxia adversely affects cells and tissues, and neuronal cells in particular have been 
shown to be more susceptible to the injurious effects of hypoxia i.e. they may begin to 
die when oxygen supply is reduced or completely eliminated. Cannabinoid (CB1) 
receptor and opioid (µ, δ and κ) receptor agonists have been shown to elicit several 
central nervous system (CNS) effects, mediated via G protein-coupled receptors. The 
aim of the research presented in this thesis was to study the effect of hypoxia on 
neuronal cell signalling and the consequent neuroprotectant effects of cannabinoid 
and opioid receptor agonists against hypoxia in the rat cortical neuronal cell line 
(B50) in culture. The B50 cells cultured in hypoxic conditions were treated and 
concurrently cultured with cannabinoid and opioid receptor agonists to determine the 
effects of these drugs on hypoxia-induced changes using downstream signalling 
activities such as cellular morphogenesis, growth, proliferation, differentiation, lactate 
dehydrogenase (LDH) leakage, second messenger (cAMP) and extracellular signal-
regulated kinases (ERK1/2) quantification, to assess the level of cellular damage and 
injury, repair and protection. Cortical B50 cells were cultured in either a normal 
incubator (21%O2; 5% CO2) as the normoxic control group, or a hypoxic incubator 
(5%O2; 5% CO2) as the experimental group. Three cannabinoid agonists [Win55,212-
2 mesylate (Win), anandamide or arachidonoylethanolamide (AEA), and 2-
arachidonylglycerol (2-AG)] and three opioid agonists [DAMGO (µ), DSLET (δ) and 
ICI-199,441 hydrochloride (κ)], were selected and administered to the cells as 
treatment group for 48 hours after 48 hours of initial culture for a total of 96 hours of 
culture and pre-treatment group treated at 0 hour for a total of 96 hours in hypoxic 
conditions at concentrations of 10nM, 50nM and 100nM for cannabinoid agonists, 
and 10µM, 50µM and 100µM for opioid agonists. Neuronal viability, proliferation, 
differentiation and second messenger activity were assessed using morphological 
same-field assessment, LDH leakage, cellular proliferation assay, second messenger 
(cAMP) assay, and phospho-ERK1 & 2 assay and dibutyryl cyclic adenosine 
monophosphate (DbcAMP) induced differentiation method. Levels of G-protein 
coupled receptor (cannabinoid, CB1 and mu opioid, MOR) mRNAs were assessed 
using the RT-PCR method. The results showed that hypoxia induced a 4-fold increase 
in LDH leakage from B50 cells cultured in hypoxia when compared to the cells 
 xxviii
cultured in normoxic conditions (440% versus 100%, respectively; p<0.05). 
Cannabinoid receptor agonist treatment was able to reduce the LDH release in 
hypoxic cells to between 2-to 4-folds: 100nM AEA (69%), 100nM 2-AG (103%) and 
10nM Win (217%), when compared to untreated hypoxic B50 cells (440% versus  
cannabinoid treated; p<0.05). The results of opioid administration showed a 3-fold 
decrease in the level of LDH leakage in B50 cells cultured in hypoxia when compared 
to untreated hypoxic cells (587%). The results of hypoxic treated B50 cells with 
opioid agonists are 100µM ICI-199,441 (318%); 50µM DSLET (339%) and 50µM 
DAMGO (352%) (p<0.05; untreated hypoxia versus opioid treated). The result of 
cAMP quantification in B50 cells in culture showed a reduction in cAMP 
concentration in untreated hypoxic B50 cells when compared to normoxic cells (0.7 
pmol/ml versus 3.0 pmol/ml; p<0.05). Cannabinoid treated hypoxic cells showed 
increases in cAMP concentration: 2-AG 10nM (3.5 pmol/ml), 50nM (3.1 pmol/ml) 
and 100nM (0.9 pmol/ml), (p<0.05; Cannabinoid treated versus hypoxia untreated). 
The cAMP concentration in B50 cells treated in hypoxia with opioid agonist, ICI 
199,441 hydrochloride, was significantly increased when compared to untreated 
hypoxic B50 cells (0.7 pmol/ml). The treatment with ICI 199,441 hydrochloride are 
10µM (10.0 pmol/ml), 50µM (3.15 pmol/ml) and 100µM (1.15 pmol/ml), (p<0.05; 
opioid treated versus hypoxia untreated). The result of phospho-ERK1&2 assay in 
B50 cells showed decrease in phospho-ERK1&2 in untreated hypoxic cells when 
compared to normoxic untreated cells (6.0 units/ml versus 87.0 units/ml; p<0.05). The 
result of cannabinoid treated hypoxic cells showed increases in phospho-ERK1&2 
when compared with the hypoxic untreated B50 cells: Win 10nM (98 units/ml), Win 
100nM (27 units/ml), AEA 10nM (62 units/ml), AEA 100nM (60.5 units/ml), 2-AG 
10nM (45 units/ml) and 2-AG 100nM (68 units/ml) (cannabinoid treated versus 
untreated hypoxia; p<0.05). The phospho-ERK1&2 in hypoxic B50 cells treated with 
opioid showed increase with DAMGO 10µM (22 units/ml), DSLET 10µM (16 
units/ml) and ICI 199,441 hydrochloride 10µM (23.5 units/ml) (P<0.05; opioid 
treated versus hypoxia untreated). The result showed a decrease in cellular 
proliferation in untreated hypoxic cells when compared to the normoxic cells (7x106 
cells/ml versus 20x106 cells/ml; p<0.05), while cannabinoid and opioid treatments 
was able to increase cell proliferation in hypoxic treated cells with: Win 10nM 
(11x106 cells/ml), AEA 100nM (12x106 cells/ml) and 2-AG 100nM (13.8x106 
cells/ml), DAMGO 10µM (16x106 cells/ml), DSLET 10µM (20x106 cells/ml) and ICI 
 xxix
199,441 100µM (21.5x106 cells/ml) when compared to hypoxic untreated cells (7x106 
cells/ml) (hypoxia untreated versus hypoxia treated; p<0.05). Some of these changes 
were shown to be concentration-dependent between the normal and hypoxic B50 
neurons, and between treated and untreated hypoxic B50 cells in culture, while the 
CB1 and MOR mRNA levels showed no appreciable change. The results show that 
B50 neuronal cells are susceptible to damage and injurious effects of hypoxia, as are 
most brain cells, while the results of the administration of cannabinoid and opioid 
agonists suggest that these agents have some potential therapeutic and protective 
benefits in the treatment and prevention of hypoxia-induced toxicity in neuronal B50 
cells in culture. This could be of potential benefit in the treatment and protection 
against hypoxia-related neurodegenerative diseases and disorders such as stroke, 
dementias, ageing, Alzheimer’s and Parkinson’s diseases. 
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                                                    CHAPTER ONE 
 
1.                                           Introduction  
 
1.1     General Introduction 
Hypoxia refers to a condition in which there is a decrease in the supply of oxygen to  
any cell or tissue (Mishra et al., 2006; Feriche et al., 2007). Neural and brain tissues  
have been shown to be extremely sensitive to oxygen deprivation and begin to die  
when the oxygen supply is reduced or completely eliminated (Zhang, 2006; Guyton  
and Hall, 2005). A decrease in the exchange of respiratory gases in the lungs or in  
their transport in the blood can prevent the supply of oxygen from meeting the  
metabolic demands of the cells and tissues. This condition is called tissue hypoxia.  
Insufficient oxygen and nutrient supply have been shown to restrain tumour growth.  
Hypoxia-inducible factors (HIF) 1alpha and HIF 2alpha are transcription regulators of  
phenotypic adaptation to low oxygen levels (Jogi, et al., 2002; Airley et al., 2000;  
Semenza, 2000a; Semenza, 2001). When hypoxia lasts for extended periods of time it  
can lead to coma, seizures and even brain death. In brain death there is no measurable  
activity in the brain although cardiovascular activities and function may be preserved  
(NINDS, 2007; Coquelle et al.,1998; Guyton and Hall, 2005). 
 
Hypoxia or oxygen deprivation can lead to oxidative stress which has been implicated 
in nerve cell death that occurs in a variety of neurodegenerative disorders like 
dementias, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease (Maher, 
2001; Benzi et al., 1994). Neuronal loss, neuritic and cytoskeletal lesions represent the 
major dementia-associated abnormalities in Alzheimer’s disease (AD) (de la Monte et 
al., 2000). The loss of protein kinase C (PKC) activity has been coupled to the 
severity of the damage although the functional relationship between oxidative stress, 
protein kinase C and cell death is unknown (Maher, 2001). 
 
Hypoxia leads to metabolic cellular processes in which oxidative species such as 
super oxide radical anions, hydrogen peroxide and lipid peroxides are generated 
intracellularly (Scandalios, 1997; Chen & Buck, 2000). These reactive species, if not 
eliminated, may damage DNA, proteins or membrane lipids and cause oxidative cell 
death. Endogenous antioxidative enzymes as well as endogenous small molecule 
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antioxidants are required for cells to survive (Scandalios, 1997; Chen & Buck, 2000; 
Semenza 2005), while exogenous small molecule antioxidants have been shown to 
effectively prevent oxidative cell death in cultured cells (Busciglio & Yankner, 1995; 
Nakao et al., 1996). 
 
Hypoxic stress results in a rapid and sustained inhibition of protein synthesis that is 
partially mediated by eukaryotic initiation factor 2alpha (eIF2alpha) phosphorylation 
by the phospho-endoplasmic reticulum (ER) kinase (PERK) (Blais et al., 2004). 
Severe hypoxia has been shown to induce apoptotic cell death in developing brain 
neurons whereas mild hypoxia has been demonstrated to stimulate neurogenesis 
(Bossenmeyer-Pourie et al., 2002). Hypoxia threatens brain function throughout the 
entire life span starting from early foetal age until death and although the 
physiological consequences of brain hypoxia are well documented, the molecular 
mechanisms involved in these adaptive processes are still not well understood (Zhu et 
al., 2005; Rossler et al., 2001; Semenza, 2006; Semenza, 2007). It has been shown 
that hypoxia or reduced oxygen tension may have severe detrimental effects on most 
cells and especially on neuronal cells. Some studies have suggested that hypoxia can 
induce cellular adaptive responses that overcome apoptosis or cell death leading to 
reduced hypoxic cell injury, damage or cell death (Yun et al., 1997; Banasiak et al., 
2000). These adaptive responses of cells to hypoxia may involve activation of some 
ion channels, as well as induction of specific gene expression which may help to 
suppress or limit the effects of hypoxia in these cells (Yun et al., 1997). For example, 
adenosine triphosphate (ATP)-sensitive potassium ion (K+) channels are activated by 
hypoxia in some cortical cerebral neuronal cells, and this may play a role in cell 
survival during hypoxia (Yamada and Inagaki, 2002). This may explain why some 
cells may survive and adapt to the hypoxic environment than others. Also, hypoxia-
induced basic fibroblast growth factor (bFGF) and nerve growth factor (NGF) 
expression appear to be associated with prevention or delay of neuronal cell apoptosis 
in hypoxic conditions (Yun et al., 1997; Banasiak et al., 2000). 
 
Gibson & Huang (2002), used the oxidative processes in the brain as a biomarker of 
Alzheimer’s disease and showed that diminished metabolism and excessive oxidative 
stress occur in brains of patients with Alzheimer’s disease. It has been observed that 
oxidative stress can cause neurodegeneration associated with enhanced susceptibility 
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to apoptosis due to the activation of proapoptotic genes (Gibson & Huang, 2002). 
Hypoxia-induced oxidative stress can also cause neurite retraction leading to 
neurodegeneration, while hypoxia-like injury can cause neuronal loss. Both oxidative 
stress and hypoxic injury could contribute to neurodegeneration similar to that found 
in Alzheimer’s disease (de la Monte et al., 2000). It has been shown that ischemia 
results in severe focal and global damage of brain tissue accompanied by biochemical 
and molecular alterations, while hypoxia results in depletion of cellular and tissue 
energy and consequent death of the cells involved (Rodrigo et al., 2005). 
 
Neuronal cell signalling is a specialized activity of the nerve cells through which they 
receive, integrate and transmit information referred to as signals within the cells and 
to the neighbouring cells. This is done by means of specific chemical stimuli or 
signals, cell-to-cell contact and through gap junctions. Chemical signal transmission is 
the major means by which nerve cells communicate within themselves and with one 
another in the nervous system (Siegel et al., 1999; Yu et al., 2001; Wenger, 2000). 
These signalling effects and mechanisms depend on the types of primary effectors to 
which the cells couple (Neubig & Thomsen, 1989). Thus according to Siegel et al. 
(1999), the first group of cells and effectors are those that have ligand-gated ion 
channels, the second group are the receptors with intrinsic guanylyl cyclase activity; 
the third group are those with intrinsic tyrosine kinase activity while the fourth group 
are the G-protein coupled receptors. The super family of G-protein-coupled receptors 
(GPCRs) is the main target for the actions exerted by hormones, drugs and 
neurotransmitters (Schmid et al., 2000). Each GPCR shows preferential coupling to 
certain members of the G-protein family (Gs, Gi or Gq) which in turn activates the 
defined second messenger pathways for example, via changes in the level of cAMP or 
protein kinase C activation or Ca²+ release from internal stores (Kukkonen et al., 2001; 
Nasman et al., 2002). 
 
The G-protein-mediated signalling system has been widely used to study 
transmembrane signalling mechanisms in eukaryotic organisms (Wettschureck et al., 
2004), which could result in many different cellular activities and effects such as 
cellular growth, proliferation and differentiation. Mammalian cells express many 
GPCRs as well as several types of heterotrimeric G-proteins and their effectors. The 
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G-protein-mediated signalling systems are made up of three main components (the 
receptors, the heterotrimeric G-proteins and the effectors) in addition to the various 
proteins that are able to modulate the G-protein-mediated signalling process like the 
regulators of G-protein signalling (RGS) proteins, which are able to adjust the 
sensitivity of the signal transduction system (De Vries et al., 2000; Neubig & 
Siderovski, 2002; Ross & Wilkie, 2002; Wettschureck et al., 2004). Most 
neurotransmitters of the central nervous system (CNS) act on GPCRs to mediate 
neuronal activity. These are present both presynaptically and postsynaptically and 
mediate slow response (Wettschureck et al., 2004). One group, the metabotropic 
glutamate receptors (mGluRs) couple to heterotrimeric G-proteins and regulate 
excitability and synaptic transmission at the glutamatergic synapses throughout the 
CNS (Saugstad et al., 1998). 
 
Some studies have indicated that in a number of animal and cell models, activation of 
receptors that interact through Gi (i.e. group II mGlu and cannabinoid receptor  types) 
appear to convey neuronal protection against hypoxic insult and resultant excitotoxic 
death (Bruno et al., 1994; Shen & Thayer, 1998; Rashidian et al., 2005). In this thesis, 
B50 neuronal cell lines derived from the neonatal rat central nervous system by 
Schubert et al. (1974), which have been widely used for the study of nervous system 
activities, were chosen as the model neuronal cell type. B50 cells have proved to be a 
useful tool for the study of neuronal cell differentiation, growth, toxicology and death 
(Otey et al., 2003). 
 
1.2.    Signalling Overview  
Cells continuously receive information called signals from within themselves, their 
environment and from other neighbouring cells. The signals are converted into 
intracellular second messenger signals which ultimately result in a coordinated 
response by the cells. These responses could be in the form of cell growth and 
division, cell proliferation and differentiation, movement or even death. When cellular 
signalling is deregulated or altered, it results in the formation of cancer, deformed 
cells and hence diseases and cellular disturbances result. These cells not only have 
altered structure and morphology, they also have defective functions which further 
exacerbate the alteration in their signalling processes and mechanisms.  
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Cells make use of second messengers to bring about their signalling activities and 
functions (Haglund and Dikic, 2005). The second messengers required for the 
different cellular activities vary, depending on the final programmed cellular activity 
which determines the signalling input by the cell thus, resulting in an effective and 
programmed response of the cell to the stimuli (Heldin, 2003). Kinases have been 
shown to be important second messenger signals which add phosphate groups to 
cellular components and hence phosphorylate and energize them for their activities 
(Cohen, 2002). 
 
Signalling activities are organised in pathways, and the beauty of cell signalling is the 
way different pathways are organised, combined and adapted to control a diverse 
array of cellular processes in widely different domains (Berridge, 2006). Many of the 
same signalling systems that control development come into play again to regulate a 
wide variety of specific activities in adult cells. These activities include cellular 
contraction, secretion, proliferation, information procession and sensory perception 
(Berridge, 2006), and these illustrate how cell signalling pathways are adapted and 
coordinated to regulate many cellular processes, mechanisms and functions 
(Hochstrasser,  2003). 
 
Cell communication and signalling mechanisms occur either through electrical signals 
or chemical signals. Cell communication through electrical signals occurs in low-
resistance gap junctions through which cells can communicate rapidly with each other 
by passing electrical current or through the diffusion of low molecular weight second 
messengers such as cyclic AMP, calcium ions, and inositol 1,4,5-trisphosphate (IP3). 
In the case of chemical communication, one cell releases a transmitter or chemical 
agent, which diffuses to a target cell that has receptors which detect the transmitter or 
chemical agent and relay the information along various cell signalling pathways. This 
results in the activation of effectors in the cytoplasm or nucleus within the target cells 
to effect the desired response (Ben-Shilomo et al., 2003). These responses could be in 
the form of cell migration, pattern formation, specification of cellular fates and 
differentiation which enhances and establishes cellular structural and morphological 
identity and functional activity in the different cells and tissues (Haglund and Dikic, 
2005; Berridge, 2006). Cell communication through electrical signals only occur in 
excitable tissues like neurons and muscles while communication through chemical 
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signals occur in all cells and tissues and make use of chemical stimuli such as 
neurotransmitters, growth factors and hormones (Berridge, 2006). 
 
The basic principle of a cell signalling pathway involves the sending of stimuli like 
hormones, neurotransmitters or growth factors which act on cell surface receptors to 
relay information through intracellular signalling pathways, that can have a number of 
components to bring about the desired response. Cell signalling usually begins with 
the activation of transducers which use amplifiers to generate internal messengers that 
either act locally or can diffuse throughout the cell. These messengers then engage 
sensors that are coupled to the effectors which are responsible for activating cellular 
responses (Kandel et al., 2000). Cell signalling has been shown to be a dynamic 
process consisting of “on” mechanisms during which information flows down the 
pathway, and this is opposed by the “off” mechanisms that switch off the different 
steps of the signalling pathway (Berridge, 2006). The cell signalling model involves 
the effect of a stimulus on the receptors which lead to the activation of  transducers 
and amplifiers that result in the generation of secondary messengers. The secondary 
messengers result in the modulation of the sensors and effectors which give rise to the 
cellular responses and effects such as cell growth and division, proliferation, 
differentiation or cell death. These cellular modulated activities are patterned and 
structured in a particular direction known as a signalling pathway which can be 
controlled by a series of substances, molecules and stimuli. As such, each of these 
pathways could be regulated, monitored, controlled, inhibited and exaggerated by 
some molecules and stimuli hence resulting in either increased or decreased output of 
the cellular activities (Kandel et al., 2000; Berridge, 2006).(Figure 1.1), 
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Fig.1.1. Schematic representation of a cell signalling pathway adapted from Berridge, 
(2006). 
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1.2.1.    Neuronal cell signalling  
The nervous system receives and transfers information, or signals, from the PNS to 
the CNS, processes the information in the CNS, and sends information back to the 
PNS. This transfer of information from the external environment, through neurons, 
and back again to the external environment is known as neuronal signalling. Neurons 
receive signals in two different forms: through chemical changes via 
neurotransmitters or receptors; and physical changes through touch receptors and 
photoreceptors. These signals cause ionic fluctuations in the plasma membrane, which 
in turn cause depolarization and generate electrical current flow in the neuron causing 
action potential generation which then travels along the neural membrane (Mel and 
Schiller, 2004). 
 
The electrical nature of neuronal signalling showed that the output of most neurons is 
a pattern of spikes of action potentials, where the inside of the neuronal membrane is 
normally electrically negative and the action potential is a transient depolarisation of 
the cell membrane (Mel and Schiller, 2004). It has been shown that diseases that 
affect action potential generation and propagation also affect neuronal signalling 
(Croxford, 2003). Mel and Schiller (2004) have shown that the neuronal activities 
depend on how frequent the excitatory and inhibitory inputs are. The impact on the 
postsynaptic cell depends not only on the number and strength of excitatory and 
inhibitory synapses, but also on their location relative to one another. The activity of 
the postsynaptic neuron will influence the activity rates of downstream neurons 
(Gough et al., 2005). The balance of excitation and inhibition is crucial to overall 
neuronal and brain function. If the balance of the activity is too far towards excitation, 
it will result in over excitation leading to seizure, while if a shift is towards inhibition, 
it can lead to a dormant state; hence this condition may predispose the brain to 
pathophysiological conditions (Adler and Gough, 2005). Adler (2006a) have shown 
that neuronal activity leads to persistent increase in the efficacy of excitatory synapses 
in the brain resulting in long-term potentiation (LTP) which is involved in memory 
storage. Memory and even LTP have been shown to be an adaptive phenomenon that 
depends on neuronal activity. Signalling through ionotropic and metabotropic 
glutamate receptors has been implicated in central mechanisms involved in the 
pathogenesis of neuropathic pain, which is also associated with abnormal neuronal 
activity (Adler, 2006a). 
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Some signalling transduction pathways respond differently depending on the type and 
amount of signalling received by the cell (Chen et al., 2005a). Hence complex multi-
component signal transduction pathways provide opportunities for feedback, signal 
amplification, and interactions inside one cell between multiple signals and signalling 
pathways (Adler, 2006a). The calcium ion (Ca2+) is a highly versatile intracellular 
signal that operates to regulate many different cellular processes, and many of the 
Ca2+ signalling components are organized into molecular complexes in which Ca2+ 
signalling functions are carried out in localized areas (Berridge et al., 2003). These 
complexes can operate as autonomous units that can be multiplied or mixed and 
matched to create larger, more diverse signalling systems, as in the case of cardiac 
Ca2+ signalling. Many disease conditions such as hypertension, heart disease, 
diabetes, manic depression and Alzheimer's disease may occur as a result of abnormal 
remodelling of Ca2+ signalling (Berridge et al., 2003). Intercellular communication in 
multicellular organisms requires the relay of extracellular signals by cell surface 
proteins to the interior of cell as shown in Figure 1.2.  
 
The signalling mechanisms that regulate actin-based motility processes in the nervous 
system have been shown by Meyer and Feldman (2002). They showed that both the 
migration of neurons and the extension of neurites require organised actin 
polymerization to push the cell membrane forward. Numerous extracellular stimulants 
of motility and axon guidance signals regulate actin-based motility through the rho 
GTPases and hence actin-based motility is critical for nervous system development. 
The signalling mechanisms by which extracellular signals guide axons to their targets 
lead to direct effects on actin filament dynamics (Mayer and Feldman, 2002) and, as 
such, showed an organised pattern which result in normal neuron development. 
Communication between neurons in the central nervous system occurs at specialized 
synaptic contacts and the strength of a synaptic signal is precisely regulated. The 
modification of synaptic strength is important in complex brain functions such as 
learning, memory and in the formation of appropriate neural maps during 
development (Walmsley, 1998). It has been shown that the fundamental building 
block of synaptic signalling is that the post-synaptic current is generated in response 
to the pre-synaptic release of a group of neurotransmitters (Walmsley, 1998). This 
shows that the neurotransmitter input from the pre-synaptic area determines the 
signalling output from the post-synaptic area. Hence if the input from the pre-synaptic 
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area is strong, the current generated at the post-synaptic area would be strong in 
response to the nature of the input. Dysregulation of this programme is thought to 
contribute to neurodegenerative diseases which are characterized by loss of the 
neurons (Gotz 2000).  
 
Glial cells are active partners of neurons in processing information and synaptic 
integration and they receive coded signals from synapses and elaborate modulatory 
responses (Bezzi and Volterra, 2001). The active properties of glia, including long-
range signalling and regulated transmitter release, and recent insights suggest that the 
active brain should no longer be regarded as a circuitry of neuronal contacts, but as an 
integrated network of interactive neurons and glia (Bezzi and Volterra, 2001). Within 
the developing nervous system, astrocytes and Schwann cells actively help to promote 
synapse formation and function, while in the adult brain, astrocytes respond to 
synaptic activity by releasing transmitters that modulate synaptic activity and as such, 
glia have been shown to be active participants in brain function (Bezzi and Volterra, 
2001). 
 
1.2.2.        Mechanisms of signalling 
Most cells possess receptors that operate through distinct effector mechanisms and the 
signalling pathways do not operate in isolation but may regulate and be regulated by 
each other called heterologous regulation (Golla and Seethala, 2002). In this way, the 
output of the cell is fine-tuned via subtle modulation of the relevant intracellular 
signalling mechanisms (Felipo, 2006). There are numerous examples in which the 
activity of one receptor can regulate, either positively or negatively, the activity of a 
second, e.g. increases in cAMP mediated by protein kinase A (PKA) can depress or 
potentiate phosphatidylinositol-specific phospholipase C (PI-PLC) activity (Golla and 
Seethala, 2002). Activation of PI-PLC, can result in modulation of the activity of 
other pathways via the activation of PKC. Also the same ligand may activate multiple 
pathways in a given tissue. For example, NE can activate β2-adrenergic receptors, 
which increase adenylyl cyclase; α2-adrenergic receptors are coupled to inhibition of 
adenylyl cyclase; and α1-adrenergic receptors are linked to the activation of PI-PLC 
(Rodrigo and Felipo, 2006). Similarly, Ach can activate muscarinic cholinergic 
receptors, which inhibit adenylyl cyclase, activate PI-PLC or activate K+ channels. In 
 11
addition, ACh can directly activate nicotinic acetylcholine receptors (nAChRs), which 
are linked to changes in Na+ and Ca2+ permeability (Rodrigo et al., 2007). 
 
Thus, although individual signalling mechanisms are most frequently studied in 
isolation, their activity in vivo is likely to be highly regulated by other signal-
transduction events (Golla and Seethala, 2002). A further consideration is that 
receptors which primarily activate one pathway may activate a second pathway. One 
example is the ability of GPCRs such as α2-adrenergic receptors or muscarinic 
acetylcholine receptors (mAChRs), to activate the MAPK cascade (Golla and 
Seethala, 2002). Activation of AC due to the stimulation of GPCRs, results, in the 
release of G protein βγ subunits, via an intermediary protein tyrosine kinase (PTK-X), 
which stimulates the phosphorylation of the adaptor protein Shc in the human 
granulosa cells (Asboth et al., 2001). The phosphorylation of the adaptor proteins then 
recruits the growth factor- binding protein 2/son of sevenless (Grb2-SOS) complex 
which then activates the MAPK pathway (Felipo, 2006; Willoughby and Cooper 
2007). The activation of PI-PLC-linked receptors such as the mAChR results in 
increased PKC activity and since the addition of phorbol esters, which are PKC 
agonists, results in phosphorylation of Raf, this mechanism may provide an 
explanation for the ability of PI-PLC-coupled receptors to activate MAPK (Rodrigo et 
al., 2007). The effect as seen in granulosa cells may be different to other cells because 
as Asboth et al.(2001) have shown there are at least nine mammalian adenylyl cyclase 
isoenzymes, which may show different sensitivities towards other signalling systems 
in different cells.  
 
Signalling molecules have been shown to activate gene transcription and in addition 
to their ability to elicit acute effects within cells, second-messenger molecules, such 
as cAMP, Ca2+ and DAG, can regulate gene transcription (Rodrigo et al., 2005). The 
transcription factors, cAMP response element-binding (CREB) protein, fos and jun, 
which respond to these signalling molecules, are members of the amphipathic helix 
family of proteins, and each contains a characteristic leucine zipper, which mediates 
dimerization (Golla and Seethala, 2002). These effects are possible because cells do 
not act in isolation, a signalling event in one cell may have a significant impact on the 
activity of neighbouring cells. Initial evidence for intracellular, nonsynaptic signalling 
was obtained from experiments with blood vessels in which it was observed that 
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addition of ACh increased cGMP concentrations and resulted in vasodilation and 
relaxation of the vascular smooth muscles (Golla and Seethala, 2002).  
 
Activation of the MAPK pathway leads to increased expression of fos and jun. As 
increases in mRNA for fos and jun are observed very rapidly following a variety of 
stimuli, they have been termed immediate early genes and CREB has been implicated 
in long-term potentiation (LTP) and memory (Felipo, 2006). 
 
1.2.3.     Influence of membrane lipid on signalling  
Plasma membrane lipids not only serve as an inert support for membrane proteins but 
also play an active role in the activity of a cell that is yet to be fully understood (Yang  
et al., 2005a). Membrane exocytic and endocytic processes, diffusion of macro- 
molecules and protein activities, among other cellular events, depend on the physical  
properties of membrane lipids. Vogler et al. (2004) have demonstrated that the 
hexagonal phase propensity of membranes differentially influences the binding of  
Gαί, Gβγ and Gαβγ proteins, indicating that membrane composition and structure can  
regulate cell signalling.  
 
It has been shown that not only G protein localization is regulated by the membrane 
structure and composition, but also the function of these transducers and related 
proteins (Yang et al., 2005a). The type and abundance of membrane lipid species is 
regulated by dietary fat intake, which thus influences the properties of the membrane 
(Escudero et al., 1998;Yang et al., 2005a). Yang et al. (2005a) have demonstrated 
that the antitumor drug daunorubicin and oleic acid changed the membrane structure 
and inhibited G protein activity in biological membranes. These fatty acids are  
chemical but not structural analogues of oleic acid, supporting the structural basis of 
modulation of membrane lipid organization and subsequent regulation of G protein- 
coupled receptor signalling (Yang et al., 2005a). Yang et al. (2005a) investigated 
GPCR-mediated signalling to determine the effect of fatty acids on the membrane 
lipid structure and propagation of signals through these receptors. They showed that 
lipid structure regulates the interaction with membranes, recruitment to membranes 
and distribution to membrane domains of heterotrimeric Gαβγ proteins, Gα subunits 
and Gβγ dimers. 
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Moffet et al. (2000) have shown the importance of membrane lipid and protein-lipid 
interactions in that the initial steps of signalling cascades are associated with  
membranes and with the propagation of signals across these barriers. The signalling 
pathways are more dependent on the initial membrane-associated signalling elements; 
the receptors, G proteins and effectors than on the downstream signalling proteins that 
simply amplify the signals received. The receptors, G proteins and effectors 
can be recruited to certain specific membrane structures like membrane rafts (Moffet 
et al., 2000), which define their activities. 
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Fig.1.2. Schematic representation of the effects of agonist-induced activation of 
receptors at the cell membrane adapted from Sigma, (2006). 
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1.3.    Receptors 
Receptors are proteins that are found on the cell membrane, cytoplasm or nuclear 
membrane that bind specific molecules such as neurotransmitters, hormones or other 
ligands and as such initiate the cellular response to these substances (Ben-Shilomo et 
al., 2003). Ligand-induced changes in the behaviour of receptor proteins result in 
physiological changes that constitute the biological actions of the ligands. There are a 
variety of different types of ligands. Full agonists are able to activate the receptors 
and produce a maximal biological response and, as such, most naturally occurring 
ligands are full agonists. Partial agonists are not able to maximally activate receptors 
resulting in a partial biological response while antagonists bind to the receptor but do 
not activate it and thus result in receptor inhibition of the binding of agonists. Inverse 
agonists are ligands which produce an effect opposite to that of an agonist, yet act at 
the same receptor. They promote or stabilize an inactive form of the receptor 
(Howlett, 2005). 
 
Receptors are activated by the binding of the specific agonist to them, which in turn 
leads to the activation of the second messenger. The activation of the second 
messenger cascade and the final biological response is achieved only when a 
significant number of receptors are activated by bound ligands. There are different 
types of receptors which depend on the ligand, function and position (Ben-Shilomo et 
al., 2003). Some receptor proteins are peripheral membrane proteins while many 
hormone receptors and neurotransmitter receptors are transmembrane proteins.  
 
The transmembrane receptors are embedded in the lipid bilayer of cell membranes 
and allow the activation of signal transduction pathways in response to the activation 
by the binding molecule, or ligand (Berridge, 2006). Metabotropic receptors are 
coupled to G proteins and affect cells indirectly through enzymes which control ion 
channels, while ionotropic receptors contain a central pore which functions as a 
ligand-gated ion channel (Howlett, 2005). Another major class of receptors are 
intracellular proteins, such as steroid hormone receptors. These receptors can often 
enter the cell nucleus and modulate gene expression in response to the activation by 
the ligand (Connor and Christie, 1999; Garzon et al., 2005). The regulatory protein 
subunits of many ion channels and transmembrane receptors, for example, may be 
defined as peripheral membrane proteins (Connor and Christie, 1999).   
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The transmembrane receptors are integral membrane proteins, which reside and 
operate in the plasma membrane of the cell and also in the membranes of some 
subcellular compartments and organelles (Chow and Stahelin, 2005). The binding of 
signalling molecule on one side of the membrane to transmembrane receptors initiate 
a response on the other side. In this way they play a unique role in cellular 
communications and signal transduction (Berridge, 2006). Many transmembrane 
receptors are composed of two or more protein subunits which operate collectively 
and may dissociate when ligands bind or fall off. The transmembrane receptors have 
both extracellular domain and intracellular domain which means that within the 
intracellular domain enzymes are found that bring about the phosphorylation of the 
effectors (Berridge et al., 2003). 
 
There are several ways that cells regulate the activity of a transmembrane receptor. 
The most important way of regulation is through phosphorylation and internalization 
(Kandel et al., 2000). Examples of transmembrane receptors are adrenergic receptors,  
olfactory receptors, receptor tyrosine kinases, epidermal growth factor receptors, 
insulin receptors, fibroblast growth factor receptors, neurotrophin receptors, nerve 
growth factor (NGF) receptors and N-methyl-D-aspartic acid (NMDA) receptors 
(Purves et al., 2001). 
 
Neurotransmitter receptors can be classified into two broad categories based on their 
structural and functional characteristics, namely metabotropic and ionotropic 
receptors. The metabotropic receptors do not form an ion channel pore, rather, they 
are indirectly linked with ion-channels on the plasma membrane of the cell through 
signal transduction mechanisms (Berridge, 2006). This class of receptor includes the 
metabotropic glutamate receptors, muscarinic acetylcholine receptors, γ-amino 
butyric acid (GABA) receptors, and most serotonin receptors, as well as receptors for 
norepinephrine, epinephrine, histamine, dopamine, endorphin, enkephalin and the 
endocannabinoids (Purves et al., 2001). 
 
All metabotropic receptors are monomeric proteins with seven transmembrane 
domains. The N terminus of the protein is on the extracellular side of the membrane 
and its C terminus is on the intracellular side (Purves et al., 2001). Metabotropic 
receptors have neurotransmitters as ligands, which, when bound to the receptors, 
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initiate a cascade of events that can lead to channel-opening or other cellular effects 
(Berridge, 2006). When a ligand or primary messenger, binds to the receptor, or the 
transducer, it activates a primary effector, which can go on to activate secondary 
messengers. Since the opening of channels by metabotropic receptors involves 
activating a number of molecules in turn, channels associated with these receptors 
take longer to open than ionotropic receptors do, and are thus not involved in 
mechanisms that require quick responses (Kandel et al., 2000). Metabotropic 
receptors also remain open from seconds to minutes and have a much longer-lasting 
effect than ionotropic receptors, which open quickly but only remain open for a few 
milliseconds (Kandel et al., 2000; Berridge et al., 2003). While ionotropic channels 
have an effect only in the immediate region of the receptor, the effects of 
metabotropic receptors can be more widespread through the cell (Berridge, 2006). 
 
Metabotropic receptors can open and close channels and can make a membrane more 
excitable by closing K+ channels. They can retain positive charge within the cell and 
thus reduce the amount of current necessary to cause an action potential (Kandel et 
al., 2000). The metabotropic receptors on the presynaptic membrane can inhibit or, 
more rarely, facilitate neurotransmitter release from the presynaptic neuron (Schmitz 
et al., 2001). These receptors can be further classified into receptor tyrosine kinases 
and G-protein-coupled receptors, known as GPCRs (Kandel et al., 2000). 
 
GPCRs are also known as seven transmembrane (7TM) receptors. Some of the 
examples are muscarinic acetylcholine receptors, adenosine receptors, adrenergic 
receptors, γ-amino butyric acid (GABA), cannabinoid receptors, dopamine receptors, 
glucagon receptors, metabotropic glutamate receptors, opioid receptors and calcium-
sensing receptor and olfactory receptors. Hence the majority of life processes occurs 
through the activation of the GPCRs. Cells can regulate their receptors by either 
downregulating or upregulating the number of receptors to a given hormone or 
neurotransmitter in order to alter their sensitivity to that molecule. This is called local 
feedback mechanism (Berridge, 2006; Kandel et al., 2000). 
 
1.3.1     G proteins 
Guanine nucleotide binding proteins (G-proteins) are important mediators of cellular 
functions. They are characterised by a recognition site for guanine nucleotides namely 
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guanine triphosphate (GTP) and guanine diphosphate (GDP), and possess intrinsic 
GTPase activity (Siegel et al., 1999). The G proteins play a central role in signal 
transduction and many other cellular processes. They are divided into three distinct 
groups namely, the switches, the sensors and the clocks (Siegel et al., 1999).  
 
The switches are the small G proteins that play important roles in cell function such as 
cytoskeletal remodelling, cellular differentiation and vesicular transport. The small G 
proteins, like other G proteins, bind guanine nucleotides, possess intrinsic GTPase 
activity and cycle through GDP-and GTP-bound forms (Siegel et al., 1999; Blaukat et 
al., 2000). The small G proteins function as molecular switches that control several 
cellular processes and examples include ras, rap, ran and ADP-ribosylation factor 1, 
as shown in Table 1.1. 
 
The ras p21 protein plays an important role in the regulation of cell differentiation 
through the stimulation of receptor tyrosine kinases (Blaukat et al., 2000). The 
binding of a growth factor to a receptor, stimulates the autophosphorylation of 
tyrosine kinase which assists in the recruitment of exchange factors. These exchange 
factors stimulate GDP-GTP exchange on the small monomeric G protein ras, leading 
to the activation of mitogen-activated protein kinases (MAPKs). MAPKs are involved 
in the phosphorylation of transcription factors that stimulate gene transcription (Siegel 
et al., 1999; Dhanasekaran and Prasad 1998; Cabrera-Vera et al., 2003). 
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Table 1.1 Examples of small G proteins and their cellular functions (Siegel et 
al.,1999). 
 
Class Cellular function 
Ras Signal transduction (control of growth factor and MAP-kinase 
pathways) 
Rac, CDC42 Signal transduction (control of cellular stress responses and 
MAP-kinase*** pathways) 
Rab Localized to synaptic vesicles, where it regulates vesicle 
trafficking and exocytosis. 
Rho Assembly of cytoskeletal structures (e.g., actin microfilaments) 
ARF* ADP-ribosylation of Gαs; Assembly and function of Golgi 
complex. 
EFTU** Association with ribosomes, where it regulates protein 
synthesis.  
Ran Nuclear-cytoplasmic trafficking of RNA and protein 
ARF*: ADP-ribosylation factor; EFTU**: eukaryotic elongation factor; MAP-
kinase***: Mitogen activated protein kinase. 
 
 
The sensors are the translation and elongation factors such as Tu and G. The 
translation factors play a pivotal role in protein synthesis especially in the second step 
of the three-step translation process (initiation, elongation and termination) (Cabrera-
Vera et al., 2003). These GTP-binding elongation factors are responsible for two 
elements of elongation. The elongation factor Tu escorts the tRNA carrying the 
correct amino acid to the correct site on the mRNA, where GTP-GDP exchange takes 
place. The elongation factor G is involved in the translocation of tRNA from the  
aminoacyl site to the peptidyl site on the ribosome which also involves GTP 
hydrolysis (Siegel et al., 1999). The clocks are the heterotrimeric G proteins present 
within the cytoplasm and are linked with GPCRs in the cell membrane as discussed in 
section 1.3.2. G protein activation occurs as shown in Figure 1.3. 
 
 
 
 
 20
 
 
 
 
     
 
                                                                                                                Cell membrane 
 
 
 
 
                                                                      ATP                                    cAMP 
                                                       
            
                                                                  
 
 
 
 
GTP        
 
                                        GDP 
 
 
 
 
 
 
 
Fig.1.3. Activation of G protein by agonists result in the use of GTP to release GDP 
and AC phosphorylating ATP to yield cAMP. Adapted from Cabrera-Vera et 
al.( 2003). 
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 1.3.2.      Heterotrimeric G proteins 
The heterotrimeric G proteins have been shown to be important in signal transduction  
and are located at the cytoplasmic face of the plasma membrane, where they interact  
with the membrane–spanning GPCRs and effector molecules (Siegel et al., 2006). G  
protein heterotrimers consist of Gα, Gβ & Gγ subunits. Lipid modification of Gα and  
Gγ subunits, help to anchor the G protein heterotrimer to the plasma membrane 
(Cabrera-Vera et al., 2003). The Gα subunits bind guanine nucleotides with high  
affinity and contain an intrinsic GTPase activity (Siegel et al., 1999). The ability of  
Gα subunits to bind guanine nucleotides arises from their homology with other  
members of the GTP binding protein super family, including small proteins such as  
p21, Ras, Rab, ran, Ral, rac, Rho, and EF-Tu (Siegel et al., 1999; Cabrera-Vera et al.,  
2003; Fromm et al., 1997; Oldham and Hamm, 2006 ). 
 
Gβ & Gγ subunits form a very tight, noncovalent heterodimer and function as a single  
entity (the Gβγ complex) throughout the G protein signalling cycle (Dolphin,1996).  
Each heterotrimeric G protein has been shown to have different subunits and the  
combination of these subunits define the specific role of  each G protein, however not  
all combinations are functional (Siegel et al., 1999). The G protein α subunit contains  
a binding site for a guanine nucleotide, which allows the binding of GDP in its non- 
activated state (Siegel et al., 2006). The G protein activation results in the exchange of  
GDP for GTP, on the Gα subunit. The Gα subunit is therefore activated, facilitating  
its dissociation from the Gβ and γ subunits respectively (Dolphin 1996; Durchánková  
et al., 2008). These activated Gα subunits then regulate the activity of effector  
enzymes such as phospholipase C, phospholipase A2, and ion channels like K+ or Ca²  
(Flavahan & Vanhoutte,1990;  Durchánková et al., 2008). 
 
Although the Gα subunit interacts with different effector domains according to each 
G protein, the Gβ and Gγ subunits appear to be interchangeable (Siegel et al, 1999).  
Other G proteins have distinct Gβ and Gγ subunit differences and these subunits may  
play a role in signal production and transduction (Levitzki,1990; Wang, 1999; Zhong,  
2003; Waters et al., 2004). The dissociation of Gα subunit and the effector is  
regulated by the intrinsic GTPase activity of the Gα subunit (Sprang, 1997). G  
proteins may be activated many more times before desensitisation of the receptor and  
consequently the reassociation of the G protein components together (Levitzki,1990;  
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Siegel et al., 1999; Durchánková et al., 2008) as shown in Figure 1.4. 
 
The different types of G protein contain distinct α subtypes, which in part, confer the  
specificity of functional activity. The types of G protein α subunit are categorized  
based on their structural and functional homologies (Siegel et al.,1999; Sprang, 1997;  
Durchánková et al., 2008).  The molecular weight (Mr) of these proteins varies  
between 38,000-52,000. Multiple subtypes of β and γ subunits include five β subunits  
of Mr 35,000–36,000 and seven γ subunits of Mr 6,000-9,000. These proteins show  
distinct cellular distributions and differences in their functional properties (Siegel et  
al., 2006; Morris & Malbon, 2000; Oldham and Hamm, 2006). Multiple forms of  
heterotrimeric G proteins have been shown to exist in the nervous system (Siegel et  
al., 1999; Oldham and Hamm, 2006). Three types of heterotrimeric G protein have  
been identified according to Siegel et al, (1999). Gt, or transducin, was identified as  
the G protein that couples rhodopsin to regulate photoreceptor cell function, and Gs  
and Gi were identified as G proteins that couple plasma membrane receptors to the  
stimulation and inhibition, respectively, of adenylyl cyclase, the enzyme that  
catalyzes the synthesis of cAMP (Siegel et al.,1999; Benians et al., 2005). Since the  
early 1990s, over 35 heterotrimeric G protein subunits have been identified by a  
combination of biochemical and molecular cloning techniques (Siegel et al., 2006;  
Mullaney, 1999; Oldham and Hamm, 2006; Dignard et al., 2008). In addition to Gt,  
Gs and Gi, the other types of G protein in the brain are designated as Go, Golf, Ggust,  
Gz, Gq and G11-16. Moreover, for some of these G proteins, multiple subtypes show  
unique distributions in the brain and peripheral tissues (Mullaney,1999; Siegel et al.,  
2006; Neer,1995; Kitanaka et al., 2008), as shown in Table 1.2. The activation of G  
protein is shown in Figure 1.4. 
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Fig.1.4: G protein cycles between active and inactive states involving  
              a) Gα binds to guanosine diphosphate (GDP) in inactive state. 
              b) Stimulation of the receptor by the agonist, leads to the release of the GDP,  
                 of which the GTP then binds to the empty site because its concentration is 
                 higher than the GDP. 
              c) The dissociation of βγ subunits due to low affinity of GTP-bound Gα    
               d) GTP is hydrolysed to GDP due to GTPase activity of Gα. 
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Table 1.2. Heterotrimeric G protein α-subunits in brain adapted from Siegel et al., 
1999. 
Family  Molecular Weight (Mr) Effector protein(s) 
Gs   
     G αs1 52,000 Adenylyl cyclase (activation) 
52,000  
45,000 
     Gαs2 
     Gαs3 
     Gα4 
     Gαolf 
45,000 
45,000 
 
Gi 
     Gαi1 
 
41,000 
 
Adenylyl cyclase (inhibition) 
     Gαi2 40,000 K+ channel (activation) 
     Gαi3 41,000 Ca2+ (inhibition) 
PI-Phospholipase C (activation) 
Phospholipase A2 
     Gαo1 39,000 K+ channel (activation) 
     Gαo2 39,000 Ca2+ channel (inhibition) 
     Gαt1 39,000 Phosphodiesterase (Activation) in rods and 
cones. 
     Gαt2 40,000  
     Gαgust  41,000 Phosphodiesterase (activation) in taste 
epithelium 
     Gαz 41,000 Adenylyl cyclase (inhibition) 
Gq 41,000-43,000  
      Gαq  PI-Phospholipase C (activation) 
      Gα11   
      Gα14   
      Gα15   
      Gα16   
G12 44,000 Unknown 
      Gα12   
 Gα13   
 
 
 
1.3.3.      The Gα subunit 
The Gα subunits are divided into four classes (Gαs, Gαi, Gαq and Gα12), based on their  
respective amino acid sequences (Table 1.2). Each of these classes has at least two  
subtypes. The Gαs class includes subtypes Gαs and Gαolf. Gαolf is located in  
chemosensory neurons only (Novotny & Svoboda, 1998; Kitanaka et al., 2008). Gαs  
stimulates adenylate cyclase (AC)1-6, thereby increasing cAMP, leading to the 
phosphorylation  and subsequent activation of  Ca²+ channels (Dolphin,1996). This G  
protein is also associated with the inactivation of cardiac Na+ channels and may be  
directly coupled to intracellular Ca²+ channels (Novotny & Svoboda, 1998; Dolphin,  
1996; Straiker et al., 2002). ADP-ribosylation of the Gαs subunit which is catalysed  
by cholera toxin, causes an increase in AC by slowing the ‘off’ phase of GTPase  
reaction (Levitzki, 1990; Oldham and Hamm, 2006). 
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Two variants of Gαs have been shown in both humans and animals- the short  
(~44kDa) and the long (~46kDa) (Milligan et al.,1999; Oldham and Hamm, 2006).  
The majority of Gαs  variants located in the kidney, placenta, cortex, cerebellum and  
adrenal medulla are Gαs-L, however Gαs-S predominates in the heart, liver, neostriatum  
and platelets (Novotny & Svoboda, 1998). Both variants of these G proteins are  
functionally similar, however a measurable difference in the rate of GDP dissociation  
is observed. Gαs-S may have a higher efficacy in stimulating AC in some cells and the  
cellular distribution of the two variants also varies (Novotny & Svoboda, 1998;  
Durchánková et al., 2008). Gαi class includes Gαi, Gαt, Gαo Gαgust and Gαz. Gαi  
inhibits AC, decreases cAMP and activates K+ channels. The Gαo (molecular weight 
39kDa), inhibits Ca2+ channels, is present in brain tissues and, is believed to be  
involved in neuronal responses and has a (Milligan, et al., 1990, Kaziro, et al., 1991;  
Hepler & Gilman, 1992; Durchánková et al., 2008). The Gαq activation stimulates  
PLC-β leading to increased Ca2+ and subsequent activation of PKC which 
respectively activates AC1 and AC2 leading to increased cAMP production and  
finally the activation of PKA (Dolphin, 1996; Murray and Shewan, 2008). The Gα  
subunits are shown in Figure 1.5.  
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Fig.1.5.The G protein alpha subunits activation through G protein coupled receptors 
present on the cell membrane. Adapted from Sigma, (2006). 
 
1.3.4.    The Gβγ dimer 
The tightly bound Gβγ dimer has been shown to regulate many effectors and may be 
involved in GPCR kinase recruitment and hence involved in the activation of second 
messengers (Hamm & Gilchrist,1996; Dignard et al., 2008). The Gβ subunit is 
approximately 36kDa and comprises subtypes that are highly homologous. The Gγ 
subtypes about 6-9kDa are more divergent and are thought to account for the 
functional differences in Gβγ (Hamm & Gilchrist,1996). The Gβγ dimer has been 
demonstrated to have several roles in signal transduction. The Gβγ subunits are 
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membrane associated, due to the isoprenylation of the Gγ subunit, which is also 
necessary for the effective interaction of Gβγ with Gα (Muller & Lohse, 1995). 
When GTP is bound to the Gα subunit, the heterotrimeric complex becomes activated 
and the subsequent dissociation of Gα from Gβγ allows the Gβγ subunit to interact 
with effectors. Although little is known about the specific sites on the Gβ or Gγ 
subunit that interact with effector systems, it is now known that Gβγ dimer is 
important in effector activation (Hamm & Gilchrist,1996; Blackmer et al., 2001). 
Some forms of AC such as  1,2 and 4 are stimulated or inhibited by interactions with 
Gβγ (Muller & Lohse,1995). These subunits can also influence GRK transportation to 
the cell membrane, K+ channel opening frequency and other effectors such as 
phospholipase A2 (PLA2). The Gβγ is also involved in the inhibition of unidentified 
Ca2+ currents, possibly by facilitating alterations in the closed state of the ion channel, 
making the ion channel less willing to open (Clapham, 1996; Blackmer et al., 2001). 
 
1.3.5.    The function of G protein βγ subunits 
It has been demonstrated that one group of protein kinase, the G protein receptor 
kinases (GRKs), can bind to βγ subunits. These kinases phosphorylate G protein-
coupled receptors that are occupied by ligand and thereby mediate one form of 
receptor desensitization (Siegel et al., 2006). It is now known that βγ play a very 
important role in receptor desensitisation and the GRK is normally a cytoplasmic 
protein that does not come in appreciable contact with the plasma membrane receptor 
under basal conditions (Siegel et al., 2006). Ligand binding to the receptor activates 
the associated G protein, which results in the generation of free α and βγ subunits. The 
βγ subunits, which remain membrane-bound, are now free to bind to the C-terminal 
domain of GRK. This draws the GRK into close physical proximity with the receptor 
and enables receptor phosphorylation. In this way, the βγ subunits target GRKs, 
which have constitutive catalytic activity to those receptors that are ligand-bound 
(Hamm & Gilchrist,1996; Siegel et al., 2006; Dignard et al., 2008). 
Another important role of βγ subunits is the regulation of the mitogen-activated 
protein kinase (MAP-kinase) pathway (Siegel et al., 1999). MAP-kinases are the 
major effector pathway for growth factor receptors however, signals that act through 
GPCRs, particularly those coupled to Gi, can modulate growth factor activation of 
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MAP-kinase pathway. This is mediated via βγ subunits (Siegel et al., 2006). 
Activation of receptors leads to the generation of free βγ subunits which then activate 
the MAP-kinase pathway at some early step in the cascade (Siegel et al., 2006). Some 
possibilities are by direct action of the βγ subunits on Ras or on one of several linker 
proteins between the growth factor receptor itself and activation of Ras (Hamm & 
Gilchrist,1996; Siegel et al., 2006; Dignard et al., 2008 ). 
 
1.3.6.      Modulation of heterotrimeric G proteins 
The functioning of heterotrimeric G proteins is modulated by several other proteins. 
One major class of modulator protein binds to G protein α subunits and stimulates 
their intrinsic GTPase activity. These are called GTPase-activating proteins (GAPs). 
The GAPs had been known to exist for small G proteins but have been identified for 
heterotrimeric G proteins (Siegel et al., 1999). The GAPs have been termed regulators 
of G protein-signalling (RGS) proteins. It has been shown that activation of α subunit, 
GTPase activity hastens the hydrolysis of GTP to GDP, more rapidly restores the 
inactive heterotrimer and, hence, the RGS proteins inhibit the biological activity of G 
proteins (Siegel et al., 1999). Nunn et al., (2006) and Siegel et al. (2006) have shown 
that some 20 forms of mammalian RGS protein are now known and most are 
expressed in the brain with highly region-specific patterns. It is also thought that 
different families of G protein α subunits are likely to be modulated by different 
forms of RGS protein (Siegel et al., 2006; Nunn et al., 2006). 
 
Another protein modulator of G protein function is phosducin, a cytosolic protein 
enriched in the retina and pineal gland but also expressed in the brain and other 
tissues of humans and other mammals (Danner & Lohse, 1996; Schroder and Lohse, 
1996). Phosducin binds to G protein βγ subunits with high affinity and this results in 
the prevention of βγ subunit reassociation with the α subunit. In this way, phosducin 
may sequester βγ subunits which initially may prolong the biological activity of the α 
subunit (Hamm & Gilchrist,1996), which eventually may inhibit G protein activity by 
preventing the direct biological effects of the βγ subunits as well as regeneration of 
the functional G protein heterotrimer (Siegel et al., 2006).  
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Jiang et al.(1998), have shown that Go is the most abundant G protein in neurons, 
where it constitutes up to 2% of membrane protein, and is also expressed in endocrine 
cells and the heart. Jiang et al.(1998), showed that Go is activated not only by the 
same class of seven-transmembrane receptors that activate the inhibitory G proteins, 
but also by at least two proteins that do not belong to the rhodopsin-like family of G 
protein-coupled receptors and the Alzheimer amyloid protein precursor protein 
responsible for familial forms of the disease. 
All G protein α subunits have been shown to be modified in their N- terminal domains 
by palmitoylation or myristoylation (Dohlman and Thorner, 1997). These 
modifications may regulate the affinity of the α subunit for its βγ subunits and, 
thereby the likelihood of dissociation or reassociation of the heterotrimer. The 
modifications also may help determine whether the α subunit, released upon ligand-
receptor interaction, remains associated with the plasma membrane or diffuses into 
the cytoplasm. This could have important consequences on the types of effector 
proteins regulated. G protein γ subunits are modified on their C- terminal cysteine 
residues by isoprenylation (Jiang et al.,1998). There is evidence that this modification 
plays a key role in anchoring the γ subunit and its associated β subunit to the plasma 
membrane (Cabrera-Vera, et al., 2003; Slessareva et al., 2003). The importance of this 
anchoring shows the ability of βγ- subunits to target GRKs to ligand-bound receptors 
depends on this membrane localization (Siegel et al., 1999; Cabrera-Vera, et al., 
2003). 
 
1.3.7.       G protein and ion channels   
Many G proteins are linked to fluctuations in intracellular ion concentrations, which  
is due to both direct activation of ion channels by G proteins and indirect second  
messenger-mediated responses (Berridge et al., 2003; Lowes et al., 2002). AC is  
stimulated by the activation of Gs which results in the elevation of intracellular cAMP  
levels. This increase in cAMP can directly open Ca2+ channels or, alternatively, can  
activate Ca2+  and K+ channels via cAMP-dependent phosphorylation of the channel.  
Protein kinase C (PKC) is involved in the phosphorylation  of several  Ca2+ channels  
in various cell populations including neurons. PKC is also involved in the inhibition  
of other ion currents including  K+, Ca2+-dependent K+, and Na+ channels. Other  
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second messenger components also influence ion channel activation and inhibition  
including phospholipase A2 (PLA2) and intracellular Ca2+ levels (Berridge et al.,  
2003; Berridge, 2006; Burgoyne, 2007). 
 
G proteins are involved in direct activation and inhibition of several ion channels.  
The stimulation of Ca2+ current has been associated with the direct interaction with G  
proteins and similarly the receptor-mediated inhibition of Ca2+ channels is also linked  
to G proteins (Dolphin, 1990; Berridge et al., 2003). G proteins couple some  
neurotransmitter receptors directly to ion channels and one of the best examples of  
this mechanism in the brain is the coupling of many types of receptors including µ- 
opioid, α2-adrenergic, D2-dopaminergic, muscarinic cholinergic, 5HT1a-serotonergic  
and GABAB receptors, to the activation of an inward rectifying K+ channel (GIRK)  
via pertussis toxin-sensitive mechanisms (Wickman & Clapham, 1995: Schneider et  
al., 1997).  
 
It has been shown that binding of the G protein subunits to the Ca2+ channels, reduces 
their probability of opening in response to membrane depolarization. This mechanism 
is best seen in L-type Ca2+ channels, which are inhibited by the dihydropyridine 
antihypertensive drugs such as verapamil but may also operate for other types of 
voltage-gated Ca2+ channel (Berridge et al., 2003). Another example of direct 
regulation of ion channels by G proteins is the stimulation L-type Ca2+ channels by 
Gs. In this case, free α subunits appear to bind to the channel and increase their 
probability of opening in response to membrane depolarization (Wickman & 
Clapham, 1995; Berridge et al., 2003). 
 
1.3.8         G proteins and MAPK 
Several G protein-coupled receptors are capable of activating the MAPK pathway  
(Luttrell et al., 1997 ; Lowes et al., 2002). Research has shown the involvement of a  
ras-dependent mechanism and MAPK was found to induce mitogenesis in cultured  
fibroblasts after stimulation of GPCRs by naturally occurring phospholipids (Howe &  
Marshall, 1993). MAPKs are localised in both the cytoplasm and nucleus and are  
suspected to be involved in the phosphorylation of nuclear transcription factors which  
regulate gene transcription (Luttrell et al., 1997). Activation of PKC and  
phospholipase C beta (PLCβ) has also been linked to MAPK activation (Kolch et al.,  
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1993). Thus, G proteins are linked to pathways that influence not only membrane  
conductance but also cell proliferation and growth, implicating a possible role of G  
proteins in disease pathology  (Luttrell et al., 1997; Berridge, 2006; Cabrera-Vera, et  
al., 2003). 
 
 
1.4.       G proteins in disease 
G Protein-mediated signal transduction is important in the regulation of a cell’s  
morphological and physiological response to external factors (Wettschureck and  
Offermanns, 2005; Ohkubo and Nakahata, 2007). G proteins have been demonstrated 
to be involved in disease pathology through several mechanisms (Ohkubo and  
Nakahata, 2007). Among them are the exotoxins such as cholera or pertussis toxins 
which interfere with the G protein activity. Other disease pathologies associated with 
abnormal mutations in G proteins can interfere with signal transduction pathways and 
disease pathogenesis may also involve signal transmission that is either excessive, by 
augmentation of G protein function, or insufficient, via inactivation of G proteins 
(Wettschureck and Offermanns, 2005).  
 
Specific mutations may affect the ability of a G protein to hydrolyze GTP which may 
interfere with signal initiation, transmission and termination (Ohkubo and Nakahata, 
2007). Other mutations alter levels of a specific G protein or produce unstable G 
proteins, leading to changes in the response to a stimulus. Mutations may also alter 
the rate of GDP release and GTP binding, resulting in modifications to downstream 
signalling (Farfel et al., 1999; Xie and Palmer., 2007). 
 
It has been shown that the regulators of G protein signalling (RGS) proteins may play 
a role in disease pathology, since the RGS proteins have been found to reduce 
termination times by accelerating GTP hydrolysis, and are important in mediating 
slowing of heart rate, photon detection in the retina and the contraction of smooth 
muscle cells (Berman & Gilman, 1998). Mutations of these RGS proteins may play a 
role in prolonged stimulation of effectors associated with these proteins (Farfel, et al., 
1999; Lorenz et al., 2007). 
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Genetic variations and defects can also cause the inactivation of G proteins. 
Pseudohypoparathyroidism type 1 is caused by the null response of cells to 
parathyroid hormone and other hormones that are mediated by Gs. This may be due to 
either decreased levels of the active Gαs subunit or the production of inactive Gαs 
subunits (Farfel et al., 1999). Pseudohypoparathyroidism type 1b may also be caused 
by a genetic defect in Gαs (Farfel et al., 1999: Lorenz et al., 2007). 
 
1.5.   Second Messengers 
Second messengers are molecules that relay signals received at receptors on the cell 
surface, such as the arrival of protein hormones and growth factors to target molecules 
in the cytosol or nucleus. In addition to this function as relay molecules, second 
messengers serve to greatly amplify the strength of the signal and the binding of a 
ligand to a single receptor at the cell surface. As a result they may end up causing 
massive changes in the biochemical and physical activities within the cell through the 
activities of the second messengers which amplify the effect of the signal on the 
effectors (Berridge et al., 2003; Berridge, 2006). 
 
Second messengers are intracellular molecules or ions that are regulated by 
extracellular signalling agents such as neurotransmitters, hormones and their ligands 
which are called first messengers. Second messengers typically operate by activation 
of protein kinases that phosphorylate target proteins, thereby altering the function of 
these proteins (Kandel et al., 2000). Such functional effects are subsequently reversed 
by protein phosphatase-mediated dephosphorylation and the second messengers 
modulate a wide range of rapid and long-term neuronal processes (Garzon et al., 
2003). Examples of second messenger molecules are cAMP, Ca2+ and inositol 
triphosphate (IP3) (Heldin, 2003). 
 
1.5.1.    Types of second messengers 
There are three main types of secondary messenger molecules:  
(1) Hydrophobic molecules like diacylglycerol, inositol trisphosphate (IP3) and 
phosphatidylinositols. These are membrane-associated and diffuse from the plasma 
membrane into the juxtamembrane space where they can reach and regulate 
membrane-associated effector proteins (Vanhaesebroeck et al., 1997; Cohen, 2002). 
(2) Hydrophilic molecules are water-soluble molecules, like cAMP, cGMP, and Ca2+, 
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that are located within the cytosol and (3) gases, nitric oxide (NO) and carbon 
monoxide (CO), that can diffuse through cytosol and across cellular membranes 
(Chow and Stahelin, 2005). Secondary messengers can be synthesized or released and 
broken down again in specific reactions by enzymes. Some, like Ca2+, can be stored in 
special organelles and quickly released when needed and their production, release and 
destruction can be localized, enabling the cell to limit space and time of signal activity 
(Siegel et al., 1999; Haglund and Dikic, 2003). 
 
 
1.5.2.   Mechanisms of action of secondary messengers  
Cyclic AMP is synthesized from ATP by the action of the enzyme adenylyl cyclase 
(AC) and the binding of the hormone to its receptor activates a G protein which, in 
turn, activates AC (Vanhaesebroeck et al., 1997). The resulting rise in cAMP turns on 
the appropriate response in the cell by either changing the molecular activities in the 
cytosol, using protein kinase A (PKA), a cAMP-dependent protein kinase that 
phosphorylates target proteins or by turning on a new pattern of gene transcription as 
shown in Figure 1.6. This new pattern of gene transcription in cells occurs through the 
activity of cAMP response element-binding (CREB) proteins.  
 
The transducin family of G proteins mediate signal transduction in the visual system 
by regulating specific forms of phosphodiesterase (PDE) which catalyse the 
metabolism of cyclic nucleotides (Neer, 1995; Wickman & Clapham, 1995). Gαt 
activates PDE via direct binding to the enzyme (Wickman & Clapham, 1995; Siegel 
et al., 1999). The ability of neurotransmitter receptors to stimulate the 
phosphoinositide second-messenger pathway is mediated by the activation of 
phosphatidylinositol-specific phospholipase C (PI-PLC), which catalyses the 
hydrolysis of phosphatidylinositol bisphosphate (PIP2) to form the second messengers 
inositol triphosphate (IP3) and diacylglycerol (DAG) (Wickman & Clapham, 1995).  
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Fig.1.6. Representation of receptor activation resulting in the splitting of G protein 
complex into Gα and Gβγ leading to the phosphorylation of ATP to cAMP which pass 
into the nuclei as cAMP response element-binding proteins (CREB) and function as 
transcription factors of some genes. Adapted from Cabrera-Vera et al.( 2003). 
 
 
 
1.6.    The nervous system  
The mammalian nervous system is made up of the central nervous system (CNS) 
composed of the brain and the spinal cord, and the peripheral nervous system (PNS), 
which consists of the sensory-somatic nervous system and the autonomic nervous 
system. The brain receives sensory input from the spinal cord as well as from its own 
nerves which include olfactory and optic nerves, and devotes most of its volume and 
computational power, to processing its various sensory inputs and initiating 
appropriate and coordinated motor outputs (Siegel et al., 2006). The basic structural 
unit of the nervous system is the nerve cell or the neuron. Both the spinal cord and the 
brain consist of white matter bundles called axons which are each coated with a 
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sheath of myelin and grey matter which are masses of the nerve cell bodies, dendrites 
and synapses (Berridge, 2006).  
 
A typical neuron is composed of three parts: a single cell body, many dendrites and a 
single axon. The dendrites receive signals from other neurons, the cell body integrates 
the signal and the axon conducts action potentials, and transmits signals to other 
neurons through the axon terminals. At the dendrite, the action potential can be 
elicited if the membrane potential is depolarized to a threshold (Berridge, 2006). The 
action potential then travels along the axon to the nerve terminal, where 
depolarization may open calcium channels for the entry of Ca2+ ions, which then 
induce the release of neurotransmitters stored in the vesicles (Kandel et al., 2000). 
 
In a neural network, the nerve terminal of a neuron may form a synapse with either 
the dendrite or nerve terminal of another neuron. The synaptic cleft between two 
neurons is about 200 - 500 Å wide (Siegel et al., 2006). Chemical transmission is the 
major means by which nerves communicate with one another in the nervous system. 
The pre- and post-synaptic events are highly regulated and subject to use-dependent 
changes that are the basis for neuroplasticity and learning in the central nervous 
system (Siegel et al., 1999). 
 
According to Siegel et al. (1999) and Berridge, (2006), chemical transmission requires 
• synthesis of the neurotransmitter in the presynaptic nerve terminal. 
• storage of the neurotransmitter in secretory vesicles 
• a regulated release of neurotransmitter in the synaptic space between the 
pre- and post-synaptic neurons. 
• the presence of specific receptors for the neurotransmitter on the post-
synaptic membrane, such that application of the neurotransmitter to the 
synapse mimics the effects of nerve stimulation. 
• a means of termination of the action of the released neurotransmitter.  
 
Different types of substances act as neurotransmitters. Classical neurotransmitters like 
acetylcholine (ACh) and norepinephrine (NE) are low molecular weight substances 
that have no other function but to serve as neurotransmitters (Purves et al., 2001). The 
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predominant excitatory neurotransmitter in the brain, glutamate, and the inhibitory 
neurotransmitter in the spinal cord, glycine, are common and essential amino acids 
(Siegel et al., 1999). They function as neurotransmitters because the membranes of 
secretory vesicles in glutamatergic and glycinergic nerve terminals have specific 
transport systems that concentrate and store these amino acids so that they can be 
released by exocytosis in a highly regulated manner (Purves et al., 2001). Aminergic 
neurotransmitters, namely ACh and GABA, also enter synaptic vesicles through 
specific transport proteins. Neurotransmitters released from the vesicle may diffuse 
through the synaptic cleft to act on their receptors in the postsynaptic neuron as shown 
in Figure 1.7. 
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Fig.1.7. Mechanism of synaptic transmission. Neurotransmitters (N) are stored in 
vesicles at the presynaptic nerve terminal. The action potential at the presynaptic 
terminal causes the entry of Ca2+ ions through voltage-activated calcium channels, 
leading to the release of neurotransmitters (N) into the synaptic cleft which then bind 
to the receptors (R) with Na+ entry into the postsynaptic neurons through sodium 
channels. Adapted from Siegel et al.(2006). 
 
 
The receptors for neurotransmitters can be classified into two categories: 
metabotropic receptors, also called GPCRs, and ionotropic receptors. GPCRs are 
involved in signal transduction. As previously described, binding of neurotransmitters 
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on GPCRs may trigger a series of signalling processes. The ionotropic receptors form 
ion channels which may be activated upon binding of specific neurotransmitters. Once 
activated, the influx of cations, such as Na+, may cause the postsynaptic membrane to 
depolarize (Berridge et al., 2003). If the depolarization reaches the threshold, an 
action potential can be generated on the postsynaptic neuron. The ion channel formed 
by neurotransmitter receptors is called the synaptic channel. Each synaptic channel 
consists of five receptor subunits (Kandel et al., 2000).  
 
1.7.    Hypoxia 
Hypoxia is a state of oxygen deficiency in a cell, tissue, a part or whole body which  
is sufficient to cause an impairment of function. Hypoxia is caused by the reduction in  
partial pressure of oxygen, inadequate oxygen transport, or the inability of the tissues  
to use oxygen. Hypoxia is also defined as a pathological condition in which the body  
as a whole (generalized hypoxia) or region of the body, tissues or cells (tissue or  
cellular hypoxia) is deprived of adequate oxygen supply. Symptoms of generalized  
hypoxia depend on its severity and speed of onset. They include headaches, fatigue,  
shortness of breath, nausea, unsteadiness, and sometimes even seizures and coma.  
This can be marked by reduced oxygen to parts of the body especially to brain and  
muscles (Guyton and Hall, 2005; Feriche et al., 2007). 
Categories of hypoxia include the following: 
• Hypoxic hypoxia, which is a reduction in the amount of oxygen passing into 
the blood. It is caused by a reduction in oxygen pressure in the lungs, a 
reduced gas exchange area, exposure to high altitude, or by lung disease, in 
which arterial oxygen pressure is reduced (Acker, 1996).  
• Hypemic hypoxia also called anaemic hypoxia is a reduction in the oxygen 
carrying capacity of the blood. It is caused by a reduction in the amount of 
haemoglobin in the blood or a reduced number of red blood cells. A reduction 
in the oxygen transport capacity of the blood occurs through blood donation, 
haemorrhage, or anaemia, while a reduction in the oxygen carrying capacity 
of the blood occurs through drugs, chemicals, or carbon monoxide.  
 39
• Stagnant hypoxia also called ischaemic hypoxia is an oxygen deficiency due 
to poor circulation of the blood or poor blood flow (Dietz et al., 2003). 
Examples of this condition are high gravity forces, prolonged sitting in one 
position or hanging in a harness, cold temperatures, and positive pressure 
breathing.  
• Histotoxic or cytotoxic hypoxia is the inability of the tissues or cells to obtain 
or use oxygen (Acker and Acker, 2004). Examples are in carbon monoxide 
and cyanide poisoning and in controlled tissues or cellular hypoxic 
experiments.  
Cerebral hypoxia is a condition in which there is a decreased oxygen supply to the 
brain even though there is adequate blood flow (Guyton and Hall, 2005). Drowning, 
strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide 
poisoning and complications of general anaesthesia can create conditions that can lead 
to cerebral hypoxia (Guyton and Hall, 2005; Kolb, 2003). Symptoms of mild cerebral 
hypoxia include inattentiveness, poor judgement, memory loss and a decrease in 
motor coordination (Kolb, 2003; Guyton and Hall, 2005). Neural and brain tissues 
have been shown to be extremely sensitive to oxygen deprivation and can begin to die 
within five minutes after oxygen supply has been cut off (Zhang et al., 2006; 
Tomaselli et al., 2005). When hypoxia lasts for longer periods of time, it can cause 
coma, seizures, and even brain death. In brain death, there is no measurable activity in 
the brain, although cardiovascular functions are preserved (Dietz et al., 2003). 
Hypoxia reoxygenation has been shown to induce premature senescence in neonatal 
Sprague-Dawley (SD) rat cardiomyocytes (Zhang et al., 2007).  
Hypoxia in the brain may lead to cell death by apoptosis and necrosis. Tomaselli et al. 
(2005) have shown that adenosine, the final metabolic product of in the stepwise 
dephosphorylation of ATP, is produced and released in the central nervous system in 
response to ischaemia and hypoxia. Adenosine acts as a powerful endogenous 
neuroprotectant during ischaemia-induced energy failure by decreasing neuronal 
metabolism, increasing cerebral blood flow (via vasodilatation) and by playing a 
variety of different roles as an intercellular messenger (Tomaselli et al., 2005).   
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Most animals experience some degree of hypoxia and hypothermia during the course 
of their life as a consequence of ambient exposure or through metabolic, respiratory 
and circulatory insufficiency (Boutilier, 2001). Like humans, the vast majority of 
mammals are unable to survive prolonged periods of hypothermia and oxygen 
deprivation owing to irreversible membrane damage and loss of cellular ion 
homeostasis in vital organs like the brain and heart. However, numerous hibernating 
endotherms, neonatal and diving mammals as well as many ectotherms can tolerate 
prolonged periods and the key to their survival under such conditions lies in an 
inherent ability to down regulate their cellular metabolic rate to new hypo metabolic 
steady states in a way that balances the ATP demand and ATP supply pathways 
(Boutilier, 2001; Bunn and Poyton, 1996). 
Most mammals possess little natural tolerance to severe hypoxia or hypothermia, and 
their excitable cells and tissues are normally debilitated by any prolonged exposure to 
either condition. The primary causes of hypoxia/anoxia-or hypothermia-induced death 
in mammals are brain dysfunction and cardiac arrhythmias due to a loss of ionic 
integrity of the cell membranes (Boutilier, 2001). Ion leakage across cell membranes 
occurs as a result of both intracellular and extracellular ions drifting towards their 
thermodynamic equilibrium (Rolfe and Brand, 1996; Priebe et al., 1996). Maintenance 
of a homeostatic intracellular environment therefore requires the redistribution of 
these ions through the use of ATP-dependent pumping systems such as the Na+/K+-
ATPase, which can consume 20–80% of the cell’s resting metabolic rate depending on 
the extent of its electrical activity (Edwards et al., 1989; Rolfe and Brown, 1997).  
Cell death occurs when ATP production fails to meet the energetic maintenance 
demands of ionic and osmotic equilibrium. The rise in free cytosolic intracellular Ca2+ 
concentration results in the activation of Ca2+-dependent phospholipases and proteases 
that further hasten the rate of membrane depolarisation, leading to uncontrolled 
cellular swelling and, ultimately, to cell necrosis (Hochachka, 1986; Boutilier, 2001). 
In severe O2 decrease, most mammalian excitable cells cannot continue to meet the 
energy demands of active ion-transporting systems, thus leading to rapid exhaustion 
of substrate which results in membrane failure and cell death (Willis, 1979). 
However, in certain lower vertebrates, neonates and diving mammals, hypoxia-
induced membrane destabilisation of the kind seen in adult mammals is either slow to 
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develop or does not occur at all as a result of adaptive decreases in membrane 
permeability (i.e. ion ‘channel arrest’) that dramatically reduce the energetic costs of 
ion-balancing ATPases (Musacchina, 1984; Hochachka, 1986).  
 
Mahura (2003), has shown that neuronal responses to hypoxia-ischaemia can be acute 
or chronic. In the early stages, neuronal responses to ischaemia-hypoxia are 
dependent on the modulation of ion channels. Acute responses rely mainly on O2-
regulated ion channels which mediate adaptive changes in neuron excitability. Energy 
failure, an early consequence of hypoxia-ischaemia, causes disruption of ionic 
homeostasis and accumulation of extracellular neurotransmitters. NMDA and 
AMPA/kainate receptors and Ca2+ channels contribute to excitotoxic neuronal 
degeneration. Excitotoxicity leads to increased Ca2+ influx, which can activate 
cytotoxic intracellular pathways (Mahura, 2003).  
 
Reactive oxygen species generated during hypoxia-ischaemia contribute to the injury. 
Oxygen free-radicals serve as important signalling molecules that trigger 
inflammation and apoptosis (Durukan and Tatlisumak, 2007). Excitatory amino acid-
receptor antagonists and Ca2+ channels blockers can provide neuroprotection in 
experimental models of hypoxia-ischaemia but disrupt normal brain function 
(Mahura, 2003; Durukan and Tatlisumak, 2007). The blockade of voltage-gated Na+ 
channels reduces the excitability of neurons, Na+ influx and the accumulation of 
intracellular Na+, which improve the ionic homeostasis and cellular energy levels and 
prevent ischaemia-hypoxia induced neuronal injury and neuronal damage mediated by 
Ca2+ overload (Mahura, 2003). These findings from Mahura (2003) have shown that 
any neuroprotective agent against hypoxia and ischaemia should be able to reduce the 
generation of oxygen free radicals and limit Ca2+ influx into neuronal cerebral cells, 
which will invariably reduce inflammation and cell death. Thus any neuroprotective 
agent should also be able improve the ionic homeostasis and cellular energy levels 
and prevent ischaemia-hypoxia induced neuronal injury and neuronal damage 
mediated by Ca2+ overload (Mahura, 2003). 
 
Prabhakaran et al. (2004) have shown that heterogeneous oxygen tension and access 
to metabolites in solid tumours may produce variability in response to adjuvant 
therapy. To better understand these micro environmental features, Prabhakaran et al. 
 42
(2004), examined survival and proliferation of neuroblastoma (NB) cells, in an in 
vitro model of hypoxia, and metabolite deprivation. They showed that human NB 
cells (SH-SY5Y) were subjected to a self-generated diffusion gradient of nutrient and 
oxygen deprivation in a modified in vitro sandwich model. In this model, the extent of 
both hypoxia and metabolite deprivation were individually altered, and the effects of 
each were studied.  
 
Prabhakaran, et al. (2004) confirmed cellular proliferation using proliferating cell 
nuclear antigen (PCNA) immunocytochemistry and morphological assessment and 
hypoxia was assessed by vascular endothelial growth factor (VEGF) and 
pimonidazole immunocytochemistry. Prabhakaran et al. (2004) examined apoptotic 
cell death using terminal uridine deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) analysis, assaying for plasma membrane transfer of phosphotidylserine and 
the presence of the anti-apoptotic protein Bcl-2 using immunocytochemistry. As 
predicted, cellular survival diminished with increasing duration and severity of 
hypoxia and metabolite deprivation. Oxygen deprivation was determined to be the 
more important contributory factor to early survival and proliferation. Proliferating 
cell nuclear antigen (PCNA) immunocytochemistry confirmed decreasing fractions of 
proliferating cells as a function of decrease in oxygen and metabolites. VEGF and 
Bcl-2 immuno-reactivity increased with prolonged exposure and increased extent of 
oxygen/metabolite deprivation. TUNEL analysis and phosphotidylserine transfer 
demonstrated cellular death of hypoxic and metabolite-deprived NB cells in a manner 
consistent with a mitochondrial apoptotic pathway (Prabhakaran et al., 2004). This in 
vitro model of hypoxia with NB cells demonstrates that increasing the severity of 
hypoxia and metabolite deprivation results in diminished proliferation and greater 
apoptotic cell death (Prabhakaran et al., 2004). 
 
Gu and Shi (1994), also investigated the effect of hypoxia on the growth and 
differentiation of NG108-15 cells, hybrid cells derived by the fusion of mouse 
neuroblastoma clone N18TG6 with rat glioma clone C6BU1. These cells proliferate in 
the presence of foetal calf serum, but are differentiated by the addition of DbcAMP to 
the culture medium. The effect of hypoxia (2% O2) on the hybrid cells, showed that 
hypoxia depressed proliferation of non-differentiated cells and induced death of 
differentiated cells and also inhibited differentiation in either non-differentiated or 
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differentiating immature cells, in the direction to look like mature neuro-like cells that 
could no longer be differentiated any more while some cells became large with flat 
short processes and had no Nissl substances (Gu and Shi, 1994). The observations of 
Prabhakaran et al.(2004) and Gu & Shi (1994) have shown that cellular hypoxia and 
metabolite deprivation lead to increased cellular death, decreased cellular growth, 
proliferation and differentiation, though both studies used established cell lines but 
differed in that Gu and Shi (1994) used hybrid cells. The effect of hypoxia in the two 
studies above was clearly shown, though the studies used established cell lines in 
contrast to primary cell lines where the effect of hypoxia would be more pronounced. 
This is because primary cultures may not survive for very long periods of time and as 
such may show more pronounced effects when compared to the established cell lines 
(Adler, 2006a).  
 
 1.7.1.     Neuronal damage in hypoxia 
Hypoxic stress has been shown to induce apoptosis of hippocampal CA1 neurons  
while selectively sparing CA2–3 neurons, while proliferation and differentiation of 
local stem cells may potentially replace lost neurons (Zhou et al., 2004). The mitogen 
activated protein (MAP) kinase mediated regulation of proliferation and 
differentiation was examined by Zhou et al.(2004) using rat organotypic hippocampal 
cultures exposed to hypoxia for up to 6 hours followed by reoxygenation. The results 
showed that the c-Jun N-terminal kinases/stress-activated protein kinases (JNKs/ 
SAPKs) and extracellular signal–regulated protein kinases (ERKs) were maximally 
activated by 4 hours, returning approximately to basal levels by 6 hours (Zhou et al., 
2004). Apoptosis of CA1 neurons was maximal by 6 hours hypoxia, although JNK 
activation had returned to basal levels. Zhou et al. (2004) demonstrated that a 
neuroprotective protein, JNK-interacting protein 1 (JIP1), an inhibitor of JNK-
mediated apoptosis, was reduced by 6 hours of hypoxia and markedly decreased by 24 
hours reoxygenation in CA1 neurons. This was the case for MAP-kinase activating 
death domain (DENN/MADD), which modulates JNK-mediated cell death (Zhou et 
al., 2004; Zhou and Miller, 2006). 
 
The second peak of ERK1 activation occurred at 24 hours reoxygenation and declined 
to control levels by 48 hours. Zhou and Miller (2006) confirmed proliferation with 
anti-proliferation cell nuclear antigen (PCNA) immunohistochemistry and 
 44
Bromodeoxyuridine (BrdU) incorporation (Zhou et al., 2004). With an inhibitor of 
ERK activation, BrdU labelling was strikingly reduced, implicating ERKs in the 
proliferation response. This showed that, hypoxia concurrently triggered both JNK 
and ERK signalling, and with reoxygenation, ERK1 activation and stem cell 
proliferation followed by neuronal progenitor cell differentiation and targeted 
migration to the site of pyramidal neuronal loss (Zhou et al., 2004).   
Pre-existing hyperglycaemia has been shown to exacerbate CNS injury after transient 
global and focal cerebral ischaemia (Kelleher et al., 1993; Vincent et al., 2005a). 
Increased anaerobic metabolism, with resultant lactic acidosis, has been shown to 
cause hyperglycaemic neuronal injury (Vincent et al., 2005a). The role of astrocytes 
in ischaemic-induced neuronal injury has been shown to be protective, and the ability 
of astrocytes to maintain energy status and ion homeostasis under hyperglycaemic 
conditions could ultimately reduce neuronal injury and hence increase neuronal 
survival rate (Kelleher et al., 1993; Vincent et al., 2005b).  
Kelleher et al. (1993) studied the effects of increased glucose concentrations on 
glucose utilization, lactate production, extracellular pH and ATP concentrations in 
hypoxia-treated astrocyte cultures using primary astrocytes from neonatal rat cerebral 
cortices. After some days in vitro, cultures were incubated with 0-60mmol/L glucose 
and subjected to hypoxic conditions at 95% N2/5% CO2 for 24 hours. In addition, 
under high glucose (30mmol/L) conditions, astrocytes were exposed to up to 72 hours 
of hypoxia. Determination of lactate dehydrogenase efflux, adenosine triphosphate 
concentrations, and extracellular lactate concentrations was used to define the status 
of the astrocytes (Vincent et al., 2007).  
The results of Kelleher et al. (1993) showed that when physiological concentrations of 
glucose (≤7.5 mmol/L) were used, significant cell damage occurred within 24 hours of 
hypoxia, as determined by increased efflux of lactate dehydrogenase and loss of cell 
protein. When higher glucose concentrations (15-60 mmol/L) were used, efflux of 
lactate dehydrogenase was similar to that observed in normoxic cultures, despite an 
increased utilization of glucose. Lactate concentrations in the media at low or normal 
glucose concentrations exceeded normoxic levels, but higher glucose concentrations 
(15-30 mmol/L), failed to increase lactate levels further (Kelleher et al., 1993; 
Vincent et al., 2005b). Values of ATP for hypoxic astrocytes treated with high glucose 
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concentrations were significantly higher than those of astrocytes with zero or low 
glucose levels (Vincent et al., 2007). 
In cultures exposed to hypoxia and high glucose levels (30 mmol/L), no cellular injury 
was observed before 48 hours of hypoxia (Kelleher et al., 1993). Lactate 
dehydrogenase concentrations in the media increased during the first 24 hours of 
hypoxia and reached steady state, while the pH of the media was decreased after 24 
hours and 48 hours. Injury occurred when the pH of the medium was less than 5.5. 
Vincent et al. (2005a) concluded that hypoxic injury to mature astrocytes was reduced 
by the presence of glucose (15-60 mmol/L) in the medium during 24-30 hours of 
hypoxia (Kelleher et al., 1993; Vincent et al., 2005a; Vincent et al., 2007). 
To investigate whether high glucose concentrations protected cells by increasing 
extracellular osmolarity, Kelleher et al. (1993) added 0, 4.5, 7.5, 15 or 30 mmol/L 
mannitol in the medium containing 7.5 mmol/L glucose under normoxic and hypoxic 
conditions. The results showed that the increased osmolarity caused by mannitol had 
no protective effect on hypoxic cultures, nor did it affect the LDH release from 
normoxic cells (Kelleher et al., 1993). Vincent et al. (2005a) have shown that the 
application of 20mM added glucose but not 20mM non-metabolizable mannitol, 
significantly decreases aconitase activity in dorsal root neurons within 1 hour and 
continues to decrease activity over a 5 hour period. The above findings show that 
cellular protection afforded by high glucose concentrations is not due to increased 
osmolarity of the culture media in hypoxic and normoxic situations. 
Brain ischaemia-induced neuronal death has been linked in part to excess Ca2+ influx 
through ionotropic glutamate receptors and voltage-gated Ca2+ channels (Choi, 1988; 
Rothman and Olney, 1986; Wei et al., 2003). As a result, considerable effort has been 
directed toward reducing neuronal circuit excitation as a strategy for neuroprotective 
intervention (Wei et al., 2003). Strategies of preventing neuronal death include direct 
blockade of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptors, while additional strategies 
include enhancing synaptic inhibition, reducing glutamate release, and reducing 
neuronal firing by blocking Na+ channels or opening K+ channels (Goldin et al.,1995; 
Taylor and Meldrum, 1995). The strategy of opening K+ channels is supported by the 
observation that drugs that enhance opening of ATP-sensitive K+ channels (KATP 
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channels) can reduce ischaemia-induced necrotic cell death in the heart (Grover,1997) 
and brain (Fujita et al.,1997). Also, the novel Ca2+-activated maxi-K+ channel opener, 
BMS-204352, was shown to be neuroprotective in rodent focal stroke models, 
(Gribkoff, et al., 2001), although clinical trial results have not been encouraging 
(Wahlgren and Ahmed, 2004; Goldberg, 2002; Goldberg, 2007).  
It has been shown that excessive K+ efflux and intracellular K+ depletion are the key 
steps in the apoptotic cascade of many cells, including neurons (Dallaporta et al., 
1998; Yu et al., 1997). One possible factor limiting the benefit of enhancing K+ 
channel activity in the ischaemic brain might be enhancement of an apoptotic 
component of focal ischaemic neuronal death (Linnik et al., 1993; Choi, 1996; Wei et 
al 2003), a component that might be especially prominent when infarction is delayed 
after mild transient insults (Endres et al., 1998). Yu et al. (1999) observed that several 
apoptotic insults induced enhancements of the outward delayed rectifier currents in 
cultured cortical neurons which occurred before cells are committed to die, which is 
consistent with a potential role as an early mechanism in apoptosis.  
A close relationship between enhanced K+ channel activity and apoptosis was also 
supported by studies in other types of neurons and peripheral cells (Yu et al., 1999). 
The potassium channel blockers, tetraethyl ammonium (TEA) and clofilium, or 
elevated extracellular K+, attenuated neuronal apoptosis in neurons and the 
neuroprotection persisted even when the concurrent Ca2+ influx and intracellular Ca2+ 
increase were prevented (Yu et al., 1999). TEA was found to be neuroprotective 
against CA1 hippocampal injury after global ischaemia in rats (Huang et al., 2001). 
Wei et al. (2003) investigated a possible role of K+ channels in ischaemia-induced 
apoptosis and potential therapeutic implications of the K+ hypothesis for apoptosis in 
ischaemic brain injury. They explored the protective effects of K+ channel blockers 
against neuronal death induced by hypoxia in vitro and by mild transient focal 
ischaemia in the rat. Their result showed that 5 mmol/L of the K+ channel blocker 
tetraethylammonium (TEA) selectively blocked K+ channels without affecting 
NMDA receptor-mediated current or voltage-gated Ca2+ currents. These findings 
suggest that preventing excessive K+ efflux through K+ channels may constitute a 
therapeutic target for the treatment of stroke and other neurodegenerative disorders. 
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 Sher and Hu (1992) investigated the comparative effects of rapid versus graded 
correction of chronic hypoxia in vitro. Cerebral cortical cell cultures obtained from 
foetal mice were exposed to 5% O2 for 24 hours and returned immediately to room 
oxygen level for 24 hours. In a second group the cultures were exposed to 5% O2 for 
24 hours followed by 10% O2 for another 24 hours and then returned to room oxygen 
level. At the end of the experiment the result showed that the partial pressure of 
oxygen in the bathing medium of the first group cultures was significantly higher than 
that of second group and non-hypoxic controls (Sher and Hu, 1992). Throughout the 
recovery period, the second group cultures showed improved neuronal survival, 
decreased lactate dehydrogenase efflux into the bathing medium and relative 
preservation of neuronal morphology (Sher and Hu, 1992). Glutamate binding was 
not differentially affected and glutamine synthetase activity, a predominantly glial 
marker, was only modestly increased after graded reoxygenation (Sher and Hu, 1992). 
These results demonstrated that gradual reoxygenation, after prolonged hypoxia in 
vitro, improves neuronal survival compared to rapid reoxygenation, and delays the 
manifestations of metabolic dysfunction even though the length of hypoxic exposure 
is increased. These results are in agreement with the concept that a period of relative 
hyperoxia may contribute to hypoxia-induced neuronal injury (Sher and Hu, 1992; 
Wei et al., 2003). This is because the initial exposure of cells to a hyperoxic 
environment will predispose the cells to severe hypoxic injury when they are 
eventually introduced to a hypoxic environment. The cells become highly susceptible 
to the injurious effects of hypoxia as a result of brief exposure to hyperoxia. Hu et al. 
(2003) have shown that the expression of two anti-apoptotic proteins (Bcl-2 and Bcl-
X(L)) was decreased, and caspase 3 activity was increased significantly at 24 hour 
after hypoxia, and hypoxia plus hyperoxia. These results suggest that both hypoxia 
and hyperoxia alone can induce cell death, while cells initially exposed to hyperoxia 
before subsequent hypoxic exposure may be more predisposed to hypoxic injuries. 
Bickler et al. (2003) showed that neonatal rats survived and avoided brain injury 
during periods of anoxia 25 times longer than adults and as such they hypothesized 
that oxygen activates and hypoxia suppresses NMDA receptor (NMDAR) responses 
in neonatal rat neurons. This explained the innate hypoxia tolerance of these cells. In 
CA1 neurons isolated from neonatal rat hippocampus with mean postnatal age of 5.8 
days, hypoxia reduced NMDA receptor-channel open-time percentage, and NMDA-
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induced a significant increase in Ca2+ and NMDA Delta Ca2+ by 38 and 68%, 
respectively. While in postnatal day 20 (P20) neurons, the reductions were not 
significant and in postnatal day 3 to 10 (P3-10) CA1 neurons within intact 
hippocampal slices, hypoxia reduced NMDA Delta Ca2+ by 52% and decreased 
NMDA-induced death by 45%. Phalloidin, a microtubule stabilizer, prevented 
hypoxia-induced inhibition of NMDA Delta Ca2+ in P3-10 neurons. Compared with 
responses in 21% O2, hypoxia reduced currents from neonatal NMDA subtype 
NR1/NR2D receptors by 25%, increased currents from NR1/NR2C by 18%, and had 
no effect on NR1/NR2A or NR1/NR2B NMDA receptor subtypes (Bickler et al., 
2003). Modulation of NMDARs by hypoxia may play an important role in the 
hypoxia tolerance of the mammalian neonate, and oxygen sensing by NMDARs could 
play a significant role in postnatal brain development (Bickler et al., 2003).  
Normally, neurotransmitter levels are highly regulated by the nervous system. In 
certain medical conditions, such as Parkinson’s disease and Alzheimer’s disease, 
injured nerve cells become unable to control the normal release of neurotransmitters 
and they tend to release excess glutamate into the extracellular environment 
(Friedman, 2006; Hedrick et al., 2005). The excess glutamate results in over 
excitation of the NMDA receptor allowing excess calcium to enter the affected 
neurons (Tremblay et al., 2000). These neurons may then swell and rupture, releasing 
more glutamate into the surrounding area, which in turn overexcites NMDA receptors 
on adjacent neurons. This cascade of neuronal injury, referred to as excitotoxicity, 
follows acute conditions such as stroke and traumatic brain injury (Hasbani et al., 
2001; Bickler et al., 2004). Damaged nerve cells also appear to release excess 
glutamate in certain chronic conditions such as neuropathic pain and dementia 
(Rivera-Cervantes et al., 2004; Schiller et al., 2000). 
Molecular mechanisms underlying foetal growth restriction due to placental 
insufficiency and in utero hypoxia are not well understood, but in the study by Huang 
et al. (2004), time-dependent changes in foetal tissue gene expression in a rat model of 
in utero hypoxia compared with normoxic controls were investigated as an initial 
approach to understand molecular events underlying foetal development in response 
to hypoxia. The result showed that litter size was reduced and insulin-like growth factor 
binding protein 1 (IGFBP-1) was up-regulated in maternal serum and in foetal liver and 
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heart (Huang et al., 2004). It has been shown that in hypoxia, there is the reduction in 
foetal growth, brought about by the decrease in the availability of growth factors 
resulting in reduced litter size. The significance of this finding is that, in hypoxia, 
there is growth hormone deficiency which leads to elevated IGFBP-1 levels (Marchini 
et al., 2005). This is because increasing stress and energy demands as in the case of  
hypoxia are accompanied by increasing foetal levels of glucose-mobilizing hormones 
in combination with depressed levels of insulin and IGF-I, and increase in IGFBP-1 is 
aimed at diminishing insulin-like activity of IGF-I, thereby reducing peripheral 
glucose utilization and hence the reduction in growth (Marchini et al., 2005).  
Tissue-specific, distinct regulatory patterns of gene expression were observed under 
acute and chronic hypoxic conditions and the induction of glycolytic enzymes was an 
early event in response to hypoxia during organ development (Huang et al., 2004). 
Tissue-specific induction of calcium homeostasis-related genes such as L-type 
voltage-gated calcium channel (rattus norvegicus calcium channel alpha-1D subunit; 
ROB3) and glutamate receptor, ionotropic, kainate 4 (Grik4), and suppression of 
growth-related genes like brain-derived neurotrophic factor (BDNF) and nerve growth 
factor-induced factor A (NGFI-A) were observed, suggesting mechanisms underlying 
hypoxia-related foetal growth restriction. Also the induction of inflammation-related 
genes, such as immunoglobulin superfamily number 6 (Igsf6) and prostaglandin-
endoperoxide synthase 2 (Ptgs2), in placentas exposed to long-term hypoxia, suggest 
that a mechanism for placental dysfunction and impaired pregnancy outcome 
accompanying in utero hypoxia (Huang et al., .2004). 
 
1.7.2.      Morphological and functional changes in hypoxia 
Transient cerebral ischaemia has been shown to lead to delayed neuronal dysfunction 
which may occur in hours and days after ischaemic insult (Lipton, 1999; Zhong et al., 
2003). Pathological conditions could result, to a variable extent, in cell damage or 
even death depending on the severity of the insult (Lushnikova et al., 2004; Mander et 
al., 2005). Strong ischaemia has been shown to lead to quick pronounced neuronal 
death while mild insults might cause less remarkable cell damage (Jourdain et al., 
2002). 
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Culture models of neurons from developing rat forebrain in moderate hypothermia, 
concomitant with a hypoxic insult, have been shown to exert protective effects on 
nervous cells and prevent apoptosis (Bossenmeyer-Pourie et al., 2000). Ischaemia has 
been suggested to be a common risk factor in Alzheimer’s Disease and Huntington’s 
disease, epilepsy and other neurodegenerative diseases (Afsar et al., 2003; Egashira et 
al., 2002). Egashira et al. (2002) have shown that hypoxia enhances β-amyloid-
induced apoptosis in rat cultured hippocampal neurons. While Bossenmeyer et al. 
(1998) have shown that hypoxia for 6 hours reduced neuronal viability by 
approximately 40% within 96 hours after reoxygenation, in line with the appearance 
of morphologic features of apoptosis, such as nuclear condensation and fragmentation. 
Such alterations are preceded by typical and reproducible changes in the rates of total 
protein synthesis, reflected by a biphasic increase in leucine incorporation taking 
place 1 hour after the onset of hypoxia and also 48 hours after reoxygenation. 
Thereafter, protein synthesis progressively declined, concomitantly with the 
appearance of cell damage and a reduction of the number of viable neurons 
(Bossenmeyer-Pourie et al., 2000; Haddad and Jiang, 1993). 
Apoptotic cell death generally occurs in a tightly regulated manner that proceeds 
mainly through highly conserved genetic mechanisms (Steller, 1995). Earlier studies 
have shown that delayed cell death resulting from a 6-hour period of hypoxia in 
cultured neurons is accompanied by an increased expression of pro-apoptotic gene 
products, such as Bax and members of the family of cysteine proteases referred to as 
caspases, including CPP32/caspase-3 (Bossenmeyer et el., 1998). Preconditioning has 
been shown to protect neuronal cells against hypoxia-induced apoptosis by 
stimulating the induction of specific cell survival-associated genes (Bossenmeyer-
Pourie et al., 2000). Adaptive mechanisms may include over expression of the 
inducible isoform of heat shock protein (HSP) 70 and Bcl-2 proteins, whereas others 
have reported the production of trophic factors, such as basic fibroblast growth factor 
(bFGF) in rat cortical neurons (Sakaki et al., 1995). Both HSP 70 and Bcl-2 have been 
directly implicated in the regulation of the apoptotic process and are largely 
recognized as anti-apoptotic effectors (Tamatani et al., 1998; Yang et al., 1997).  
It has been shown that when neuronal cells are exposed to hypoxia for 6 hours they 
respond by early and transient induction of HSP 70, but the protein level progressively 
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decreases, while preconditioned neurons are able to maintain high amounts of HSP 70 
until the experimental end point (Bossenmeyer-Pourie et al., 2000). Preconditioning 
also induces expression of Bcl-2, the prototypic repressor of apoptotic death, which 
functions by counteracting the death promotor activity of some of its conserved 
homologs, such as Bax (Oltvai et al., 1993) and may additionally contribute to 
inhibition of apoptosis by preventing the posttranslational activation of caspase 
members (Srinivasan et al., 1996; Allen et al.1998). Shimizu et al. (1996) reported 
that, although Bcl-2 and caspase inhibitors are efficient in attenuating hypoxia-
induced neuronal death, they might also be involved in the reduction of at least some 
types of necrotic damage. Bossenmeyer-Pourie et al. (2000) have shown that hypoxia 
induces neuronal death mainly through an apoptotic process, but the rate of necrosis 
appears to increase significantly during the course of the experiment. Although this 
may reflect necrosis secondary to apoptosis, necrotic damage may partly account for 
hypoxia-induced cell loss. In conditioned neurons, the final number of necrotic cells 
after hypoxia remains in the range of control cells, suggesting that if it does not reduce 
basal necrosis observed during the normal life-span of cultured neurons, 
preconditioning might suppress the necrotic component of hypoxic injury 
(Bossenmeyer-Pourie et al., 2000).  
Hypothermia has been shown to promote the early post ischaemic recovery to normal 
glucose utilization in rats subjected to transient global cerebral ischaemia 
(Bossenmeyer-Pourie et al., 2000). Temperature reduction contributes to reducing the 
release of neurotransmitters, especially glutamate, which mediates excitotoxicity 
(Globus et al., 1995). Neuronal preconditioning before a hypoxic insult appears to 
trigger adaptive cell responses via active mechanisms that include the production of 
anti-apoptotic molecules. Probably through its depressant actions on cell activity, 
hypothermia impairs active processes that are necessary for the cells to undergo 
apoptosis, and possibly secondary necrosis, in response to hypoxia-reoxygenation 
(Bossenmeyer-Pourie et al., 2000). 
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1.7.3.     Hypoxic disorders 
Hypoxia has been shown to regulate growth, proliferative capacity and collagen type-
1 production in cardiac fibroblasts and, therefore, may play a part in the post-infarct 
remodelling of the cardiac collagen matrix (Agocha et al., 1997). Inflammation and 
myocardial injury occurs as a result of apoptosis of cardiomyocytes (Gottlieb et al., 
2003). Apoptosis has been shown to represent the major independent form of myocyte 
death during, and after, infarction (Kajstura et al., 1996). Hypoxia has been shown to 
induce apoptosis in many cell types (Tanaka et al., 2001). Apoptosis has been induced 
in rat myocardium within 45 minutes of ischaemia and this was shown to advance 
substantially during 3 hours of reperfusion (Black et al., 2005).  
Apoptosis found in hypoxic cardiomyocytes has been found to be concomitant with 
raised protein 53 (p53) activity, a transcription factor that regulates cell cycle and 
functions as a tumour suppressor, indicating a critical role for p53 activated pathways 
(Long et al., 1997). However, it has been demonstrated that hypoxia-induced 
apoptosis seen in acute myocardial infarction also occurs in the absence of p53 (Bialik 
et al., 1997). Diagnosis of acute myocardial infarction is facilitated by raised levels of 
the enzymes lactate dehydrogenase (LDH) and creatinine kinase (CK), levels of 
which increase in response to hypoxia/reoxygenation, along with a corresponding 
increase in levels of nitric oxide (NO) (Wei and Zhu, 1997). The vasodilatory effect 
of nitric oxide contributes to the inflammatory response, thereby leading to 
reperfusion injury (Wallace and Ma, 2001). 
The production of the nitric oxide is catalysed by the enzyme nitric oxide synthase 
(NOS) and the most common form, when considering cardiac ischaemia, is 
endothelial NOS (eNOS). This has been shown to be produced by blood vessel 
endothelia and is responsible for the synthesis of endothelium-derived relaxing factor 
(EDRF). The two other enzyme forms are cytokine-inducible NOS (iNOS) and the 
neuronal form of nitric oxide synthase (nNOS) (Polster and Fiskum 2004). It is known 
that nitric oxide is released from cardiomyocytes in response to hypoxia/ 
reoxygenation (Wei and Zhu, 1997; Polster and Fiskum, 2004) and a decreased 
production of endothelial nitric oxide by both acute and chronic hypoxia has been 
observed in pulmonary arteries (Cokkinos et al., 2005; Ikonomidis et al., 2005). 
Pacher et al. (2007) have shown that mammalian cells are able to generate a large 
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amount of reactive oxygen species (ROS) in response to oxidative stress. These ROS 
include oxygen ions, free radicals and peroxides. The reactive oxygen ions can react 
rapidly with nitric oxide to form peroxynitrite (ONOO−), which is an oxidizing agent 
that can damage cells and their DNA (Pacher et al., 2007). 
Cells exposed to a hypoxic environment are radio- and chemo-resistant, and these 
resistant cells can remain viable after cancer treatment, leading to the possibility of 
recurrence and metastasis on cessation of therapy (Airley et al., 2000). In addition, the 
adaptations necessary to maintain viability of these cells in hypoxic conditions may 
cultivate a more malignant phenotype. There is some evidence that hypoxia favours 
the selection of aberrant p53 tumour suppresser gene (Graeber et al., 1996; Weinmann 
et al., 2004a), and that exposure to hypoxia increases tumour growth rate and 
experimental metastatic potential (Stackpole et al., 1994; Weinmann et al., 2004b; 
Cooper et al., 1998). Cells cultured in anoxic conditions are approximately three times 
more resistant to the cytotoxic effects of radiation than fully aerated cells, with radio-
sensitivity rapidly increasing with increasing oxygen concentration (Airley et al., 
2000; Serkova et al., 2002). 
 Radio-resistance occurs due to the deficiency of molecular oxygen, which acts as a 
radiosensitiser due to its action as an electron acceptor. As a consequence, the free 
radical formation that results in cell damage occurs to a much lesser extent under 
hypoxic conditions, leading to survival of these dangerous cells (Weinmann et al., 
2004a; Seta et al., 2002; Semenza, 2007). Hypoxia also confers changes in radio- 
sensitivity due to the proliferative, physiologic and metabolic changes associated with 
cells exposed to this adverse microenvironment (Rockwell, 1992; Knisely and 
Rockwell, 2002; Semenza, 2007). 
 
1.8.    Neuroprotection in hypoxia 
Hypoxia has been known to generate ROS, the by-products of cellular oxidative 
metabolism (Adams, 1979; Halliwell and Gutteridge, 1989). It has been shown that of 
all the cells in the body, the neurons are highly vulnerable to ROS damage and ROS 
may play an important role in the processes leading to neuronal cell damage due to 
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hypoxia (Ratan et al., 1994; Jayalakshmi et al., 2005). The high vulnerability of brain 
cells to oxidative injury is due to their high metabolic rate (which hypoxia disrupts), 
elevated levels of polyunsaturated lipids (a target of lipid peroxidation) and low levels 
of natural antioxidants and anti-oxidative enzymes such as superoxide dismutase 
(Reiter, 1995; Warner et al., 2004).  
Jayalakshmi et al. (2005) have shown that neurons from rat hippocampus exposed to 
transient hypoxia, showed increased oxidative stress and decreased antioxidant 
enzyme defence system. The administration of N-acetyl cysteine (NAC) resulted in 
significant neuroprotection against oxidative stress induced by the hypoxia. Research 
is being directed towards identifying and characterizing proteins that maintain neuron 
survival in the normal brain, as well as those that, when altered by hypoxia and 
mutation, result in neuronal oxidative stress and even death (Shaul et al., 1993; 
Cavanaugh et al., 2005). Although many of these proteins are found specifically in 
neurons, some are located in other brain cells such as astrocytes, oligodendrocytes and 
cells within the cerebrovascular system (Halliwell and Gutteridge 1989; Silver and 
Erecinska, 1998). These proteins are potential targets for drugs that could be used to 
prevent or treat neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s 
disease, multiple sclerosis (MS) and stroke, which may lead to the design of novel 
drugs that are effective against neurological and neurotoxic disorders (Cavanaugh et 
al., 2005). 
 Mohanakumar et al. (2000) investigated the hydroxyl radical (-OH) scavenging action 
and neuroprotective effects of salicylate (SA) in mice treated with neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Their study showed that MPTP 
treatment resulted in in vivo generation of -OH and nigral neuronal insult as evidenced 
by dopamine depletion in nucleus caudatus putamen (NCP). They showed that MPTP 
caused a significant reduction in glutathione, an antioxidant that protects cells against 
toxins such as free radicals, in the substantia nigra (SN) and NCP. The administration 
of salicylate alone in mice did not affect total monoamine oxidase (MAO) activities in 
the mitochondrial fraction or the crude enzyme preparation from SN or NCP 
(Mohanakumar et al., 2000).   
Pre-treatment of the animals with SA, resulted in the dose-dependent production of 
dihydroxybenzoic acid (DHBA) in NCP, while the administration of SA before and 
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after MPTP treatment, blocked the neurotoxin-induced behavioural dysfunction, 
(glutathione and dopamine depletion) which indicates the neuroprotective action of 
SA (Mohanakumar et al., 2000). The results suggest that SA acts as a free radical 
scavenger in the brain and indicates its strength as a valuable neuroprotectant 
(Mohanakumar et al., 2000). Though the results from the study by Mohanakumar et 
al. (2000) showed that SA could act as a free radical scavenger and a potential 
neuroprotective agent, the study was conducted using a whole animal experiment 
which may not produce the same effect when these are studied in an isolated cellular 
or tissue system as in a culture model. This is due to the fact that the body could have 
put together different defensive systems to produce the observed effects, compared to 
that seen in a culture system composed of one cell type. 
Studies are continuously being conducted in collaboration with researchers within the 
clinical, neuroscience and neuroprotection research groups in universities and 
hospitals to identify and develop clinically useful neuroprotective agents. The work of 
life sciences companies such as the Neurobiological Technologies, Inc. (NTI®) are 
focused on the development of neuroprotective agents, some of which have been 
shown to protect nerve cells from injury in laboratory experiments and are pending 
their clinical evaluation and final approval. It has been shown that in multiple nervous 
system disorders, including neuropathic pain and AIDS-related dementia, over 
activation of the NMDA receptors on the membranes of neurons leads to neuronal 
injury, resulting in progressive neurological impairment (Cavanaugh et al., 2005). 
Thus, drugs that modulate or inhibit the activity of NMDA receptors restore 
progressive neuronal impairment and thereby improve neurologic symptoms such as 
chronic pain, motor difficulties, memory loss and other cognitive deficits. Such agents 
would, therefore, be a valuable treatment for a number of serious neurological 
disorders (Cavanaugh et al., 2005).  
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1.9.    Opioid receptor agonists 
The term opioid refers to any natural or synthetic drugs that have morphine-like 
activity. They are classified as natural, semi-synthetic and synthetic opioids. 
Examples of natural opioids are morphine, codeine noscopine; semi-synthetic are 
heroin, oxymorphone and hydromorphone; while the synthetic opioids are methadone, 
morphinians and benzamorphans (Piestrzeniewicz et al., 2006). 
 
Opioid receptors are found in the central nervous system and are classified as mu (µ), 
kappa (κ), delta (δ) and sigma (σ) opioid receptors. Opioid receptors are not uniformly 
distributed in the CNS and are found at areas concerned with pain receptors, with the 
highest concentration in the cerebral cortex, followed by the amygdala, septum, 
thalamus, hypothalamus, midbrain and spinal cord (Raynor et al., 1996; Chaturvedi et 
al., 2000). The mu receptor has been shown to be high in areas of pain perception and 
in the medulla, especially in the area for respiration (Reisine and Bell 1993; Reisine 
and Brownstein 1994; Massotte and Kieffer 1998; Hasbi et al., 2000).  
 
The opioid receptors (mu, delta, and kappa) belong to the large family of GPCRs and 
have diverse and important physiological roles (Piestrzeniewicz et al., 2006; Rhim 
and Miller 1994). Laugwitz et al.(1993) have shown that activated delta opioid 
receptors are coupled to Gi1 while activated mu opioid receptors are coupled to Gi3 in 
neuroblastoma cells (SH-SY5Y). Mu opioid receptors have been shown to be 
activated by mu receptor agonists and are coupled through the Gαi1 and GαoA in 
human embryonic kidney (HEK 239) cells (Saidak et al., 2006). Tso and Wong 
(2000), have shown that both mu and kappa opioid receptors are coupled via both Gi 
and Gz in HEK 239 cells. The opioid receptors are important targets for thousands of 
pharmacological agents (Hasbi et al., 2000; Wang et al., 2007). The stimulation of 
these receptors triggers analgesic effects and affects the function of the nervous 
system, gastrointestinal tract and other body systems (Piestrzeniewicz et al., 2006). 
The discovery of opioid peptides (including delta-selective enkephalins, kappa-
selective dynorphins, and mu-selective endomorphins), which are endogenous ligands 
of opioid receptors, initiated their structure-activity relationship studies (Fichna et al., 
2006). 
 
 57
Piestrzeniewicz et al. (2006), have shown that in the last 30 years, hundreds of 
analogs of opioid peptides have been synthesized in an effort to make the compounds 
more active, selective, and resistant to biodegradation than the endogenous ligands. 
Different unnatural amino acids, as well as cyclisation procedures, leading to 
conformationally restricted analogs, were employed. All these modifications resulted 
in obtaining very selective agonists and antagonists with high affinity at mu-, delta-, 
and kappa-opioid receptors, which are extremely useful tools in further studies on the 
pharmacology of opioid receptors in a mammalian organism (Piestrzeniewicz et al., 
2006; Xiong et al., 2007). GPCRs typically require activation or stimulation by 
agonists for their signalling activity to be initiated but Wang et al. (2007), have shown 
that some of the GPCRs display basal or spontaneous signalling activity in the 
absence of an agonist. This basal or spontaneous signalling activity is also called 
constitutive activity (Wang et al., 2007; Piiper and Zeuzem, 2004). 
 
As mentioned, opioids exert their biological activity through the activation by 
GPCRs, and their effects can be blocked by receptor antagonists. Opioid antagonists 
with different inverse agonist properties have different effects in precipitating 
withdrawal in acute morphine dependent mice, and constitutive opioid receptor 
activation is critically involved in acute opioid withdrawal (Freye and Levy, 2005; 
Wang et al., 2007; Xiong et al., 2007). It has been shown that the pharmacological 
properties and activities of the three opioid receptor classes are distinct and can be 
clearly differentiated (Raynor et al., 1996). Opioid receptors have high affinity for 
both agonists and antagonists as shown from Table 1.3. 
 
DAMGO and its antagonists do not bind to delta or kappa receptors, and morphine 
and its derivatives are much less potent at the delta or kappa receptors. All the three 
opioid receptors are sensitive to the antagonist naloxone (Raynor et al., 1996; Raynor 
et al., 1994; Wang et al., 2007). 
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Table 1.3. Some agonists and antagonists of opioid receptor subtypes  
Opioid receptor subtype Agonists  Antagonists 
Delta Deltorphin- 
Penicillamine-
2,Penicillamine-5-
enkephalin (DPDPE) 
[D-serine 2, O-Leu5]-
enkephalin-Thr (DSLET) 
TAN-67 
D-Ala2]-Deltorphin II 
Naltrindole 
ICI 174,864 
Dalargin 
SDM25N hydrochloride 
Naltriben mesylate   
ICI 154,129   
Benzylnaltrindole- 
hydrochloride 
Kappa U50,488 
[3H]U69,593 ([3H]U69) 
ICI 204,448 (ICI) 
ICI-199441hydrochloride 
U-54494A hydrochloride 
 BRL 52537- 
hydrochloride   
nor-binaltorphimine (nor-
BNI) 
7-benzylidenenaltrexone 
(BNTX) 
[3H]diprenorphine 
([3H]DIP) 
GNTI dihydrochloride   
Mu (D-Ala2-MePhe4, Gly-ol5) 
enkephalin (DAMGO) 
Morphine  
Loperamide-
hydrochloride   
Endomorphin-1 
Endomorphin-2 
 
D-Phe-Cys-Tyr-D-Trp-
Orn-Pen-Thr-NH2           
(CTOP) 
Naloxonazine 
Cyprodime hydrochloride 
H-D-Phe-Cys-Tyr-D-Trp-
Arg-Thr-Pen-Thr-NH2. 
(CTAP) 
 
 
 
1.9.1.   Uses of opioids 
Opioids have long been used to treat acute pain, such as post-operative pain (Raynor 
et al., 1994). They are commonly prescribed, and used, because of their effective 
analgesic properties. Studies have shown that properly managed medical use of opioid 
analgesic compounds is safe and rarely causes addiction. Taken exactly as prescribed, 
opioids can be used to manage pain effectively. They have also been found to be 
invaluable in palliative care to alleviate the severe, chronic and disabling pain of 
terminal conditions such as cancer and AIDS (Doyle et al., 2004). Contrary to popular 
belief, high doses are not required to control the pain of advanced or end-stage 
disease. In recent years there has been an increased use of opioids in the management 
of non-malignant chronic pain. This practice has grown from over 30 years 
experience in palliative care of long-term use of strong opioids, which has shown that 
dependence is rare when the drug is being used for pain relief (Doyle et al., 2004) 
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In addition to analgesia, clinical uses of opioids include: codeine and hydrocodone for 
cough, natural opioids for diarrhoea; oxymorphone for anxiety due to shortness of 
breath; and methadone and buprenorphine for heroin detoxification and maintenance 
programs during heroin replacement therapy (Eap et al., 1999; Eap et al., 2002). 
Despite the fact that opioids have been extensively reported to have psychological 
benefits, they are never officially prescribed to treat psychological illnesses, even in 
circumstances where researchers have reported opioids to be especially effective (e.g. 
in the treatment of senile dementia, geriatric depression, and psychological distress 
due to chemotherapy or terminal diagnosis) (Berridge, 2006). 
Doyle et al. (2004) have shown that opioids are used to treat pain of moderate or 
greater severity, irrespective of the underlying pathophysiological mechanism. 
Morphine has been used to treat breathlessness of which several mechanisms have 
been suggested for its action. Codeine and loperamide are the most widely used 
opioids for diarrhoea. Loperamide has the advantage of acting only on the gut, since 
very little is absorbed and topical morphine in an aqueous gel can be an effective 
agent for treatment of painful wounds. Their use is based on the discovery of 
activated opioid receptors in damaged tissue (Doyle et al., 2004). Opioid medications 
can affect regions of the brain, resulting in the initial euphoria that many opioids 
produce. They can also produce drowsiness, cause constipation, and, depending upon 
the amount taken, depress breathing. When taken as a large single dose, opioids could 
cause severe respiratory depression or death (Wang et al., 2007). 
 
1.9.2.   Opioid receptor activation 
Milligan (2004) has shown that the opioid receptors form homomeric as well as 
heteromeric receptor complexes. Opioid receptors are capable of forming a 
heterodimer with each other and certain non-opioid receptors, for example, mu with 
alpha2a-adrenoceptors (Devi, 2001). This heterodimerisation between opioid receptors 
has been shown to result in changes in the pharmacology of the receptors as well as 
changes in receptor coupling to second messengers and trafficking (Corbett, et al., 
2006). It has been shown that both mu and delta receptors internalise on exposure to 
agonists, whereas kappa receptors do not and when such dimers such as delta/kappa 
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dimers are formed, the trafficking properties of the kappa receptor predominates, 
while the heterodimer does not internalise on exposure to agonists of either receptors 
(Corbett et al., 2006; Koch & Hollt, 2007). Opioid receptor subtypes have been 
proposed largely on the basis of radioligand binding studies and as such there is little 
or no evidence for the presence of the different genes encoding these subtypes but in 
some cases, receptor heterodimerisation of opioid receptors has been proposed as a 
possible explanation (Corbett et al., 2006). 
 
All of the opioid receptors are GPCRs and couple to their cellular effectors primarily 
through Gi/Go proteins, and thus the majority of opioid responses are pertussis toxin-
sensitive (Milligan & Kostenis, 2006). Corbett et al. (2006), have shown that the 
different behaviours mediated by each of the receptor subtype in the intact animal 
such as euphoria for mu and dysphoria for kappa, result not from each type of 
receptor evoking different cellular responses but from the different anatomical 
distributions of each receptor (Corbett et al., 2006). Although the predominant action 
of opioids in the nervous system is inhibitory, in several brain regions such as 
periaqueductal grey (PAG) (important for supraspinal analgesia) or ventral tegmental 
area (VTA) (for euphoria/reward), opioids are excitatory (Corbett et al., 2006). It has 
been shown that opioid-induced excitations are due, not to a direct excitatory action of 
opioids, but to disinhibition (Corbett et al., 2006). The apparent excitation of a neuron 
by opioids is as a result of inhibition of the release of inhibitory neurotransmitters 
such as gamma amino butyric acid (GABA) from the interneurons into the cell 
(Corbett et al., 2006).   
 
Opioids have been shown to act via receptors interacting with heterotrimeric pertussis 
toxin (PTX) sensitive G proteins. The mu-selective agonist, DAMGO, and the delta-
selective agonist, [D-Pen2,D-Pen5]-enkephalin (DPDPE) stimulated  the incorporation 
of the photo-reactive GTP analogue into proteins co-migrating with the alpha subunits 
of Gi1, Gi2, Gi3, Go1, and Go2 in the membranes of neuroblastoma SH-SY5Y cells 
while in the membranes of PTX-treated cells, both agonists were ineffective, because 
mu and delta opioid receptors appear to discriminate between PTX-sensitive G 
proteins which lead to activation of distinct G protein subtypes (Laugwitz et al., 
1993). Subtype-specific immuno-precipitation of G protein alpha subunits photo-
labelled in the absence or presence of agonists revealed profound differences between 
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mu and delta opioid receptors in coupling to PTX-sensitive G proteins (Milligan, 
2004). 
 
Opioid inhibition of neuronal excitability resulting in the down-regulation of pain 
occurs largely by activation of potassium channels in the plasma membrane 
(Samways & Henderson, 2006). Opioid receptors are now known to activate a variety 
of potassium channels, including G-protein-activated inwardly rectifying (GIRK), 
calcium-activated inwardly rectifying, dendrotoxin-sensitive and M-type channels 
(Williams et al., 2001). Opioid receptors have been shown to inhibit high threshold 
voltage-activated calcium channels, like other members of the Gi/Go-coupled receptor 
family such as cannabinoid (CB1) receptors (Corbett et al., 2006). In some cell types, 
such as neuronal cells, opioid receptor activation can also cause an elevation of the 
free calcium concentration inside cells by releasing calcium from intracellular stores 
or by enhancing calcium entry by a dihydropyridine-sensitive mechanism (Samways 
& Henderson, 2006). It has been shown that the activation of opioid receptors, 
stimulates a variety of intracellular signalling mechanisms including activation of 
inwardly rectifying potassium channels, and inhibition of both voltage-operated N-
type Ca2+ channels and adenylyl cyclase activity (Samways & Henderson, 2006). It is 
now apparent that like many other Gi/Go-coupled receptors, opioid receptor activation 
can significantly elevate intracellular free Ca2+, although the mechanism underlying 
this phenomenon is not well understood (Samways & Henderson, 2006). In some 
cases opioid receptor activation alone appears to elevate intracellular Ca2+, but in 
many cases it requires concomitant activation of Gq-coupled receptors, which 
themselves stimulate Ca2+ release from intracellular stores via the inositol phosphate 
pathway (Samways & Henderson, 2006). 
 
Opioid receptors, like other Gi/Go-coupled receptors, inhibit adenylyl cyclase 
resulting in a fall in intracellular cAMP (Corbett et al., 2006). Williams et al., (2001), 
have shown that in primary afferent neurons, opioid receptors activate and regulate 
multiple second messenger pathways associated with effector coupling, receptor 
trafficking, nuclear signalling and modulates the activation of hyperpolarization-
activated cation channels. In opioid withdrawal, cAMP levels are elevated and 
enhanced protein kinase A (PKA) activity increases neurotransmitter release (Corbett 
et al., 2006). Opioid receptors, like many other GPCRs, cycle to and from the plasma 
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membrane from intracellular compartments (Corbett et al., 2006). This cycling is 
caused by agonist activation of the receptors which results in the cycling of the 
receptors to the plasma membrane in response to various stimuli (Williams et al., 
2001). The generally accepted mechanism underlying mu and delta receptor 
desensitization, is that agonist-activated receptors on the plasma membrane are 
phosphorylated by G-protein-coupled receptor kinases (GRKs), which facilitates 
arrestin binding and prevents the receptor from coupling to G-proteins (Bailey & 
Connor, 2005). Arrestin-bound receptors are rapidly concentrated in clathrin-coated 
pits and undergo dynamin-dependent internalisation into early endosomes (Corbett et 
al., 2006). Delta receptors are trafficked into lysosomes and are down-regulated, 
whereas mu receptors are trafficked into endosomes, where they are dephosphorylated 
and recycled back to the plasma membrane in a re-sensitised state (Corbett et al., 
2006). Thus, for mu receptor, internalisation can be considered to be involved in re-
sensitisation, but not in desensitisation and there is evidence that different C-terminus 
splice variants of the mu receptor re-sensitise at different rates while the kappa 
receptors do not appear to internalise in response to agonist activation (Corbett et al., 
2006). 
 
Chakrabarti et al. (1995), have suggested that different G-proteins can be activated 
with different potencies by mu receptor agonists in Chinese-hamster ovary cell 
membranes, which agrees with studies on delta- and kappa-opioid receptors, 
suggesting that commonly used agonists of these receptors can activate multiple G-
protein subtypes with similar potency (Burford et at., 2000). Carter and Medzihradsky 
(1993), have shown that mu-selective agonist, DAMGO inhibited cAMP formation in 
membranes of human neuroblastoma cells (SH-SY5Y), differentiated with retinoic 
acid. Antibodies to Gi alpha 1, 2 or Gi alpha 3 reduced the mu-opioid signal 
insignificantly and inhibition of adenylyl cyclase by the delta-opioid agonist (DPDPE) 
was very sensitive to the Gi alpha 1, 2 antibodies (Carter and Medzihradsky, 1993).  
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1.10.    Cannabinoids 
Cannabinoids are a group of terpenophenolic compounds present in Cannabis sativa 
L. and are made up of three types, namely natural or herbal cannabinoids, synthetic 
cannabinoids and endogenous cannabinoids (ElSohly and Slade, 2005). Cannabinoids 
were first characterised in the 1930s and 1940s as active ingredients of the cannabis 
plant (marijuana plant) from where the name was derived (Gardner, 2006). Some 68 
natural plant cannabinoids have been described to date with ∆9- tetrahydrocannabinol 
being shown as the main psychoactive component (ElSohly and Slade, 2005), and 
since the 1970s, many synthetic compounds have been developed by various 
laboratories to exert effects like those of the plant cannabinoids. These are the 
synthetic agonists and to block such effects are the antagonists (Gardner, 2006). 
 
Three main cannabinoids found in the cannabis plant are cannabidiol (CBD) (Baker et 
al., 1980; Lewis et a., 2005), ∆9-tetrahydrocannabinol (∆9-THC) (Gaoni and 
Mechoulam, 1964; Stefanidou et al., 1998), and cannabinol (CBN) (Gambaro et al., 
2002). The amount and relative abundances of these three main cannabinoids has 
been used to characterize cannabis and this also varies according to geographical 
origin (Hillig and Mahlberg, 2004). It was believed that ∆9-THC produced its effect 
by perturbing neuronal cell membranes due to its lipid-soluble, hydrophobic nature 
(ElSohly and Slade, 2005). However, the structural and steric selectivity of the actions 
of ∆9-THC and its synthetic analogues suggested the involvement of receptors (Begg 
et al., 2005) This was later demonstrated by studies that documented the existence of 
saturable, stereo-selective, high affinity membrane-binding sites for cannabinoids in 
the mammalian brain (Begg et al., 2005). 
 
In the 1990s, several chemicals in the body were identified as acting similarly and are 
called endocannabinoids or endogenous cannabinoids. Cannabinoid receptors are 
concentrated mainly in the cerebellum and the basal ganglia, the areas of the brain 
responsible for motor control which may help explain why marijuana eases muscle 
spasticity in disorders like multiple sclerosis, as well as in the hippocampus, which is 
responsible for storage of short-term memory, and the amygdala, which is part of the 
limbic system involved in emotional control, memory of fear, and memory of pain 
(Gardner, 2006; Begg et al., 2005). These receptors are now known as CB1 receptors 
and are predominant in the central nervous system (Matsuda et al., 1990; Soderstrom  
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and Johnson, 2000). 
 
A second cannabinoid receptor was initially detected in spleen cells, white blood 
cells, and other tissues associated with the immune system. This second receptor is 
called the CB2 receptor and is mainly present in the peripheral system (Munro et al.,  
1993). William Devane and colleagues were the first to identify the original  
endogenous cannabinoid called arachidonyl ethanolamine (AEA), which they named  
“anandamide” (Devane et al., 1992). The AEA, is a brain-derived lipid that binds to  
cannabinoid receptors and mimics the biological effects of ∆9-THC (Begg et al.,  
2005). Some years later, the second endocannabinoid was isolated from the intestinal  
tract and brain, called 2-arachidonoylglycerol (2-AG) (Sugiura et al., 1995).  
 
Subsequently, several other related lipids with endocannabinoid  properties have been  
identified however, these have been less extensively characterized (Begg et al., 2005). 
The biological effects of endogenous, plant-derived and synthetic cannabinoids are 
mediated through specific G protein coupled cannabinoid (CB) receptors. The CB1 
receptor is highly conserved in mice, rats and humans while the CB2 receptors are 
more divergent (Begg et al., 2005). Both CB1 and CB2 receptors are coupled through 
Gi/o proteins to inhibit adenylyl cyclase and regulate calcium (↓) and potassium (↑) 
channels (Begg et al., 2005; Mackie, 2006). In tissues naturally expressing CB 
receptors and in transfected cell lines, CB1 and CB2 receptors have been shown to 
have a high level of ligand-independent activation (Begg et al., 2005). It has been 
shown that in the population of wild-type CB1 receptors, only about 30% exists in the 
activated form while 70% are inactive (Kearn et al., 1999; Begg et al., 2005; Carter  
and Weydt, 2002). Some of the CB1 receptors exist in inactivated form within the 
cytosol and are in GDP-bound state while some exist in a tonically activated state, and 
are coupled to active G-proteins within the plasma membrane in their GTP-bound 
state (Vásquez and Lewis, 1999; Nie and Lewis, 2001). It has been shown that in their 
activated state, the receptors have a higher affinity for the cannabinoid agonists 
(Vásquez and Lewis, 1999; Nie and Lewis, 2001). Therefore, the cannabinoid 
receptors exist predominantly in two states: the activated and inactivated forms, of 
which they show differences in their affinities to their agonists and ligands (Kearn et 
al., 1999; Nie and Lewis, 2001). 
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The expression of the CB2 receptor is more restricted and is limited primarily to 
immune and haematopoietic cells (Munro et al., 1993). The human CB2 receptors 
show 68% amino acid homology with the CB1 receptor in the transmembrane 
domains and a  44% overall homology (Munro et al., 1993; Begg et al., 2005). 
However, despite the low level of homology between the two receptors, their 
pharmacology is similar, with most plant-derived, endogenous and classical synthetic 
cannabinoids having similar affinities for the two receptors (Showalter et al., 2005; 
Begg et al., 2005), although synthetic agonists with greater than 100-fold affinity for 
CB1 or CB2 receptors have been developed (Hillard et al., 1997; Malan et al., 2001). 
The CB1 receptors are highly conserved in mice, rats and humans while the CB2 
receptors are much more divergent. The amino acid homology of CB2 between mouse 
and rat is 93% while that between rat and human is only 81% (Munro et al., 1993; 
Griffin et al., 2000). Both CB1 and CB2 receptors are the primary targets of 
endogenous cannabinoids and they play important role in many processes, including 
metabolic regulation, craving, pain, anxiety, bone growth, and immune function 
(Mackie, 2006). It has been shown that various intracellular kinases, including the 
mitogen-activated protein kinases (MAPK), extracellular signal-regulated kinases 
type 1 and 2 (ERK 1&2), C-Jun N-terminal kinase (JNK), focal adhesion kinase and 
protein kinase B/Akt, are also activated by both CB1 and CB2 receptors (Derkinderen 
et al., 2001; Derkinderen et al., 2003; Bouaboula et al., 1999). 
 
There is also evidence of agonist selectivity for CB1 receptors coupled to different 
subtypes of Gi proteins or to Gi versus Gο proteins (Howlett, 2004 ). Cannabinoid- 
activated receptors distinct from CB1 or CB2 have been postulated to exist in the 
central nervous system (Begg et al., 2005). Cannabinoids are known to inhibit 
GABA-mediated inhibitory postsynaptic currents (IPSCs) in the hippocampus via a 
presynaptic action at CB1 receptors located on GABAergic terminals (Wilson et al., 
2001). CB1 receptors have also been implicated in the inhibition of glutamatergic 
excitatory postsynaptic currents. The synthetic cannabinoid, Win 55,212-2, a mixed 
CB1-CB2 cannabinoid receptor agonist, was found to attenuate hyperalgesia in a rat 
model of neuropathic pain, and suppress opioid-induced emesis in ferrets (Bridges et 
al., 2001; Simoneau et al., 2001). 
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1.10.1.      Therapeutic potential of cannabinoids 
Cannabis and its derivatives have a great therapeutic potential and have been used for 
centuries for medicinal purposes. However, cannabinoid-derived drugs on the market 
today lack specificity and produce many side effects, thus limiting their therapeutic 
usefulness (Pertwee, 2008). These side effects include euphoric mood changes, acute  
psychotic episodes, initiation and exacerbation of schizophrenic psychosis in  
predisposed persons, impaired cognitive and psychomotor performance, tachycardia  
and hypotension (Pertwee, 2008). The production of complex behavioural effects by  
cannabinoids are mediated by cannabinoid receptors (CB1 and CB2), and by  
interactions with other neurochemical systems (Adams and Martin, 1996; Carter and  
Weydt, 2002). 
 
It has been shown that the therapeutic and physiological effects of cannabinoids are  
dependent upon whether the administration is acute or chronic and on the route of  
administration (Halpin et al., 1998; Fride et al., 2004). The physiological effects of 
cannabis and its derivatives include: reduction in psychomotor coordination and  
performance, alterations in thermoregulation, endocrine and reproductive functions  
and gut motility (Martins et al., 2006; Fride et al., 2004 ; Jackson et al.,2004). The  
therapeutic uses of some cannabinoid agonists and antagonists are shown in Table 1.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67
Table 1.4 Therapeutic uses of cannabinoid agonists and antagonists 
Agonist Antagonist 
Dronabinol (Marinol), an analogue of ∆9-
THC as  anti-emetic agents in cancer 
therapy 
SR141716 (Rimonabant), a selective 
cannabinoid (CB1) receptor antagonist 
used as an anti-obesity drug  
Nabilone (Cesamet), a synthetic 
cannabinoid and an analogue of Marinol 
reduces pain, an appetite stimulant and 
increases general well being in AIDS 
SR141716 (Acomplia) is also used for the 
treatment of tobacco addiction 
Sativex, a cannabinoid extract oral spray 
containing both ∆9-THC and CBD, use 
for neuropathic pain and spasticity 
 
SR141716A attenuated ∆9-THC- or 
anandamide-induced memory impairment 
and attenuated the anandamide-induced 
impairment of performance. 
Cannabichromene (CBC), an anti-
inflammatory agent. 
 
Cannabidiol(CBD),a major anti-
convulsant, anti-spasmodic, anti-
asthmatic and anti-glaucoma agent 
 
Other effects of CB agonist include 
antinociceptive effects in animal models 
of acute inflammatory and neuropathic 
pain. 
 
  
The active ingredient of cannabis, ∆9-THC, and other cannabinoids and their  
derivatives are being used to treat a variety of disorders (Baker et al., 2003). Drugs  
which selectively activate CB1 and CB2 receptors which include dronabinol and  
nabilone (synthetic analogues of ∆9-THC) are used for the treatment of nausea and  
vomiting caused during cancer chemotherapy treatments (Martins et al., 2006). Many  
cannabinoids produce inhibition of pain responses and there is laboratory evidence to  
support the analgesic effect of cannabinoids (Martins et al., 2006; Martinez-Orgado et  
al., 2003). Other therapeutic uses of cannabinoid receptor agonists may include the  
suppression of some symptoms associated with multiple sclerosis, with spinal injury  
and with certain other movement disorders such as muscle spasticity and spasm, and  
the management of glaucoma, bronchial asthma, pain and inflammatory disorders  
(Halpin, 1998; Adams and Martin, 1996; Martins et al., 2006;Garcia-Arencibia et al.,  
2007).  
 
The CB1 receptor antagonist, SR141716A (rimonabant; Acomplia®), may have  
therapeutic potential in reducing memory deficits associated with ageing or  
neurological diseases (Pertwee,1997; Halpin, 1998). There is evidence that  
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cannabinoids are effective in relieving spasticity, tremor and pain caused by multiple  
sclerosis or spinal injury ( Croxford, 2003; Pertwee, 2005; Pertwee, 2008). Animal  
experiments have shown that cannabinoid receptor agonists suppress spinal reflexes,  
produce marked behavioural changes in motor function, for example hypokinesia and  
catalepsy, and have significant efficacy in standard tests of antinociception (Halpin et  
al.,1998; Martins et al., 2006). In a clinical trial in healthy volunteers, using 2%, 4%,  
and 8% ∆9-THC by weight on pain induced by capsaicin injected 5 and 45 mins after  
drug exposure, pain and hyperalgesic effects were assessed. The results show that by  
45 mins after cannabinoid exposure, there was a significant decrease in capsaicin- 
induced pain with the medium dose and a significant increase in capsaicin-induced  
pain with the high dose (Wallace et al., 2007). 
 
The effects on motor function are mediated by large populations of cannabinoid CB1  
receptors that are present in the basal ganglia of the brain, but whether they produce 
their putative antispasticity effect by acting at these brain sites remain to be  
established (Halpin et al., 1998; Neitzel and Hepler, 2006 ). Experiments have shown  
that ∆9-THC can delay the onset and reduce the intensity of the clinical signs of  
experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.  
It has also been shown that the synthetic cannabinoid receptor agonist, Win55212-2, 
can decrease the severity of dystonia in mutant Syrian hamsters with primary  
generalized dystonia (Herzberg et al., 1997). These indicate that cannabis, ∆9-THC or  
nabilone can reduce the intensity of some signs and symptoms of multiple sclerosis or  
spinal injury, particularly spasticity, pain, tremor and nocturia (Baker et al., 2003).  
There is substantial evidence to suggest that various cannabinoids possess analgesic  
properties, but most of this evidence is based on experiments in laboratory animals.  
Results of studies which have employed clinically relevant models of inflammatory or  
neuropathic pain are now appearing and generally support the concept of  
cannabinoid-induced analgesia (Herzberg et al., 1997; Martins et al., 2006; Gilbert et  
al., 2007; Jackson et al., 2004). 
 
Cannabinoids can alleviate tremor and spasticity in animal models of multiple 
sclerosis and clinical trials of the use of these compounds for these and other  
symptoms are continuously in progress (Croxford, 2003; Felder et al., 2006;  
Makriyannis, 2007). Anecdotal evidence has shown that patients with disorders such  
 69
as multiple sclerosis smoke cannabis to relieve disease-related symptoms and pains  
(Croxford, 2003; Diaz-Laviada and Ruiz-Llorente, 2005). Evidence has also shown 
that cannabinoids may prove useful in Parkinson’s disease by inhibiting the  
excitotoxic neurotransmitter, glutamate, and counteracting oxidative damage to  
dopaminergic neurons (Halpin et al., 1998; Russo and McPartland, 2003). The  
inhibitory effect of cannabinoids on reactive oxygen species, glutamate and tumour  
necrosis factor suggests that they may be potent neuroprotective agents (Croxford,  
2003; Croxford and Miller, 2003). Dexanabinol (HU-211), a synthetic cannabinoid is  
currently being assessed in clinical trials for traumatic brain injury and stroke  
(Croxford, 2003).  
 
Animal models of mechanical, thermal and noxious pain suggest that cannabinoids 
may be effective analgesics (Croxford, 2003; Dikic et al., 2003 ; Docagne et al., 
2007). Cannabinoids have proved more effective than the placebo in clinical trials of   
post operative and cancer pain and pain associated with spinal cord injury. However, 
they may be less effective than existing therapies (Russo, 2001; Docagne et al., 2007). 
Dronabinol, a commercially available form of  ∆9-THC, has been used successfully 
for increasing appetite in patients with HIV wasting disease and cannabinoid receptor 
antagonists may reduce obesity (Russo and McPartland, 2003). Acute adverse effects 
following cannabis usage include sedation and anxiety. These effects are transient and 
may be less severe than those that occur with existing therapeutic agents (Russo, 
2003). Russo (2001), have shown that the use of nonpsychoactive cannabinoids such 
as cannabidiol and dexanabinol may allow the dissociation of unwanted psychoactive 
effects from potential therapeutic benefits. Rog et al. (2007) and Nurmikko et al. 
(2007) have demonstrated the analgesic property and efficacy of Sativex, an oro- 
mucosal ∆9-THC/CBD endocannabinoid modulator compound against neuropathic 
pain caused by multiple sclerosis in humans. 
 
The existence of additional cannabinoid receptors may provide novel therapeutic 
targets that are independent of CB1 receptors, and the development of compounds that  
are not associated with CB1 receptor-mediated adverse effects (Russo, 2001). In a  
study to investigate the therapeutic benefits and adverse effects of prolonged use of  
medical marijuana in a cohort of chronically ill patients, the result demonstrated  
clinical effectiveness in these patients in treating glaucoma, chronic musculoskeletal  
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pain, spasm and nausea, and spasticity of multiple sclerosis (Russo, 2001; Russo,  
2003). There has been substantial evidence from experiments with animals, healthy  
human subjects and patients with primary open-angle glaucoma that cannabinoids can  
lower intra-ocular pressure (Green, 1998; Halpin et al., 1998 ; Russo, 2003).  
 
Cannabinoids have shown great promise for the treatment of early phase response of 
asthma (Halpin et al., 1998). This is because they can significantly dilate the  
bronchioles of both healthy and asthmatic subjects and seem to be no less effective 
than conventional drug treatment of asthma (Hollister, 1986; BMA, 1997; Halpin et 
al., 1998). It has been shown that both cannabis and individual cannabinoids are 
active when taken orally or when inhaled, either in smoke or in an aerosol produced 
by a nebulizer inhaler (Hollister, 1986; BMA, 1997). The mechanism behind the  
bronchodilator effect of cannabinoids remains to be established. However, only 
cannabinoids with psychotropic properties have been found to produce  
bronchodilation, indicating that the effect may be mediated through cannabinoid CB1 
receptors. 
 
Cannabis and cannabinoids, like all other drugs, have unwanted effects, as reported by  
Pertwee (1997), in a clinical study with 34 cancer patients, and  include dizziness,  
sedation and dry mouth, blurred vision, mental clouding, ataxia, disorientation,  
disconnected thought, slurred speech, muscle twitching and impaired memory.  
Cannabis on its own may sometimes induce transient confusion, panic attacks,  
depersonalization, paranoid delusions and hallucinations (Chaudry et al., 1991) and  
has been reported to produce a subtle impairment of postural control (Pertwee, 1997).  
Cannabis may aggravate existing psychoses and can elevate heart rate; hence it would  
be unwise to give psychotropic cannabinoids to patients with schizophrenia, coronary  
arteriosclerosis or congestive heart failure (Hollister, 1986; Pertwee, 1997).  
The list of some known cannabinoid agonists and antagonists used in experimental 
studies is shown in Table 1.5. 
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Table 1.5. List of some known cannabinoid agonists and antagonists used in 
experimental studies. 
 
Type Agonist  Antagonist 
Win 55,212 mesylate 
CP 55940  
HU-210 
SR141716A 
AM 281 
AM 251 
∆9-tetrahydrocannabinol (∆9-
THC) 
8- tetrahydrocannabinol 
( 8-THC) 
Cannabinol (CB) 
Leelamine hydrochloride  
Tetrahydrocannabivarin 
(THCV) 
LY 320135  
 
CB1 
Arachidonoylethanolamide  
(Anandamide or AEA) 
2-arachidonylglycerol (2-AG) 
arachidonyl-2-
chloroethylamide (ACEA) 
methanandamide 
Arachidonylcyclopropylamide 
(ACPA) 
 
 
 
 
 
 
Cannabidiol (CBD) 
CB2 AM-1241 SR144528 
 JWH-015 
JWH-133 
AM 630 
 CB 65  
L-759,633 
JTE 907  
 
 
 
1.10.2.  Neuroprotection by cannabinoids 
Cannabinoids have been shown to provide neuroprotection in acute and chronic  
neurodegeneration (Lastres-Becker et al., 2004; Jentsch et al., 1998). In a study to  
examine the effect of cannabinoids against the toxicity caused by 6-hydoxydopamine  
both in vivo and in vitro, it was found that the non-selective cannabinoid agonist  
HU-210 increased cell survival in cultures of mouse cerebellar granule cells exposed  
to the toxin. However, the effect was significantly less when cannabinoids were  
directly added to neuronal cultures than when these cultures were exposed to  
conditioned medium obtained from mixed glial cell cultures treated with HU-210,  
suggesting that the cannabinoid exerted its major protective role by regulating glial  
influence to neurons (Lastres-Becker et al., 2004; Pryce et al., 2003 ; Drysdale et al.,  
2006).  
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Cannabinoids may also be neuroprotectant in Parkinson’s disease (PD), a motor  
neurodegenerative disorder characterised by progressive death of nigrostriatal  
dopaminergic neurons that mainly results in bradykinesia or slowness of movement,  
rigidity, and tremor as major motor abnormality (Sethi, 2002; Lastres-Becker et al.,  
2005). In an experiment to investigate if cannabinoids might provide neuroprotection  
in PD, Lastres-Becker et al.(2005), conducted two sets of experiments to demonstrate 
that cannabinoids are effective against the in vivo and in vitro toxicity of 6- 
hydroxydopamine, a toxin currently used to generate Parkinsonism in laboratory 
animals. In the first experiments, Lastres-Becker et al. (2005), examined the ability of 
∆9-THC and cannabidiol (CBD), to alter in vivo the progress of neurodegeneration in 
rats subjected to unilateral injections of 6-hydroxydopamine into the medial forebrain 
bundle. In the second experiments, Lastres-Becker et al. (2005), evaluated whether  
the termination of ∆9-THC administration to 6-hydroxdopamine-lesioned rats after 2 
weeks would result in re-initiation of the process of neuronal injury during two 
subsequent weeks. This experiment also examined whether the potential effects of ∆9- 
THC against in vivo toxicity of 6-hydroxydopamine are mainly neuroprotective 
because they do not disappear after discontinuation of cannabinoid treatment. The 
results from the studies by Lastres-Becker et al. (2005), showed that the daily 
administration of ∆9-THC for 2 weeks produced a significant increase in dopamine 
content and tyrosine hydroxylase activity in the lesioned striatum and these were 
accompanied by an increase in tyrosine hydroxylase-mRNA levels in the substantia 
nigra. This suggests a potential neuroprotective action of cannabinoids against the in 
vivo and in vitro toxicity caused by 6-hydroxydopamine, which might be relevant in 
Parkinson’s disease. 
 
Cannabinoids have been shown to protect against neurotoxicity in a number of  
different cellular, animal and human experimental models (Davies et al., 2002; Fride  
and Shohami, 2002; Mechoulam et al., 2002; Pryce et al., 2003; Zhuang et al., 2005).  
Zhuang, et al.(1999) had earlier demonstrated that cultured rat hippocampal neurons  
were protected from excitotoxic insults by pre-treatment with either ∆9-THC or Win  
55,212-2, and that these compounds were effective in preventing cell death even if  
administered prior to the neurotoxin exposure. Cannabinoids have been demonstrated  
to be protective in vivo with respect to neurodegeneration resulting from experimental  
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ischaemia (Zhuang et al., 2005; Molina-Holgado et al., 2005). Leker et al.(2003) have  
shown that in vivo administration of CB1 agonist HU-210, was able to significantly  
reduce motor disability and infarct volume after focal irreversible cerebral ischaemia.  
The mechanisms involved in the neuroprotective properties of cannabinoid have not  
yet been fully characterised (Mechoulam et al.,2002; Baker et al., 2003; Zhuang et al.,  
2005). 
 
Zhuang et al. (2001) have shown that cannabinoid receptor-mediated 
 neuroprotection is sensitive to intracellular calcium levels. In their work, Zhuang et  
al. (2002), presented a detailed analysis of how cannabinoids act to reduce or block  
release of intracellular calcium [Ca2+]i under neurotoxic conditions. They  
demonstrated that such neuroprotection is based on cannabinoid CB1 receptor- 
mediated decreases in cAMP-dependent protein kinase (PKA), an effect that alters the  
sensitivity of particular intracellular calcium channels. Several possible alternative  
signalling pathways were also investigated and systematically ruled out on the basis  
that they did not block the NMDA provoked increase in [Ca2+]i in the same manner as  
CB1 receptor activation (Ryan et al., 2007). It has been shown that there is a similar  
time course for the protective effect on cultured neurons, the blockade of intracellular  
calcium release and the inhibition of  PKA (Zhuang et al., 2005). Common factors  
underlying these changes  are the alteration in sensitivity of type-II ryanodine receptor  
(RyR)-coupled intracellular calcium channels and the decrease in cAMP due to  
cannabinoid inhibition of adenylyl cyclase, as originally demonstrated by Howlett et  
al. (1990).  
 
Most of these protectant effects appear to be mediated by activation of the 
cannabinoid CB1 receptor subtype (Parmentier-Batteur et al., 2002), although 
additional mechanisms may be involved (Lastres-Becker et al., 2005). It has been 
shown that the same neuroprotective effect is also produced by cannabidiol (CBD), 
another plant-derived cannabinoid, with negligible affinity for cannabinoid CB1 
receptors (Pertwee, 1999; Ryan et al., 2006), suggesting that antioxidant properties 
of both compounds might be involved in these in vivo effects. However, an alternative 
explanation might be that, the neuroprotection exerted by both compounds is due to 
their anti-inflammatory potential (Lastres-Becker et al., 2005; Jentsch et al., 1998; 
Jackson et al., 2004). 
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Cannabinoids’ anti-inflammatory properties are likely related to their ability to 
modulate glial influence on neurons (Walter and Stella, 2004; Lastres-Becker et al., 
2005; Marchalant et al., 2007). These anti-inflammatory properties might be 
important in Parkinson’s disease (PD) since nigral cell death is accompanied by 
astrocyte proliferation and reactive microgliosis at the sites of neurodegeneration. 
Microglial activation may play important role in the initiation and early progression of 
the neurodegenerative process especially in regions which are particularly rich in 
microglia and other glial cells (Gao et al., 2002; Lastres-Becker et al., 2005; Louw et 
al., 2000). 
  
It is shown that activated microglia produce a wide array of cytotoxic factors, 
including tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), eicosanoids, 
nitric oxide and reactive oxygen species that impact on neurons to induce 
neurodegeneration and that some of them have been reported to be increased in the 
substantia nigra and the caudate-putamen of  PD patients (Gao et al., 2002).    
 
1.11.3. The role of cannabinoids in neuroinflammation 
Inflammation is a complex biological response and active defence reaction of tissues 
against harmful stimuli and insults (Walter and Stella, 2004). Inflammation is 
designed to remove or inactivate noxious agents and to inhibit their detrimental 
effects (Walter and Stella, 2004). It has been shown that inflammation, even though it 
serves a protective function in controlling infections and promoting tissue repair, can 
also cause tissue damage and disease (Walter and Stella, 2004; Lu et al., 2005). There 
is growing evidence that a major physiological function of cannabinoid signalling is 
to modulate neuroinflammation. The anti-inflammatory properties of cannabinoids 
have been studied at the molecular, cellular and whole animal levels, by examining 
the evidence for anti-inflammatory effects of cannabinoids obtained using in vivo 
animal models of clinical neuroinflammatory conditions, especially rodent models of 
multiple sclerosis (Walter and Stella, 2004; Jackson et al., 2004; Marchalant et al., 
2007).  
 
CNS inflammations occur in myelin degenerative disorders such as multiple sclerosis 
(MS), Alzheimer’s disease, HIV encephalopathy, ischaemia and traumatic brain 
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injury (Martino et al., 2002). Experimental autoimmune encephalopathy (EAE) has 
been shown to be a widely used animal model to study MS owing to histological 
similarities (Zamvil and Steinman, 1990). The EAE is initiated and maintained as a 
result of T lymphocytes becoming sensitized to myelin proteins and eliciting a cell-
mediated immune response. The pathological changes involve demyelination and a 
progression of inflammation in the CNS (Walter and Stella, 2004). Cannabinoid 
administration has been shown to influence the course of the disease progression on 
several studies performed on various rodent models of MS (Matsuda et al., 1990; 
Matsuda, 1997; Munro et al., 1993). In animals administered with ∆9-THC prior to 
inoculation with lymphocytes from CNS of animals with  acute EAE, full clinical 
development of EAE was prevented, suggesting that that ∆9-THC suppressed the 
immune system (Lyman et al., 1989). In animals given ∆9-THC after inoculation with 
the lymphocytes, onset of symptoms was delayed and clinical index was lowered, 
while histological examination of spinal cords showed significantly less inflammation 
in ∆9-THC treated animals (Lyman et al., 1989). 
 
Wirguin et al. (1994), administered delta-8-tetrahydrocannabinol (∆8-THC), a minor 
form of THC, daily to rats with EAE beginning several days prior to symptoms onset. 
The ∆8-THC treated animals had a delayed symptom onset, lowered incidence of EAE 
and a shorter mean duration of EAE but not a lower mean severity. In mice with EAE, 
a synthetic cannabinoid receptor agonist (Win 55212-2), THC, methanadamide, and 
selective CB2 receptor agonist (JWH-133), but not cannabidiol, relieved the spasticity 
and tremor symptoms within 1 to 10 minutes (Baker et al., 2000). The effects of Win 
55212-2 were reversed by treatment with the selective cannabinoid receptor 
antagonists SR141716A (CB1) and SR144528 (CB2) and these two compounds 
administered alone worsened symptoms (Baker et al., 2000). Since the CB2 receptor 
agonist and a CB2 receptor antagonist influenced these symptoms, these results point 
towards an anti-inflammatory effect mediated via CB2 receptors, which are expressed 
mainly on immune cells (Walter and Stella, 2004).  
 
The effects of cannabinoid compounds over several weeks were studied on a model of 
human multiple sclerosis (MS) in which the cannabinoid agonists Win 55212-2, 
arachidonyl-2-chloroethylamide (ACEA), and  a CB2 selective agonist JWH-015 were 
administered daily for 10 days following Theiler’s murine encephalomyelitis virus 
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(TMEV) infection of the CNS. This induces an immune-mediated demyelinating 
disease in susceptible mouse strains, but prior to symptoms (Walter and Stella, 2004). 
These drugs improved motor function, decreased the number of activated microglia in 
the spinal cord, decreased major histocompactibility complex class II (MHC II) 
expression, decreased the number of CD4 T cells in spinal cord, and promoted spinal 
cord remyelination (Arevalo-Martin et al., 2003; Walter and Stella, 2004). Also, Win 
55212-2 was administered daily for 5 days to mice with TMEV either prior to 
symptoms, at onset of symptoms, or several days after symptom onset (Croxford and 
Miller, 2003). The results showed that clinical disease symptoms are decreased under 
all these conditions, while Win 55212-2 increased the susceptibility of mice to TMEV 
infection, suggesting an immunosuppressive effect, although it had no effect on 
splenic cell populations (Croxford and Miller, 2003). Win 55212-2 also decreased 
CNS mRNA encoding for proinflamatory cytokine tumour necrosis factor α (TNFα), 
interleukin (IL)-1β, and IL-6 in these mice (Croxford and Miller, 2003; Walter and 
Stella, 2004; Lu et al., 2000). However, in EAE animals there was increased CB1 
receptor activity in the cerebral cortex and caudate-putamen, suggesting that the 
remaining receptors in these areas may be efficiently coupled to G protein-mediated 
signalling mechanisms (Berrendero et al., 2001; Walter and Stella 2004).These results 
show that cannabinoid agonists ameliorate symptoms both acutely and over several 
weeks in EAE and TMEV models of MS, and the CB1 receptor expression and 
function change in EAE, while the absence of CB1 receptors worsens symptoms of 
EAE (Simonds, 2003). Although these studies provide insights into the effects of 
cannabinoids on neuroinflammation, the mechanism of action of these drugs is still 
incomplete due to differences in the compounds, animal models of MS, rodent 
species, routes of drug administration, and dosing schedules used (Walter and Stella, 
2004). 
 
Microglia have been shown to regulate the initiation and progression of immune 
responses in the CNS (Carson and Sutcliffe, 1999; Walter and Stella, 2004). Primary 
cultures of rat and mouse microglia express both CB1 and CB2 receptor mRNA and 
protein (Walter et al., 2003). Human microglia express both CB1 and CB2 receptor 
mRNA, while primary mouse microglia express CB2 receptors at the leading edges of 
lamellipodia and micro spikes, suggesting a function in motility (Walter et al., 2003; 
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Walter and Stella, 2004). The proinflamatory cytokine interferon-gamma (IFN-γ), 
which is produced by T-helper (TH) 1 cells and natural killer (NK) cells in MS and  
EAE, increases CB2 receptor mRNA and protein in rat microglia (Carlisle et al., 
2002).  
 
Astrocytes are the main non-neuronal supporting glial cells in the brain which help to 
regulate aspects of inflammation in the CNS and may be involved in the pathogenesis 
of MS. While some evidence of CB1 receptor expression by astrocytes has been 
found, it has not been found by all workers (Salio et al., 2002; Walter and Stella, 
2004). These conflicting results may indicate variations in CB1 receptor expression 
due to differences in species, culture systems, CNS structures from which cultures are 
derived, ages of cultures, or activation levels of cells, while CB2 receptor expression 
by astrocytes has not been found (Walter and Stella 2003; Walter and Stella, 2004). 
Oligodendrocytes, which undergo degeneration during MS and EAE, also express 
CB1 and CB2 receptors (Walter and Stella, 2004). Some of the major types of glial 
cells expressing cannabinoid receptors may account for some of the anti-inflammatory 
effects by cannabinoids in rodent models of MS (Walter and Stella, 2004). It is known 
that cannabinoid receptor expression is modulated by cytokines in microglial cells but 
it is not known if cannabinoid receptor expression is modulated in astrocytes or 
oligodendrocytes (Carlisle et al., 2002; Walter and Stella, 2004).  
 
Neuroinflammation induces a complex and dynamic change in glial cell phenotypes. 
Microglial cells are one of the first cell types to respond by retracting their processes 
and migrating towards the site of injury where they release proinflamatory cytokines 
such as IL-1β, TNFα, and IL-6 (Becher et al., 2000). In primary cultures of mouse 
microglia, 2-AG induces cell migration and this is reversed by the selective CB2 
antagonist SR144528, cannabinol, and cannabidiol (Walter et al., 2003). This suggests 
that under neuroinflammatory conditions, neurons or astrocytes produce  
endocannabinoids as a means of recruiting microglia (Walter et al., 2003; Walter and  
Stella, 2003). 
 
Nitric oxide (NO) production by glial cells is also associated with immune-mediated 
cellular cytotoxicity and pathogenesis of MS and EAE (Parkinson et al., 1997). The  
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cannabinoid agonist CP55940 inhibits NO production in IFN-γ- and 
lipopolysaccharide (LPS)-stimulated rat microglia (Waksman et al., 1999; Cabral et 
al., 2001). Primary cultures of rat microglia, when activated by LPS, release TNFα, 
which is inhibited by cannabinoid agonists: anandamide, 2-AG, Win 55212-2, 
CP55940, and HU210. However, the antagonists SR141716A, AM251, and 
SR144528 do not alter the effects of Win 5212-2 on the microglia, suggesting a non 
CB1/2-mediated effects (Facchinetti et al., 2003). ∆9-THC reduces IL-1β, IL-6, and 
TNFα production in LPS-stimulated rat microglia (Puffenbarger et al., 2000). The 
selective CB2 agonist JWH-015 treatment reduces toxicity of human microglia 
towards neurons (Klegeris et al., 2003). When these results are compared, they 
showed that cannabinoid decrease neurotoxicity and release of proinflamatory 
cytokines from microglia. However it is not known whether these effects are mediated 
through cannabinoid receptors or other mechanisms (Facchinetti et al., 2003; Klegeris 
et al., 2003). 
 
Cannabinoids may suppress the immune response and hence the inflammatory 
response by modulating proliferation or inducing apoptosis in lymphocytes (Malfait et 
al., 2000). An increase in the number of lymphocytes is crucial for an inflammatory 
response to occur. The ∆9-THC induces apoptosis in macrophages (Zhu et al, 1998). 
Cannabidiol causes a dose-dependent suppression of lymphocyte proliferation 
(Malfait et al., 2000). ∆8-THC, CP55940 and anandamide also suppress T- and B- cell 
proliferation (Schwarz et al., 1994), while CP55940 enhances proliferation of B cells 
an effect blocked by the antagonist SR144528 (Carayon et al.,1998; Walter and Stella, 
2004). Also ∆9-THC inhibits nitric oxide (NO) production in LPS/IFN-γ-stimulated 
mouse macrophages and in LPS-stimulated RAW 264.7 macrophages (Coffey et al., 
1996; Jeon et al., 1996). Win inhibits the LPS-induced release of NO in macrophages, 
an effect blocked by the antagonist SR144528 (Ross et al., 2000). The agonist 
CP55940, reduces NO production from IFN-γ/LPS-stimulated feline macrophages 
and this is reversed by antagonists SR141716A in CB1 receptors and SR144528 in 
CB2 receptors in both macrophages and primary dorsal root ganglion cells (Ponti et 
al., 2001; Ross et al., 2000). Plant and synthetic cannabinoids inhibit NO production 
from immune cells, while the endogenous cannabinoids induce it (Walter and Stella, 
2004). Anandamide increases NO production in human monocytes and macrophages 
(Stefano et al., 1998).  
 79
 
Anandamide stimulates arachidonic acid (AA) release in monocytes and J774 mouse 
macrophages, an effect blocked by pertussis toxin, an inhibitor of Gi/o proteins 
(Berdyshev et al., 1997; Di Marzo et al., 1997). Anandamide also induces AA release 
in cells that do not express CB1 or CB2 receptors (Felder et al., 1996; Felder and 
Glass, 1998). ∆9-THC induces AA release in RAW 264.7 mouse macrophages and 
this is likely to be mediated by the CB2 receptor (Hunter & Burstein, 1997; Felder et 
al., 2006). The effects of cannabinoids on AA release indicate a proinflamatory 
influence on peripheral immune cells. It has been shown that cells and tissues 
involved in neuroinflammation produce and degrade endocannabinoids and 
anandamide and 2-AG levels are differentially regulated in cells (Walter and Stella, 
2004).  
 
1.11.   Interaction of opioids and cannabinoids 
Opioids and cannabinoids are among the most widely consumed drugs of abuse in the 
world (Manzanares et al., 1999; Smart and Ogborne, 2000). Both drugs have been 
shown to share some pharmacological properties including antinociception, 
hypothermia, sedation, hypotension, inhibition of both intestinal motility and 
locomotor activity (Manzanares et al., 1999). It has been reported that there is a cross-
tolerance or mutual potentiation of these pharmacological effects. These phenomena 
have supported the possible existence of functional linkage in the mechanisms of 
action of both drugs especially in antinociception and drug addiction (Manzanares et 
al., 1999; Manzanares et al., 2005).  
The cannabinoid and opioid compounds mimic endogenous ligands and act through 
the GPCRs, cannabinoid and opioid receptors (Felder and Glass, 1998; Kieffer, 1995). 
It has been shown that chronic administration of ∆9-THC increases opioid gene 
expression while, acute administration of ∆9-THC increases extracellular levels of 
endogenous enkephalins in the nucleus accumbens of mice (Corchero et al., 1997; 
Valverde et al., 2001). Some studies have also demonstrated the existence of cross-
tolerance between opioid and cannabinoid agonists and such, morphine-tolerant 
animals show decreased ∆9-THC antinociceptive responses, whereas ∆9-THC-tolerant 
rodents show a decrease in morphine antinociception (Thorat and Bhargava, 1994; 
Ghozland et al., 2002). There is cross-dependence between opioid and cannabinoid 
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compounds and opioid antagonist naloxone precipitated a withdrawal syndrome in ∆9-
THC-tolerant rats, whereas cannabinoid antagonist SR171416A was able to 
precipitate abstinence in morphine-dependent rats (Navarro et al., 1998; Ghozland et 
al., 2002). The severity of opioid withdrawal was reduced by the administration of ∆9-
THC or anandamide (Vela et al., 1995; Valverde et al., 2001). This bidirectional cross-
dependence was confirmed by using knock-out mice and opioid dependence was 
reduced in mice lacking the CB1 receptor whereas, cannabinoid dependence was 
reduced in mice lacking the preproenkephalin gene (Ledent et al., 1999; Valverde et 
al., 2000).  
Cannabinoids produce their rewarding effects by stimulating mesolimbic 
dopaminergic transmission which has been shown to be a common substrate for the 
rewarding effects of other substances of abuse (Tanda et al., 1997). The activation of 
mu-opioid receptors could be involved in the bidirectional interaction between the 
endogenous cannabinoid and opioid systems in reward that extends to central 
mechanisms underlying relapsing phenomena (Fattore et al., 2004). This is because 
the endogenous cannabinoid system participates in the rewarding effects of opioids 
(Ghozland et al., 2002), and both morphine self-administration and place preference 
are decreased in mice lacking the CB1 receptors (Ledent et al., 1999; Martin et al., 
2000). The possible involvement of the endogenous opioid system in the different 
motivational responses induced by cannabinoids is not yet well understood, however, 
GABAergic and corticotrophin-releasing factor systems, have been suggested to be 
involved in the anxiogenic responses induced by cannabinoids and these anxiogenic 
behaviours could have some influence in the dysphoric effects of cannabinoids 
(Rodriguez de Fonseca et al., 1996; Ghozland et al., 2002) 
Ghozland et al. (2002), have shown that the disruption of mu-, delta-, or kappa-opioid 
receptor gene does not modify acute ∆9-THC responses while the expression of ∆9-
THC withdrawal, and the development of ∆9-THC tolerance is only slightly altered in 
kappa opioid receptor (KOR) knockout mice. Both mu- and kappa-opioid ligands 
have been reported to modulate cannabinoid antinociception (Manzanares et al., 
1999). The ∆9-THC antinociception was blocked in mice by the kappa-selective 
opioid antagonist norbinaltorphimine, and by high doses of the non-selective opioid 
antagonist naloxone (Smith et al., 1998; Ghozland et al., 2002). The synergistic effects 
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of morphine and ∆9-THC on antinociception were also blocked by 
norbinaltorphimine, a mu selective antagonist (Reche et al., 1996) and high doses of 
opioid antagonists are usually required to block ∆9-THC antinociception (Manzanares 
et al., 1999). Laboratory reports have shown that kappa receptors could contribute to 
the development of adaptive responses to chronic ∆9-THC administration, in 
agreement with the demonstration of cross-tolerance between ∆9-THC and kappa-
opioid agonists (Smith et al., 1994).  
A non-selective opioid antagonist naloxone, precipitates an opioid-like withdrawal 
syndrome in cannabinoid-dependent rodents while, the CB1 cannabinoid receptor 
antagonist SR 141716A, induces withdrawal in morphine-dependent rats (Navarro et 
al., 1998). This suggests that simultaneous activation of the two endogenous systems 
could participate in both opioid and cannabinoid dependence (Ghozland et al., 2002; 
Manzanares et al., 2005). Pre-treatment with ∆9-THC and anandamide, have been 
shown to decrease morphine withdrawal (Valverde et al., 2001), and the morphine-
induced rewarding effects were suppressed in mice deficient in CB1 cannabinoid 
receptors, suggesting a bidirectional influence of µ-opioid and CB1 receptors on 
reward processes (Ledent et al., 1999; Ghozland et al., 2002). 
Ghozland et al. (2002), have proposed that the opposing µ-opioid and κ-opioid 
receptor activities mediate the dual euphoric-dysphoric effects of ∆9-THC and a 
possible mechanism for this could be that cannabinoid receptor activation modifies 
endogenous opioid peptide levels in mesolimbic areas, that would in turn, modulate 
dopaminergic activity (Viganò et al., 2005a). The release of opioid peptides by 
cannabinoids or endocannabinoids by opioids and their interactions at the level of 
receptor and their signal transduction mechanisms supports the finding of increased 
opioid peptide levels in the hypothalamus after cannabinoid treatment (Corchero et al., 
1997; Viganò et al., 2005a).  
Cannabinoids and opioids can also interact at the level of their signalling activities. 
This is because reports have shown that both cannabinoid and opioid receptor types 
are coupled to similar intracellular effectors via Gi/o-proteins, modulating cAMP 
levels, K+ and Ca2+ channel activities, and MAP kinase phosphorylation (Bouaboula 
et al., 1995; Fukuda et al., 1996; Manzanares et al., 1999). Vigano et al. (2005a), 
studied the mechanism of cross-modulation between cannabinoid and opioid systems 
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for analgesia during acute and chronic exposure. The result showed that acute co-
administration of ineffectual sub-analgesic doses of synthetic cannabinoid CP-55,940 
and morphine resulted in significant antinociception whereas, in rats made tolerant to 
CP-55,940, morphine challenge did not produce any analgesic response. The result of 
Vigano et al., (2005a), study also showed alterations in the cAMP system, which 
seem to mirror the behavioural responses, indicating that the two systems may interact 
at the post receptor level which might open-up new therapeutic opportunities for relief 
of chronic pain through cannabinoid-opioid co-administration. 
 
1.12.    B50 Cells  
B50 cells are neuronal cell lines derived from the neonatal rat central nervous system 
(CNS) in 1974 by Schubert et al. (1974). These neuronal cells were cloned using ethyl 
nitrosourea which form multiple neuronal and glial cell lines, among which are B35 
cells, and the B50 cells are the most widely used, while the less widely used ones 
include B65, B103 and B104 cells. Otey et al. (2003), have shown that of 14 cell lines 
initially characterised by Schubert and co-workers, two have been in wide use today. 
These B35 and B50 cells have a near normal karyotype and display normal neuronal 
properties such as membrane excitability and expression of enzymes for 
neurotransmitter metabolism, but do not appear to be highly differentiated (Schubert, 
et al., 1974; Otey et al., 2003; Fashola-Stone, 2005). The B35 and B50 cell lines offer 
a number of advantages to researchers who study CNS neurons in culture. This is 
because they are easy to grow, differentiate and transfect.  
 
B50 cells have been used extensively in the study of neuronal cell death, toxicology 
and differentiation. They have also proved useful in the molecular analysis of 
endocytosis and of signalling pathways in particular those that guide axonal 
outgrowth and cell motility (Otey et al., 2003). The B50 cell lines offer substantial 
advantages over primary CNS neurons for use in cell biological and biochemical 
experiments, including ease of culture, efficiency of transfection and ability to 
establish stable cell lines (Reboulleau, 1990; Wu and Ledeen, 1991; Otey et al., 
2003). Soon after their development, B50 cells became widely used in the study of 
factors that control the morphological differentiation of CNS neurons, due to the fact 
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that they can grow at low density so that neurite outgrowth can be imaged easily in 
non-overlapping cells, and the rate of neurite extension can be measured 
unambiguously (Otey et al., 2003).  
 
The B35 cell lines are held by the American Type Culture Collection (ATCC) while 
the B50 cell lines are held by the European Collection of Cell Cultures (ECACC). 
Adler (2006b), has shown that the use of cultured cells grown in vitro has many 
advantages over the use of an intact animal or an isolated preparation as an 
experimental approach. Cultured cells provide a more controlled cellular environment 
than that achievable in an intact animal. This is because the researcher can selectively 
alter a single experimental variable and evaluate its effects on a cell with much less 
concern about possible secondary and tertiary indirect effects from other systems 
(Adler, 2006b; Adler et al., 2006). Adler (2006b), showed that because cells in culture 
continue to grow and divide, they can be used to study long-term questions about 
differentiation, development and the regulation of gene expression.  
 
Cell culture experiments can be divided into two general categories namely those that 
utilize primary cultures and those that utilize established or secondary cell lines 
(Adler, 1996). Primary cultures contain cells that have been harvested from an animal 
or human, dissociated and grow in a culture dish while the established or secondary 
cell lines are cells that have become adapted to living in culture though they are 
originally isolated from an animal or a human and have been grown and propagated in 
vitro for many years (Adler, 2006b; Adler et al., 2006; Otey et al., 2003). These 
secondary cell lines either derived from normal tissues, tumours or transfected with 
viruses or genes, have been separated from their original tissue sources and have 
adapted to life outside the body environment where they survive by using nutrients 
provided in the culture media (Alder, 2006b). 
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1.13.         Aim of the study 
The aim of the study was to investigate the effect of hypoxia on neuronal cell 
signalling and consequent potential neuroprotectant efficacy of cannabinoid and 
opioid receptor agonists against hypoxia in cortical neuronal B50 cells in culture. 
 
 
1.14.      Objectives and hypotheses of the study 
The objectives of the study were to investigate the following: 
• The effects of hypoxia on B50 neuronal cell growth and morphology in 
culture.  
• The effects of hypoxia on B50 neuronal cell proliferation, viability and 
differentiation in culture 
• The effects of hypoxia on cannabinoid (CB1) and opioid (mu) receptors and 
associated signalling molecules in B50 neuronal cells 
• The effects of cannabinoid receptor agonists in the treatment and prevention of 
hypoxia in neuronal B50 cells in culture 
• The effects of opioid receptor agonists in the treatment and prevention of 
hypoxia on the neuronal B50 cells in culture 
• The cannabinoid and opioid agonist-induced effects on the signalling 
molecules (cAMP and ERK1/2) in cultured B50 cells in hypoxia.   
 
These objectives, when achieved, would enable the testing of the hypotheses of the 
study that hypoxia adversely affects neuronal cells and cannabinoid, and opioid 
receptor agonists may have potential therapeutic and protective benefits in hypoxia-
induced toxicity in neuronal cells. 
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                                           CHAPTER TWO 
2.                                             Method 
2.1            Raising Stable Cells in Culture 
2.1.1      Introduction 
The cells used in the research were cortical neuronal B50 cell line obtained from the 
European Collection of Cell Cultures (ECACC) No 85042302. This neuronal cell line 
was derived from rat central nervous system (CNS) in 1974 and deposited in the 
tissue culture bank (Schubert et al., 1974). The cells are able to produce action 
potentials and to extend neurites in culture however, they express higher levels of 
neurotransmitters and acetylcholine receptors and exhibit a more flattened 
morphology, suggesting that they represent a more differentiated state than the rest of 
the cell lines characterised by Schubert and co-workers (Schubert, et al., 1974; Otey et 
al., 2003; Fashola-Stone, 2005). The B50 cells can be split for sub-culturing at 
confluency of 70-80% (Fashola-Stone, 2005; ECACC, 2005).  
 
2.1.2      Materials 
One ampoule/vial of B50 cells; Dulbecco’s Modified Eagle medium (DMEM); Fetal 
Bovine serum (FBS); Tissue culture Flasks (25cm2 and 75cm2); Trypsin-EDTA 
(0.05% Trypsin, 0.53mM EDTA Liquid); Penicillin-Streptomycin solution; L-
Glutamine solution; Dibutyryl cyclic AMP (DbcAMP); Dimethyl sulfoxide (DMSO); 
Normal Incubator at 37oC and 5% CO2; Hypoxic Incubator at 37oC, 5% CO2;95% N2; 
Pasteur Pipettes; Water bath at 37oC; 12 well culture plates; Cryogenic Vials; 
Centrifuge tubes; Micro-centrifuge tubes. 
 
2.1.3       Method 
One ampoule containing 1ml of neuronal B50 cells ECACC No 85042302 was 
ordered from the European Collection of Cell Cultures (ECACC). The cells were 
resuscitated by warming-up the cells to room temperature for one minute until they 
were fully thawed. The thawing process was carried out quickly to avoid damage to 
the cell membrane (ECACC, 2005). The ampoule was then wiped with tissue soaked 
with 70% alcohol before opening to prevent cross-contamination of cells. The cells 
were slowly pipetted into a pre-warmed culture media in a 25cm2 culture flask and 
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incubated in the normal incubator at 37oC and 5% CO2. The culture media was made-
up of the following components: 
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% Foetal Bovine Serum (FBS) 
(Inactivated), 1% Penicillin-Streptomycin solution (100U/ml) and 2mM L-Glutamine. 
The method of inactivation of the foetal bovine serum (FBS) was by the thermal 
method in which the FBS was heated in a hot water bath at 56-60oC for 90 minutes 
and allowed to cool before being mixed in the appropriate proportion with the 
Dulbecco’s modified eagle’s medium, penicillin-streptomycin and L-glutamine 
solutions to make up the working solution of the culture media. 
The cells were stored in the normal incubator and were observed under the 
microscope every 24 hours of incubation to monitor their growth and wellbeing in 
culture. At about 80 to 95% confluency level since the recommended confluency for 
B50 cells sub-culturing is between 70 to 80% (Fashola-Stone, 2005; ECACC, 2005), 
the culture medium was decanted. Since the B50 neuronal cells are adherent, they 
were treated with 0.25% solution of Trypsin-EDTA at 2ml to the 25cm2 culture flask 
to ensure that all the cells were covered. The cells were incubated for approximately 2 
minutes at 37oC to enable all the cells to be removed from the bottom of the flask. At 
the end of the incubation period, a fresh culture medium was added which stops the 
activity of the Trypsin-EDTA solution and then resuspend the cells. The cells were 
then centrifuged at a speed of 2500 x g for 5 minutes. After the centrifugation, the 
medium was decanted and a fresh medium added to the cells. The cells were split into 
new culture flasks in 1:4 ratios with fresh media for sub-culturing while some of the 
cells were frozen at -70oC to enable them to be preserved for future use. 
2.1.4      Method for Freezing B50 Cells  
The freezing media was prepared using 90% foetal bovine serum (FBS) and 10% 
cryoprotectant dimethylsulphoxide (DMSO). The cells were resuspended in the 
freezing medium and then aliquoted at 1ml per cryogenic ampoule. The ampoules 
were wrapped in cotton wool, placed in a box container and frozen at -70oC. After 24 
hours the cells were removed from the box and restored at -70oC. The cells were 
tested for viability by thawing one ampoule and starting a new culture with it. 
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2.2         Total cell count and viability  
2.2.1     Introduction  
A cell and viability count is a determination of living or dead cells based on a total 
cell sample (Ellis-Christensen, 2007). Cell viability measurements are used to 
evaluate the number of live or dead cells in experimental conditions. The 
measurement of cell viability involves looking at a sample cell population and 
staining the cells, or applying a dye, to show which cells are living and which ones are 
dead under the microscope (Yamauchi et al., 2003). The objective of this study was to 
determine the total cell count (cell concentration), total number of living cells (viable) 
and dead cells (non-viable) and the percentage of living cells (%viable cells), in B50 
cells cultured under normal and hypoxic incubators, using the trypan blue exclusion 
method. In this method, the dead or non-viable cells take up the dye, while the viable 
or living cells do not (Li and Gong, 2007). 
 
2.2.2.     Materials  
12-well culture plates; Culture media; Olympus microscope; Trypan blue (0.4%); 
Haemocytometer; Pasteur pipettes and Cover slips. 
 
2.2.3.       Method 
The cells were cultured in 12-well culture plates in both normal and hypoxic 
incubators. The cells were harvested after 24, 48, 72, 96, 120 and 144 hours of 
culture, while the 0 hour was regarded as the starting point of the culture. The cells 
were harvested by detaching them from the plates using a 0.25% solution of Trypsin-
EDTA and centrifuged at 2500 x g for 5 minutes. The supernatants were decanted and 
cellular pellets collected. The cells were resuspended in the culture medium and 
studied using trypan blue exclusion method. This method involved pipetting 50µl of 
cell suspension into a tube with 50µl of the 0.4% (w/v) solution of trypan blue dye 
and left to stand at room temperature for 5 minutes. The haemocytometer was fixed 
with a cover-slip and 20µl of the cell suspension/trypan blue mixture was applied 
between the coverslip and the haemocytometer. The haemocytometer chambers were 
filled by capillary action and the cells were viewed under the microscope 
(magnification x 400) to show a single counting square (Figure 2.1). With the 
microscope focused on the gridlines of the chamber, the viable cells (those that did 
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not take-up the dye) were not coloured, while the non-viable cells (those that absorbed 
the dye) were coloured blue (Yamauchi et al., 2003; Li and Gong, 2007) . The cells 
were counted in four corner squares of one chamber as shown in Figure 2.2. The cells 
that lie on the lines were not counted unless they were touching the top and left-hand 
lines of each corner square, in accordance with the manufacturer’s instruction. At 
each session of the experiment, three independent samples were randomly selected 
from different plates and each experiment was repeated two times to give the number 
of samples (n = 6) for measurement of viability and cell death, and was used to obtain 
the mean and standard deviation. Viability of culture was calculated as the percentage 
of the ratio of the number of unstained cells (viable cells) to the total number of cells 
counted (viable cells plus nonviable cells). The total number of cells, total viable 
cells, and percentage viability were calculated using the formulae below: 
 
Total cell count/ml ═ (number of viable cells counted + number of non-viable cells  
                                     counted) x104 x dilution factor                                                                      
 
Viable cell number/ml =    (number of viable cells counted) x 104 x dilution factor 
                                              number of squares counted    
                                                                                                                                                                    
Percentage Viability =   (number of viable cells counted)  x 100 
                                           Total cell count           
 
 
                                       
                   
Fig.2.1. Representation of the counting chambers of haemocytometer.  
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Fig 2.2 Representation of the haemocytometer counting squares. 
 
 
2.3      The effect of hypoxia on B50 neuronal cells in culture using LDH assay 
2.3.1    Introduction  
Lactate dehydrogenase (LDH) release has been shown to be a reliable marker and 
index of cellular damage (Zhang et al., 2002; Zhang et al., 2005; Ma et al., 2005; 
Zhang et al., 2006). The LDH assay measures cytotoxicity and cell lysis by detecting 
the LDH activity released from damaged and injured cells (Zhang et al., 2006; Ma et 
al., 2005). The LDH assay can be used in many different in vitro cell systems where 
cellular damage, lysis or injury of the plasma membrane may occur (Andre et al., 
2004; Laughton et al., 2007). The assay can also be used to quantify the number of 
viable cells and cellular growth in neuronal cultures (Aoki et al., 2007; Tweedie et al., 
2006). The LDH assay is simple, accurate and yields reproducible results (Decker and 
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Lohmann-Matthes, 1988; Weidmann et al., 1995; Sigma, 2006; Arthur et al., 2007). 
This assay method is simple and convenient because all the assay components are 
included in one complete assay kit and could be measured using different types of 
microplate reader. It is accurate and reliable because it has long been used as a 
measure of cellular death and viability in hospitals as a marker for myocardial 
infarction (Elikowski et al., 2006), but was later introduced as a measure of cellular 
viability and death in neuronal cultures (Zhang et al., 2006; Li et al., 2005; Tateno et 
al., 2008). The assay is based on the reduction of NAD+ by the action of the LDH 
enzyme and the resulting reduced NAD+ (NADH) is utilised in the conversion of 
tetrazolium dye, resulting in a coloured compound, formazan that is measured 
spectrophotometrically (Sigma, 2006; Carr et al., 2005; Legrand et al., 1993; Abe and 
Matsuki, 2000). The amount of formazan that is actually measured correlates directly 
to the amount of the LDH released by the injured, damaged or lysed cells in the 
culture (Tian et al., 2007; Xu et al., 2007). The LDH assay has been shown to be 
sensitive, convenient and precise and is applicable to a variety of toxicity studies (Abe 
and Matsuki, 2000; BioVision, 2006; Guzman, 2005). The aim of the study was to 
investigate the effect of hypoxia on LDH release from cultured B50 neuronal cells. 
 
2.3.2     Materials  
Lactate Dehydrogenase Assay Kit (Sigma Tox-7), containing: LDH Assay Substrate 
Solution (L2402); LDH Assay Cofactor Preparation (L2527); LDH Assay Dye 
Solution (L2277) and LDH Assay Lysis Solution (L2152); 1N Hydrochloric acid 
(H9892); 12 well culture plates; culture media; Trypsin-EDTA solution; Centrifuge 
and Centrifuge tubes; Normal and hypoxic Incubators; 96 well Plates; Dynex MRX 
Micro plate Reader at 490 nm. 
 
2.3.3      Method  
The B50 neuronal cells were allowed to grow in 12-well culture plates for 96hrs after 
resuscitation in both normal and hypoxic incubators. The cells with the culture plates 
were removed from the incubators into the laminar flow hood and centrifuged at 250 
x g for 4 minutes to pellet cells. Aliquots of the supernatants were transferred into a 
clean flat bottom 96 well micro plate. 
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LDH assay working solution 
The working solution of LDH assay cofactor was prepared by adding 25ml of 
deionized, sterilized tissue culture water to the bottle of lyophilized cofactors. The 
lactate dehydrogenase assay mixture was prepared by mixing equal amounts (20ml) 
of LDH assay substrate, LDH assay cofactor and LDH assay dye solution. The LDH 
assay mixture was added at two times (40µl) the volume of the supernatant medium 
(20µl) removed for assaying. The plates were covered with aluminium foil to protect 
them from light and incubated at room temperature for 30 minutes. The reaction was 
terminated by the addition of one tenth volume (6µl) of 1N HCL solution to each 
well. The experiment was done in triplicate for two times (n = 6) according to the 
method of Bouaboula et al. (1995). The absorbance was spectrophotometrically 
measured at a wavelength of 490nm using a Dynex MRX model of micro plate 
reader. The result was calculated by using the formula below: 
 
1) Total Absorbance = Sum of (n) Absorbances (n = 6) 
 
2) Mean Absorbance =  Total Absorbance  
                                     Number of Absorbance (n) 
 
3)  Mean Corrected Absorbance = (Mean test Absorbance – Mean Background  
                                                          Absorbance)   
 
4)  Percentage (%) absorbance =       Mean Test Absorbance   x 100              
                                                           Mean Control Absorbance 
 
Background Absorbance = Absorbance from the culture medium only 
Control Absorbance = Absorbance from the normal cells with medium 
Corrected Absorbance = corrected Absorbance without background   
Test absorbance = Absorbance from the experimental cells with the culture medium 
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2.4.    The effect of culture duration on LDH release from B50 cells in normal                   
and hypoxic cultures 
2.4.1      Introduction 
The duration of cultures have been shown to influence and affect the amount and level 
of cellular damage, lysis and finally death in both normal and experimental conditions 
(Ying et al., 2003; McInnis et al., 2002). This study was designed to evaluate the 
influence of time duration of B50 cells in culture on LDH release in both normal and 
hypoxic cultures. 
 
2.4.2    Materials 
12 well culture plates; Centrifuge and centrifuge tubes; Culture media; LDH kit; 
Normal Incubator and hypoxic Incubator. 
 
2.4.3    Method 
The B50 cells were cultured normally in 25cm2 culture flasks and split into 12 well 
culture plates. The cells were cultured in both normal and hypoxic conditions at 
different time durations (24, 48, 72, 96, 120 and 144 hours). At the end of each time 
interval using 0 hr as the starting point of culture, the cells were harvested and 
assayed for LDH release from both the normal and hypoxic groups of cells. The 
results were calculated as in session 2.3 above and compared between the groups of 
normal and hypoxic cells. 
 
2.5.     Neuronal cell proliferation  
2.5.1      Introduction  
Different types of cells have different levels of metabolic activity. It has been shown 
that factors that affect the metabolic activity of cells may affect their viability and 
consequently their proliferation (Ellis-Christensen, 2007; Kumar, 2004). 
Dhanasekaran et al. (2004) have shown that the alpha-subunits and the beta-gamma-
subunits of G proteins regulate several critical metabolic and signalling pathways 
involved in cell proliferation, differentiation and apoptosis. These pathways include 
the mitogen activated protein kinase (MAPK), cyclic adenosine monophosphate 
(cAMP) and cAMP response element-binding (CREB) protein (Barco et al., 2006).  
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Adherent cells that undergo contact inhibition may show a change in metabolic 
activity per cell at high densities, resulting in a non-linear relationship between cell 
number and cell proliferation when using assays involving metabolic function to 
assess proliferation (Promega, 2006; Gibbs, 2003). Cells undergoing contact 
inhibition especially at 100% confluency in culture result in arrest of further cell 
proliferation and growth due to lack of culture space (Morgan, 2007). It has been 
shown that factors which affect the physiology of the cells or their cytoplasmic 
volume will affect their metabolic activities and hence their proliferation and viability 
(Zhang et al., 2002). Hence cell proliferation and viability assessment was measured 
by the use of CellTiter 96 AQueous One Solution Assay (Promega). This assay 
method is a non-radioactive procedure that measures metabolic function and directly 
correlates it with living cell numbers (Roehm et al., 1991; Goodwin et al., 1995). The 
aim of this work was to study the effect of hypoxia on neuronal B50 cell proliferation 
and viability using the Promega CellTiter one solution method. 
 
 2.5.2.       Materials 
12 well culture plates; Culture media; Normal and hypoxic incubators; Promega Cell 
Titer One solution cell proliferation assay kit; Dynex MRX Model 96 well micro plate 
reader at 490nm; Centrifuge tubes and 96 well plates. 
 
 Cell Titer 96® One solution 
The Cell Titer 96® One Solution cell proliferation assay is a colorimetric method for 
determining the number of viable cells in proliferation or cytotoxic assays (Promega, 
2006; Goodwin et al., 1995). The reagent contains a novel tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethyoxyphenyl)2-(4-sulfophenyl)-2H-
tetrazolium, inner salt]; [MTS] and an electron coupling reagent, Phenazine 
ethosulphate (PES) (Roehm et al., 1991; Promega, 2006). PES has an enhanced 
chemical stability, which allows it to be combined with MTS to form a stable solution 
(Roehm et al., 1991). The MTS tetrazolium compound, Owen’s reagent is bio-
reduced by cells to form a coloured formazan product that is soluble in tissue culture 
medium (Roehm et al., 1991; Promega, 2006). This conversion is accomplished by 
the NADPH or NADH produced by dehydrogenase enzymes in metabolically active 
cells (Goodwin et al., 1995; Zhang, et al., 2002). 
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2.5.3        Method 
The neuronal B50 cells were cultured in 12 well culture plates in both normal and 
hypoxic incubators for time intervals of 24hrs, 48hrs, 72hrs, 96hrs, 120hrs and 144hrs 
prior to being harvested. The Cell Titer 96® one solution reagent was obtained from 
Promega and stored frozen at -70oC and thawed at time of use to room temperature. 
Since the B50 cells are adherent cells, 0.25% Trypsin-EDTA was used to detach the 
cells from the plate and at the end of the trypsinization process, the culture medium 
was used to stop the action of the trypsin-EDTA solution. The cell solutions were 
centrifuged at 2500 x g for 5 minutes and the supernatants were removed leaving the 
cells. The cells were collected and resuspended with the culture media. 100µl of the 
culture media containing the resuspended cells, were pipetted into each well of the 96-
well assay plate and 20µl of the Cell Titer 96® One Solution reagent added. The 
solutions were incubated for 2 hours at 37oC in a humidified 5% CO2 chamber. The 
absorbance was recorded at 490nm using the Dynex MRX Model 96 well micro-plate 
reader. Each experiment was performed in triplicate and repeated two times (n = 6). 
The absorbance values were corrected by subtracting the mean absorbance of the 
groups from the absorbance of the wells containing only culture medium with no cells 
(background) and were used to determine the number of viable cells in proliferation 
from the normal and hypoxic cultures of B50 cells. Since it has been shown that 
cellular viability and proliferation are directly proportional to the absorbance 
measured (Xiong et al., 2007; Chett et al., 2007), the absorbance can be used as an 
index of cellular proliferation and viability.  The results were calculated as follows. 
 
a)  Mean Absorbance = Sum of absorbances   
                                     Number of assays (n= 6) 
 
b) Mean Test Absorbance= [Absorbance of cells (Tests) ̶ Absorbance of medium (Background)] 
 
c) A standard curve for B50 cells was prepared using trypan blue cell counting 
method. A culture plate containing 46.5 x 106cells/ml was used to prepared five 
dilutions (0, 2, 4, 5 and 10) x 106cells/ml. Cells were transferred into the microplate, 
treated with CellTiter Aqueous One Solution and absorbance (n=5) was measured 
spectrophotometrically at 490nm. The absorbance was plotted against the known 
number of cells to give a standard curve (Figure 2.3). The number of cells from the 
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test groups was derived by plotting the absorbance of the test groups against the 
known cell numbers from the standard. 
 
d) The rate of proliferation was calculated by dividing the cell numbers by time 
(24hrs) to give the daily proliferation rate. 
 
Proliferation rate = Number of cells per ml 
                                   Time (24 Hours) 
 
 
 
 
 
 
 
 
Fig.2.3.Standard curve of the time-course effect of hypoxia on B50 cell absorbance of 
the CellTiter One solution proliferation assay at 490nm as a function of cell 
concentration
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2.6.      Morphological Studies  
2.6.1      Introduction 
The study of the morphological changes in B50 neuronal cells is necessary to 
ascertain the level of their activity and functionality. This is because the morphology 
of cells indicates the status of the cells, both in terms of the health of the cells and 
their physiological activities. Changes in the physiological processes and activities in 
cells are often accompanied by changes in cellular morphology. Examples include 
changes in the intracellular location, arrangement and structure of cellular constituents 
(such as organelles, macromolecular clusters or the cytoskeleton), changes in the 
morphology of the entire cell (such as its shape and area), changes in the spacing and 
proximity between cells, and properties of multi-cellular colonies (such as its shape, 
size and cell locations) (Yamamoto et al., 2001). It has been shown that normal 
morphology is concomitant to normal physiology, while abnormal morphology is 
synonymous to altered function which is mostly observed in the pathological changes 
that occur in different organs and tissues of the body (Lobner et al., 2000). If the 
morphology of B50 cells is normal that gives an indication of their normal signalling 
function and activities. The aim was to study the changes that may occur in the 
morphology of neuronal B50 cells in normal and hypoxic conditions. 
 
2.6.2     Materials 
12 well culture plates; 25cm2 culture flasks; Culture media; Microscope and 
peripheral accessories. 
 
2.6.3     Method 
The frozen B50 cells were thawed and revived into active cell cultures. The cells were 
raised in culture for 24, 48, 72, 96, 120 and 144 hours while 0 hour was regarded as 
the starting point of culture during splitting of cells for sub-culturing. At each stage of 
the experimental period, the cells were observed under the microscope, using same 
field morphological assessment in which the culture plates were examined from the 
centre to the sides in a quadri-point analysis method (Ellingson et al., 2007; Sato and 
Momose-Sato, 2007), and any change in the morphology of the cells was noted. This 
was repeated three times for each experiment. Micrographs of the cells were taken at 
the different time intervals at a magnification of 200 times (x 200), to show the 
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morphological changes that may have occurred between the normal and hypoxic cells 
in culture.  
 
2.7     Neuronal B50 cell differentiation 
2.7.1     Introduction  
Neuronal functions and activities depend on their normal differentiation. Neuronal 
differentiation makes it possible for neurons to differentiate into the cell body 
containing the nucleus and cytoplasm, a single axon and different numbers of 
dendrites (Yoshimura et al., 2006). This neuronal differentiation makes it possible for 
nerve cells to receive neural signals from the dendrites, integrate them in the cell body 
and finally send these signals out to other neighbouring neural cells through the axon 
into the synapses. If these neurons are undifferentiated or not properly differentiated, 
the signals cannot be normally received and transmitted through the dendrites, cell 
body and axons since the primary function of the nerve cells is to receive, integrate 
and transmit signals (Yoshimura et al., 2006). Dibutyryl cyclic adenosine 
monophosphate (DbcAMP), has been shown to induce neuronal cell differentiation in 
culture (Park et al.,1998; Fahrig and Sommermeyer, 1993). DbcAMP has been shown 
to be an inducer of cellular morphological differentiation in culture in varying 
concentrations ranging from 0.5mM, 1.0mM, 1.5mM and 2.0mM depending on the 
type of cell used (Boghaert et al., 1991; Nagamine et al., 1990; Shimizu et al., 1994). 
It has been shown that neuron-type cells undergo cellular differentiation when treated 
with 1mM concentration of DbcAMP (Oda et al., 2007; Hu et al., 2007). On addition 
of DbcAMP to cells grown in culture, cell division is arrested and the cells rapidly 
undergo distinctive morphological transformation characterized by neurite extension 
and reduction in saturation densities (Siegel and Lukas, 1988; Oda et al., 2007). The 
aim of this experiment was to study the effect of hypoxia on the neuronal B50 cells 
differentiation in culture using DbcAMP. 
 
2.7.2.      Materials 
Dibutyryl cyclic adenosine monophosphate (DbcAMP); Culture media; 12 well 
culture plate; Microscope. 
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2.7.3       Method 
The neuronal B50 cells were cultured in both normal and hypoxic incubators. The 
B50 cells were stimulated to differentiate by making up the culture media with 1mM 
DbcAMP. The level of neuronal differentiation was assessed microscopically, after 
96hrs of culture in both normal and hypoxic cultures. The B50 cells were assessed by 
observing the appearance of the neurites specifically the axons and dendrites called 
the neural processes (Fahrig and Sommermeyer, 1993). The third group of cells are 
those that were cultured for 48hrs in a normal incubator and then transferred into the 
hypoxic incubator for a further 48hrs followed by a microscopic assessment of the 
level of cellular differentiation. The level of the effect was studied by random field 
strip counting of the number of differentiated B50 cells, under the microscope at a 
magnification of 200 times (x 200), for the three groups. The differentiated cells 
counted contained two neuritic processes (axon and dendrite), which were longer than 
cell body diameter according to the method of Richter-Landsberg and Jastorff (1986) 
and Oda et al. (2007). Each count was repeated two times and all the experiments 
were performed three times (n = 6). 
 
 
2.8    Neuronal pattern and pattern formation 
2.8.1     Introduction  
Neuronal pattern and pattern formation makes it possible for neurons to organise 
themselves into groups called nerve fibres that carry neural signals into specific areas 
of the body to and from the brain. These patterns and the pattern formation itself are 
very important in ensuring that specific signals are carried to specific areas for the 
effective and efficient coordinated neural response (Golubitsky et al., 2004). The 
neuronal fibres are arranged in bundles that receive and transmit related signals. 
These bundles form a neural tract e.g. the visual tract carries visual signals from the 
eyes to relay centres in the brain and back to the eyes for visual perception to occur 
(Cowan and Thomas, 2004). Asare et al. (1996), have shown that spatial difference 
exist in the distributional pattern of neurons in the superior frontal gyrus of 32 
subjects who died of acquired immune deficiency syndrome. This gives support to the 
fact that, if there is a disruption in the tracts, the signal may not be properly 
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coordinated and relayed for the perfect response to occur. Genetic coding has been 
shown to play a role in the pattern formation in various part of the nervous system 
(Schmid et al., 2000a). The aim of this experiment was to study the effect of hypoxia 
on neural pattern and pattern formation in B50 neuronal cells in culture. 
 
2.8.2.      Materials 
25cm2 culture flask; 12 well culture plates; culture media with and without serum; 
Microscope; normal and hypoxic Incubators. 
 
2.8.3      Method 
The B50 neuronal cells were cultured in both normal and hypoxic incubators for 48 
hrs with normal culture media containing 10% Foetal bovine serum (FBS). The 
culture media was decanted after the first 48hrs and another culture media, without 
FBS (serum-free culture medium), was added to the cells for 72 hours to induce 
neuronal differentiation and hence pattern formation (Martín-Orozco et al., 2007). It 
has been shown that cellular differentiation is induced in a serum-free culture media 
(Gu et al., 2007; Nam et al., 2007). After 120 hrs of culture, the cells were observed 
under the Nikon Eclipse TS100 microscope using same field morphological 
assessment in which the culture plates were examined from the centre to the sides in a 
quadri-point method (Ellingson et al., 2007) at a magnification of 200 times. Each 
experiment was repeated three times and micrographs were taken using an IBM 
computer based Image Solutions® to analyse the changes that may have occurred 
between the normal and hypoxic cells in culture. 
 
 
2.9   Cannabinoid (CB1) and Mu opioid receptor expression in neuronal B50 cells 
using semi-quantitative RT-PCR Method 
2.9.1       Introduction  
Reverse transcription (RT) polymerase chain reaction (PCR), is a laboratory method 
used for amplifying a piece of ribonucleic acid (RNA) molecule (Prasad et al., 2001). 
The RNA strand is first reverse-transcribed into its deoxyribonucleic acid (DNA) 
complement or complementary DNA, followed by amplification of the resulting DNA 
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using a polymerase chain reaction (Prasad et al., 2001). The RT-PCR based assay is 
one of the most common methods for characterizing and confirming gene expression 
patterns using messenger ribonucleic acid (mRNA) in different sample populations 
(Orlando et al., 1998; Bustin, 2002). The amplification of RNA using RT-PCR 
provides for a highly sensitive technique, where a very low copy number of RNA 
molecules can be detected and is widely used in the diagnosis of genetic diseases and, 
quantitatively, in the determination of the specific RNA molecules within a cell or 
tissue as a measure of gene expression (Nolan et al., 2006; Burdyga et al., 2004). 
Bustin (2002), has shown that accurate determination of total RNA concentration is 
important for the  quantification of mRNA levels and any DNA contamination will 
result in inaccurate quantification. The RT is important for sensitive and accurate 
quantification and the amount of cDNA produced by the reverse transcriptase 
accurately represents the RNA input (Gnanapavan et al., 2002). It has been shown that 
the range, sensitivity and specificity of the enzyme are important considerations for a 
successful RT-PCR assay (Bustin, 2002; Wall and Edwards, 2002; Liu et al., 2002). 
The RT-PCR quantification of mRNA has been used to monitor transcription in vitro 
and direct detection of the effects of receptor signalling (Liu et al., 2002; Yuen et al., 
2002; Cohen et al., 2002). The RT-PCR method has also been used to study the 
effects of some experimental agents on the expression of cannabinoid and opioid 
receptors in whole animal and culture conditions (Lalonde et al., 2006; Chen et al., 
2005; Zhang et al., 2006). The aims of the experiment were to study the following: 
• to investigate the expression, and hence the presence, of cannabinoid 
(CB1) and mu opioid receptor mRNA in B50 neuronal cells.   
• to investigate the effect of hypoxia on the expression of cannabinoid 
(CB1)and mu opioid receptor mRNA on B50 neuronal cells 
• to investigate the effect of cannabinoid and opioid receptor agonist 
treatment on cannabinoid (CB1) and mu opioid receptor mRNA in cultured 
B50 cells using semi quantitative RT-PCR. 
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2.9.2     Extraction of total RNA 
  Introduction 
The B50 cells were cultured and exposed to different experimental conditions. The 
total cellular RNA was extracted from the cultured B50 neuronal cells using the 
TRIzol reagent method (Invitrogen No 15596-026), as outlined below. 
 
 Materials 
Cultured B50 cells in different experimental conditions; Chloroform; Isopropyl 
alcohol; 75% Ethanol in DEPC-treated Water; RNase-free water; Diethylpyro 
carbonate (DEPC); TRIzol reagent (Invitrogen No 15596-026); RNaseZAP (Sigma 
R2020), used in washing all the wares to eliminate RNA contamination; Micro 
centrifuge tubes and Centrifuge. 
 
Method  
The B50 cells in different experimental conditions were grown and lysed in culture 
plates by adding 0.5ml of TRIzol reagent to each well. The cells were homogenized 
and incubated for 5mins at room temperature. The homogenates were transferred to 
micro-centrifuge tubes, 0.1ml of chloroform added, the cap secured and the tubes 
shaken vigorously by hand for 15 seconds. The cellular mixture was incubated at 
room temperature for 3 minutes. The mixture was then centrifuged at 12,000 x g for 
15 minutes at room temperature. Following centrifugation, the mixture was separated 
into 3-layers namely a lower phenol-chloroform phase (Red), a middle interphase 
(Cloudy) and an upper aqueous colourless phase. 
The RNA is  present at the upper aqueous colourless phase and formed about 60% of 
the total volume of the mixture and was transferred to a fresh micro-centrifuge tube. 
The aqueous phase was mixed with 0.25ml of isopropyl alcohol and incubated for 10 
minutes at room temperature. The mixture was then centrifuged at 12,000 x g for 10 
minutes at room temperature. At this point the RNA precipitated and formed a gel-
like pellet. 
The supernatant was removed and the remaining RNA pellet was washed once with 
0.5ml of 75% ethanol and mixed by vortexing. The mixture was centrifuged at 7,500 
x g for 5 minutes at room temperature and the ethanol was decanted. The RNA was 
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then air dried for 10 minutes, dissolved in 100% deionized formamide and stored at    
-70oC to be used in RT-PCR analysis. 
 
2.9.3.     Semi-Quantitative One step RT-PCR Analysis 
  Introduction  
The semi-quantitative one step reverse transcriptase polymerase chain reaction (RT-
PCR) was used to study the expression of cannabinoid and opioid receptors. The 
method used was the Superscript III One-Step RT-PCR system with Platinum Taq 
DNA polymerase from Invitrogen (12574-018). This method is a sensitive, 
reproducible, end point detection and analysis of RNA molecules by RT-PCR (Chen 
et al., 2005; Invitrogen, 2005). This method offers a convenient One-Step formulation 
which can be used to perform both complementary DNA (cDNA) synthesis and PCR 
amplification in a single tube using gene specific primers and target RNAs from either 
total RNA or mRNA (Prasad et al., 2001; Invitrogen, 2005). The system uses a 
mixture of superscript III Reverse Transcriptase and Platinum Taq DNA polymerase 
in an optimized reaction buffer and can detect a wide range of RNA targets, while the 
amount of starting material can range from 0.01pg to 1.0 µg of total RNA (Invitrogen, 
2005). 
 
Cannabinoid (CB1) and mu opioid receptors (MOR) were selected for the semi-
quantitative RT-PCR analysis because the CB1 receptors are predominantly found in 
the neurons of the CNS and the B50 neuronal cells are derived from the CNS neurons. 
MOR were selected for study because opioid receptor subtypes have been shown to 
have 68% sequence homology between them and the differences between them was 
proposed largely, on the basis of radioligand binding studies and as such there is little 
or no evidence for the presence of the different genes encoding the opioid receptor 
subtypes (Corbett, et al., 2006). In some cases receptor heterodimerisation of opioid 
receptors has been proposed as a possible explanation for the different opioid receptor 
subtypes (Corbett, et al., 2006; Milligan, 2004). 
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  Materials 
The extracted total RNA, Superscript III RT/Platinum Taq Mix, Reaction Mix, 5nM 
Magnesium Sulphate, GeneAMP PCR System thermal cycler. CB1 primers, sense 5’-
GAT GTC TTG GGA AGA TGA ACA AGC-3’(nt 365-373) and  antisense 5’-AGA 
CGT GTC TGT GGA CAC AGA CAT GG-3’(nt 460-468). The primers were 
selected from Esposito et al. (2002), since they were used for the study of CB1 
expression and the effect of cannabinoid agonist treatment in neuronal glial cells. Mu 
opioid receptor (MOR) sense primers, 5-GGA ACA TGG CCC TTC GGA ACC 
ATC-3' (574-597) and antisense 5'-TAC CAG GTT GGG TGG GAG AAC GTG-3' 
(863-840), were selected from Silbert et al. (2003), where they were used to study the 
effect of MOR expression and opioid treatment in myelinated and unmyelinated 
neurons. Alpha actin primer Sense  5’-GAT CAC CAT CGG GAA TGA ACG C-3’  
(389bp) and Antisense 5’-CTT AGA AGC ATT TGC GGT GGA C-3’, selected from 
Park et al., (1997), where they were used as an internal control for cytoskeletonal 
study in pericytes.                    
Method      
Programming of the thermal cycler  
• cDNA synthesis    1 cycle at 55oC for 30 minutes  
• Denaturation         1 cycle at 94oC for 2 minutes  
• PCR amplification  40 cycle at 94oC for 15 seconds (Denature)    
                                                              60oC for 30 seconds (Anneal) 
                                                              68oC for 60 seconds (Extend) 
• Final extension         1 cycle at 68oC for 5 minutes  
Preparation of Master Mix 
The master mix was prepared on ice using 0.2ml nuclease free, thin walled PCR 
tubes. Each PCR tube contained the following: 
• 2 x Reaction mix (dNTPs:200µM; MgSO4:1.6mM)          25µl 
• Template RNA (200ng/µl)                                                1µl 
• Sense Primer (0.2µM)                                                       1µl 
• Antisense Primer (0.2µM)                                                 1µl 
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• SuperScript III RT/ Platinum Taq mix (5mM)                  2µl 
• Autoclaved distilled water; 20µl was added to make up total volume to 
50µl 
These were mixed together gently and all the components were allowed to settle at 
the bottom of the amplification tube. The tubes were then centrifuged briefly by 
pulse centrifugation, over-laid with one drop of mineral oil and placed in a 
preheated thermal cycler (GeneAMP PCR System) as programmed above. One 
tube was used as blank and contained only master mix and water. 
Analysis of the RT-PCR products 
The analysis of the PCR products was carried out using the following method. 
Agarose gel (2%) was made by dissolving 2.5g agarose in 112.5ml of distilled water 
which was subsequently micro-waved in a conical flask for 5 minutes. 12.5ml buffer 
solution of Tris/Borate/EDTA (TBE) was added and 5µl of ethidium bromide added 
for staining the mRNA and mixed thoroughly. The mixture was poured into the gel 
tray with combs in place and air bubbles pushed to the sides with a pipette. The gel 
was allowed one hour to set. 5µl of Blue loading buffer (Sigma, G7654), which 
contain bromphenol blue (0.25% w/v), xylene cyanole FF (0.25% w/v), sucrose (40% 
w/v), was added to each of the samples and centrifuged briefly to mix and settle.  
A 10µl DNA ladder (Promega, G2101) and 5µl Blue loading buffer was used to 
makeup the DNA marker, and one litre of gel buffer was made using the TBE in a 
1:10 dilution. The gel was placed in an electrophoresis tank with wells at the negative 
electrode such that RNA will move towards the positive electrode. The gel was then 
surrounded with gel buffer and the wells completely covered by the buffer. The DNA 
marker (5µl), was added to the gel on position one, followed by adding a 10µl blank 
sample to the next position, and continuing to add 10µl of each sample to the 
remaining wells. The electrophoresis tank was connected to a power supply set at 
125V for one hour. Photographs of the gels were taken and scanned using the digital 
densitometer to evaluate and semi-quantify the mRNA of the receptors, and then 
compared between the different groups. 
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2.10.   The effect of cannabinoid receptor agonists on B50 neuronal cell 
morphology, proliferation and viability. 
2.10.1       The effect on morphology 
Introduction  
Cannabinoid receptors of the CB1 type mediate the central nervous system actions and 
they belong to the super family of seven transmembrane G-protein coupled receptors 
(Breivogel et al., 1997; Griffins et al., 1998; Breivogel et al., 2004). Cannabinoids 
have been shown to protect neurons from death caused by glutamatergic over 
stimulation, ischaemia and oxidative damage (Chen et al., 2005; Hansen et al., 2002; 
Guzman et al., 2002; van der Stelt and Di Marzo 2005). The aim of this study was to 
evaluate the effects of three different synthetic cannabinoid receptor agonists on the 
morphology of B50 neuronal cells cultured under hypoxic conditions. 
 
Materials 
Three different synthetic cannabinoid agonists from Tocris, namely: Win 55,212-2 
mesylate (Win); anandamide or arachidonylethanolamide (AEA); and 2-arachidonyl 
glycerol (2-AG); normal and hypoxic incubators, culture media and 12 well culture 
plates. 
 
Method 
The cells were defrosted and resuscitated in culture plates for 24hrs and the three 
synthetic cannabinoid agonists (Win; AEA and 2-AG) were dissolved separately in 
2% DMSO (Sigma) to form 5mM stock solution of the drugs. The three agonists were 
selected because of their activation of the CB1 receptors which are found mostly in the 
CNS neurons and each agonist was selected because: 1) Win is a potent non-selective 
CB1/CB2 cannabinoid receptor agonist, with higher affinity for the CB1 receptors in 
the CNS when compared to CB2 receptors (Ferraro et al., 2001; Devlin and 
Christopoulos, 2002). 2) AEA is a synthetic form of the endocannabinoid, 
anandamide which binds to the CB1 receptors and, to a lesser extent CB2 receptors. 
Anandamide is as potent as ∆9-THC on CB1 receptors (Grotenhermen, 2005; Pertwee 
and Ross, 2002). 3) 2-AG is a synthetic endocannabinoid that binds to both the CB1 
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and CB2 receptors with similar affinity, and is present at significantly higher 
concentrations in the brain (Stella et al., 1997; Pertwee, 2005).  
 
Once dissolved, serial dilutions were made in the culture media from the 5mM stock 
solution of the drugs, and aliquots of 10nM, 50nM and 100nM solutions of Win, AEA 
and 2-AG, containing 4 x 10-6%, 2 x 10-5% and 4 x 10-5% of DMSO were made. The 
effect of DMSO on the cells was not performed because, since the final concentration 
of DMSO was less than 0.01%, of which at this concentration, DMSO has been 
shown not to affect neuronal cells and glutamate levels in neuronal cell cultures 
(Ferraro et al, 2001; Otey et al., 2003; Fashola-Stone, 2005; Bottone et al., 2008). 
Glutamate has been shown to be the most common neurotransmitter in the brain and 
excessive glutamate release resulting in excessive Ca+2 entry into cells leads to 
excitotoxicity which initiates neuronal cell and brain ischaemic/hypoxic damage seen 
in stroke and cardiac arrest (Shigeri et al., 2004; Manev et al., 1989). 
 
The drug concentrations were chosen by considering the concentrations used by other 
workers (Ferraro et al., 2001;  Breivogel  et al., 2004; Zhuang et al., 2005), and as 
such low dose (10nM), intermediate dose (50nM) and a higher dose (100nM) was 
selected to give a balanced view of the effect of the drugs from the low to a higher 
concentration. These solutions of the agonists were administered at 48hrs of culture to 
investigate the therapeutic effect of the agonists. Some cells were treated 
simultaneously at 0hr before they were exposed to the hypoxic incubator to assess the 
protective (pre-treatment) effect of the agonists against hypoxia. At each stage of the 
experimental period, the cells were observed under the microscope, using same field 
morphological assessment in which the culture plates were examined from the centre 
to the sides in a quadri-point analysis method (Ellingson et al., 2007; Sato and 
Momose-Sato, 2007), and this was repeated three times for each experiment. 
Micrographs of the cells were taken at the different time intervals (0hr to 120hrs), at a 
magnification of 200 times (x 200), using the Nikon Eclipse TS100 microscope and 
analysed using the IBM computer based Image Solution to investigate if changes have 
occurred between the normal and hypoxic cells in culture. 
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2.10.2 The effect of cannabinoid receptor agonists ± antagonists treatment on 
cellular proliferation in B50 cells in culture. 
Introduction 
Different bioactive agents have been shown to affect cellular proliferation and 
viability either negatively or positively. This study investigates the effect of treatment 
and pre-treatment with cannabinoid receptor agonists on cellular proliferation in B50 
cells in culture using the Cell Titre 96 proliferation assay. 
 
Materials 
B50 neuronal cells, normal incubator, hypoxic incubator, Cell Titer 96® (Promega) 
assay kit, 12 well plates, and culture media, cannabinoid agonists (Win, AEA and 2-
AG) at 10nM, 50nM and 100nM concentrations and cannabinoid antagonists (AM251 
and AM630) at 10nM, 50nM and 100nM concentrations. 
 
 Method 
The B50 cells were raised in normal culture in 25cm2 culture flask and then split into 
12 well plates and were pre-treated immediately at 0hr with differing concentrations 
of the cannabinoid agonists as pre-treatment groups (simultaneous exposure groups) 
and cultured for 96hrs. The treatment groups were initially cultured for 48hrs and then 
treated with different concentrations of cannabinoid agonists in the presence or 
absence of cannabinoid antagonists for another 48hrs of culture. The cells were 
cultured for a total of 96hrs in culture. At the end of the time period in the incubators, 
the cells were harvested and assayed for cellular proliferation in B50 cell cultures, 
treated and pre-treated with cannabinoid agonists in the presence or absence of 
antagonists. The absorbance was read from the DYX MRX model of microplate 
reader and results calculated. Since it has been shown that cellular proliferation is 
directly proportional to the absorbance measured using the CellTiter One Solution 
(Xiong et al., 2007; Chett et al., 2007), the absorbance is used as an index of cellular 
proliferation.  The results were calculated as follows. 
a)  Mean Absorbance = Sum of absorbances   
                                     Number of assays (n= 6) 
 
b) Test Mean Absorbance= [Absorbance from the cells (Tests) ̶ Absorbance from the  
medium (Background)] 
 
 108
c) A standard curve was prepared using trypan blue cell counting method. A culture 
plate containing 42.5 x 106 cells/ml was used to prepared five dilutions (0, 2, 4, 5 and 
10) x 106 cells/ml. Cells were transferred into microplate, treated with CellTiter 
Aqueous One Solution and absorbance (n=5) was measured at 490nm. The 
absorbance was plotted against the number of cells to give a standard curve as shown 
in Figure 2.4. The numbers of cells from the test groups were derived by plotting the 
absorbance of the test groups against the known cell numbers from the standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2.4. Standard curve of agonist treated B50 cell absorbance of the CellTiter One 
solution proliferation assay at 490nm as a function of cell concentration. 
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2.10.3     The effect of cannabinoid agonist ±antagonist on cellular viability using 
LDH release from neuronal B50 cells in culture. 
      
Introduction 
Kreutz et al. (2007), have shown the various effects of different cannabinoids in 
neuronal damage using activated microglial cells. Chen et al. (2005), have 
investigated the neuroprotective effects of ∆9-tetrahydrocannabinol (∆9-THC) using 
an in vitro model in which the AF5 CNS cell line was exposed to toxic levels of N-
methyl-D-aspartate (NMDA) in which the cannabinoid antagonist SR141716A did 
not inhibit the neuroprotection induced by the ∆9-THC, suggestive of a CB1-
independent protective mechanism. Louw et al. (2000), had shown a region specific 
protection by ∆9-THC which implies that either the hippocampus undergoes 
suprathreshold ischaemic injury or that mechanisms of ischaemic injury vary in 
different brain regions. The aim of the study was to evaluate 1) the effect of 
cannabinoid agonist treatment or pre-treatment in the presence or absence of 
cannabinoid antagonists on neuronal viability using LDH assay. 2) the effect of 
different in vitro concentrations of the selective CB1 receptor antagonist (AM251), 
that would antagonize the activities of a standard concentration of the cannabinoid 
agonist [Win 522,212-2 (10nM)], using LDH release from cultured neuronal B50 
cells in treatment and pre-treatment groups.  
 
Materials 
LDH assay kit (Sigma 007); 1N hydrochloric acid; 12 well culture plates; 25cm2 
culture flasks and 96 well microplate; Centrifuge and MRX Microplate reader; B50 
cells, normal and hypoxic incubators; Cannabinoid receptor agonists (Win, AEA and 
2-AG), at 10nM, 50nM, 100nM; Cannabinoid antagonists (Tocris) [AM251 (No 117) 
and AM630 (No 1120)] at 10nM, 50nM and 100nM); Cannabinoid antagonist AM251 
(1.0nM, 5.0nM, 10nM, 15nM, 20nM and 25nM). 
 
Method 
The B50 neuronal cells were resuscitated and cultured in 75cm2 culture flasks in a 
normal incubator to confluency level of about 80-95% in 96hrs. The cells were split 
for sub-culturing in 12 well culture plates and the cannabinoid receptor agonists (Win, 
AEA and 2-AG in 10nM, 50nM and 100nM concentrations), were added to the 
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different wells at the same time as the cells were added to the wells (pre-treatment). 
The drugs were added to the cells simultaneously as the cells were exposed to the 
hypoxic condition at 0hr and cultured for a total of 96hrs. The cells in the treatment 
groups were cultured for 48hrs and then treated with the different concentrations of 
the agonists for another 48hrs. The cells pre-treated and treated with different 
cannabinoid agonists were cultured in different culture plates (Figure 2.5).  
 
Some cells were treated or pre-treated with the agonist in the presence or absence of 
the antagonist at either 0hr for pre-treatment group or 48hrs for treatment group with 
the agonist (Win 10nM) and different concentrations of antagonist AM251 (1.0nM, 
5.0nM, 10nM, 15nM, 20nM and 25nM). The cells were cultured for 96hrs in both 
treatment and pre-treatment groups. The cells were then harvested for LDH assay at 
96hrs of culture and analysed. Tables 2.1 and 2.2, show the exposure time and the 
experimental conditions of the treatment and pre-treatment groups of cannabinoid 
agonists and antagonists. The LDH released was calculated as follows: 
 
1) Total absorbance = Sum of (n) absorbances (n = 6) 
2) Mean absorbance =    Total absorbance  
                                     Number of absorbances (n) 
 
3)  Mean Corrected Absorbance= (Mean Absorbance–Mean Background Absorbance)   
4)  Percentage (%) Absorbance =  Mean Test Absorbance  x 100              
                                                       Mean Control Absorbance 
                                                                         
Background Absorbance = absorbance from the normal culture medium only 
Control Absorbance = Absorbance from the normal cells with medium 
Corrected absorbance = Corrected Absorbance without any background 
Test Absorbance = Absorbance from the experimental cells with the culture medium 
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Fig.2.5. A 12-well culture plate showing the experimental conditions of each plate 
at the treatment or pre-treatment: Three cannabinoid agonists with different 
agonist concentrations 
 
 
 
 
 
 
 
 
10nM 50nM 100nM
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AEA 
2 -AG 
Control No Drug
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Table 2.1.Exposure time and experimental conditions of the treatment and pre- 
 treatment groups of cannabinoid and opioid agonists in cultured B50 cells. 
A)Drug treatment Initial culture Time 
           (hrs) 
Treatment Time 
      (hrs) 
Total culture Time 
     (hrs) 
Win 
 
AEA 
 
2-AG 
 
CONTROL 
48 
48 
48 
48 
48 
48 
48 
48 
96 
96 
96 
96 
DAMGO 
 
DSLET 
 
ICI-199441 
 
CONTROL 
48 
48 
48 
48 
48 
48 
48 
48 
96 
96 
96 
96 
B)Drug pre-
treatment 
Initial culture time 
          (hrs) 
Pre-treatment Time 
      (hrs) 
Total culture Time 
(hrs) 
Win 
 
AEA 
 
2-AG 
 
CONTROL 
0 
0 
0 
0 
96 
96 
96 
96 
96 
96 
96 
96 
DAMGO 
 
DSLET 
 
ICI-199441 
 
CONTROL 
0 
0 
0 
0 
96 
96 
96 
96 
96 
96 
96 
96 
Win: Win 55,212-2 mesylate, a potent non-selective CB1/CB2 receptor agonist with higher 
affinity for CB1, AEA: Anandamide, a CB1 receptor agonist; 2-AG: 2-arachidonylglycerol, a 
non-selective CB1/CB2 receptor agonist with same affinity. DAMGO:([D-Ala2, N-MePhe4, 
Gly-ol]-enkephalin, a Mu (µ) opioid receptor agonist 
DSLET: [D-Ser2, Leu5, Thr6]-enkephalin, a delta (δ) opioid receptor agonist 
ICI-199441: ICI-199,441 hydrochloride, a kappa (κ) opioid receptor agonist 
CONTROL: Experimental control 
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Table 2.2. Exposure time and experimental conditions in cannabinoid agonists/ 
antagonists treated and pre-treated groups of B50 cells in culture 
A) Drug treatment 
Agonist/antagonist 
Initial culture 
Time (hrs) 
Treatment Time  
      (hrs) 
Total culture Time 
 (hrs) 
CONTROL/normal 48 48 96 
Hypoxia no drug 48 48 96 
10nM AM251/Win 48 48 96 
50nM AM251/Win 48 48 96 
100nM AM251/Win 48 48 96 
10nM AM630/AEA 48 48 96 
50nM AM630/AEA 48 48 96 
100nM AM630/AEA 48 48 96 
B)Drug Pre-
treatment 
Agonist/antagonist 
Initial culture 
time (hrs) 
Pre-treatment  
Time (hrs) 
Total culture Time  
(hrs) 
CONTROL/normal 0 96 96 
Hypoxia no drug 0 96 96 
10nM AM251/Win 0 96 96 
50nM AM251/Win 0 96 96 
100nM M251/Win 0 96 96 
10nM M630/AEA 0 96 96 
50nM M630/AEA 0 96 96 
100nM M630/AEA 0 96 96 
AM251:1-(2,4-dichlorophenyl)-5-(4-iodophenyl]])-4-methyl-N-(1-piperidyl)pyrazole-
3-carboxamide, a potent and selective CB1 receptor antagonist. Win: Win 55,212-2 
mesylate, a potent non-selective CB1/CB2 receptor agonist with higher affinity for 
CB1 receptors, AM630:6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-y l] 
(4-methoxyphenyl)methanone, a non-selective CB1/CB2 antagonist with higher 
affinity for CB2 receptors. AEA: Anandamide, a CB1 receptor agonist; 
 
 114
2.11. The effect of opioid agonists on neuronal B50 cell morphology, proliferation 
and viability  
2.11.1. The effect on morphology 
 Introduction 
He et al. (2002), have shown that the ability of an agonist to promote endocytosis of µ 
opioid receptor (MOR) is not linearly related with agonist activity, indicating that 
MOR endocytosis is an independent functional property (Whistler et al., 1999; 
Whistler, et al., 2001). Delta opioid receptors have been shown to play an important 
role in delayed hypoxia preconditioning-induced neuroprotection against severe 
hypoxic injury (Zhang et al., 2006). The aim of this study was to evaluate the effect of 
opioid receptor agonists on the morphology of cultured neuronal B50 cells in hypoxia. 
Materials   
Three different highly potent synthetic opioid agonists were obtained from Tocris UK. 
These opioids agonist are DAMGO, (µ opioid), DSLET, (δ opioid) and ICI-199,441 
hydrochloride, (κ opioid), normal and hypoxic incubators, culture media, 12 well 
culture plates, Nikon Eclipse TS100 Microscope using IBM Image solutions. 
 
Method 
The B50 cells were defrosted and resuscitated in the culture media for 24hrs. The 
three opioid receptor agonists [DAMGO (µ), DSLET (δ) and ICI (κ)], were dissolved 
separately in 100mM of 2%DMSO solution which formed the stock solution. Serial 
dilutions were made in the culture media and aliquoted into 10µM, 50µM and 100µM 
solutions of DAMGO, DSLET and ICI with DMSO concentrations of 0.0002%; 
0.001% and 0.002% respectively. The effects of DMSO on the cells was not assessed 
since the concentration of DMSO in the drugs was less than 0.01% (Ferraro et al, 
2001; Otey et al., 2003; Fashola-Stone, 2005; Bottone et al., 2008). The drugs were 
administered to the cells in cultures after 48 hours of initial culture to evaluate the 
therapeutic effects of the agonists on the cells for another 48 hours of culture, while 
some of the cells were simultaneously treated and exposed to hypoxic condition in the 
cultures at 0 hour to evaluate the protective effects of these agonists. All the cells 
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were cultured for a total of 96 hours in both normal and hypoxic conditions.  The cells 
were examined as in 2.10.1 above.  
 
2.11.2   The effect of opioid receptor agonists ± antagonists treatment on cellular 
proliferation in B50 cells in culture. 
 Introduction 
Different bioactive agents have been shown to affect cellular proliferation and 
viability either negatively or positively. This study investigates the effect of treatment 
and pre-treatment with opioid receptor agonists on cellular proliferation in B50 cells 
in culture. 
 
Materials 
B50 neuronal cells, normal incubator, hypoxic incubator, Cell Titer 96® (Promega) 
assay kit, 12 well plates, and culture media, opioid agonists (DAMGO, DSLET and 
ICI-199,441) and opioid antagonists [CTAP (µ), ICI-174,864 (δ) and Nor (κ)] from 
Tocris at 10µM, 50µM and 100µM concentrations. 
 
Method 
The B50 cells were raised in normal culture in a 25cm2 culture flask and then split 
into 12 well plates and were pre-treated against hypoxia immediately at 0hr with 
differing concentrations of opioid agonists in the presence or absence of the 
antagonists as pre-treatment groups (simultaneous exposure groups) and were 
cultured for a total of 96hrs. The treatment groups were initially cultured for 48hrs 
and then treated with different concentrations of opioid agonists in the presence or 
absence of the antagonists for another 48hrs of culture to make up for a total of 96hrs 
of culture time. At the end of the period in the incubators, the cells were harvested and 
assayed for cellular proliferation in B50 cell cultures, treated and pre-treated with 
opioid agonists and antagonists, using CellTiter One Solution proliferation assay. The 
absorbance was read from the DYX MRX model of microplate reader. Since it has 
been shown that cellular proliferation is directly proportional to the absorbance 
measured using the CellTiter One Solution (Xiong et al., 2007; Chett et al., 2007), the 
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absorbance was used as an index of cellular proliferation. The results were calculated 
as follows. 
 
a)  Mean Absorbance = Sum of absorbances   
                                     Number of assays (n= 6) 
 
b) Test Mean Absorbance= [absorbance from the cells (Tests)-absorbance from the  
                                                                                                   medium (Background)] 
 
c) A standard curve was prepared using trypan blue cell counting method. A culture 
plate containing 42.5 x 106 cells/ml was used to prepared five dilutions (0, 2, 4, 5 and 
10) x 106 cells/ml. Cells were transferred into the microplate, treated with CellTiter 
Aqueous One Solution and absorbance (n=5) was measured spectrophotometrically at 
490nm. The absorbance was plotted against the number of cells to give a standard 
curve as shown in Figure 2.4. The numbers of cells from the test groups were derived 
by plotting the absorbance of the test groups against the known cell numbers from the 
standard. 
 
2.11.3 The effect of opioid agonist ± antagonist treatment on cellular viability 
using LDH release from B50 neuronal cells 
 Introduction  
Opioid antagonists have been used to reverse the pharmacological actions of the 
opioid agonists. The present study examines the effects of the opioid receptor agonists 
in the presence or absence of the antagonists on cellular viability of B50 cells using 
LDH release. 
 
Materials 
Lactate dehydrogenase Assay kit (Sigma);12-well culture plates and culture media; 
normal and hypoxic incubators and centrifuge; 96 well Microplates and Dynex 
Microplate reader at 490nm; 1N hydrochloric acid (Sigma H9892); opioid agonists 
[DAMGO (µ), DSLET (δ), ICI-199,441 (κ)]; opioid antagonists [CTAP (µ), ICI-
174,864 (δ) and Nor (κ)] from Tocris at 10µM, 50µM and 100µM concentrations. 
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Method 
The B50 neuronal cells were raised in normal and hypoxic cultures for 48hrs, after 
which they were administered with the opioid receptor agonists at concentrations of 
10µM, 50µM or 100µM for the treatment groups and cultured for another 48hrs for a 
total of 96hrs of culture, while the pre-treatment groups were treated at 0hr and then 
cultured for a total of 96hrs in culture. Some of the cells were treated with equivalent 
concentrations of the agonists and antagonists. The cells were processed for LDH 
release at the end of the culture period. The culture plates with the cells were removed 
from the incubator into the laminar flow hood. The plates were centrifuged at 250 x g 
for 4 minutes in order to pellet the cells. The supernatants were aliquoted into clean 
flat bottom 96 well microplates for the LDH procedure. 
 
The LDH working solution was made by adding 25ml of deionized sterilized tissue 
culture water to the bottle of lyophilized cofactor. The lactate dehydrogenase assay 
mixture was prepared by mixing equal amounts (20ml) of LDH assay substrate, LDH 
assay cofactor and LDH assay dye solution. The LDH assay mixture was added to the 
aliquoted supernatant in the 96 well micro plates for assaying in a ratio of 2:1 
(40µl:20µl). The plates were covered with aluminium foil to protect them from light 
and incubated for 30 minutes at room temperature. The reaction was stopped by the 
addition of one tenth volume (6µl) of 1N HCL to each well. The absorbance was 
measured spectrophotometrically at a wavelength of 490nm using DYX MRX model 
of micro plate reader. The exposure time and the experimental conditions of the 
treatment groups of opioid agonists are shown in Figure 2.6 and Tables 2.1 and 2.3. 
The LDH released from both control and experimental groups were calculated by 
subtracting the mean background absorbance of the wells from the mean primary 
absorbance of the test group and expressed as the percentage of the control group as 
shown below: 
1) Total absorbance = Sum of (n) absorbances (n = 6) 
2) Mean absorbance = Total absorbance  
                                     Number of absorbances (n) 
 
3)  Mean Corrected Absorbance= (Mean Absorbance–Mean Background Absorbance)   
4)  Percentage (%) Absorbance = Mean Test Absorbance  x 100              
                                                     Mean Control Absorbance    
    
 118
                                                              
Background Absorbance = Absorbance from the normal culture medium only 
Control Absorbance = Absorbance from the normal cells with medium 
Corrected Absorbance = Corrected Absorbance without any background 
Test Absorbance = Absorbance from the experimental cells with the culture medium. 
 
 
 
 
 
10µM 50µM 100µM
DAMGO
DSLET
ICI
Control No Drug
B
 
Fig.2.6. Diagram of 12-well culture plate showing the experimental conditions of 
each plate at the treatment and pre-treatment: Three opioid agonists in different 
treatment concentrations distinguished with three different colours. 
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Table 2.3. Exposure time and experimental conditions in opioid agonist/antagonist 
treated and pre-treated groups of B50 cells in culture. 
A) Drug treatment 
Agonist/antagonist 
Initial culture 
time (hrs) 
Treatment time   
 (hrs) 
Total culture 
 time  (hrs) 
Control/normal 48 48 96 
10µM DAMGO/CATP 48 48 96 
50µM DAMGO/CATP 48 48 96 
100µM DAMGO/CATP 48 48 96 
10µM DSLET/ICI- 
  174,864 
48 48 96 
50µM DSLET/ICI- 
  174,864 
48 48 96 
100µM DSLET/ICI- 
  174,864 
48 48 96 
10µM ICI-199,441/NOR 48 48 96 
50µM ICI-199,441/NOR 48 48 96 
100µM ICI- 
 199,441/NOR 
48 48 96 
B)Drug Pre-treatment 
Agonist/antagonist 
Initial culture 
time (hrs) 
Pre-treatment  time   
(hrs) 
Total culture 
 time  (hrs) 
Hypoxia no drug 0 96 96 
10µM DAMGO/CATP 0 96 96 
0 96 96 50µM DAMGO/CATP 
100µM DAMGO/CATP 0 96 96 
10µM DSLET/ICI- 
  174,864 
0 96 96 
50µM DSLET/ICI- 
  174,864 
0 96 96 
100µM DSLET/ICI- 
  174,864 
0 96 96 
10µM ICI-199,441/NOR 0 96 96 
50µM ICI-199,441/NOR 0 96 96 
100µM ICI-
199,441/NOR 
 0 96 96 
DAMGO: ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin, a Mu (µ) opioid receptor agonist 
CATP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; a selective µ-opioid receptor 
antagonist, DSLET: [D-Ser2, Leu5, Thr6]-enkephalin, a δ-opioid receptor agonist,  
ICI-174,864: ([allyl]2-Tyr-alpha-amino- isobutyric acid-Aib-Phe-Leu-OH), a selective 
δ-opioid receptor antagonist. ICI-199,441: ICI-199,441 hydrochloride, κ-opioid 
receptor agonist. NOR: Norbinaltorphimine, a potent  κ-opioid receptor antagonist. 
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2.12 The effect of DbcAMP on LDH release from B50 cells treated with 
cannabinoid and opioid agonists ± antagonists. 
2.12.1    Introduction 
Some agents have been shown to stimulate cell differentiation while some are known 
to cause cellular death and degeneration (Boghaert et al., 1991). Some cell types 
exhibit increased numbers of long cellular processes known as morphological 
differentiation following treatment of monolayer cultures with 1mM dibutyryl cyclic 
adenosine monophosphate (DbcAMP) (Hu et al., 2007; Oda et al., 2007). It has been 
shown that DbcAMP induces neuronal differentiation by inhibition of cellular 
proliferation, followed by neurite outgrowth (Kim et al., 2002). It has also been 
shown that mitogen activated protein kinase (MAPK) signalling is required for neurite 
outgrowth in neuronal cells and hence dbcAMP-induced neurite outgrowth in cells, 
may be by amplifying both the MAPK-dependent and -independent DbcAMP 
signalling pathways (Li et al., 2003). The aim of this study was to investigate the 
effect of DbcAMP on LDH release from B50 cells treated with cannabinoid and 
opioid agonists in the presence or absence of antagonists in hypoxic cultures. 
2.12.2      Materials 
Cannabinoid agonists at 10nM, 50nM and 100nM concentrations; opioid agonists at 
10µM, 50µM and 100µM concentrations; cannabinoid antagonists (AM251 and 
AM630) at 10nM, 50nM and 100nM; opioid antagonists (CTAP for µ, ICI-174,864 
for δ, Nor for κ) at 10µM 50µM and 100µM; B50 cells, 12 well plates and 25cm2 
culture flasks; LDH kit, normal and hypoxic incubators. 
2.12.3       Method  
The B50 cells were raised in normal culture and split at full confluency. The split cells 
were subcultured and treated with 1mM DbcAMP at 0hr. The different group of cells 
were treated for 48 hrs after the initial culture of 48hrs, or pre-treated at 0hr for 96hrs 
with the different concentrations of cannabinoid agonists and antagonists, or opioid 
agonists and antagonists. At the end of 96 hrs of culture, the cells were harvested and 
the effect of DbcAMP on the treatment and pre-treatment with cannabinoid agonists ± 
antagonists and opioid agonists ± antagonists were assessed by LDH release using the 
LDH assay. The results were calculated using the LDH formulae shown in Section 
2.11.3. The exposure time and the experimental conditions are shown in Table 2.4. 
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Table 2.4. Exposure time and experimental conditions on the B50 cells treated with 
DcAMP/cannabinoid and opioid agonists ± antagonists in culture. 
A) Cannabinoid 
 agonist treatment 
Initial culture 
 time   (hrs) 
Treatment/pre-
treatment  time   (hrs) 
Total culture 
 time  (hrs) 
Control/normal 48 48 96 
Hypoxia no drug 48 48 96 
DbcAMP 48 48 96 
DbcAMP/10nM Win 48 48 96 
DbcAMP/50nM Win 48 48 96 
DbcAMP/100nM Win 48 48 96 
B) Opioid agonist 
 treatment 
Initial culture 
 time (hrs) 
Treatment time  
(hrs) 
Total culture 
 time (hrs) 
DbcAMP/10µM DAMGO 48 48 96 
DcAMP/100µm DSLET 48 48 96 
DbcAMP/10µM ICI-
199,441 
48 48 96 
DbcAMP/100µM ICI-
199,441 
48 48 96 
C) Opioid agonist 
 pre- treatment 
Initial culture 
time (hrs) 
Pre-treatment time 
(hrs) 
Total culture 
 time (hrs) 
DbcAMP/10µM DAMGO 0 96 96 
DbcAMP/100µM 
DAMGO 
0 96 96 
DcAMP/10µM DSLET 0 96 96 
DbcAMP/100µm DSLET 0 96 96 
DbcAMP/10µM ICI- 
199,441 
0 96 96 
DbcAMP/100µMICI-
199,441 
0 96 96 
D) Cannabinoid/ 
Antagonist treatment 
Initial culture 
time (hrs) 
Treatment time  
(hrs) 
Total culture 
 time (hrs) 
DbcAMP/10nMAM251/
Win 
48 48 96 
DbcAMP/50nMAM251/
Win 
48 48 96 
DbcAMP/100nMAM251/
Win 
48 48 96 
DbcAMP: dibutyryl cyclic adenosine monophosphate; Win: Win 55,212-2 mesylate, a potent 
non-selective CB1/CB2 receptor agonist with higher affinity for CB1 receptors,  DAMGO:([D-
Ala2, N-MePhe4, Gly-ol]-enkephalin, a µ opioid receptor agonist 
DSLET: [D-Ser2, Leu5, Thr6]-enkephalin, a delta (δ) opioid receptor agonist 
ICI-199441: ICI-199,441 hydrochloride, a kappa (κ) opioid receptor agonist 
AM251:1-(2,4-dichlorophenyl)-5-(4-iodophenyl]])-4-methyl-N-(1-piperidyl)pyrazole-3-
carboxamide, a potent and selective CB1 receptor antagonist 
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2.13    The effect of hypoxia on cAMP levels in cultured B50 cells: cAMP enzyme 
immunoassay (ELISA) method. 
2.13.1   Introduction 
Adenosine 3’5’-cyclic monophosphate (cAMP) form intermediate signals in cellular 
processes, making them popular targets for research and drug discovery processes. 
There has been considerable interest in the measurement of intracellular cAMP in 
tissues and cell cultures and this may help to provide an understanding of the 
physiology and pathology of many disease conditions (Tremblay et al., 1988; 
Sevetson et al., 1993; Morton, 2004; Sigma, 2006). The aim of this study was to 
evaluate the effect of hypoxia on the level of intracellular cAMP content in normal, 
hypoxic and treated neuronal B50 cells in culture using the direct cAMP enzyme-
linked immunosorbent assay (ELISA) method. The direct cAMP ELISA have been 
validated and shown to be a reliable method for the quantification of intracellular 
cAMP in cultured cells (Kim et al., 2006; Qiu et al., 2002; Cai et al., 2001; Andersen 
et al., 2001). 
 
2.13.2    Materials 
Cultured B50 cells in normal and experimental groups, Sigma direct cAMP enzyme 
immunosorbent assay kit (CA-200) containing the followings; Goat anti-Rabbit IgG 
microtiter plates, cAMP direct conjugate, cAMP direct Antibody, 0.1M HCL, 
Neutralizing reagent, Wash buffer concentrate, cAMP standard, p-NPP substrate, Stop 
solution, Triethylamine, acetic anhydride and Micro plate sealer, deionized water, 
Pipettes, Micro plate shaker, adsorbent paper for blotting and Micro plate Reader at 
410 nm.   
 
2.13.3.     Method  
The B50 neuronal cells were cultured in 12-well culture plates in both normal and 
hypoxic incubators. The cells were treated with cannabinoid and opioid agonists at 
10nM, 50nM and 100nM concentrations for cannabinoid and 10µM, 50µM and 
100µM concentrations for opioid agonists. At the end of 96hrs of culture, the culture 
media were decanted and the cells were treated with 0.1M HCL and incubated for 
about 15 minutes. The cells were visually inspected to verify complete cell lysis. The 
cells in the wells were centrifuged at 600 x g at room temperature for 5 minutes. The 
supernatants were then collected and used directly for cAMP assay. 
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Cyclic AMP standard solutions were prepared in 5 glass tubes (1 to 5). 900µl of 0.1M 
HCl was added to tube 1, while to tubes 2-5 were 750µl of the 0.1M HCl added. Then 
100µl of the 2,000pM/ml Standard was added to tube 1 and mixed thoroughly. 250µl 
of tube 1 was added to tube 2 and mixed. This was continued for tubes 3 through tube 
5 as in Table 2.5. Wash buffer was prepared by diluting 10ml of the wash buffer 
concentrate with 90ml of deionized water.  
 
Then 50µl of the neutralizing reagent was pipetted into each well except the Total 
activity (TA) and Blank wells. 100µl of the 0.1M HCl was added into Non-specific 
binding (NSB) and Blank 0 Standard (Bo) wells and 100µl of the standard tubes 1 
through 5 was added into standard wells. Then 100ul of the cell supernatant samples 
were added into sample wells and 50ul of 0.1M HCl was added to NSB wells. Also 
50µl of cAMP conjugate was added into each of the wells except the TA and Blank 
wells. Then 50µl of cAMP antibody was added into each well except the Blank, TA 
and NSB wells. The well arrangements are shown in Table 2.6. 
 
The plate was incubated at room temperature for 2 hours on a plate shaker at 500rpm 
with the plates covered with the plate sealer. At the end of the incubation period, the 
contents were emptied and washed 3 times by adding 200µl of the wash solution to 
every well. At the end of the washing, the wells were emptied completely to remove 
all wash buffer. Then 5µl of the cAMP conjugate was added to the TA wells and 
200µl of the p-NPP substrate solution was added to every well and incubated at room 
temperature for one hour without shaking. At the end of the incubation period, 50µl of 
the stop solution was added to every well and the optical density of the plate was read 
at 410nm. Each assay was performed in triplicate and repeated twice (n=6). 
Calculation of the cAMP concentration in the cell supernatant samples was done as 
follows: 
• Average Bound OD = Sum of the optical density of the sample wells 
                                                    Number of wells (n=6) 
 
• Average NSB OD = Sum of the optical density of non specific binding wells 
(Background)                                Number of wells (n=6) 
 
• Net Optical Density (Net OD) = (Average Bound OD) – (Average NSB OD) 
• Net Bo OD = (Average Bo - Average NSB OD) 
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• Percent Bound = Net Optical Density (OD)   X 100 
                                 Net Bo OD  
• Using graph paper plot percent bound from the maximum binding wells 
(B/Bo) versus the known cAMP concentrations from the standard to generate 
a standard curve as shown in Figure 2.7 from where the cAMP concentration 
from the unknown experimental groups were derived. 
Where OD = Optical density  
Net OD = Mean optical density 
NSB OD = Non-specific binding optical density 
Net Bo OD = Maximum binding wells  
 
 
 
 
Table 2.5. Dilution table for making cAMP Standards 1-5: 
Standards 0.1MHCL 
Vol.(µL) 
cAMP Standard 
Vol. Added(µL) 
cAMP(Conc.) 
(pmol/mL) 
1 900 100, Stock 200 
2 750 250, Std. 1 50 
3 750 250, Std 2 12.5 
4 750 250, Std 3 3.12 
5 750 250, Std 4 0.78 
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 Fig.2.7. Standard curve of B50 cell optical density (410nm) 
for determination of cAMP concentration
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   Table 2.6: cAMP Assay Protocol Flow Chart 
 Blank TA NSB Zero Std   
(Bo) 
Stds Samples 
Well Type and reagent 
added 
A1,B1 C1,D1 E1,F1 G1,H1 A2-B3 C3-H12 
Neutralizing reagent ------- ------- 50µL 50µL 50µL 50µL 
0.1M HCL ------- ------- 150µL 100µL ------- ------- 
Standard & Sample --------- ------- ------- -------- 100µL 100µL 
Conjugate --------- ------ 50µL 50µL 50µL 50µL 
Antibody --------- ------- -------- 50µL 50µL 50µL 
Incubate for 2hrs at 
room temperature with 
shaking 
 
_______ 
 
_____
_ 
 
_______ 
 
______ 
 
_____ 
 
______ 
Wash with 3x200µL of 
washing solution 
______ _____
__ 
_______ _______ _____ ______ 
 
Conjugate ------- 50µL ------ ------- ------- ------- 
Substrate 200µL 200µL 200µL 200µL 200µL 200µL 
Incubate for 1hr at room 
temperature without 
shaking 
 
______ 
 
_____
__ 
 
_______ 
 
______ 
 
_____ 
 
_______ 
Stop Solution 50µL 50µL 50µL 50µL 50µL 50µL 
 
 
TA        Total activity 
NSB      Non specific binding 
Bo         Maximum binding 
Std        Standard 
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2.14   The effect of hypoxia on extracellular signal regulated protein kinases    
(ERK) in cultured B50 neuronal cells: ERK1/2 enzyme immunoassay (ELISA) 
method 
2.14.1    Introduction 
Increased extracellular signal-regulated protein kinases (ERK1&2) phosphorylation 
has been noted in vulnerable penumbra following acute ischaemic stroke in human, in 
addition to other chronic neurodegenerative diseases (Grewal, et al., 2000: Liebmann 
and Bohmer, 2000; Wang et al., 2004). The aim of this study was to investigate the 
effect of hypoxia on phospho-ERK1/2 in cultured neuronal B50 cells. 
 
2.14.2.    Materials  
Cultured normal, hypoxic and treated neuronal B50 cells; Sigma ERK1&2 (EK0100) 
ELISA kit containing: ERK1&2 Standard, Standard diluent buffer, monoclonal Anti-
ERK1&2-coated well plates, Anti-ERK1&2, Anti Rabbit IgG-HRP, HRP diluent, 
Wash buffer concentrate, Stabilized chromogen, Tetramethylbenzidine (TMB), Stop 
solution, Plate covers and Adhesive strips; MRX Micro plate reader at 450nm; 
Pipettes, deionized water, Plate washer, Glass tubes, Absorbent paper towels for 
blotting plate, Vortex mixer; Sigma RIPA cell lysis buffer (N080-1284); 
Phenylmethlsulfonyl fluoride (PMSF)(Sigma P7626); Protease Inhibitor cocktail 
(PIC) (Sigma P8340); Sodium orthovanadate (Sigma S6508); Sodium pyrophosphate 
(Sigma S6422), Phosphate buffered saline(PBS). 
 
2.14.3     Method 
 Protein Extraction from B50 Cells 
  Materials  
The cell extraction buffer was made by the addition of 20mM sodium pyrophosphate, 
2mM sodium orthovanadate, while 1mM Phenylmethlsulfonyl fluoride (PMSF) and 
500µl of protease inhibitor cocktail (PIC), was added to every 10ml of the cell 
extraction buffer, prior to use. Rubber scrapers were used to remove the cells from the 
culture plate. The cell extraction buffer was prepared on ice. 
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 Method of cell extraction 
The B50 ells are adherent and were removed from the plate by scraping the culture 
plate with the rubber scrapper and washed twice with cold phosphate buffered saline 
(PBS) and centrifuged at 2500 x g for 5 minutes. The supernatant was removed 
leaving the cell pellets. The cell pellets were lysed using 500µl of the made-up cell 
extraction buffer for 30mins on ice with vortexing every 10mins intervals. The 
extracts were transferred into micro centrifuge tubes and centrifuged at 13,000rpm for 
10 minutes. The lysates were aliquoted into clean micro centrifuge tubes. 
 
 Pre-treatment of cell extracts before assay. 
The cell extracts were heated in boiling water for 5 minutes, upon cooling, the 
extracts were centrifuged and equal aliquots were used for the ERK1/2 ELISA Assay. 
 Reagent Preparation for ERK1/2 ELISA 
 Standard Dilution 
The ERK1/2 standard was reconstituted by adding 0.88ml of standard diluent buffer 
into one vial of the standard. The solution was mixed gently and allowed to stay for 
10 minutes to ensure complete reconstitution. This was labelled as 100Units/mL 
ERK1/2. The serial dilutions of the standard were made as shown in Table 2.7 
 
Anti-ERK1/2 antibody 
Monoclonal antibody specific for ERK1/2 was supplied as monoclonal Anti-ERK1/2-
coated well plates in the assay kit (Sigma E2655), while the detection antibody 
specific for the phospho-ERK1/2 was supplied as phospho-Anti-ERK1/2 (Sigma 
E4155) ready to use.  
 
Anti-Rabbit IgG-HRP 
The Anti-Rabbit IgG-HRP concentrate was allowed to equilibrate to room 
temperature. 10µl IgG-HRP concentrate was mixed with 1ml of HRP diluent to make-
up 1:100 dilution which is sufficient for 8 well strips. This was labelled as Anti-
Rabbit IgG-HRP working solution and the unused concentrate returned to the 
refrigerator. 
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Wash buffer  
The wash buffer concentrate was allowed to equilibrate to room temperature and one 
volume of the wash buffer concentrate was mixed with 24 volumes of deionized 
water. This was labelled as the working wash buffer and both the concentrate and the 
working wash buffer was then put in the refrigerator until when needed. 
2.14.4    Method for phospho-ERK 1&2 assay in B50 cells 
Well Arrangement 
The number of wells for the assay was determined by adding together 2 Blank/Zero 
wells, 2 Chromogen Blank wells, 14 Standard dilution wells and 2 wells for each of 
the samples to be assayed. Appropriate number of multi well strips removed, while 
the remaining was resealed and returned to the refrigerator. The layout of the wells is 
as shown in Table 2.8. 
 
Assay incubation 
100µl Standard diluent was added to Zero wells and 100µl Standards, Samples or 
Controls were added to appropriate wells as shown in Table 2.8. The plate was tapped 
gently to mix and was covered with the plate cover and incubated for 2hrs at room 
temperature as the first incubation step. At the end of the incubation, the wells were 
washed 4 times with the working wash buffer. After the final wash, the plates were 
blotted dry to remove any remaining wash buffer. 100µl of Anti-ERK1/2 detection 
antibody (Sigma E 4155), which was supplied ready to use, was added to all the wells 
except Chromogen Blank wells and the plate was tapped gently to mix, covered with 
the plate cover and incubated for 1hr at room temperature as the second incubation. 
The wells were washed 4 times and blotted dry to remove any remaining wash buffer. 
Then 100µl Anti-Rabbit IgG-HRP working solution in a dilution of 1:100, was added 
to each well except Chromogen Blank wells. The plate was covered and incubated for 
30 minutes at room temperature as a third incubation. The wells were washed 4 times 
and blotted dry. Then 100µl of Stabilized Chromogen was added to all the wells and 
the wells turned blue. The plate was left open and incubated for 30 minutes at room 
temperature in the dark as the substrate incubation. Finally 100µl Stop solution was 
added to all the wells to stop the reaction. The plate was tapped gently to mix and the 
solution turned yellow at this point. The assay was done in triplicate and repeated 
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twice (n = 6). The absorbance of the plate was read at 450nm on MRX Micro plate 
reader. 
 
Calculation of ERK concentration 
The concentrations of ERK in the different groups of the B50 cells were calculated 
using the formulae below; 
1)    Average Optical density = Sum of the optical densities  
                                                   Number of wells (n = 6)   
2)    Net OD = (Average Bound OD –Average Chromogen Blank OD) 
3)  Net OD (nm) of the standard dilutions was plotted against the standard 
concentration (Units/mL) of phospho-ERK1& 2 and the best curve was drawn to give 
a standard curve (Figure 2.8) through which the concentrations of the phospho-
ERK1/2 in the test groups were derived. 
 
OD= Optical density 
Net OD= Net optical density  
 
Fig.2.8. Quantitative determination of phospho-ERK in standards
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2.15. Statistical Analysis 
The different parameters measured from the normal, hypoxic, treated and pre-treated 
experimental groups of cultured B50 neuronal cells were compared using mean and 
standard deviation (SD). The parameters were assayed in triplicate and repeated twice 
(n = 6) and the results presented as the mean ± SD. The Students’ t-test was used for 
testing the level of significance between two groups and a P-value less than 0.05 was 
considered to be significant using Microsoft Excel® package. For multiple treatment 
data, One-Way Analysis of Variance (ANOVA) was used followed by Multiple 
Range Test post hoc subgroup testing to find the least significant difference (LSD) 
between the groups.  
 
 
Table 2.7. Dilution for making ERK1 & 2 standards 
Tube No Standard Diluent    
Buffer  
Standard from tube 
Number  
Final(ERK1&2) 
Units/mL 
1 0 .88mL                     ________ 100U/mL 
2 0.25mL 0.25mL (1) 50 
3 0.25mL 0.25mL (2) 25 
4 0.25mL 0.25mL (3) 12.5 
5 0.25mL 0.25mL (4) 6.25 
6 0.25mL 0.25mL (5) 3.12 
7 0.25mL 0.25mL (6) 1.6 
8 0.25mL ________   0 
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Table 2.8 Phospho-ERK 1 & 2 assay protocol flow chart 
   Blank A1,   B1 Chromogen 
Blank C1, D1 
Standards G1 to  
B3 
Samples C3 to 
H12 
Std Diluent 100µl --------- -------- ------- 
Stds/Samples -------- --------- 100µl 100µl 
Incubate for 2 
hrs at room  
temperature 
____________ __________ ____________ __________ 
Wash  4 times 
with washing 
solution 
__________ _________ ___________ __________ 
Anti-ERK1&2 100µl --------- 100µl 100µl 
Incubate for 1hr 
at room 
temperature 
___________ ____________ ____________ __________ 
Wash 4 times 
with washing 
solution 
_____________ __________ ___________ __________ 
Anti-RabIgG 
HRP 
100µl --------- 100µl 100µl 
Incubate for 30 
mins at room 
temperature 
____________ __________ ____________ _________ 
Wash for 5 times 
with washing 
solution. 
____________ ___________ ____________ _________ 
Chromogen 100µl 100µl 100µl 100µl 
Incubate for 30 
mins at room 
temperature. 
__________ ________ ___________ __________ 
Stop solution __________ _________ __________ _________ 
     
Std = Standard 
Stds = Stangards 
Anti = Antibody 
RabIgG HRP = Rabbit immunoglobulin G-Horse radish peroxidise 
Hrs = Hours 
Mins = Minutes 
A1-H12 = Plate number 
Stop solution = Ready to use solution that stop the reaction in the plate 
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                                              CHAPTER THREE  
3.                                                 Results 
3.1.        Cell characteristics 
The effects of hypoxia on neuronal cell signalling and the consequent neuroprotectant 
effects of cannabinoid and opioid agonists against hypoxia were investigated using 
cortical B50 neuronal cells that were cultured in both normal and hypoxic incubators. 
Cannabinoid and opioid receptor agonists were administered during the treatment and 
pre-treatment against hypoxia and the effects and cellular changes were studied using 
different parameters. 
3.1.1      B50 cell culture 
The B50 neuronal cells were initially cultured in normal incubator in normoxic 
conditions (21% O2; 5% CO2) in order to raise normal B50 cells for continuous sub-
culturing during the course of the research. The initial B50 cell culture was used to 
raise 100 vials (1ml ampoules) of normal B50 cells which were frozen and stored at -
70oC, from which subsequent cultures were raised for various experimental studies 
conducted in both normal and hypoxic incubators. The B50 cells cultured in the 
normal incubator were used as the control cells, while those cultured in the hypoxic 
(5% O2; 5% CO2) incubator were used as B50 cells in hypoxia which underwent 
therapeutic and protective treatments under different experimental conditions. 
3.1.2.   Morphological studies 
Morphological changes were observed in B50 cells cultured under hypoxia when 
compared with those cultured in normal incubator. The B50 cells in hypoxia showed 
clustered groups of neuronal B50 cells, evidence of degenerating, dying cells and 
already degenerated and dead neuronal B50 cells. The normal B50 neuronal cells 
cultured under normal incubator showed normal neuronal morphology as shown in 
Plates 1 and 2, when compared to B50 cells in hypoxia as shown in Plates 6, 7 and 8. 
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3.1.3.    Pattern formation 
The results from the pattern and pattern formation experiments showed the B50 
neuronal cells in the normal incubator with normal neuronal pattern and tract 
formation resembling those nerve fibres in normal neuronal cellular development in 
the body, when compared to the disoriented pattern found in B50 cells cultured under 
hypoxia. The normal neuronal pattern and pattern formation is shown in Plates 3,4 
and 5, when compared to the abnormal pattern found in hypoxic cells as shown from 
Plates 6, 7 and 8. 
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Plate 1:Representative of B50 cells at 0hrs with normal B50 cells (arrow) at the point of starting the culture at 
21% O2 and 5% CO2. B50 cells were observed in three different plates with same field method in a quadri-point 
analysis under the  Nikon Eclipse TS100 microscope and microphotographs processed with an IBM Image 
Solutions®. Scale bar =5mmx40 magnification.
_____
 
Plate 2:Representative of B50 cells at 48hrs of normal culture (21%O2 and 5% CO2) with  B50 cells
(arrow). B50 cells were observed in three different plates with same field method in a quadri-point 
analysis under the Nikon Eclipse TS100 microscope and microphotographs processed with  IBM 
Image Solutions®. Scale bar =5mmx40 magnification.
____
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Plate 3:Representative of normal B50 cells at 48hrs of culture (21%O2 and 5% CO2) with normal pattern
(arrow). Pattern of groups of nerves in a particular direction were observed in six different plates with 
same field method in a quadri-point analysis under the Nikon Eclipse TS100 microscope and 
microphotographs processed with an IBM Image Solutions®. Scale bar = 5mmx20 magnification.
______
Plate 4:Representative of normal B50 cells at 96hrs of culture (21%O2 and 5% CO2) with normal pattern (arrow). 
Pattern of groups of nerves in a particular direction were observed in six different plates with same field method in 
a quadri-point analysis under the Nikon Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mmx40 magnification.
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Plate 5:Representative of normal B50 cells at 96hrs of culture (21%O2 and 5% CO2) 
with normal pattern (arrow). Pattern of groups of nerves in a particular direction were 
observed in six different plates with same field method in a quadri-point analysis under 
the Nikon Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mmx40 magnification
______
 
Plate 6:Representative of hypoxic B50 cells at 96hrs of culture (5%O2 and 5% CO2), with groups of 
degenerating cells (black arrow) and altered pattern of cell arrangement (blue arrow). Groups of 
degenerating and altered nerve arrangement were observed in six different plates with same field method 
in a quadri-point analysis under the Nikon Eclipse TS100 microscope and microphotographs processed 
with an IBM Image Solutions®. Scale bar = 5mmx40 magnification.
______
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Plate 7:Representative of hypoxic B50 cells at 96hrs of culture (5%O2 and 5% CO2), with groups of degenerating cells (black arrow) and altered pattern of cell arrangement (blue arrow). Groups of 
degenerating and altered nerve arrangement were observed in six different plates with same field 
method in a quadri-point analysis under the Nikon Eclipse TS100 microscope and 
microphotographs processed with an IBM Image Solutions®. Scale bar = 5mmx40 magnification.
______
______
Plate 8:Representative of hypoxic B50 cells at 48hrs of culture (5%O2 and 5% CO2) without 
drug administration, showing groups of degenerating cells (arrow). Groups of degenerating 
cells were observed in six different plates with same field method in a quadri-point analysis 
under the Nikon Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mmx40 magnification
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3.1.4     Cell count and viability  
The time course effect of hypoxia on total cell count and viability showed that at 0 
hour, the mean total cell count in B50 neuronal cell culture was 2.67±1.64x106cells/ 
ml, the total viable cells was 2.50±1.40x106cells/ml, while the percentage viability 
was 93.64±2.79% and the range of percentage viability was 90-97%. There was no 
difference in the total cell count and total viable cells at 0 hour of culture, between the 
normoxic and hypoxic cells since the cells were split from the normal cells which 
serve as 0 hour at the beginning of the culturing experiment. The 0 hour serves as the 
base line for the culture of both normoxic and hypoxic cells.  
At 24 hours, the normal cultured B50 cells had a total cell count of 3.51±0.87x106 
cells/ml, total viable cells 3.05±0.83x106 cells/ml, with 87.14±0.72 as percentage 
viability and range of 86-88% while B50 cells cultured under hypoxia had 
2.80±0.36x106cells/ml; 1.95±0.24x106cells/ml; 70.91±5.41% and 63-76% as total cell 
count, total viable cells, percentage viability and range of percentage viability, 
respectively. The difference in the total cell count and total viable cells between the 
normal and hypoxic cells was not statistically significant. 
At 48 hours of culture, the normal cultured B50 cells had 6.50±0.84 x106cells/ml; 
6.01±0.85 x 106cells/ml; 92.25 ±1.17%; 90-93%, as total cell count, total viable cells, 
percentage viability and range of percentage viability respectively, while the hypoxic 
cells had 5.34±1.45 x 106cells/ml, 3.89±1.22 x106cells/ml, 72.01±3.39% and 67-76% 
as total cells count, total viable cells, percentage viability and range of percentage 
viability, respectively. The difference in the total cell count and total viable cells 
between the normal and hypoxic cells was not statistically significant. 
At 72 hours, the normal culture had 18.80±5.09x106cells/ml as total cell count, 
17.11±4.41 x106cells/ml as total viable cells and 91.24±3.77% as percentage viability 
and 83-95% as percentage total viability range, while the hypoxic cell culture had 
12.62±4.90x106cells/ml, 9.10±2.62 x106cells/ml, 75.32±11.59% and 60-94% as total 
cell count, total viable cells, percentage viability and percentage viability range, 
respectively. The difference in the total cell count and total viable cells between the 
normal and hypoxic cells was statistically significant (P<0.05). 
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At 96 hours of culture, the normal cells had 35.35±12.92x106cells/ml, 32.90±12.0x106 
cells/ml, 93.34±2.3% and 89-95% as total cell count, total viable cells, percentage 
viability and percentage viability range, respectively, while the B50 cells under 
hypoxia had 12.46±4.04x106cells/ml, 10.90±4.17x106cells/ml, 87.70±7.04% and 76-
93% as total cell count, total viable cells, percentage viability and range of percentage 
viability, respectively. The difference in the total cell count and total viable cells 
between the normal and hypoxic cells was statistically significant (P<0.05). 
At 120 hours of culture following splitting of cells in culture plates, the normal B50 
cells had 6.77±2.67x106cells/ml, 6.30±2.58x106cells/ml, 92.15±2.77% and 88-94% as 
total cell count, total viable cells, percentage viability and range of percentage 
viability, while the B50 cells in hypoxia had 7.50±1.11x106cells/ml, 6.07±0.71x106 
cells/ml, 81.54±4.39% and 76-87% as total cell count, total viable cells, percentage 
viability and range of percentage viability, respectively. There was a non significant 
decrease (P= 0.06) in the total cell count and a slight increase in the total number of 
viable cells between the normal and hypoxic cells. The results showed a decrease in 
total cell count and an increase the total viable cells in the normal cells when 
compared with the cells in hypoxia. This may be as a result of cells staying in the 
culture medium for a long period of time without changing the medium resulting in 
the depletion of the nutrients and build-up of toxic metabolites giving rise to more 
cellular death but more viable cells in normal than in hypoxic cells. The colour of the 
culture media would have been changed from purple to light yellow. If the culture 
medium is changed, the cells would be revived and proliferate with increase in total 
cell count and total viable cells but if the medium is not changed all the cells would 
normally die the following day.  
At 144 hours of culture, the normal B50 cells had 46.50±9.32x106cells/ml, 
44.00±9.10x106cells/ml, 94.53±0.8%, and 93-96% as total cell count, total viable 
cells, percentage viability and percentage viability range, respectively, while those 
cells cultured under hypoxia had 14.85±6.00x106cells/ml, 11.56±6.38x106cells/ml, 
74.18±13.60% and 56-91% as total cell count, total viable cells, percentage viability 
and range of percentage viability, respectively, as shown in Figures 3.1; 3.2 and Table 
3.1. The difference in the total cell count and total viable cells between the normal 
and hypoxic cells was significant (P<0.05). 
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Fig.3.1 Time course effects of hypoxia on total cell count of B50 cells in 
culture  
 
Comparative time effect of hypoxia on total cell count in B50 cells using trypan blue 
exclusion method (n=6). The cells were cultured in normal (21% O2; 5% CO2) and 
hypoxia (5%O2; 5%CO2) conditions. The B50 cells were split at 120 hours 
represented by split axis (*P<0.05 versus normal; Student’s t-test).   
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Fig.3.2. Time course effects of hypoxia on total viable cell count in B50 
cells in culture. 
 
 
 
0
10
20
30
40
50
60
0 24 48 72 96 0 120 144
Time (Hours)
To
ta
l V
ia
bl
e 
C
el
ls
 (X
10
6)
 C
el
ls
/m
l
Normal
Hypoxia
*
*
*
 
 
 
Time effect of hypoxia on total viable cells in B50 cells in culture using trypan blue 
exclusion method (n= 6). The normal cells cultured in (21% O2; 5% CO2) and hypoxic 
cells (5% O2; 5% CO2). The B50 cells were split at 120 hours represented by split axis 
(*P<0.05 versus normal cells; Student’s t-test).       
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Table 3.1: The time effect of hypoxia on total cell count and viability in B50 cells. 
 
Time(hours)/Type 
of treatment (n=6) 
Total cell count 
(x106)cells/ml 
Total Viable Cells 
(x106)cells/ml 
Viability 
(%) 
0 HRS 
Range 
2.67 ± 1.64 
(1.2-5.0) 
  2.5 ± 1.4 
  (1.1-4.7) 
93.6 ± 2.8 
(89.5-97.4) 
24 HRS 
NORMAL 
Range 
HYPOXIA 
Range 
 
3.5 ±0.9 
(2.4-4.6) 
2.8 ± 0.4 
(2.1-3.1) 
 
  3.05 ±0.8 
   (2.1-4.0) 
  1.96 ± 0.2 
   (1.6-2.3) 
 
87.1 ± 0.7 
(86.1-88.1) 
70.9 ± 5.4 
(63.3-76.2) 
48HRS 
NORMAL 
Range 
HYPOXIA 
Range 
 
6.5±0.8 
(5.2-7.4) 
5.34±1.45 
(3.4-7.5) 
 
   6.0±0.9 
   (4.7-6.9) 
   3.9±1.2 
   (2.3-4.7) 
 
 92.3±1.2 
 (90.4-93.6) 
 72.0±3.4 
 (67.7-76.0) 
72HRS 
NORMAL 
Range 
HYPOXIA 
Range 
 
18.8±5.1 
(10.7-26.8) 
12.6±4.9* 
 (5.3-21.2) 
 
   17.1±4.4 
   (9.4-22.4) 
   9.10±2.62* 
   (4.3-12.8) 
 
 91.2±3.8 
 (82.8-95.4) 
 75.3±11.6 
 (60.4-94.4) 
96HRS 
NORMAL 
Range 
HYPOXIA 
Range 
  
35.4±12.9 
(16.9-51.0) 
12.5±4.0* 
 (8.19) 
 
   32.9±12 
   (16.1-48.5) 
   10.9±4.2* 
    (6-17) 
 
 93.3±2.3 
 (89.5-95.3) 
 85.7±7.0 
 (76.1-93.3) 
120HRS 
NORMAL 
Range 
HYPOXIA 
Range 
 
6.8±2.7 
(3.4-9.9) 
7.5±1.1 
(6.1-8.8) 
 
    6.3±2.6 
    (3.0-9.3) 
    6.1±0.7 
    (5.3-6.7) 
 
  92.2±2.8 
  (88.2-94.3) 
  81.5±4.4 
  (76.1-86.9) 
144HRS 
NORMAL 
Range 
HYPOXIA 
Range 
 
46.5±9.3 
(36.6-57.2) 
14.9±6.0* 
(9.1-26.4) 
 
   44.0±9.1 
   (34.4-54.2) 
   11.6±6.4* 
   (5.1-24.0) 
 
  94.5±0.8 
  (93.7-95.7) 
  74.2±13.6 
  (55.6-90.9) 
Data show a comparative time effect of hypoxia on total cell count, total viable cells 
and percentage viability in B50 cells in culture using trypan blue exclusion method 
from three different experiments repeated twice (n=6). The normal cells cultured in 
(21% O2; 5% CO2) and hypoxic cells in (5% O2; 5% CO2), showed a significant 
increase (*P<0.05 versus normoxic cells; Student’s t-test) in total cell count and total 
viable cells at 72, 96 and 144 hours. The data expressed as mean ±SD (n=6) and 
Range.  
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3.1.5.    B50 cell proliferation 
The effect of hypoxia on cell proliferation was studied using B50 cells cultured in 
normal and hypoxic conditions. The cellular proliferation was assayed using Promega 
cellTiter 96® Plus. Since it has been shown that cellular proliferation is directly 
proportional to the absorbance at 490nm in the proliferation cellTiter assay method, 
the time course effect of hypoxia on cellular proliferation, showed that, at 24 hours 
the absorbance was 1.73±0.61 and 1.78±0.39 for the normal and hypoxic B50 cells 
respectively, however the difference was not statistically significant (P=0.085). At 48 
hours of culture the absorbance was 1.37±0.31 and 1.36±0.21 for the normal and 
hypoxic cells respectively, which showed no significant difference (P=0.066). At 72 
hours of culture the absorbance was 3.50±0.03 and 3.40±0.15 for normal and hypoxic 
cultures respectively. At 96 hours the absorbance for normal and hypoxic cells were 
2.54±0.48 and 2.00±0.25 respectively and the difference was significant (P<0.05). At 
120 hours of culture, the normal and hypoxic cells had absorbance of 1.53±0.38 and 
1.35±0.19 respectively while at of 144 hours of culture the normal and hypoxic cells 
had absorbance of 1.72±0.40 and 1.24±0.20 respectively of which the level of 
difference was statistically significant (P<0.05).The results are shown in Figures 3.3a, 
3.3b and Table 3.2 respectively. 
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Fig.3.3a.Effect of hypoxia on cell proliferation using absorbance at 490nm 
of CellTiter Aqueous One soultion assay.  
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Fig.3.3b. Effect of hypoxia on cell proliferation using CellTiter Aqueous One 
Solution assay on B50 cells
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Figs.3.3a & b. The effect of hypoxia on B50 cell proliferation using CellTiter Aqueous One 
Solution proliferation assay (a): Since the absorbance from the CellTiter One Solution has 
been shown to be directly proportional to the number of proliferated cells, the absorbance was 
plotted against the time of B50 cells in culture. (b): effect on B50 cell proliferation was 
derived from a standard curve for B50 cells prepared using the trypan blue cell counting 
method. A plate containing 46.5 x 106 cells/ml was prepared and five dilutions (0, 2, 4, 5 and 
10) x 106 cells/ml were prepared from the 46.5 x 106cells/ml. Cells were transferred into 
microplate and treated with CellTiter and the absorbance at 490nm was measured. The 
proliferated cells were derived from the standard curve versus the time cell stayed in 
culture.(n=6; Data as mean ±SD; *P<0.05 versus normal; Student’s t-test) normal (21%O2; 
5%CO2) and hypoxia (5%O2;5%CO2). 
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Table 3.2: The effect of hypoxia on neuronal cell numbers in B50 cells in normal 
and hypoxic culture. 
                     Normal                       Hypoxia Time 
(Hours) Absorbance Cell No 
(x106)/ml
Rate(x106)/ 
24hrs  
Absorbance Cell No 
(x106)/ml 
Rate (x106)/  
24hrs 
24 1.73±0.61 31.0 1.29 1.78±0.39 31.5 1.31 
48 1.37±0.31 24.50 1.02 1.36±0.21 23.75 0.99 
72 3.50±0.03 56.25 2.34 3.40±0.15 53.0 2.20 
96 2.54±0.48 41.25 1.72 2.00±0.25* 33.75 1.41 
120 1.53±0.38 27.80 1.16 1.35±0.19* 24.80 1.03 
144 1.72±0.40 30.50 1.27 1.24±0.20* 21.20 0.88 
The effect of hypoxia on B50 cell proliferation was measured as absorbance at 490nm 
using CellTiter Aqueous One Solution proliferation assay. The cell numbers was 
derived from the absorbance versus cell number from the standard curve prepared and 
the daily rate of proliferation was calculated by dividing the number of cells by Time 
(24hrs). Data is expressed as mean ±SD of the assay (n=6; *P<0.05 versus normal; 
Student’s t-test) normal (21%O2; CO2 5%) and hypoxia (5%O2;5% CO2). 
 
 
3.1.6.     Neuronal differentiation  
The effect of hypoxia on neuronal B50 cell differentiation was studied using 
DbcAMP to induce differentiation in normal and hypoxic cultures. Neuronal 
differentiation was assessed by random field strip counting of the differentiated B50 
cells, under the microscope at a magnification of 200 times. The differentiated cells 
counted contained two neuritic processes (axon and dendrite), longer than cell body 
diameter. The result in Figure 3.4, show that a significantly greater number of B50 
cells were differentiated in normal culture compared to those under hypoxia (P<0.05), 
and compared to those cells that were raised under normal condition but were 
subjected to hypoxia after 48 hours of normal culture (P<0.05). The extent of 
neuronal differentiation was affected more in those B50 cells cultured in normal 
culture and then transferred to hypoxic conditions than those cultured under hypoxia 
exclusively. The differences in number of differentiated cells was statistically 
significant (P<0.05).  
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The effect of hypoxia on B50 neuronal cell differentiation using 1mM DbcAMP in 
culture media and neuronal differentiation was assessed by random field strip 
counting of the differentiated B50 cells at a magnification x 200. The counted 
differentiated cells contained an axon and a dendrite longer than cell body diameter 
and the cells were cultured in Normal (21%O2;5%CO2) and Hypoxia (5%O2;5%CO2) 
for 96hrs and Normal/Hypoxia; cells were cultured for 48hrs in normal 
(21%O2;5%CO2) and then transferred to hypoxia (5%O2;5%CO2) for another 48 hrs 
for a total of 96hr culture. (Data as mean ±SD; n=6; *P<0.05 versus normal; #P<0.05 
versus hypoxia; Student’s t-test). 
 
 
 
 
Fig.3.4.The effect of hypoxia on B50 cells differentiation 
using DbcAMP and random field assessment  
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3.1.7.    LDH release from cultured B50 cells 
 The time-course comparative LDH leakage from normal and hypoxic B50 cells in 
culture is as shown in Figure.3.5 and Table 3.3. The results show that the greater the 
time the cells were kept in the culture media, the more LDH was released into the 
culture media. This occurred in both the normal and hypoxic cultured B50 cells, but 
the leakage tended to be greater in hypoxic cells than the normal cells, reaching a 
peak at 144 hours for both normal and hypoxic cells. The result shows that at 24hrs of 
culture there was no significant difference in LDH release between the hypoxic cells 
and the normal cells (P=0.11), but subsequently there was a significant difference 
(P<0.05) in LDH release between the hypoxic and normal B50 cells in culture. 
 
Time-course comparative LDH release from B50 cells cultured in normoxia (21%O2, 
5%CO2) and hypoxia (5%O2; 5%CO2). The LDH released from the normal cells at 24 
hrs was used as the control and LDH was expressed relative to the control. The cells 
were split at 120 hours represented by split line (Data points indicate mean ±SD; 
n=6;*P<0.05 versus normal; Student’s t-test). 
 
 
Fig.3.5.Comparative LDH release from B50 cells cultured in 
normal and hypoxic conditions
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 Table 3.3: Comparative LDH release from normal and hypoxic cells in culture 
Time 
(Hrs) 
Normal  % of 
Control 
  Hypoxia   % of 
Control 
24 9.92±1.21(Control) 100±12.20   11.12±1.89 112±19.04 
48 13.95±2.04 141±20.56   17.18±2.32 173±23.36* 
72 14.12±2.32 142±23.39   20.04±2.45 202±24.70* 
96 21.41±2.06 216±20.78   23.92±2.47 241±24.89* 
144 33.6±5.58 339±56.30   46.31±6.12 467±61.72* 
Table shows a time-course comparative LDH release from B50 cells cultured in 
normoxia (21% O2, 5%CO2) and hypoxia (5%O2, 5%CO2). Since LDH is present in 
the normal cells, the LDH released from the 24hrs normal culture was used as a 
control (100%) for the experiment and the LDH was expressed relative to the control. 
Cells were split at 120 hours (Data as mean ±SD; n=6; *P<0.05 versus Control; 
Student’s t-test).                                          
 
3.2      Expression of cannabinoid CB1 and mu opioid (MOR) receptors in B50 
neuronal cells using semi-quantitative RT-PCR  
3.2.1    The effect of hypoxia on the expression of CB1 and MOR receptor mRNA in 
B50 cells 
The result of CB1 and opioid receptor mRNA expression in B50 neuronal cells in 
normal, hypoxic and treated cells was studied using reverse transcription polymerase 
chain reaction (RT-PCR) is shown in Figures 3.6 and 3.7. The results showed that the 
RT-PCR experiments with the B50 neuronal cells in normal, hypoxic and treated 
cultures demonstrated positive expression of the cannabinoid CB1 and mu opioid 
(MOR) receptors. The mRNA levels of CB1 and MOR receptors in hypoxic culture of 
B50 cells were expressed relative to CB1 and MOR receptors in B50 cells cultured 
under normal conditions, and these were also compared with mRNA levels of CB1 
and MOR in hypoxic B50 cells treated with different  receptor agonists (Figures 3.8 
and 3.9). The result showed that there was no significant difference in the level of 
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CB1 and MOR receptor mRNA expression between the normal, hypoxic and agonist 
treated cultured B50 cells. 
 
3.2.2       Semi quantitative RT-PCR of cannabinoid CB1 and MOR 
CB1 and MOR expression products were subjected to semi quantitative analysis using 
digital densitometric measurements. The result showed a significant decrease 
(P<0.05)  in the density of the RT-PCR products of CB1 in hypoxic cells  treated  with  
100nM AEA (85%) and 10nM 2-AG (80%) agonists when compared with normal 
cultured B50 cells (100%), while the increase of 102%; 101%; 107%; 104% and 
104% in untreated hypoxic cells and cells treated with 10nM Win, 50nM Win, 10nM 
AEA and 50nM AEA, were not significantly different from the control (100%). The 
decrease in the density of CB1 receptors with 100nM Win (97%); 50nM 2-AG (92%) 
and 100nM 2-AG (95%), was not significant when compared with the control. The 
decrease in the density of MOR RT-PCR products was not significant in untreated 
(MOR) hypoxic cells (93%) and those treated with 10µM DAMGO (98%); 50µM 
DAMGO and 100µM DAMGO (98%). There was no significant change in 
densitometric measurements of mRNA area, mRNA volume, height and width 
respectively when compared with the normal control B50 cells (Tables 3.4A and 
3.4B). 
When the density of the RT-PCR products was normalised to alpha actin (100%), 
there was no observed difference in the level of the receptor mRNA expression of 
CB1 and MOR in normal, hypoxic and treated cultured B50 cells. The results showed 
no significant difference between the normal (CB1) cultured B50 cells (110%), 
untreated hypoxic cells (112%) and hypoxic treated cells with 10nM Win (111%); 
50nM Win (117%); 100nM Win (106%); 10nM AEA 114%; 50nM 2-AG (101%); 
normal MOR (119%); 10µM DAMGO (118%); 50µM DAMGO (111%) and 100µM 
DAMGO (118%). Also the CB1 receptor density showed a non-significant decrease 
with the cells treated with 100nM AEA (93%) and 10nM 2-AG (83%), when 
compared to those of alpha actin (100%) (Tables 3.4A , 3.4B and Figures 3.8). 
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I
300bp→ ←310bp
←350bp
A BCD E FGHI JKLM
Fig.3.6.The effect of hypoxia and cannabinoid treatment 
on CB1receptor expression in B50 cells.
A=DNA Ladder; B=Normal B50 cells; C=Hypoxic B50 cells;
D-I=Hypoxic treated cells with different cannabinoid agonist; 
J-M= Hypoxic cells treated cannabinoid agonist/antagonist; 
I=Alpha actin
Cannabinoid (CB1) receptor expression in B50 neuronal cells in culture. Total RNA 
was extracted from cultured B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 
5%CO2) and hypoxia treated with CB1 agonists. RT-PCR amplification was 
performed with specific CB1 primers. The gel was electrophoresed and stained with 
ethidium bromide to visualise the intensity of the cDNA for CB1 (310bp) and was 
normalised relative to alpha actin (350bp). 
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←209bp200bp→
←350bp
Fig.3.7 The effect of opioid treatment on MOR 
expression in cultured B50 cells in hypoxia 
A=DNA Ladder, B=Normal cells; C=Hypoxic cells; 
DEF=Hypoxic MOR treated G=Alpha Actin
A     B C D E  F
G
Mu opioid (MOR) receptor expression in B50 neuronal cells in culture. Total RNA 
was extracted from cultured B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 
5%CO2) and hypoxia treated with MOR agonists. RT-PCR amplification was 
performed with specific MOR primers. The gel was electrophoresed and stained with 
ethidium bromide to visualise the intensity of the cDNA for MOR (209bp) and was 
normalised relative to alpha actin (350bp). 
 
 
 
 
 
 
 153
Table 3.4A: Semi-Quantitative RT-PCR product of CB1 in B50 cells in culture. 
 
Treatment 
Type 
Vol. 
mm3 
Area 
mm2 
STD 
  ± 
Density
 
Width Height    % of 
Normal 
% of  
Control
CB1Norma 09.61 4.17 0.39 571.41 1.40 2.98 100 110.0 
Hypoxia 15.75 6.66 0.33 586.22 1.78 3.75 102.59 112.85 
10nM Win 12.32 5.24 0.33 577.20 1.58 3.36 101.01 111.12 
50nM Win 10.59 4.28 0.35 612.24 1.77 2.40 107.15 117.86 
100nM 
Win 
6.35 2.83 0.35 555.37 1.21 2.35 97.19 106.91 
10nM 
AEA 
10.65 4.44 0.35 595.31 1.40 3.18 104.18 114.60 
50nM 
AEA 
5.91 2.60 0.35 595.31 1.40 3.18 104.18 93.98 
100nM 
AEA 
3.91 1.98 0.21 488.19 0.76 2.60 85.44* 83.37 
10nM 2-
AG 
6.99 3.53 0.03 459.07 0.38 1.40 80.34* 101.53 
50nM 2-
AG 
8.64 4.06 0.30 527.40 1.21 3.37 92.30 104.65 
100nM 2-
AG 
8.90 4.06 0.31 543.60 1.21 3.37 95.13 104.65 
Alpha 
actin 
10.35 3.22 0.32 519.46 2.02 3.12 90.91 100 
Cannabinoid CB1 receptor was expressed in B50 neuronal cells in culture with total 
RNA extracted from B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 5%CO2) 
and hypoxia treated with CB1 agonists. The RT-PCR was amplified with specific CB1 
primers and gel was electrophoresed and stained with ethidium bromide to visualise 
the intensity of the cDNA and normalised relative to alpha actin. The RT-PCR 
product was quantified with digital densitometer and expressed as percent of control. 
(Data presented as mean ±SD; *P<0.05 versus control; Student’s t-test).  
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Cannabinoid (CB1) receptor was expressed in B50 neuronal cells in culture with total 
RNA extracted from B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 5%CO2) 
and hypoxia treated with CB1 agonists. The RT-PCR was amplified with specific CB1 
primers and gel was electrophoresed and stained with ethidium bromide and 
normalised relative to alpha actin. The RT-PCR product was quantified with digital 
densitometer and expressed as percent of control. (Data presented as mean ±SD; 
*P<0.05 versus control; Student’s t-test).  
 
 
 
 
 
 
 
 
Fig. 3.8. The effect of hypoxia on the expression density 
of CB1 receptor in B50 cells
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Table 3.4B: Semi-Quantitative RT-PCR product of MOR receptors in B50 cells 
in culture.  
Treatment 
Type 
 Vol. 
mm3 
Area 
mm2 
STD 
  ± 
Density 
 
Width Heigh
t 
   % of 
Normal 
% of  
Control 
MOR 
Normal 
MOR 
Hypoxia 
11.20 
 
04.55 
 
4.04 
 
1.94 
0.32 
 
0.24 
621.12 
 
583.40 
2.78 
 
0.76 
1.56 
 
2.54 
100 
 
93.93 
 
119.57 
 
112.31 
10µM 
DAMGO  
50µM 
DAMGO 
14.57 
 
12.48 
5.90 
 
5.34 
0.35 
 
0.34 
613.07 
 
579.21 
2.73 
 
1.59 
2.16 
 
3.37 
98.70 
 
93.27 
 
118.02 
 
111.50 
100µM 
DAMGO 
DAMGO/
CTAP 
Alpha 
actin 
10.61 
 
11.29 
 
10.35 
4.29 
 
4.44 
 
3.22 
 
0.35 
 
0.33 
 
0.32 
613.22 
 
631.09 
 
519.46 
1.78 
 
2.79 
 
2.02 
2.41 
 
1.59 
 
3.12 
98.73 
 
101.61 
 
83.63 
118.05 
 
121.49 
 
100 
MOR receptor was expressed in B50 neuronal cells in culture with total RNA 
extracted from B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 5%CO2) and 
hypoxia treated with MOR agonists. The RT-PCR was amplified with specific MOR 
primers and gel was electrophoresed and stained with ethidium bromide and 
normalised relative to alpha actin. The RT-PCR product was quantified with digital 
densitometer and expressed as percent of control. (Data presented as mean ±SD; 
Student’s t-test). 
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MOR receptor was expressed in B50 neuronal cells in culture with total RNA 
extracted from B50 cells in normal (21%O2, 5%CO2), hypoxic (5%O2, 5%CO2) and 
hypoxia treated with MOR agonists. The RT-PCR was amplified with specific MOR 
primers and gel was electrophoresed and stained with ethidium bromide and 
normalised relative to alpha actin. The RT-PCR product was quantified with digital 
densitometer and expressed as percent of control. (Data presented as mean ±SD; 
Student’s t-test).  
 
 
 
 
 
 
Fig.3.9. The effect of hypoxia on the expression density of MOR 
receptor in B50 cells.
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3.3.      Cannabinoid receptor agonist administration. 
3.3.1. The effect of cannabinoid treatment on the morphology of cultured B50 cells 
The result of administration of cannabinoid agonists with concurrent exposure of cells 
to hypoxic conditions, referred to here as pre-treatment against hypoxia, showed B50 
cells with fewer aggregates of degenerating and dead B50 cells when compared with 
hypoxic non-treated B50 cells. The effects of cannabinoid agonist pre-treatment on 
B50 cells are shown in Plates 9-15. The results showed the effects of pre-treatment 
with different concentrations of cannabinoid receptor agonists against hypoxia on the 
B50 neuronal cell morphology as compared to Plates 6-8 for hypoxic un-treated 
groups. The cells in hypoxic culture without the drug pre-treatment, showed higher 
incidence of cellular death as evidenced by the number of aggregates of degenerating 
and dead B50 cells when compared to those cultured under normal condition as 
shown in Plate 16 and the B50 cells in hypoxia but with cannabinoid agonist pre-
treatment as shown in Plates 10-13. The results from the morphological observations 
showed some changes in the morphology which could have been due to the effects of 
the different concentrations of the cannabinoid agonists used in the pre-treatments of 
the B50 cells cultured in hypoxia. 
The results of the effect of cannabinoid receptor agonist administration to cells in 
hypoxic conditions, referred to here as cannabinoid treatment of B50 cells cultured in 
hypoxia, show cells with fewer aggregates of degenerating and dead cells in 
cannabinoid treated hypoxic cultures when compared to cultured B50 cells in hypoxia 
without the cannabinoid treatment (Plates 6-8), while the B50 cells in hypoxia treated 
with different concentrations of cannabinoid agonists are shown in Plates 17-20. The 
results of the morphological studies showed that the cannabinoid receptor agonist 
treatment of the hypoxic B50 cells in culture could have alleviated some of the toxic 
effects of hypoxia by reducing the number of cellular deaths when compared with 
cells in hypoxia without treatment. As a result, there was reduced cell death and a 
healthier cellular morphology in those B50 cells treated with cannabinoid receptor 
agonists. The results also showed that the cannabinoid treated and pre-treated hypoxic 
cultured B50 cells were morphologically healthier when compared to the untreated 
hypoxic cultured B50 cells as shown in the Plates (17-20). The results show that 
cannabinoid receptor agonists could have some therapeutic and protective benefits 
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morphologically in hypoxic cultured B50 cells when administered as treatment and 
pre-treatment.   
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_____
Plate 9:Representative of B50 cells pre-treated against hypoxia with 10nM 
Win at 0hrs and cultured for 96hrs under hypoxic (5%O2 and 5% CO2) 
conditions, showing some degenerating cells (Black arrow) and some 
normal cells (Blue arrow). The changes in the B50 cells were observed in six 
different plates with same field morphological method in a quadri-point 
analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar = 5mmx40 
magnification
Plate10:Representative of B50 neuronal cells pre-treated against hypoxia with 
100nM Win at 0hrs and cultured for 96hrs (5%O2 and 5% CO2), showing few 
clumps of degenerating cells (Black arrow) and many normal cells (Blue 
arrow). The changes in the B50 cells were observed in six different plates with 
same field morphological method in a quadri-point analysis under the Nikon 
Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mmx40 magnification.
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Plate11:Representative of B50 neuronal cells pre-treated against hypoxia 
with 50nM Win at 0hrs and cultured for 96hrs (5%O2 and 5% CO2), showing 
few degenerating cells (Black arrow) and many normal cells (Blue arrow). 
The effects in the cells were observed in six different plates with same field 
morphological method in a quadri-point analysis under the Nikon Eclipse 
TS100 microscope and microphotographs processed with an IBM Image 
Solutions®. Scale bar = 5mmx40 magnification.
 
Plate12:Representative of B50 neuronal cells pre-treated against hypoxia with 
50nM Win at 0hrs and cultured for 96hrs (5%O2 and 5% CO2), showing few 
degenerating cells (Black arrow) and many normal cells (Blue arrow). The effects 
in the cells were observed in six different plates with same field morphological 
method in a quadri-point analysis under the Nikon Eclipse TS100 microscope and 
microphotographs processed with an IBM Image Solutions®. Scale bar = 5mmx40 
magnification.
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______
Plate 13:Representative of B50 neuronal cells pre-treated against hypoxia with 
50nM 2-AG at 0hrs and cultured for 96hrs (5%O2 and 5% CO2),showing many 
normal cells (Blue arrow) and few degenerating cells (Black arrow). The effects of 
hypoxia in the cells were observed in six different plates with same field 
morphological method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar =5mmx40 magnification.
______
Plate14:Representative of B50 neuronal cells pre-treated against hypoxia with 50nM 
AEA at 0hrs and cultured for 96hrs (5%O2 and 5% CO2), showing some degenerating 
cells (Black arrow) and few normal cells (Blue arrow). The effects in the cells were 
observed in six different plates with same field morphological method in a quadri-point 
analysis under the Nikon Eclipse TS100 microscope and microphotographs processed 
with an IBM Image Solutions®. Scale bar =5mmx40 magnification.
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Plate15:Representative of B50 neuronal cells pre-treated against hypoxia with 
100nM 2-AG at 0hrs and cultured for 96hrs (5%O2 and 5% CO2),showing many 
normal cells (Blue arrow) and few degenerating cells (Black arrow). The effects 
in the cells were observed in six different plates with same field morphological 
method in a quadri-point analysis under the Nikon Eclipse TS100 microscope 
and microphotographs processed with an IBM Image Solutions®. Scale bar = 
5mm x40 magnification.
______
_______
Plate16:Representative of Normal B50 neuronal cells cultured for 96hrs at 21% 
O2 and 5% CO2, showing normal cell morphology (Blue arrow). The cells were 
observed in six different plates with same field morphological method in a quadri-
point analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar =5mmx40 magnification.
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Plate17:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 100nM Win against hypoxia for 48hrs making up 96hrs of culture in 5%O2 and 
5% CO2, showing some groups of degenerating cells (Black arrow) and many 
healthy cells (Blue arrow). The changes in the cells were observed in six different 
cultures with same field morphological method in a quadri-point analysis under the 
Nikon Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mm x40 magnification.
 
Plate18:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 10nM Win against hypoxia for 48hrs making up 96hrs of culture in 5%O2 and 
5% CO2, showing many normal and healthy cells (Blue arrow). The changes in 
the cells were observed in six different cultures with same field morphological 
method in a quadri-point analysis under the Nikon Eclipse TS100 microscope and 
microphotographs processed with an IBM Image Solutions®. Scale bar = 5mm 
x40 magnification.
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Plate19:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 50nM Win against the hypoxia for 48hrs making up 96hrs of culture in 5%O2 
and 5% CO2. The plate show many normal and healthy cells (Blue arrow). The 
changes in the cells were observed in six different cultures with same field 
morphological method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar = 5mm x40 magnification.
Plate 20:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 100nM AEA against hypoxia for 48hrs making up 96hrs of culture in 5%O2 and 
5% CO2), showing some degenerating cells (Black arrow) and some normal cells (Blue 
arrow). The changes in the cells were observed in six different cultures with same field 
morphological method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. Scale 
bar = 5mm x40 magnification.
______
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3.3.2.        The effect of cannabinoid agonist treatment on cellular proliferation in 
normal and hypoxic cultured B50 cells. 
The effect of cannabinoid receptor agonist treatment on cellular proliferation in 
normal cultured neuronal B50 cells is shown in Figure 3.10 and Table 3.5. The result 
shows an increase in cellular proliferation from the normal cells (20x106cells/ml) 
without drug treatment: those cells treated with 10nM Win had 22x106cells/ml, 
100nM Win had 24x106cells/ml, 10nM AEA had 25x106cells/ml, 100nM AEA had 
25x106cells/ml. Those treated with 10nM 2-AG had 20x106cells/ml and 100nM 2-AG 
had 17x106cells/ml. The increase in cellular proliferation in B50 cells from the normal 
was significant (P<0.05) with those treated with 100nM Win, 10nM AEA and 100nM 
AEA, but the decrease in cellular proliferation in cells treated with 100nM 2-AG was 
not significant (P=0.21). The treatment with 10nM 2-AG (20x106cells/ml) produced 
no change in the level of cellular proliferation in B50 cells when compared with the 
normal control B50 cells (20x106cells/ml). The effect of cannabinoid agonist 
treatment on cellular proliferation in cultured B50 cells in hypoxia is shown in Figure 
3.11 and Table 3.6. The results showed a significant reduction (P<0.05) in B50 cell 
proliferation in hypoxic cells with and without cannabinoid treatment when compared 
with normal cultured B50 cells with no drug treatment. The results are: normal cells 
without drug treatment 20x106cells/ml, hypoxic cell with no treatment 7x106cells/ml, 
10nM Win 11x106cells/ml, 100nM Win 13.7x106cells/ml, 10nM AEA 
10.6x106cells/ml, 100nM AEA 12.2x106cells/ml, 10nM 2-AG 10x106cells/ml and 
100nM 2-AG 13.8x106cells/ml. When the results of cellular proliferation in B50 cells 
were compared between the hypoxic B50 cells without drug treatment (7x106cells/ml) 
and the hypoxic B50 cells treated with different concentrations of cannabinoid 
agonists, the result showed a significant increase (P<0.05) in cellular proliferation. 
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Table 3.5: The effect of cannabinoid agonist treatment on cellular proliferation 
in normal cultured B50 cells using proliferation assay. 
Type of Treatment Measured Optical 
Density 
Calculated Value 
 (x106)cells/ml 
 Normal Cells no Drug 1.5 20.00±0.47 
10nM Win  1.6 22.40±1.25* 
100nM Win 1.9 24.40±0.70* 
10nM AEA 2.0 25.00±0.01* 
100nM AEA  2.2 25.25±0.51* 
10nM 2-AG 1.5 20.00±0.12 
100nM 2-AG 1.3 17.50±0.42 
(Data presented as means ±SD; n=6;*P<0.05 versus untreated normal cells; Student’s t-test). 
 
Table 3.6: The effect of cannabinoid agonist treatment on cellular proliferation 
in cultured B50 cells in hypoxia using proliferation assay. 
Type of Treatment  Measured Optical 
Density 
Calculated Value 
        (x106)cells/ml  
Normal Cells no Drug 1.5 20.00±0.47* 
 Hypoxic cells no drug 0.35 7.0±0.12 
10nM Win  0.62 11.25±0.24* 
100nM Win 0.81 13.70±0.42* 
10nM AEA 0.58 10.60±0.04* 
100nM AEA  0.74 12.20±0.02* 
10nM 2-AG 0.46 10.00±0.04* 
100nM 2-AG 0.87 13.80±0.29* 
(Data presented as means ±SD; n=6;*P<0.05 versus hypoxic, untreated cells; Student’s t-test).  
Tables 3.5 and 3.6 show effect of cannabinoid agonist on cell proliferation of B50 
cells cultured in normal (21%O2; 5%CO2) and hypoxic (5%O2; 5%CO2) conditions 
using proliferation assay method. The cells were cultured for 48hrs and then treated 
with different cannabinoid agonists at different concentrations for 48hrs i.e. a total of 
96hrs of cell culture. The number of proliferated B50 cells was obtained from the 
standard curve prepare using trypan blue counting method and CellTiter Aqueous One 
Solution assay method. Culture plate containing 42.5x106 cells/ml was used to 
prepared five dilutions (0, 2, 4, 5 and 10) x106 cells/ml and the absorbance (n=5) was 
measured at 490nm and plotted against the number of cells to give the standard curve. 
The numbers of cells from the test groups were derived by plotting the absorbance of 
the test groups against the known cell numbers from the standard. 
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Fig.3.10. The effect of cannabinoid treatment on cellular 
proliferation in normal cultured B50 cells
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Fig.3.10. Effect of cannabinoid agonist on cell proliferation of B50 cells cultured in 
normal (21%O2; 5%CO2) conditions using proliferation assay method. The cells were 
cultured for 48hrs and then treated with the cannabinoid agonists for 48hrs, i.e. a total 
of 96hrs of culture. The number of proliferated cells was quantified using standard 
curve prepared using trypan blue counting method and CellTiter Aqueous One 
Solution assay method. Culture plate containing 42.5x106cells/ml was used to prepare 
five dilutions (0, 2, 4, 5 and 10) x 106 cells/ml and the absorbance (n=5) was 
measured at 490nm and plotted against the number of cells to give a standard curve. 
The number of cells from the tests was quantified using the absorbance of the test 
groups against the known cell numbers from the standard.(*P<0.05 versus normal, 
untreated cells; Student’s t-test). 
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Fig. 3.11.The effect of cannabinoid agonist treatment on cellular 
proliferation in cultured B50 cells in hypoxia
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Fig.3.11. Effect of cannabinoid agonist on proliferation of B50 cells cultured in 
hypoxia (5%O2; 5%CO2) using proliferation assay method. The cells were cultured 
for 48hrs and then treated with the cannabinoid agonists for 48hrs, i.e. a total of 96hrs 
of culture. The number of proliferated cells was quantified from standard curve 
prepared using trypan blue counting method and CellTiter Aqueous One Solution 
assay method. Culture plate containing 42.5x106cells/ml was used to prepare five 
dilutions (0, 2, 4, 5 and 10) x106cells/ml and the absorbance (n=5) was measured at 
490nm and plotted against the number of cells to give a standard curve. The numbers 
of cells from the tests were quantified using the absorbance of the test groups against 
the known cell numbers from the standard. (*P<0.05 versus hypoxic untreated cells; 
Student’s t-test). 
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The effect of cannabinoid agonist concurrent administration at 0hr and culture of B50 
cells, referred as pre-treatment on cellular proliferation in normal cultured B50 cells is 
shown in Figure 3.12. The cells were cultured for 96hrs and the results show that 
normal cultured B50 cells with drug pre-treatment had either increased or decreased 
cellular proliferation when compared to the normal untreated B50 cells. The results 
were normal, untreated cells 20x106cells/ml, 10nM Win 10.9x106cells/ml, 50nM Win, 
15.6x106cells/ml; 100nM Win, 13.7x106cells/ml; 10nM AEA, 7.5x106cells/ml; 50nM 
AEA, 20x106cells/ml; 100nM AEA, 21x106cells/ml; 10nM 2-AG, 20.5x106cells/ml; 
50nM 2-AG, 20.5x106cells/ml; 100nM 2-AG, 26.8x106cells/ml. The decrease in cell 
proliferation was significant (p<0.05) between the untreated normal B50 cells and 
those pre-treated with 10nM Win (10.9x106cells/ml) and 10nM AEA (7.5x106cells/ 
ml). The decrease in cell proliferation was not significant (P=0.63) between the 
normal untreated B50 cells and those pre-treated with 50nM Win (15.6x106cells/ml) 
and 100nM Win (13.7x106cells/ml). There was a significant increase (p<0.05) in cell 
proliferation between the normal untreated cells and those pre-treated with 100nM 2-
AG (26.8x106cells/ml) while the slight increase in proliferation in 100nM AEA 
(21x106cells/ml) was not significant (P=0.82) and those pre-treated with 50nM AEA 
(20x106cells/ml), 10nM 2-AG (20.5x106cells/ml), and 50nM 2-AG (20.5 x106cells/ 
ml) showed no change in cellular proliferation when compared with the untreated 
normal cells which served as the control (20x106cells/ml) (Table 3.7). 
The effects of cannabinoid agonist pre-treatment against hypoxia on cellular 
proliferation in B50 cells cultured in hypoxia are shown in Figure.3.13. The results 
showed that the untreated normal B50 cells (20x106cells/ml), had the same 
proliferation with the B50 cells pre-treated against hypoxia with 10nM Win 
(20x106cells/ml). The proliferation of untreated B50 cells in hypoxia (7x106cells/ml) 
was significantly increased (P<0.05) when compared with the cells pre-treated against 
hypoxia with 50nM AEA (10.6x106cells/ml); 100nM AEA (10.7x106cells/ml); 
100nM 2-AG (10.5x106cells/ml), 50nM Win (14.8x106cells/ml); 100nM Win 
(14.7x106cells/ml); 10nM Win (20x106cells/ml) and 10nM AEA (15.6x106cells/ml), 
while there was no appreciable change in cellular proliferation in cells pre-treated 
with 10nM 2-AG (7.5x106cells/ml); 50nM 2-AG (7.6x106cells/ml), when compared 
with the untreated hypoxic B50 cells in culture as shown in Table 3.8. 
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The effects of cannabinoid agonist and antagonist treatment on cellular proliferation 
in cultured B50 cells in hypoxia are shown in Figure 3.14. The result showed a  
significant increase (P<0.05) in cellular proliferation between the hypoxic untreated 
B50 cells (7x106cells/ml), and those treated with 100nM AM251/100nM Win 
(20.10x106cells/ml), 50nM AM630/50nM Win (13.5x106cells/ml) and 50nM AM251/ 
50nM Win (11.25x106cells/ml) and normal untreated B50 cells (20x106cells/ml), 
while the increase with 100nM AM630/100nM Win (9x106cells/ml) was not 
significant (P=0.15)(Table 3.9).  
 
 
Table 3.7: The effect of cannabinoid agonist pre-treatment on cellular 
                    proliferation in normal cultured B50 cells.   
Type of Treatment  Measured Optical 
Density(490nm) 
Calculated Value 
     (x106cells/ml) 
Normal Cells no Drug 1.5 20.00±0.47 
10nM Win 0.53 10.90±0.02* 
50nM Win  1.03 15.60±0.44* 
100nM Win 0.82 13.75±0.23* 
10nM AEA 0.37 07.50±0.05* 
50nM AEA 1.51 20.00±0.11 
100nM AEA 1.65 21.25±0.24 
10nM 2-AG 1.57 20.50±0.50 
50nM 2-AG 1.57 20.50±0.36 
100nM 2-AG 2.16 26.88±0.84* 
(Data presented as mean ±SD; n=6; *P<0.05 versus normal untreated cells; Student’s t-test). 
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Table 3.8: The effect of cannabinoid agonist pre-treatment on cellular    
                   proliferation in cultured B50 cells in hypoxia. 
Type of Treatment  Measured Optical 
Density(490nm) 
Calculated Value 
      (x106cells/ml) 
 Normal Cells no Drug 1.5 20.00±0.47* 
 Hypoxic cells no drug 0.35 07.00±0.12 
10nM Win  1.52 20.10±0.64* 
50nM Win 0.94 14.80±0.31* 
100nM Win 0.94 14.70±0.16* 
10nM AEA 1.03 15.60±0.82* 
50nM AEA 0.57 10.60±0.04* 
100nM AEA 0.59 10.70±0.28* 
10nM 2-AG 0.37 07.50±0.25 
50nM 2-AG 0.39 07.60±0.29 
100nM 2-AG 0.53 10.50±0.43* 
(Data presented as mean ±SD; n=6; *P<0.05 versus hypoxic untreated cells; Student’s t-test). 
 
The cannabinoid agonist pre-treatment on proliferation of B50 cells in normal (21%O2; 
5%CO2) condition using proliferation assay method. The cells were treated with cannabinoid 
agonists at 0hr and then cultured for 96hrs. The number of proliferated cells was quantified 
from standard curve prepared using trypan blue cell counting and CellTiter assay methods. 
Culture plate containing 42.5 x 106cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 
10) x106cells/ml and the absorbance at 490nm (n= 5) was plotted against the number of cells. 
The number of cells from the tests was quantified using the absorbance of the test groups 
(n=6) against the known cell numbers from the standard.(Data presented as mean ±SD; n=6; 
*P<0.05 versus untreated normal cells; Student’s t-test). 
Fig.3.12.The effect of cannabinoid agonist pre-treatment on 
cellular proliferation in normal cultured B50 cells
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Fig.3.13. The effect of cannabinoid agonist pre-treatment on 
cellular proliferation in cultured B50 cell in hypoxia
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The effect of cannabinoid agonist pre-treatment on proliferation of B50 cells cultured 
in hypoxic (5%O2; 5%CO2) conditions using proliferation assay method. The cells 
were treated with different cannabinoid agonists in different concentrations at 0hr 
(concurrent treatment) and then cultured for 96hrs in culture. The number of 
proliferated cells was quantified from standard curve prepared using trypan blue 
counting method and CellTiter Aqueous One Solution assay method. Culture plate 
containing 42.5 x 106cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 10) x 
106 cells/ml and the absorbance (n= 5) was measured at 490nm and plotted against the 
number of cells to give a standard curve. The number of cells from the tests were 
quantified using the absorbance of the test groups (n=6) against the known cell 
numbers from the standard.(Data as mean ±SD; n=6; *P<0.05 versus hypoxic, 
untreated cells; Student’s t-test). 
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Table 3.9: The effect of treatment of cannabinoid agonist/antagonist on   
                    cellular proliferation in cultured B50 cells in hypoxia. 
 
 
Type of Treatment  Measured Optical 
Density 
Calculated Value 
   (x106cells/ml) 
 Normal Cells no Drug 1.5 20.00±0.47* 
 Hypoxic cells no drug 0.35 07.00±0.12 
50nM Win 0.94 14.80±0.31* 
100nM Win 0.81 13.70±0.42* 
AM251/50nM Win 0.69 11.25±0.29* 
AM251/100nM Win 1.55 20.10±0.03* 
AM630/50nM win 0.86 13.50±0.64* 
AM630/100nM Win 0.50 09.00±0.11 
(Data presented as mean ±SD; n=6; *P<0.05 versus hypoxic untreated cells; Student’s t-test). 
The effect of cannabinoid agonist ±antagonist on the proliferation of B50 cells 
cultured in hypoxia (5%O2; 5%CO2), using proliferation assay method. The cells were 
cultured for 48hrs and then treated with cannabinoid agonists/antagonists for another 
48hrs making-up 96hrs of culture. The number of proliferated cells was quantified 
from the standard curve prepared using trypan blue counting method and CellTiter 
Aqueous One Solution assay method. Culture plate containing 42.5 x 106cells/ml was 
used to prepare five dilutions (0, 2, 4, 5 and 10) x 106cells/ml and the absorbance 
(n=5) was measured at 490nm and plotted against the number of cells to give a 
standard curve. The number of cells from the tests were quantified using the 
absorbance of the test groups (n=6) against the known cell numbers from the 
standard.(*P<0.05 versus hypoxic, untreated cells; Student’s t-test). 
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The effect of cannabinoid agonist±antagonist on the proliferation of B50 cells 
cultured in hypoxia (5%O2; 5%CO2), using proliferation assay method. The cells were 
cultured for 48hrs and then treated with cannabinoid agonists/antagonists for another 
48hrs making-up 96hrs of culture. The number of proliferated cells was quantified 
from the standard curve prepared using trypan blue counting method and CellTiter 
Aqueous One Solution assay method. Culture plate containing 42.5 x 106cells/ml was 
used to prepare five dilutions (0, 2, 4, 5 and 10) x 106cells/ml and the absorbance 
(n=5) was measured at 490nm and plotted against the number of cells to give a 
standard curve. The number of cells from the tests were quantified using the 
absorbance of the test groups (n=6) against the known cell numbers from the 
standard.(Data as mean ±SD; *P<0.05 versus hypoxic, untreated cells; Student’s t-
test). 
 
 
 
 
Fig.3.14.The effect of cannabinoid agonist/antagonist treatment on 
cellular proliferation in cultured B50 cells in hypoxia 
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3.4.     LDH release from neuronal B50 cells in culture using LDH assay 
3.4.1     LDH release from treatment with cannabinoid agonist/antagonist in B50 
neuronal cells cultured in hypoxia. 
The LDH release from cultured B50 neuronal cells was used as an index of neuronal 
injury. LDH release from cultured B50 cells in hypoxia treated with different 
concentrations of cannabinoid receptor agonists is shown in Figure 3.15. The results 
show a significant 4-fold increase in LDH leakage in non-treated hypoxic cells 
(440%), when compared to normal B50 cells (100%) in culture (p<0.05). The results 
of the treatment with different concentrations of cannabinoid agonists, show that 
cannabinoid agonists have a significant 2-to 4-fold decrease in LDH release from B50 
cells treated in hypoxia when compared to the untreated hypoxic B50 cells (440%) 
(p<0.05). The results are 10nM Win (217%), 50nM AEA (181%), 100nM AEA 
(69%) 50nM 2-AG (209%) and 100nM 2-AG (103%). (Table 3.10). 
The results in Figures 3.16a and 3.16b, show the B50 cells treated with cannabinoid 
agonist in the presence or absence of antagonists. The results show a significant 4-fold 
increase in LDH released from B50 cells treated with 10nM AM251/10nM Win 
(840%) when compared to the cells treated with 10nM Win (217%) alone ((p<0.05), 
while there was a 2-to 3-fold increase in LDH release from cells treated with 50nM 
AM630/50nM AEA (212%) and 100nM AM630/100nM AEA  (236%) when 
compared to the cells treated with the cannabinoid agonist alone: 50nM AEA (181%) 
and 100nM AEA (69%) (Table 3.11). 
The LDH release from normal cultured B50 cells treated with cannabinoid agonists is 
shown in Figure 3.17. The results show that the LDH released in those cells treated 
with 10nM Win (49%), 100nM Win (31%), and 50nM AEA (57%), 50nM Win 
(61%), 10nM AEA (59%), 100nM AEA (60%), 50nM 2-AG (59%), was significantly 
decreased (P<0.05) when compared with that from the normal cultured cells without 
treatment (100%), while the decrease in LDH release was not significant in those B50 
cells treated with, 10nM 2-AG (81%) (P=0.92) and 100nM 2-AG (66%) (P= 0.24), as 
shown in Table 3.12. 
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Table 3.10: The effect of cannabinoid agonist treatment on LDH release in  
              cultured B50 cells in hypoxia. 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
Normal culture 0.207±0.101    100±10.1 
Hypoxia no Drug 0.911±0.211 440±21.1* 
10nM Win 0.450±0.102 217±10.2* 
50nM Win 0.564±0.112 273±11.2* 
100nM Win 1.090±0.225 527±22.5* 
10nM AEA. 0.932±0.323 450±32.3* 
50nM AEA. 0.374±0.125 181±12.5* 
100nM AEA. 0.142±0.101 69±10.1* 
10nM 2-AG. 0.482±0.221 233±22.1* 
50nM 2-AG. 0.432±0.201 209±20.1* 
100nM 2-AG. 0.214±0.111 103±11.1 
The effect of cannabinoid agonist treatment on LDH release in B50 cells in hypoxia 
(5%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs in hypoxia and then 
treated for 48hrs in hypoxia making 96hrs of culture and the absorbance (n=6) was 
measured at 490nm. The LDH released from the normal culture (21%O2; 5%CO2),  
was used as the control (100%) for the experiment and LDH release was expressed 
relative to the control. (Data as mean ±SD; *P<0.05 versus normal untreated cells; 
Student’s t-test).     
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Table 3.11: The effect of cannabinoid agonist/antagonist treatment on LDH  
                  release in cultured B50 cells in hypoxia. 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control 
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 0.911±0.211 440±21.1 
10nM Win 
10nmAM251/ 
10nM Win 
 
50nM Win 
0.450±0.102 
1.738±0.451 
0.564±0.112 
217±10.2 
840±45.1* 
273±11.2 
50nM AM251/  
50nM Win 
100nM Win 
0.464±0.251 
1.090±0.225 
224±25.1 
527±22.5* 
100nM AM251/ 
100nM Win 
0.848±0.336 410±33.6 
10nM AEA 
10nM AM630/  
10nM AEA 
 
50nM AEA 
0.932±0.323 
1.202±0.455 
0.374±0.125 
450±32.3 
581±45.5* 
181±12.5 
50nM AM630/ 
50nM AEA 
100nM AEA 
0.438±0.321 
0.142±0.101 
212±32.1 
69±10.1 
100nM AM630/ 
100nM AEA 
0.488±0.333 236±33.3* 
The effect of cannabinoid agonist treatment in the presence of antagonist on LDH 
release in B50 cells in hypoxia (5%O2; 5%CO2), using LDH assay. Cells were 
cultured for 48hrs in hypoxia and then treated with cannabinoid agonist and 
equivalent concentration of antagonist for 48hrs in hypoxia making 96hrs of culture 
and the absorbance (n=6) was measured at 490nm. The LDH released from the 
normal culture (21%O2; 5%CO2), was used as the control (100%) for the experiment 
and the LDH release was expressed relative to the control. (Data presented as mean 
±SD; *P<0.05 versus agonist/antagonist treated hypoxic cells; Student’s t-test).     
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Table 3.12: The effect of cannabinoid agonist treatment on LDH release in  
                      cultured normal B50 cells. 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
 Normal  no Drug   0.172±0.122 100±12.2 
10nM Win   0.083±0.055 49±5.5* 
50nM Win   0.104±0.095 61±9.5* 
100nM Win   0.053±0.051 31±5.1* 
10nM AEA   0.101±0.099 59±9.9* 
50nM AEA   0.098±0.089 57±8.9* 
100nM AEA   0.103±0.101 60±10.1* 
10nM 2-AG   0.139±0.110 81±11.0 
50nM 2-AG   0.101±0.100 59±10.0* 
100nM 2-AG   0.112±0.102 66±10.2 
The effect of cannabinoid agonist treatment on LDH release in normal cultured B50 
cells (21%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs in normal 
culture and then treated for 48hrs in normal conditions making 96hrs of culture and 
the absorbance (n=6) was measured at 490nm. The LDH released from the untreated 
normal cultured cells, was used as the control (100%) for the experiment and LDH 
release was expressed relative to the control. (Data presented as mean ±SD; *P<0.05 
versus untreated normal cells; Student’s t-test).     
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The effect of cannabinoid agonist treatment against hypoxia on LDH release in B50 
cells in hypoxia (5%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs and 
treated for 48hrs i.e. total of 96hrs of culture. The absorbance (n=6) was measured at 
490nm. The LDH released from the normal untreated culture (21% O2; 5% CO2) was 
used as the control (100%) and LDH released was expressed relative to the control 
(*P<0.05 versus normal; Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.15.The effect of cannabinoid treatment on LDH 
release from cultured B50 cells in hypoxia.
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Figs.3.16a&b:The effect of cannabinoid agonist treatment against hypoxia in the presence or 
absence of antagonist on LDH release in B50 cells in hypoxia (5%O2; 5%CO2), using LDH 
assay. Cells were cultured for 48hrs and then treated with agonist and equivalent 
concentrations of antagonist for another 48hrs for a total of 96hrs of culture in hypoxia. The 
absorbance (n=6) was measured at 490nm. The LDH released from the normal untreated 
culture (21%O2; 5%CO2) was used as the control (100%) and LDH released was expressed 
relative to the control.(*P<0.05 versus normal; #P<0.05 versus hypoxic untreated cells; 
Student’s t-test). 
Fig.3.16a.The effect of cannabinoid agonist/antagonist treatment 
on LDH release in cultured B50 cells.
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Fig.3.16b.The effect of cannabinoid agonist/antagonist treatment 
on LDH release in cultured B50 cells
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The effect of cannabinoid agonist treatment on LDH release in normal cultured B50 
cells (21%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs in normal 
culture and then treated with cannabinoid agonists for 48hrs in normal conditions to 
make-up 96hrs of culture and the absorbance (n=6) was measured at 490nm. The 
LDH released from the untreated normal cultured cells, was used as the control 
(100%) for the experiment and LDH release was expressed relative to the control. 
(*P<0.05 versus untreated normal cells; Student’s t-test).     
 
 
 
 
 
 
 
Fig.3.17.The effect of cannabinoid treatment on LDH release 
in normal cultured  B50 cells 
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3.4.2.    LDH release from pre-treatment with cannabinoid agonist/antagonist in 
cultured B50 cells in hypoxia. 
The LDH release from cultured B50 neuronal cells pre-treated against hypoxia with 
cannabinoid agonists, show that the LDH released was significantly increased in 
untreated hypoxic cells (440%) and cells pre-treated with various concentrations of 
cannabinoid agonists (p<0.05) when compared to the normal cultured B50 cells 
(100%), except for the cells pre-treated with 10nM Win (99%). The results show that 
the LDH leakage from untreated B50 cells in hypoxia (440%), and cells pre-treated 
with 50nM Win (404%) and 100nM Win (447%); 10nM AEA (386%); 50nM AEA 
(236%);100nM AEA (285%); 10nM 2-AG (677%), 50nM 2-AG (206%) and 100nM 
2-AG (494%), produced increases in LDH release ranging from approximately 2- to 
7- fold higher than the level released from normal B50 cells (100%). The results are 
shown in Figure 3.18. When the LDH release from the untreated B50 cells in hypoxia 
(440%) was compared with cells pre-treated with cannabinoid agonists, a significant 
2- to 4-fold decrease (p<0.05) in LDH release was observed in those pre-treated with 
10nM Win (99%), 50nM AEA (236%), 100nM AEA (285%) and 50nM 2-AG 
(206%), and a 2-fold increase in LDH release from cells pre-treated with 10nM 2-AG 
(677%) when compared with untreated B50 cells in hypoxia (440%) (Table 3.13). 
 The LDH release from cultured B50 neuronal cells pre-treated against hypoxia with 
different concentrations of cannabinoid agonist/antagonist is shown in Figures 3.19a 
and 3.19b. The results showed a significant 2-fold increase in LDH release from cells 
pre-treated with 10nM AM251/10nM Win (193%), when compared to cells with 
10nM Win (99%), a 1.5-fold increase in LDH release from 50nM AM251/50nM Win 
(550%) when compared to cells with 50nM Win, a 4-fold increase in LDH release 
from 10nM AM630/10nM AEA (816%) when compared with 10nM AEA (386%) 
and a 3-fold increase from 100nM AM630/100nM AEA (551%) when compared to 
cells with 100nM AEA (286%) (P<0.05) (Table 3.14). 
The effect of cannabinoid agonist pre-treatment on LDH leakage in normal cultured 
B50 cells is shown in Figure 3.20. The results show that the LDH released in normal 
cells pre-treated with 10nM Win (54%), 50nM AEA (54%) and 100nM AEA (50%), 
50nM Win (58%), 100nM Win (58%), 10nM AEA (62%), and 50nM 2-AG (61%), 
was significantly reduced (P<0.05) when compared with those from normal cultured 
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B50 cells (100%) without drug pre-treatment, while the decrease in LDH release from 
those cells pre-treated with 10nM 2-AG (74%) (P=0.21) and 100nM 2-AG (71%) 
(P=0.54), was not significant (Table 3.15). 
 
 
 
The effect of cannabinoid agonist pre-treatment against hypoxia on LDH release in 
B50 cells in hypoxic condition (5%O2;5%CO2), using LDH assay. Cells were 
concurrently cultured and treated with cannabinoid agonists at 0hr and then cultured 
for a total of 96hrs. The absorbance (n=6) was measured at 490nm. The LDH released 
from the normal untreated culture (21%O2;5%CO2) was used as the control (100%) 
and results expressed relative to the control. (*P<0.05 versus normal; #P<0.05 versus 
hypoxic untreated cells; Student’s t-test). 
 
 
Fig.3.18.The effect of cannabinoid pre-treatment on LDH 
release from cultured B50 cells in hypoxia
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Fig.3.19a.The effect of cannabinoid agonist/antagonist pre-
treatment on LDH release in cultured B50 cells in hypoxia
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Fig.3.19b.The effect of cannabinoid agonist/antagonist pre-
treatment on LDH release in cultured B50 cells in hypoxia
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Figs.3.19a & b:The effect of cannabinoid agonist pre-treatment in the presence or absence of 
antagonist against hypoxia on LDH release in B50 cells cultured in hypoxia (5%O2;5%CO2), 
using LDH assay. Cells were concurrently cultured and treated with the agonists only or 
agonist/antagonists at 0hr and then cultured for a total of 96hrs. The absorbance (n=6) was 
measured at 490nm. The LDH released from the normal untreated culture (21% O2; 5% CO2) 
was used as the control (100%) and results expressed relative to the control. (*P<0.05 versus 
agonist pre-treated hypoxic cells; Student’s t-test). 
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Table 3.13: The effect of cannabinoid pre-treatment on LDH release on  
                   cultured B50 cell in hypoxia 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control 
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 0.911±0.211 440±21.1* 
10nM Win 0.206±0.101 99±10.1# 
50nM Win 0.836±0.321 404±32.1* 
100nM Win 0.926±0.335 447±33.5* 
10nM AEA. 0.799±0.422 386±42.2* 
50nM AEA. 0.488±0.225 236±22.5*# 
100nM AEA. 0.590±0.321 285±32.1*# 
10nM 2-AG. 1.400±0.456 677±45.6*# 
50nM 2-AG. 0.428±0.115 206±11.5*# 
100nM 2-AG. 1.021±0.441 494±44.1* 
The effect of cannabinoid agonist pre-treatment on B50 cells concurrently exposed to 
hypoxia (5%O2; 5%CO2) and cannabinoid agonist on LDH release, using LDH assay. 
Cells were pre-treated at 0hr and then cultured for 96hrs in hypoxia and then assayed 
for LDH release. The absorbance (n=6) was measured at 490nm. The LDH released 
from the normal untreated culture (21%O2; 5%CO2), was used as the control (100%) 
and the result was expressed relative to the control. (Data expressed as mean ±SD;  
*P<0.05 versus normal; #P<0.05 versus hypoxic untreated cells; Student’s t-test). 
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Table 3.14: The effect of cannabinoid agonist/antagonist pre-treatment  
                   on LDH release in cultured B50 cells in hypoxia. 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control 
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 0.911±0.211 440±21.1 
10nM Win 
 
10nM AM251/ 
10nM Win 
0.206±0.101 
0.400±0.212 
99±10.1 
193±10.1* 
50nM Win 
50nM AM251/ 
50nM Win 
0.836±0.321 
1.380±0.522 
404±32.1 
550±52.2* 
100nM Win 
100nM AM251/ 
100nM Win 
0.926±0.335 
0.563±0.221 
447±33.5 
272±22.1* 
10nM AEA 
 
10nM AM630/ 
10nM AEA 
0.799±0.422 
 
1.688±0.455 
386±42.2 
 
816±45.5* 
 
50nM AEA 
50nM AM630/ 
50nM AEA 
 
0.488±0.225 
0.627±0.352 
 
236±22.5 
303±35.2 
100nM AEA 
100nM AM630/ 
100nM AEA 
0.590±0.321 
1.140±0.542 
285±32.1 
551±54.2* 
The effect of cannabinoid agonist in the presence of antagonist pre-treatment against 
hypoxia on LDH release in B50 cells cultured in hypoxia (5%O2;5%CO2), using LDH 
assay. Cells were cultured and pre-treated at 0hr and cultured for a total of 96hrs in 
hypoxia and assayed for LDH release. The absorbance (n=6) was measured at 490nm. 
The LDH released from the normal untreated culture (21%O2; 5%CO2), was used as 
the control (100%) and the result was expressed relative to the control. (Data 
expressed as mean ±SD; *P<0.05 versus agonist/antagonist treated cells; Student’s t-
test). 
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Table 3.15: The effect of cannabinoid pre-treatment on LDH release in normal 
                   cultured B50 cells. 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
Normal no Drug 0.172±0.122 100±12.2 
10nM Win 0.092±0.090 54±9.0* 
50nM Win 0.100±0.099 58±9.9* 
100nM Win 0.100±0.099 58±9.9* 
10nM AEA 0.106±0.101 62±10.1* 
50nM AEA 0.092±0.089 54±8.9* 
100nM AEA 0.086±0.085 50±8.5* 
10nM 2-AG 0.126±0.101 74±10.1 
50nM 2-AG 0.104±0.100 61±10.0* 
100nM 2-AG 0.122±0.101 71±10.1 
The effect of cannabinoid agonist concurrent treatment and culture of B50 cells on 
LDH release in normal cultured B50 cells (21%O2; 5%CO2), using LDH assay. Cells 
were pre-treated with cannabinoid agonist at 0hr and then cultured for a total of 96hrs 
in normal culture and the absorbance (n=6) was measured at 490nm. The LDH 
released from the untreated normal cultured cells was used as the control (100%) and 
LDH release was expressed relative to the control. (Data presented as mean ±SD; 
*P<0.05 versus untreated normal cells; Student’s t-test).     
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The effect of cannabinoid agonist pre-treatment on LDH release in normal cultured 
B50 cells (21%O2;5%CO2), using LDH assay. Cells were treated with cannabinoid 
agonists at 0hr of culture and then cultured for a total of 96hrs in normal conditions. 
The LDH assay absorbance (n=6) was measured at 490nm. The LDH released from 
the untreated normal cultured cells was used as the control (100%) and LDH release 
was expressed relative to the control. (*P<0.05 versus untreated normal cells; 
Student’s t-test).     
 
 
 
 
 
 
Fig.3.20.The effect of cannabinoid pre-treatment on LDH 
release in normal B50 cells in culture
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3.5         The effect of DbcAMP on LDH release from cultured B50 cells  
3.5.1      Effect of DbcAMP and cannabinoid agonists treatment ± antagonist on 
LDH release in cultured normal B50 cells. 
The effect of 1mM dibutyl cyclic adenosine monophosphate (DbcAMP) 
administration and cannabinoid agonist treatment on LDH release in normal cultured 
B50 cells, show a non-significant increase in LDH release from the cells treated with 
different concentrations of cannabinoid agonist and 1mM concentration of DbcAMP 
when compared with the normalized LDH release from the untreated normal cultured 
cells (100%). The results as shown in Figure 3.21, are normal cells with only 
DbcAMP (110%), DbcAMP with 10nM Win (108%), DbcAMP with 50nM Win 
(118%) and DbcAMP with 100nM Win (134%). When the result of LDH release from 
B50 cells treated with DbcAMP only (110%) was compared to those treated with 
DbcAMP and different concentrations of cannabinoid (Win) agonist, the result show a 
non-significant increase from DbcAMP with 50nM Win (118%) and DbcAMP with 
100nM Win (134%), and a non-significant decrease in LDH  release from DbcAMP 
with 10nM Win (108%). 
The effect of normal culture of B50 cells with 1mM DbcAMP, pre-treated with 
different concentrations of cannabinoid agonists is shown in Figure 3.22. The results 
show an increase in LDH release from cannabinoid agonist pre-treated and DbcAMP 
administered cells in normal culture when compared to the untreated normal cultured 
B50 cells (100%). The results are cells with only DbcAMP (110%), DbcAMP with 
10nM Win (109%), DbcAMP with 50nM Win (175%) and DbcAMP with 100nM 
Win (188%). The increase in LDH leakage was significant in those cells pre-treated 
with DbcAMP and 50nM Win (175%); and DbcAMP with 100nM Win (188%) 
(P<0.05), while the increase in LDH release in those B50 cells treated with DbcAMP 
only (110%) (P=0.98), DbcAMP with 10nM Win (109%) (P=0.77), was not 
significant. When the LDH release in B50 cells pre-treated with DbcAMP only 
(110%) was compared with those pre-treated with DbcAMP and cannabinoid agonist, 
the result showed a pattern of significance similar to that seen when compared with 
the normal untreated B50 cells. 
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The result of the culture of B50 cells in 1mM DbcAMP and treated with cannabinoid 
agonists in the presence of antagonists on LDH release in normal cultured B50 cells is 
shown in Figure 3.23. The results show that the LDH release was significantly 
increased (P<0.05) in those treated with 50nM AM251/50nM Win (130%) and 
100nM AM251/100nM Win (191%) when compared with untreated normal B50 cells 
(100%). When the LDH release was compared between the cells treated with 
DbcAMP only (110%) and the other groups, the result showed a significant increase 
(P<0.05) in LDH release in those B50 cells treated with 100nM AM251/100nM Win 
(191%), a non-significant increase in 50nM AM251/50nM Win (130%) (P=0.11) and 
a non-significant decrease in 10nM AM251/10nM Win (107%) (P=0.76).  
The effect of cannabinoid agonist/DbcAMP treatment on LDH release in normal cultured B50 
cells (21%O2; 5%CO2) using LDH assay. Cells were cultured in the presence of 1mM 
concentration of DbcAMP for 48hrs and then treated with different concentrations of 
cannabinoid agonist (Win) for 48hrs for a total of 96hrs of normal culture and the LDH assay 
absorbance (n=6) was measured at 490nm. The LDH released from the untreated normal 
cultured cells, was normalized and used as the control (100%) and LDH release was 
expressed relative to the control.(Data as Mean ±SD; Student’s t-test).  
Fig.3.21.The effect of cannabinoid/ DbcAMP treatment on 
LDH release in normal cultured B50 cells.
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Fig.3.22: Effect of cannabinoid agonist/DbcAMP pre-treatment on LDH release in 
normal cultured B50 cells (21%O2; 5%CO2), using LDH assay. Cells were cultured in 
1mM DbcAMP and pre-treated with cannabinoid agonist at 0hr and then cultured for 
96hrs in normal culture and the absorbance (n= 6) was measured at 490nm. The LDH 
released from the untreated normal cultured cells, was normalized and used as the 
control (100%) for the experiment and LDH release was expressed relative to the 
control. (Data point as mean ±SD; *P<0.05 versus untreated normal cells in culture; 
#P<0.05 versus cells with DbcAMP only; Student’s t-test).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.22.The effect of Cannabinoid/DbcAMP pre-treatment on LDH 
release in normal B50 cells.
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The effect of DbcAMP with cannabinoid agonist/antagonist treatment on LDH release 
in normal cultured B50 cells (21%O2; 5%CO2), using LDH assay. Cells were cultured 
in the presence of 1mM concentration of DbcAMP for 48hrs and then treated with 
different concentrations of cannabinoid agonist (Win) and antagonist AM251 for 
48hrs making up a total of 96hrs of normal culture. The absorbance of the LDH assay 
(n=6) was measured at 490nm. The LDH released from the untreated normal cultured 
cells, was normalized and used as the control (100%) and LDH release was expressed 
relative to the control.(Data as mean ±SD; *P<0.05 versus untreated normal cells; 
#P<0.05 versus Cells in DbcAMP only; Student’s t-test). 
 
 
 
Fig.3.23. The effect of DbcAMP and cannabinoid agonist/antagonist 
treatment on LDH release in normal B50 cells
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3.5.2     Effect of DbcAMP and cannabinoid agonists treatment and pre-treatment ± 
antagonist on LDH release in cultured B50 cells in hypoxia. 
The effect of B50 cell culture in 1mM DbcAMP, treated with different concentrations 
of cannabinoid agonist on LDH release in hypoxia is shown in Figure 3.24. The 
results show a significant (P<0.05) increase in LDH release from untreated B50 cells 
in hypoxia (158%), hypoxia with DbcAMP only (190%), and DbcAMP with 100nM 
Win (141%). There was a non-significant increase in DbcAMP with 10nM Win 
(133%) (P=0.91) and DbcAMP with 50nM Win (136%) (P=0.87). When the LDH 
release from the hypoxic untreated B50 cells (158%) was compared with cells treated 
with different concentrations of DbcAMP and cannabinoid agonist, the result show a 
significant increase (p<0.05) in LDH release in hypoxia with DbcAMP only (190%); 
a non-significant increase from DbcAMP with 100nM Win (141%) (P=0.22), and a 
non-significant decrease in LDH release from DbcAMP with 10nM Win (133%) 
(P=0.15) and DbcAMP with 50nM Win (136%) (P=0.23). 
The effect of B50 cell culture in 1mM DbcAMP, pretreated against hypoxia using 
different concentrations of cannabinoid agonist on LDH release is shown in Figure 
3.25. There was a significant increase (P<0.05) in LDH leakage from cells in different 
pre-treatment groups when compared with the untreated normal cells. The LDH 
release in the different groups are, hypoxia with no drug (158%), hypoxia with only 
DbcAMP (190%), DbcAMP with 10nM Win (146%), DbcAMP with 50nM Win 
(183%) and DbcAMP with 100nM Win (191%). When the level of LDH release was 
compared between the untreated hypoxic B50 cells (158%) and treated hypoxic cells, 
the results show that LDH release was significantly increased (P<0.05) in hypoxia 
with DbcAMP only (190%), DbcAMP with 50nM Win (183%) and DbcAMP with 
100nM Win (191%), while there was a non-significant decrease when compared to 
DbcAMP with 10nM Win (146%) (P=0.58). 
The culture of B50 cells in 1mM DbcAMP and treated with cannabinoid agonists in 
the presence of the antagonists on LDH release in B50 cells in hypoxia is shown in 
Figure 3.26. The results show that the LDH release from cells cultured with different 
concentrations of cannabinoid agonist/antagonist in hypoxia were significantly 
increased (P<0.05) in cells treated with 10nM AM251/10nM Win (182%) and 
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AM251/100nM Win (213%), when compared to the cells treated with agonist only 
DbcAMP/10nM Win (146%) and DbcAMP/100nM Win (191%).  
 
 
The effect of cannabinoid agonist and DbcAMP treatment on LDH release in B50 cells 
cultured in hypoxia (5%O2;5%CO2), using LDH assay. Cells were cultured in the presence of 
1mM concentration of DbcAMP for 48hrs and treated with different concentrations of 
cannabinoid agonist (Win) for 48hrs for a total of 96hrs of hypoxic culture. The LDH was 
assayed and absorbance (n=6) was measured at 490nm. The LDH released from the untreated 
normal cultured cells (21%O2; 5%CO2), was normalized and used as the control (100%) and 
LDH release was expressed relative to the control.(Data as Mean ±SD; *P<0.05 versus 
normal control; #P<0.05 versus untreated hypoxic cells; Student’s t-test). 
 
 
 
 
 
 
Fig.3.24.The effect of cannabinoid agonist/DbcAMP treatment on 
LDH release on B50 cells in Hypoxia
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The effect of cannabinoid agonist pre-treatment against hypoxia in the presence of 
DbcAMP on LDH release in B50 cells cultured in hypoxia (5%O2;5%CO2), using 
LDH assay. Cells were cultured in 1mM DbcAMP and pre-treated against hypoxia 
with cannabinoid agonist at 0hr and then cultured for 96hrs in culture and the LDH 
assay absorbance (n=6) was measured at 490nm. The LDH released from the 
untreated normal cultured cells (21%O2; 5%CO2), was normalized and used as the 
control (100%) and LDH release was expressed relative to the control. (Data as Mean 
±SD *P<0.05 versus untreated normal cells; #P<0.05 versus untreated hypoxic cells; 
Student’s t-test).     
 
 
 
 
Fig.3.25.The effect of cannabinoid/DbcAmp pre-treatment 
on LDH release in B50 cells in Hypoxia.
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The effect of B50 cell culture in DbcAMP and treated with cannabinoid agonist in the 
presence or absence of the antagonist on LDH release in cultured B50 cells in hypoxia 
(5%O2; 5%CO2), using LDH assay. Cells were cultured in the presence of 1mM 
concentration of DbcAMP for 48hrs and then treated with different concentrations of 
cannabinoid agonist (Win) and antagonist (AM251) for 48hrs for a total of 96hrs of 
hypoxic culture. The absorbance of the LDH assay (n=6) was measured at 490nm. 
The LDH released from the untreated normal cultured cells (21%O2; 5%CO2), was 
normalized and used as the control (100%) and LDH release was expressed relative to 
the control.(Data as mean ±SD; *P<0.05 versus untreated normal cells; # P<0.05 
versus agonist treated cells in hypoxia; Student’s t-test). 
 
 
 
Fig.3.26. The effect of DbcAMP and cannabinoid 
agonist/antagonist treatment on LDH release in B50 cells in 
hypoxia
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3.6    The concentration-dependent effect of a CB1 antagonist on cannabinoid 
agonist. 
3.6.1   Concentration-dependent activity of a selective CB1 antagonist (AM251) on 
10nM Win agonist treatment on LDH release in cultured B50 cells in hypoxia. 
The effect of concentration on the activity of a selective cannabinoid antagonist 
(AM251) on cannabinoid agonist (10nM Win) treatment using LDH release as an 
indicator of cell damage in B50 cells cultured in hypoxia is shown in Figure 3.27. The 
results show different concentrations of the antagonist (AM251) used to reverse the 
effect of a fixed concentration of the agonist (10nM Win). The result of LDH leakage 
from B50 cells treated with the agonist (10nM Win) and the antagonist are; 1.0nM 
AM251 (373%); 2.5nM AM251 (330%), 5.0nM AM251 (443%), 10nM AM251 
(586%), 15nM AM251 (380%), 20nM AM251 (468%) and 25nM AM251 (420%). 
The results show that treatment of B50 cells with 10nM Win  and 5.0nM AM251 
concurrently, brought the LDH release to 443% when compared to the agonist 10nM 
Win alone (217%) and untreated hypoxic B50 cells (440%). This shows that 5.0nM 
AM251 could be an ideal concentration of the antagonist to abolish the activity of the 
agonist (10nM Win) in the treatment of B50 cells in hypoxia. The result showed a 
significant increase (P<0.05) in LDH release in the experimental groups when 
compared to the normal cells. However, when the LDH release from the B50 cells in 
hypoxia (440%) was compared with those treated with different concentrations of the 
antagonist, the result showed a significant increase (P<0.05) in LDH release in 10nM 
AM251 (586%), while there was a significant decrease (p<0.05) in LDH release from 
hypoxic cells with 10nM Win treatment only (217%) and 2.5nM AM251 (330%) 
(Table 3.16). 
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Table 3.16:  Concentration-dependent activity of a selective CB1 antagonist 
(AM251) on 10nM Win agonist treatment on LDH release in cultured B50 cells 
in hypoxia 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 0.911±0.211 440±21.1* 
10nM Win 0.450±0.102 217±10.2*# 
1.0nM AM251 0.772±0.153 373±15.3* 
2.5nM AM251 0.684±0.074 330±7.4*# 
5.0nM AM251 0.886±0.182 443±18.2* 
10nM AM251 1.215±0.173 586±17.3*# 
15nM AM251 0.771±0.155 380±15.5* 
20nM AM251 0.969±0.123 468±12.3* 
25nM AM251 0.870±0.192 420±19.2* 
The effect of concentration-dependent activity of a selective CB1 antagonist on the 
agonist in B50 cells cultured in hypoxia. B50 cells were cultured in hypoxia (5%O2; 
5%CO2) and treated with different concentrations of the cannabinoid antagonist 
(AM251) against a fixed concentration of the agonist (10nM Win) using LDH assay 
method. Cells were cultured for 48hrs and then treated with cannabinoid agonist 
(10nM Win) and different concentrations of the cannabinoid antagonist (AM251) and 
then cultured for 48hrs for a total of 96hrs of culture. The absorbance of LDH assay 
(n=6) was measured at 490nm and the LDH released from the untreated normal 
cultured cells (21%O2; 5%CO2), was normalized and used as the control (100%) and 
the level of LDH release was expressed relative to the control. (Data presented as 
mean ±SD; *P<0.05 versus untreated normal cells; #P<0.05 versus hypoxia untreated 
cells; Student’s t-test).     
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The effect of concentration-dependent activity of a selective CB1 antagonist (AM251) 
on the agonist (10nM Win) in B50 cells cultured in hypoxia (5%O2; 5%CO2), using 
different concentrations of the cannabinoid antagonist against a fixed concentration of 
the agonist (10nM Win) treatment on LDH assay. Cells were cultured for 48hrs and 
then treated with the cannabinoid agonist (10nM Win) and different concentrations of 
the antagonist (AM251) and then cultured for another 48hrs making a total of 96hrs of 
culture. The LDH assay absorbance (n=6) was measured at 490nm and the LDH 
released from the untreated normal cultured cells (21%O2; 5%CO2), was normalized 
and used as the control (100%) and the level of LDH release was expressed relative to 
the control. (Data presented as mean ±SD; *P<0.05 versus untreated normal cells; 
#P<0.05 versus hypoxia, untreated cells; Student’s t-test).     
 
 
 
 
Fig.3.27. Concentration dependent activity of the antagonist 
(AM251) on agonist (10nM) Win treatment on LDH release in B50 
cells in hypoxia 
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3.6.2     Concentration-dependent activity of a selective CB1 antagonist (AM251) on 
10nM Win pre-treatment using LDH release in cultured B50 cells in hypoxia. 
The effect of concentration-dependent activity of a selective CB1 antagonist (AM251) 
pre-treated against hypoxia with a fixed concentration of 10nM Win on LDH release 
in B50 cells in hypoxia is shown in Figure 3.28. The results show that normal cells 
had 100% LDH release, the untreated hypoxic cells with 440% and the cells in 
hypoxia pre-treated with 10nM Win only (99%), while the pre-treated cells with 
different concentrations of the antagonist on a fix concentration of the agonist (10nM 
Win), had a significant increase in LDH release between 2-to 5-fold when compared 
with the normal cells (P<0.05) as follows: 1.0nM AM251 (450%); 2.5nM AM251 
(597%); 5.0nM AM251 (609%);10nM AM251 (312%); 15nM AM251 (375%); 20nM 
AM251 (156%); 25nM AM251 (255%). The result showed that the pre-treatment of 
B50 cells concurrently with 10nM Win and 1.0nM AM251 (452%) was able to 
abolish the effect of the agonist and brought LDH release close to the hypoxic level 
(440%). When the LDH release from the untreated hypoxic cells (440%) was 
compared with those pre-treated with 10nM Win agonist and different concentrations 
of the antagonist, the result showed a significant increase (P<0.05) in LDH release in 
those cells pre-treated with 2.5nM AM251 (597%) and 5.0nM AM251 (609%), and a 
significant decrease (P<0.05) in LDH release from those B50 cells pre-treated with 
10nM AM251 (312%), 15nM AM251 (375%), 20nM AM251 (156%) and 25nM 
AM251 (255%) (Table 3.17). 
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Table 3.17:  Concentration-dependent activity of a selective CB1 antagonist 
(AM251) on 10nM Win pre-treatment using LDH release in cultured B50 cells in 
hypoxia 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
Normal Culture 0.207±0.101   100±10.1 
Hypoxia no Drug 0.911±0.211   440±21.1* 
10nM Win 0.206±0.101   99±10.1# 
1.0nM AM251 0.936±0.40   452±40.0* 
2.5nM AM251 1.235±0.60   597±60.0*# 
5.0µM AM251 1.260±0.39   609±39.0*# 
10nM AM251 
15nM AM251 
0.647±0.142 
0.777±0.50 
  312±14.2*# 
  375±50.0*# 
20nM AM251 0.322±0.02   156±2.0# 
25nM AM251 0.527±0.34   255±34.0*# 
The effect of concentration-dependent activity of a selective CB1 antagonist (AM251) 
on pre-treatment with the agonist (Win) in B50 cells cultured in hypoxia using LDH 
release. B50 cells were cultured in hypoxia (5%O2;5%CO2), using different 
concentrations of the selective cannabinoid (CB1) antagonist (AM251) against a fixed 
concentration of cannabinoid agonist (10nM Win) using LDH assay. Cells were 
cultured and pre-treated against hypoxia with cannabinoid agonist (10nM Win) and 
with different concentrations of the antagonist at 0hrs and then cultured for a total of 
96hrs. The absorbance of LDH assay (n=6) was measured at 490nm and the LDH 
released from the untreated normal cultured cells (21%O2; 5%CO2), was normalized 
and used as the control (100%), the level of LDH release was expressed relative to the 
control. (Data expressed as mean ±SD; *P<0.05 versus untreated normal cells; 
#P<0.05 versus hypoxia untreated; Student’s t-test).     
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The effect of concentration-dependent activity of the selective CB1 antagonist 
(AM251) on the pre-treatment against hypoxia with the agonist (Win) in B50 cells 
cultured in hypoxia using LDH release. B50 cells were cultured in hypoxia 
(5%O2;5%CO2), using different concentrations of the cannabinoid antagonist 
(AM251) against a fixed concentration of the agonist (10nM Win). Cells were 
cultured and pre-treated with cannabinoid agonist (10nM Win) and different 
concentrations of the antagonist at 0hrs and then cultured for 96hrs. The absorbance 
of the LDH assay (n=6) was measured at 490nm and the LDH released from the 
untreated normal cultured cells (21%O2; 5%CO2), was normalized and used as the 
control (100%) for the experiment, the level of LDH release was expressed relative to 
the control. (Data expressed as mean ±SD; *P<0.05 versus untreated normal cells; 
#P<0.05 versus hypoxia untreated; Student’s t-test).     
 
 
 
 
 
 
 
 
 
Fig.3.28.Concentration dependent activity of antagonist (AM251) 
on the agonist (10nM Win) pre-treatment using LDH release in B50 
cells in hypoxia.
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3.7   Opioid receptor agonist administration 
3.7.1.    The effect of opioid treatment on the morphology of cultured B50 Cells. 
Morphological changes in untreated hypoxic B50 cells in culture are shown in Plates 
23, 25 and 26 when compared to normal B50 cells in Plates 21, 22 and 24. The 
normal cells showed the anticipated morphology of the neuronal B50 cells with 
normal neuronal cell arrangements while the B50 cells in hypoxia, showed groups of 
dead and degenerating cells when compared with the normal cells in culture. The 
effect of opioid agonist treatment on B50 neuronal cells in hypoxia, showed some 
dead and degenerating B50 cells when compared with normal B50 cells but when 
compared with untreated hypoxic cells, the hypoxic opioid-treated B50 cells, showed 
reduced cell death and improved morphology of the neuronal cells, Plates 27-29 for 
different concentrations of opioid receptor agonist treatment. 
The effect of pre-treatment against hypoxia with different concentrations of opioid 
agonists on the morphology of B50 cells in culture, show groups of degenerating cells 
as in Plates 30-35 for opioid pre-treated cells in hypoxia. The results show that the 
pre-treated B50 cells in hypoxia with different concentrations of opioid agonists, have 
improved morphology of the cells when compared with the untreated B50 cells in 
hypoxia. When the morphology of the pre-treated cells was compared to the B50 cells 
treated with the opioid agonist, results showed that the cells with opioid treatment had 
better and improved morphology of the cells. The results from the morphological 
changes in B50 cells either treated or pre-treated with opioid agonists, suggests that 
opioid agonists may have some therapeutic and protective benefits. When the results 
were further analyzed, they showed that the effect of hypoxia could have been 
aggravated by the length of time the cells stayed in hypoxia (Plates 23; 25 and 26), for 
24, 72 and 96 hours of culture respectively. This is because the more cells are exposed 
to hypoxia, the more the damage to the cells resulting in more dead and degenerated 
cells in culture. The results also tend to suggest that these drug-induced changes may 
be concentration dependent in which there were more dead and degenerating cell 
aggregates at higher concentration of the opioid agonist especially with the cells pre-
treated with the opioid agonists. This suggests that the B50 neuronal cells may show 
more sensitivity to the drugs when administered prior to exposure to hypoxic 
environment. Hence the higher the dose of the drugs, the more the adverse effects 
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especially when they are administered as a pre-treatment against hypoxia. Example is 
in the case of 100µM DAMGO administered as treatment (Plate 29) and pre-treatment 
(Plate 30), which showed that the treatment group was able to preserve the 
morphology of the B50 cells better than that of pre-treatment group in hypoxia. This 
could provide an explanation why some more adverse drug effects are experienced 
with some drugs in presymptomatic conditions rather than in symptomatic situations.    
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Plate 21:Representative of normal B50 cells at 0hrs of culture (21%O2 and 5% CO2) 
with normal cells (arrow). B50 cells was observed in six different plates with same 
field method in a quadri-point analysis under the Nikon Eclipse TS100 microscope 
and microphotographs processed with an IBM Image Solutions®. Scale bar 
=5mmx40 magnification.
__
 
 
 
Plate 22:Representative of normal B50 cells at 24hrs of culture (21%O2 and 5% CO2) with 
normal cells (arrow). B50 cells was observed in six different plates with same field method in 
a quadri-point analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar =5mmx40 magnification.
__
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Plate 23:Representative of B50 cells in hypoxia at 24hrs of culture (5%O2 and 5% CO2) 
with some groups of degenerating cells (Black arrow) and some normal cells (Blue arrow). 
Cells was observed in six different plates with same field morphological method in a quadri-
point analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar =5mmx20 magnification.
__
 
Plate 24:Representative of normal B50 cells at 72hrs of culture (21%O2 and 5% 
CO2) with normal cells (arrow). B50 cells was observed in six different plates with 
same field method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. Scale 
bar =5mmx40 magnification.
__
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Plate 25:Representative of B50 cells in hypoxia at 72hrs of culture (5%O2 and 5% CO2) 
with groups of degenerating cells (arrow). B50 cells was observed in six different plates 
with same field morphological method in a quadri-point analysis under the Nikon Eclipse 
TS100 microscope and microphotographs processed with an IBM Image Solutions®. Scale 
bar =5mmx20 magnification.
__
 
Plate 26:Representative of B50 cells in hypoxia at 96hrs of culture (5%O2 and 5% CO2) 
with groups of degenerating cells (arrow). B50 cells was observed in six different plates 
with same field morphological method in a quadri-point analysis under the Nikon Eclipse 
TS100 microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar =5mmx20 magnification.
__
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Plate27:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 10µM ICI-199,441 against hypoxia for 48hrs making-up 96hrs of culture (5%O2 
5% CO2), showing many normal cells (Blue arrow) and few degenerating cells (Black 
arrow). The cell was observed in six different cultures with same field morphological 
method in a quadri-point analysis under the Nikon Eclipse TS100 microscope and 
microphotographs processed with an IBM Image Solutions®. Scale bar = 5mm x40 
magnification.
__
Plate28:Representative of B50 cells cultured for 48hrs in hypoxia and then treated 
with 50µM DSLET against hypoxia for 48hrs making-up 96hrs of culture (5%O2 
5% CO2), showing many normal cells (Blue arrow) and few degenerating cells 
(Black arrow). The cell was observed in six different cultures with same field 
morphological method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar = 5mm x40 magnification.
__
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Plate29:Representative of B50 cells cultured for 48hrs in hypoxia and then treated with 
100µM DAMGO against hypoxia for 48hrs making-up 96hrs of culture (5%O2 5% CO2), 
showing many normal cells (Black arrow). The cell was observed in six different cultures 
with same field morphological method in a quadri-point analysis under the Nikon Eclipse 
TS100 microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar = 5mm x40 magnification.
__
 
 
 
Plate30:Representative of B50 cells pre-treated with 100µM DAMGO against hypoxia for 
96hrs of culture (5%O2 5% CO2), showing many degenerated cells (Black arrow) and 
some normal cells (Blue arrow). The cell was observed in six different cultures with 
same field method in a quadri-point analysis under the Nikon Eclipse TS100 microscope 
and microphotographs processed with an IBM Image Solutions®. Scale bar = 5mm x40 
magnification.
__
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Plate31:Representative of B50 cells pre-treated with 100µM DSLET against hypoxia for 
96hrs of culture (5%O2 5% CO2), showing few degenerated cells (Black arrow) and 
some normal cells (Blue arrow). The cells was observed in six different cultures with 
same field method in a quadri-point analysis under the Nikon Eclipse TS100 
microscope and microphotographs processed with an IBM Image Solutions®. Scale bar 
= 5mm x40 magnification.
 
 
 
Plate32:Representative of B50 cells pre-treated with 100µM  ICI-199,441 against 
hypoxia for 96hrs of culture (5%O2 5% CO2), with groups of degenerated cells (Black 
arrow) and some normal cells (Blue arrow). The cells was observed in six different 
cultures with same field method in a quadri-point analysis under the Nikon Eclipse 
TS100 microscope and microphotographs processed with an IBM Image Solutions®. 
Scale bar = 5mm x40 magnification.
__
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Plate33:Representative of B50 cells pre-treated with 10µM  ICI-199,441 against hypoxia 
for 96hrs of culture (5%O2 5% CO2), with many normal cells (arrow). The cells was 
observed in six different cultures with same field method in a quadri-point analysis under 
the Nikon Eclipse TS100 microscope and microphotographs processed with an IBM 
Image Solutions®. Scale bar = 5mm x40 magnification.
__
 
Plate34:Representative of B50 cells pre-treated at 0hrs with 10µM DAMGO against hypoxia for 
96hrs of culture (5%O2 5% CO2), with few degenerated cells (Black arrow) and many normal 
cells (Blue arrow). The cells were observed in six different cultures with same field method in a 
quadri-point analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar = 5mm x40 magnification.
__
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Plate35:Representative of B50 cells pre-treated at 0hrs with 10µM DSLET against 
hypoxia for 96hrs of culture (5%O2 5% CO2), with many normal cells (arrow). The 
cells were observed in six different cultures with same field method in a quadri-point 
analysis under the Nikon Eclipse TS100 microscope and microphotographs 
processed with an IBM Image Solutions®. Scale bar = 5mm x40 magnification.
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3.7.2.    The effect of opioid agonists on cellular proliferation in normal and 
hypoxic cultured B50 cells. 
The effect of opioid agonist treatment on cellular proliferation in normal cultured B50 
cells is shown in Figure 3.29. The result showed a significant decrease (P<0.05) in 
cell proliferation in cells treated with 10µM DAMGO (15x106cells/ml); 100µM 
DSLET (13.75x106cells/ml) and a non-significant decrease in proliferation in cells 
treated with 100µM DAMGO (17.5x106cells/ml) (P=0.73); 10µM DSLET (17.5x106 
cells/ml)(P=0.62); and 10µM ICI-199441 (16.88x106cells/ ml)(P=0.56), when 
compared to untreated normal B50 cells (20.20x106 cells/ml). The results of the 
effects of opioid agonist treatment on cellular proliferation in cultured B50 cells in 
hypoxia, showed about the same pattern of proliferation between the cells treated with 
100µM DAMGO (20x106cells/ml); 10µM DSLET (20x106cells/ml) and 100µM ICI-
199441 (21.52x106cells/ml), when compared to untreated normal cells (20x106cells/ 
ml). There was a non-significant decrease in cells treated with 10µM DAMGO 
(16.25x106cells/ml) (P=0.66); 100µM DSLET (17.6x106cells/ml) (P=0.69) and 10µM 
ICI-199441 (17.7x106 cells/ml) (P=0.72), when compared to control cells (20x106cells 
/ml). However, the decrease in cellular proliferation was significant (P<0.05) when 
compared with the hypoxic untreated B50 cells (7.0x106cells/ml). When the effect of 
opioid agonist treatment on cellular proliferation was compared between the treated  
hypoxic B50 cells with different concentrations of opioid agonists and the untreated 
hypoxic cells (7.0x106cells/ml), the results showed a significant increase (P<0.05) in 
cellular proliferation in all treated B50 cell groups in hypoxia (Figure 3.30).   
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The effect of opioid agonist on cell proliferation of B50 cells cultured in normal 
(21%O2;5%CO2) conditions using proliferation assay method. The cells were cultured 
for 48hrs and then treated with the opioid agonists for 48hrs for a total of 96hrs of 
culture. The cells were quantified using standard curve prepared from trypan blue 
counting method and CellTiter Aqueous One Solution assay method. Culture plate 
containing 42.5 x 106cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 10) x 
106 cells/ml and the absorbance of the CellTiter assay (n=5) was measured at 490nm 
and plotted against the number of cells to give a standard curve. The number of cells 
from the tests was quantified using the CellTiter assay absorbance of the test groups 
against the known cell numbers from the standard.(Data presented as mean ±SD; n=6; 
*P<0.05 versus normal, untreated cells; Student’s t-test). 
 
 
 
Fig.3.29.The effect of opioid agonist treatment on cellular 
proliferation in normal cultured B50 cells.
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The effect of opioid agonist on cell proliferation of B50 cells cultured in hypoxic 
(5%O2; 5%CO2) conditions using proliferation assay method. The cells were cultured 
for 48hrs and then treated with different opioid agonists at different concentrations for 
48hrs for a total of 96hrs of culture. The number of proliferated cells was quantified 
using standard curve prepared from trypan blue counting method and CellTiter 
Aqueous One Solution assay method. Culture plate containing 42.5 x 106cells/ml was 
used to prepare five dilutions (0, 2, 4, 5 and 10) x106cells/ml and the absorbance of 
the CellTiter assay (n= 5) was measured at 490nm and plotted against the number of 
cells to give a standard curve. The number of cells from the tests was quantified using 
the absorbance of the test groups against the known cell numbers from the standard. 
The number of cells from untreated normal cultured cells (21%O2; 5%CO2), was used 
as the control.(Data presented as mean ±SD; n=6; *P<0.05 versus normal, untreated 
cells; #P<0.05 versus hypoxia, untreated cells; Student’s t-test). 
 
 
Fig.3.30.The effect of opioid agonist treatment on cellular 
proliferation in cultured B50 cells in hypoxia
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The effect of concurrent culture and treatment of opioid agonist (pre-treatment) on 
cellular proliferation in normal cultured B50 cells showed that the B50 cells pre-
treated with 10µM DAMGO (20x106cells/ml); 50µM DAMGO (20.8x106cells/ml) 
and 100µM DSLET (19.8x106cells/ml), had about the same cell proliferation pattern 
when compared with the normal untreated B50 cells (20x106cells/ml). There was a 
non-significant increase in cell proliferation in cells pre-treated with 100µM DAMGO 
(24.75x106cells/ml) (P=0.16) and 50µM ICI-199441 (22.4x106cells/ml) (P=0.09), a 
non-significant decrease in cell proliferation in cells pre-treated with 10µM DSLET 
(17.5x106cells/ml) (P=0.07), 50µM DSLET (15.7x106cells/ml) (P=0.18), 10µM ICI-
199441 (17x106cells/ml) (P=0.082) and a significant decrease (P<0.05) in cellular 
proliferation in cells pre-treated with 100µM ICI-199441 (14.5x106cells/ml) when 
compared with the untreated normal cells (20x106cells/ml) in culture (Figure 3.31).  
The effect of opioid agonist pre-treatment against hypoxia on cellular proliferation of 
B50 neuronal cells is shown in Figure 3.32. The result shows a significant decrease 
(P<0.05) in neuronal proliferation in untreated B50 cells cultured in hypoxia 
(7.0x106cells/ml) and other cells pre-treated with different concentrations of opioid 
agonist when compared to the untreated normal cells (20x106cells/ml). There was a 
significant increase (P<0.05) in cellular proliferation in B50 cells pre-treated with 
10µM DAMGO (11.25x106cells/ml); 50µM DAMGO (12.0x106cells/ml); 100µM 
DAMGO (9.75x106cells/ml); 50µM DSLET (13.75x106cells/ml) and 100µM DSLET 
(12.50x106cells/ml) when compared with hypoxic untreated B50 cells in culture 
(7x106cells/ml) (Figure 3.32). 
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The effect of opioid agonist pre-treatment on cell proliferation of normal cultured B50 
cells (21%O2; 5%CO2) using proliferation assay method. The cells were concurrently 
treated with different opioid agonists at 0hr and then cultured for a total of 96hrs. The 
number of proliferated cells was quantified using standard curve prepared from trypan 
blue counting method and CellTiter Aqueous One Solution assay method. Culture 
plate containing 42.5 x 106cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 
10) x 106cells/ml and the absorbance of the CellTiter assay (n= 5) was measured at 
490nm and plotted against the number of cells to give a standard curve. The number 
of cells from the tests was quantified using the absorbance of the test groups against 
the known cell numbers from the standard.(Data presented as mean ±SD; n=6; 
*P<0.05 versus normal, untreated cells; Student’s t-test). 
 
 
 
Fig.3.31.The effect of opioid agonist pre-treatment on 
cellular proliferation in cultured normal B50 cells
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The effect of opioid agonist pre-treatment against hypoxia on cell proliferation of B50 
cells cultured in hypoxic (5%O2; 5%CO2) conditions using proliferation assay 
method. The cells were concurrently treated with different opioid agonists and 
exposed to hypoxia at 0hr and then cultured for a total of 96hrs. The number of 
proliferated cells was quantified using standard curve prepared from trypan blue 
counting method and CellTiter Aqueous One Solution assay method. Culture plate 
containing 42.5 x 106cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 10) x 
106 cells/ml and the absorbance of the CellTiter assay (n= 5) was measured at 490nm 
and plotted against the number of cells to give a standard curve. The number of cells 
from the tests was quantified using the absorbance of the test groups against the 
known cell numbers from the standard. The untreated normal cells (21%O2; 5%CO2), 
was used as the control. (Data presented as mean ±SD; n=6; *P<0.05 versus normal, 
untreated cells; #P<0.05 versus hypoxia, untreated cells; Student’s t-test). 
 
 
 
 
 
Fig.3.32.The effect of opioid agonist pre-treatment on 
cellular proliferation in cultured B50 cells in hypoxia
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The result of opioid agonist treatment in the presence of antagonist on cellular 
proliferation in cultured B50 cells in hypoxia, shows similar trends in untreated 
normal B50 cells (20x106cells/ml) and cells treated with 100µM CTAP/100µM 
DAMGO, while the cells treated with different concentrations of opioid agonists and 
antagonists showed different levels of non-significant decreases in cell proliferation 
from the untreated normal cells. The results are 50µΜ CTAP/50µM DAMGO 
18.5x106cells/ml (P=0.19); 50µM ICI-174864/50µM DSLET 16x106cells/ml 
(P=0.09); 50µM NOR/ 50µM ICI-199441 18.7x106cells/ml (P=0.21); 100µM 
NOR/100µM ICI-199441 17.5x106cells/ml (P=0.11) and a significant decrease 
(P<0.05) in cellular proliferation from 100µM ICI-174864/100µM DSLET (14.9x106 
cells/ml) when compared to the proliferation of the untreated normal cells 
(20x106cells/ml). The results show a significant decrease (P<0.05) in cellular 
proliferation in B50 cells treated with agonist/antagonist  in 100µM DSLET/100µM 
ICI-174864  (14.9x106cells/ml) and 100µM ICI-1999441/100µM NOR (17.5x106cells 
/ml) when compared to that of hypoxic agonist treated B50 cells (Figure 3.33).  
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The effect of opioid agonist treatment in the presence of antagonist on cell 
proliferation of B50 cells cultured in hypoxic (5%O2;5%CO2) conditions using 
proliferation assay method. The cells were cultured for 48hrs and then treated with the 
opioid agonists and antagonist for another 48hrs for a total of 96hrs of culture. The 
number of proliferated cells was quantified using standard curve prepared from trypan 
blue counting method and CellTiter Aqueous One Solution assay method. Culture 
plate containing 42.5 x 106 cells/ml was used to prepare five dilutions (0, 2, 4, 5 and 
10) x 106 cells/ml and the absorbance of the CellTiter assay (n=5) was measured at 
490nm and plotted against the number of cells to give a standard curve. The number 
of cells from the tests was quantified using the absorbance of the test groups against 
the known cell numbers from the standard. The untreated normal cultured cells 
(21%O2; 5%CO2) was used as the control.(Data as mean ±SD; n=6; *P<0.05 versus 
normal, untreated cells; #P<0.05 versus agonist/antagonist treated cells; Student’s t-
test). 
 
 
 
Fig.3.33.The effect of opioid agonist and antagonist 
treatment on cellular proliferation in cultured B50 cells in 
hypoxia.
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3.8   Opioid receptor agonist effect on LDH   
3.8.1    LDH release from treatment with opioid agonists ± antagonists in B50 
neuronal cells cultured in hypoxia 
The LDH leakage from opioid agonists treated B50 neuronal cells in hypoxia is 
shown in Figure 3.34. The results show a significant 5-fold increase in LDH release 
(P<0.05) from untreated hypoxic B50 cells (587%) when compared with normal cells 
(100%), and a non-significant increase in LDH release from cells treated with 100µM 
DAMGO (143%) (P=0.51); 50µM DSLET (140%) (P=0.58); 100µM DSLET (143%) 
(P=0.55); 10µM ICI-199441 (113%) (P=0.64) and 50µM ICI-199441 (109%) 
(P=0.81). The results of the treatment with opioid agonists showed a significant 3-to 
5-fold decrease (P<0.05) in LDH release in cells treated with 10µM DAMGO 
(338%), 100µM ICI-199441 (322%), 100µM DAMGO (143%); 50µM DSLET 
(140%); 100µM DSLET (143%);10µM ICI-199441 (113%) and 50µM ICI-199441 
(109%), when compared with the untreated hypoxic cells (Figure 3.34). 
The results showed approximately, between a 2- and 8-fold increase in LDH leakage 
from hypoxia untreated cells and cells treated with opioid agonists/antagonists when 
compared to the LDH release from the normal B50 cells. When the LDH release from 
opioid agonist treated hypoxic cells was compared with cells treated with opioid 
agonist/antagonist, the results showed a significant increase (P<0.05) in LDH release 
from 100µM DAMGO (143%) and 100µM DAMGO/100µM CTAP (364%);  50µM 
DSLET (140%) and 50µM DSLET/50µM ICI-174864 (416%); 10µM ICI-1999441 
(113%) and 10µM ICI-199441/10µM NOR (821%); 100µM ICI-1999441(322%) and 
100µM ICI-199441/100µM NOR (665%) (Figures 3.35a, b and c). 
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The effect of opioid agonist treatment on LDH release from B50 cells cultured in 
hypoxia (5%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs and then 
treated with different concentrations of opioid agonists for 48hrs for a total of 96hrs of 
culture. The absorbance of the assay (n=6) was measured at 490nm. The LDH 
released from the untreated normal cultured cells (21%O2;5%CO2) was normalized 
and used as the control (100%) and the LDH release was expressed relative to the 
control. (Data as mean ±SD; *P<0.05 versus untreated normal cells; #P<0.05 versus 
hypoxic untreated cells; Student’s t-test). 
 
 
Fig.3.34.The effect of opioid treatment on LDH release in 
B50 cells culture in hypoxia
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Fig.3.35a.The effect of opioid treatment on LDH release in B50 cells 
cultured in hypoxia
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Fig.3.35b.The effect of opioid treatment on LDH release in B50 
cells cultured in hypoxia.
0
100
200
300
400
500
600
700
Type of Treatment 
LD
H
 R
el
ea
se
 (%
 o
f C
on
tr
ol
)
Normal Hypoxia DSLET 10uM
DSLET 10uM/ICI-174864 10uM DSLET 50uM DSLET 50uM/ICI-174864 50uM
DSLET 100uM DSLET 100um/ICI-174864 100uM
*
* *
#
#
#
Figs.3.35a & b.The effect of opioid agonist/antagonist treatment on LDH release from B50 
cells cultured in hypoxia (5%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs 
and then treated with different concentrations of opioid agonists for 48hrs for a total of 96hrs 
of culture. The absorbance of the assay (n=6) was measured at 490nm. The LDH released 
from the untreated normal cultured cells (21%O2;5%CO2) was normalized and used as the 
control (100%) and the LDH release was expressed relative to the control.(Data as mean ±SD; 
*P<0.05 versus untreated hypoxic cells; #P<0.05 versus agonist/antagonist treated hypoxic 
cells; Student’s t-test). 
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The effect of opioid agonist/antagonist treatment on LDH release from B50 cells 
cultured in hypoxia (5%O2; 5%CO2), using LDH assay. Cells were cultured for 48hrs 
and then treated with different concentrations of opioid agonists for 48hrs for a total 
of 96hrs of culture. The absorbance of the assay (n=6) was measured at 490nm. The 
LDH released from the untreated normal cultured cells (21%O2;5%CO2) was 
normalized and used as the control (100%) and the LDH release was expressed 
relative to the control.(Data as mean ±SD; *P<0.05 versus untreated hypoxic cells; 
#P<0.05 versus agonist/antagonist treated hypoxic cells; Student’s t-test). 
 
 
 
 
Fig.3.35c.The effect of opioid treatment on LDH release in B50 cells 
cultured in hypoxia.
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3.8.2    LDH Release from opioid agonists and antagonist pre-treated B50 cells 
cultured in hypoxia. 
The effect of opioid agonist pre-treatment against hypoxia showed a significant 3- to 
5-fold increase in LDH release (P<0.05) from untreated hypoxic B50 cells (587%), 
and the hypoxic cells pre-treated with different concentrations of opioid agonists are; 
10µM DAMGO (425%), 50µM DAMGO (352%), 100µM DAMGO (355%), 10µM 
DSLET (520%), 50µM DSLET (339%), 100µM DSLET (450%), 10µM ICI-199441 
(346%), 50µM ICI-199441 (419%) and 100µM ICI-199441 (318%) when compared 
to normal B50 cells (100%). The results showed a significant 2- to 3-fold decreases in 
LDH release (p<0.05) in cells pre-treated with different concentrations of opioid 
agonist when compared with the untreated hypoxic cells in culture (Figure 3.36) 
The LDH release from hypoxic B50 cells pre-treated with opioid agonists in the 
presence of antagonists, showed a significant 2-to 6-fold increase in LDH release 
(p<0.05) from untreated hypoxic B50 cells (587%) and cells pre-treated with different 
concentrations of opioid agonists/antagonists when compared to the normal B50 cells 
(100%). When the result of the LDH release from hypoxic pre-treated cells was 
compared with cells pre-treated with the different concentrations of the opioid 
agonist/antagonist, the result showed a significant increase (p<0.05) in LDH release 
between 50µM DAMGO (352%) and 50µM DAMGO/50µM CTAP (690%); 50µM 
DSLET (339%) and 50µM DSLET/50µM ICI-174864 (611%), 50µM ICI-1999441 
(419%) and 50µM ICI-199441/50µM NOR (619%).(Figures 3.37a, b and c). 
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The effect of opioid agonist pre-treatment against hypoxia on LDH release from B50 
cells in hypoxic culture (5%O2; 5%CO2), using LDH assay. Cells were concurrently 
treated with different concentrations of opioid agonists and exposed to hypoxia at 0hr 
and cultured for 96hrs. The absorbance of the assay (n=6) was measured at 490nm. 
The LDH released from the untreated normal cultured cells (21%O2;5%CO2) was 
normalized and used as the control (100%) and LDH release was expressed relative to 
the control.(Data as means ±SD; *P<0.05 versus untreated normal cells; #P<0.05 
versus hypoxic untreated cells; Student’s t-test). 
 
 
 
 
Fig.3.36.The effect of opioid agonist pre-treatment on LDH 
release in B50 cells cultured in hypoxia.
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Fig.3.37a.The effect of opioid agonist/antagonist pre-treatment on 
LDH release in cultured B50 cells in hypoxia.
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FIG.3.37b.The effect of opioid agonist/antagonist pre-treatment on 
LDH release in cultured B50 cells in hypoxia 
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Figs.3.37a & b:The effect of opioid agonist and antagonist pre-treatment against hypoxia on 
LDH release from B50 cells cultured in hypoxia (5%O2; 5%CO2), using LDH assay. Cells 
were treated concurrently with different concentrations of opioid agonists/antagonists and 
exposed to hypoxia at 0hr and then cultured for 96hrs. The absorbance of the assay (n=6) was 
measured at 490nm. The LDH released from the untreated normal cultured cells 
(21%O2;5%CO2) was normalized and used as the control (100%) and the LDH release was 
expressed relative to the control.(Data as mean ±SD; *P<0.05 versus hypoxic untreated cells; 
#P<0.05 versus agonist/antagonist treated cells; Student’s t-test). 
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The effect of opioid agonist and antagonist pre-treatment against hypoxia on LDH 
release from B50 cells cultured in hypoxia (5%O2; 5%CO2), using LDH assay. Cells 
were treated concurrently with different concentrations of opioid agonists/antagonists 
and exposed to hypoxia at 0hr and then cultured for 96hrs. The absorbance of the 
assay (n=6) was measured at 490nm. The LDH released from the untreated normal 
cultured cells (21%O2;5%CO2) was normalized and used as the control (100%) and 
the LDH release was expressed relative to the control.(Data as mean ±SD; *P<0.05 
versus hypoxic untreated cells; #P<0.05 versus agonist/antagonist treated cells; 
Student’s t-test). 
 
 
 
Fig.3.37c.The effect of opioid agonist/antagonist pre-treatment on 
LDH release in cultured B50 cells in hypoxia.
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3.8.3.     LDH Release from normal cultured B50 cells treated and pre-treated with 
opioid agonists. 
The effect of opioid agonist treatment on LDH leakage from normal B50 cells in 
culture, showed a significant reduction (P<0.05) in LDH release in B50 cells treated 
with 10µM DSLET (80%), 50µM DSLET (80%), 50µM ICI-199441 (81%) and 
100µM DSLET (87%); a significant increase (P<0.05) in cells treated with 50µM 
DAMGO (125%), and an insignificant decrease in LDH release in cells treated with 
100µM ICI-199441 (92%) (P=0.18) and 10µM DAMGO (96%) (P=0.09). The cells 
treated with 100µM DAMGO (107%) (P=0.08) and 10µM ICI-199441 (103%) 
(P=0.07), showed a non-significant increase in LDH release when compared with the 
untreated normal B50 cells in culture (100%). (Figure 3.38) 
The effect of opioid agonist pre-treatment on LDH release from normal B50 cells in 
culture, showed a significant increase (P<0.05) in LDH release from B50 cells pre-
treated with 100µM DAMGO (131%) and a non-significant increase in LDH release 
in cells pre-treated with 50µM DAMGO (107%) (P=0.11), when compared with the 
untreated normal cells (100%). There was a significant decrease (P<0.05) in LDH 
release from B50 cells pre-treated with 50µM DSLET (75%), 100µM DSLET (70%), 
10µM ICI-199441 (59%), 50µM ICI-199441 (68%), 100µM ICI-199441 (82%), 
10µM DSLET (85%), and a non-significant decrease in LDH release in cells with 
10µM DAMGO (96%) (P=0.07) when compared with the untreated normal B50 cells 
(100%) in culture (Figure 3.39). 
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The effect of opioid agonist treatment on LDH release from normal B50 cells in 
culture using LDH assay. Cells were cultured in normal (21%O2; 5%CO2) conditions 
for 48hrs and then treated with different concentrations of opioid agonists for 48hrs 
for a total of 96hrs of culture time. The absorbance of the assay (n=6) was measured 
at 490nm. The LDH released from the untreated normal cultured cells was normalized 
and used as the control (100%) and the LDH release was expressed relative to the 
control.(Data as mean ±SD; *P<0.05 versus untreated normal cells; Student’s t-test). 
 
 
 
 
 
 
Fig.3.38.The effect of opioid treatment on LDH release in 
normal B50 cells 
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The effect of opioid agonist pre-treatment on LDH release from normal B50 cells in 
culture using LDH assay. Cells were cultured in normal (21%O2;5%CO2) conditions 
and treated at 0hr with different concentrations of opioid agonists and cultured for 
96hrs in culture. The absorbance of the assay (n=6) was measured at 490nm. The 
LDH released from the untreated normal cultured cells was normalized and used as 
the control (100%) for the experiment and LDH release was expressed relative to the 
control.(Data as mean ±SD; *P<0.05 versus untreated normal cells; Student’s t-test). 
 
 
 
 
Fig.3.39.The effect of opioid pre-treatment on LDH release in 
normal B50 cells
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3.9      Effect of hypoxia on signalling molecules 
3.9.1    The effect of hypoxia on cAMP levels in B50 cells treated with cannabinoid 
agonists. 
The effect of hypoxia on cAMP levels in B50 cells treated with cannabinoid agonists 
(Win, AEA and 2-AG) is shown in Figure 3.40. The result showed an inverse 
relationship between the percentage bound cAMP and the amount of free cAMP 
released into the B50 cells in picomoles per ml as in Figure 3.41. The result showed 
that the untreated normal cells had 3.0pmol/ml of free cAMP while the untreated 
hypoxic cells had 0.70pmol/ml of free cAMP. The hypoxic treated cells with different 
concentrations of cannabinoid agonists had cAMP release as shown in Table 3.18. 
When intracellular cAMP release in untreated hypoxic B50 cells was compared to the 
hypoxic treated B50 cells with different concentrations of cannabinoid agonists, the 
results showed a significant increase (P<0.05) in cAMP levels in the treated cells 
except for cells treated with 10nM AEA (0.75pmol/ml) and 100nM 2-AG 
(0.9pmol/ml) where the increase was not significant. There was a non-significant 
decrease in cAMP from cells treated with 50nM AEA (0.50pmol/ml) (Table 3.18). 
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Table 3.18: The effect of hypoxia on cAMP levels in B50 cells treated  with 
cannabinoid agonists. 
 
Type of Treatment Net Optical 
Density (NoD) 
Percent Bound 
(% Bound) 
 cAMP 
(pmol/ml) 
Normal cells  0.292±0.163 57.78 3.0 
Hypoxia no Drug  0.391±0.133 77.50 0.70* 
Hypoxia/10nM Win   0.305±0.141 60.37 1.10*# 
Hypoxia/50nM Win 0.346±0.090 68.58 1.0*# 
Hypoxia/100nM 
Win  
 
0.261±0.119 51.64 3.3# 
Hypoxia/10nM 
AEA 
 
0.390±0.047 77.30 0.75* 
Hypoxia/50nM 
AEA  
 
0.416±0.225 82.36 0.50* 
Hypoxia/100nM 
AEA 
 
0.348±0.156 68.89 1.00*# 
Hypoxia/10nM 2-
AG 
 
0.162±0.121 51.83 3.50# 
Hypoxia/50nM 2-
AG  
 
0.285±0.195 56.39 3.10# 
Hypoxia/100nM 2-
AG 
0.350±0.059 69.28 0.90* 
The effect of hypoxia on cAMP levels in B50 cells treated with cannabinoid agonist 
in hypoxia. Cells were cultured for 48hrs in hypoxia (5%O2;5%CO2) and then treated 
for 48hrs with different concentrations of different cannabinoid agonists for a total of 
96hrs of culture. The absorbance of the cAMP assay (n=6) was measured at a 
wavelength of 410nm. cAMP from the untreated normal (21%O2;5%CO2) B50 cells 
was used as the control (Data presented as mean ±SD; *P<0.05 versus untreated 
normal cells; #P<0.05 versus hypoxia untreated cells; Student’s t-test). 
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Fig.3.40. The effect of cannabinoid agonist treatment on 
intracellular cAMP levels in B50 cells in hypoxia. 
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The effect of cannabinoid agonist treatment on intracellular and bound cAMP in B50 cells in 
hypoxia, as estimated by cAMP immunoassay. Cells were cultured for 48hrs in hypoxia 
(5%O2; 5%CO2) and then treated for 48hrs with different concentrations of cannabinoid 
agonists for a total of 96hrs of culture. The absorbance of the cAMP assay (n=6) was 
measured at a wavelength of 410nm. The intracellular cAMP from the untreated normal 
(21%O2;5%CO2) cultured B50 cells was used as the control (Data presented as mean ±SD; 
*P<0.05 versus untreated normal cells; #P<0.05 versus hypoxia untreated; Student’s t-test). 
Fig.3.41. The effect of cannabinoid agonist treatment on 
bound cAMP levels in B50 cells in hypoxia
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3.9.2.       The effect of hypoxia on cAMP levels in B50 cells treated with opioid 
agonists. 
The effect of hypoxia on cAMP levels in B50 cells treated with opioid agonists is 
shown in Figure 3.42. The results showed that the normal cultured B50 cells had 3.0 
pmol/ml of cAMP released into the cytoplasm while the untreated hypoxic cells had 
0.70 pmol/ml of cAMP released. The cAMP releases following treatment with the 
different concentrations of opioid agonists are shown in Table 3.19. The result 
showed a significant increase (P<0.05) in intracellular cAMP release in hypoxic B50 
cells treated with 10µM ICI-199441 (10.0pmol/ml), and a non-significant increase in 
cAMP release in cells treated with 10µM DSLET (3.25pmol/ml); 50µM DSLET 
(3.25pmol/ml); 100µM DSLET (3.20pmol/ml) and 50µM ICI-199441 (3.15pmol/ml) 
when compared with the control (3.0pmol/ml). There was a significant decrease 
(P<0.05) in cAMP release from 10µM DAMGO (2.5pmol/ml); 100µM DAMGO 
(1.5pmol/ml); 100µM ICI-199441 (1.15pmol/ml) and hypoxia untreated cells 
(0.70pmol/ml) and a significant increase (P<0.05) in cAMP release in all the opioid 
treated cells in hypoxia when compared with the untreated hypoxic cells in culture. 
The result showed an inverse relationship between the bound intracellular cAMP and 
the released intracellular cAMP in the neuronal B50 cells (Figure 3.43). The result 
showed that the more the intracellular cAMP is bound, the less the intracellular cAMP 
released into the cytoplasm for cellular signalling activities while the less the cAMP 
that is bound, the more the cAMP that is released into the cytoplasm of the B50 cells. 
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Table 3.19: The effect of hypoxia on cAMP levels in B50 cells treated with 
opioid Agonists 
 
Type of Treatment Net Optical 
Density (NoD) 
Percent Bound 
(% Bound) 
 cAMP 
(Pmol/ml 
Normal Cells  0.292±0.163 57.78 3.00 
Hypoxia no Drug  0.391±.0.133 77.50 0.70* 
Hypoxia/10µM 
DAMGO  
 
0.296±0.263 58.57 2.50*# 
Hypoxia/50µM 
DAMGO  
 
0.279±0.119 55.20 3.00# 
Hypoxia/100µM 
DAMGO  
 
0.316±0.026 62.54 1.50*# 
Hypoxia/10µM 
DSLET 
 
0.265±0.155 52.43 3.25# 
Hypoxia/50µM 
DSLET 
 
0.267±0.149 52.83 3.25# 
Hypoxia/100µM 
DSLET 
 
0.268±0.054 53.02 3.20# 
Hypoxia/10µM ICI-
199441 
 
0.166±0.169 32.81 10.00*# 
Hypoxia/50µM ICI-
199441 
 
0.270±0.157 53.42 3.15# 
Hypoxia/100µM 
ICI-199441 
0.319±0.062 63.13 1.15*# 
Direct cAMP immunoassay in B50 cells treated with opioid agonists in hypoxia. Cells 
were cultured for 48hrs in hypoxia (5%O2;5%CO2) and then treated for 48hrs with 
different concentrations of different opioid agonists for a total of 96hrs of culture. The 
absorbance of the cAMP assay (n=6) was measured at a wavelength of 410nm. cAMP 
from the untreated normal (21%O2;5%CO2) B50 cells was used as the control (Data 
presented as mean ±SD; *P<0.05 versus untreated normal cells; #P<0.05 versus 
hypoxia untreated; Student’s t-test).  
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Fig.3.42.The effect of opioid agonist on intracellular cAMP 
levels in cultured B50 cells in hypoxia. 
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The effect of opioid agonist treatment on intracellular and bound cAMP levels in B50 cells in 
hypoxia, as estimated by cAMP immunoassay. Cells were cultured for 48hrs in hypoxia 
(5%O2;5%CO2) and then treated for 48hrs with different concentrations of different opioid 
agonists for a total of 96hrs culture. The absorbance of the cAMP assay (n=6) was measured 
at a wavelength of 410nm. The intracellular cAMP from the untreated normal (21%O2; 
5%CO2) cultured B50 cells was used as the control (Data as mean ±SD; *P<0.05 versus 
untreated normal cells; #P<0.05 versus hypoxia untreated; Student’s t-test). 
Fig.3.43. The effect of opioid agaonist treatment on bound 
intracellular cAMP levels in B50 cells in hypoxia.
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3.10      The effect of hypoxia on extracellular signal regulated receptor kinase 
(ERK) in B50 neuronal cells in culture. 
2.10.1      Quantitative determination of the effect of hypoxia on Phospho-ERK1& 2 
in  hypoxic treated B50 cells with cannabinoid agonists. 
The quantitative determination of the effect of hypoxia on phospho-ERK1& 2 in 
untreated hypoxic cells and hypoxic cells treated with different concentrations of 
cannabinoid receptor agonists is shown in Figure 3.44. The results showed that the 
normal cultured B50 cells had 87.0units/ml of phospho-ERK1/2 which was 
significantly decreased (p<0.05) in untreated hypoxic cells to 6.0units/ml (Table 
3.20). The result also showed a significant increase (p<0.05) in phospho-ERK1/2 in 
B50 cells in all cannabinoid treated hypoxic B50 cells when compared to the hypoxic 
untreated B50 cells (6.0units/ml). However in cells treated with cannabinoid agonist 
and antagonist, there was no significant difference between them and untreated 
hypoxic cells (Table 3.20). 
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Table 3.20: Quantitative determination of the effect of hypoxia on phospho-
ERK1&2 levels in B50 cells treated with cannabinoid agonists and antagonists. 
 
Type of Treatment Net Optical Density 
(NoD)(450nm) 
PhosphoERK1/2 
(Units/ml) 
Normal cells  2.59±0.65 87.0 
Hypoxia no Drug  0.35±0.21 6.0* 
Hypoxia 10nM Win   2.81±0.89 98.0*# 
Hypoxia 50nM Win  1.02±0.28 28.0*# 
Hypoxia 100nM Win. 0.97±0.12 27.0*# 
Hypoxia 10nM AEA 2.02±0.62 62.0*# 
Hypoxia 50nM AEA  1.90±0.82 60.0*# 
Hypoxia 100nM AEA 1.97±0.22 60.5*# 
Hypoxia 10nM 2-AG 1.59±0.15 45.0*# 
Hypoxia 50nM 2-AG  2.05±0.32 60.25*# 
Hypoxia 100nM 2-AG 2.39±0.65 68.0*# 
Hypoxia 10nM 
Win/10nM AM251 
0.29±0.20 3.75* 
 
Hypoxia 10nM 
AEA/10nM AM630 
0.34±0.53 5.0* 
The effect of hypoxia on phospho-ERK1&2 levels in B50 cells treated with 
cannabinoid agonists. Cells were cultured for 48hrs in hypoxia (5%O2;5%CO2) and 
then treated for 48hrs with different concentrations of cannabinoid agonists for a total 
of 96hrs of culture. The absorbance of the ERK1&2 assay (n=6) was measured at a 
wavelength of 450nm.Phospho-ERK1&2 from the untreated normal (21%O2;5%CO2) 
.B50 cells was used as the control. (Data presented as mean ±SD; *P<0.05 versus 
untreated normal cells; #P<0.05 versus hypoxia untreated; Student’s t-test).  
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The effect of cannabinoid agonist on phospho-ERK1&2 levels in B50 cells in 
hypoxia. B50 cells were cultured for 48hrs in hypoxia (5%O2;5%CO2) and then 
treated for 48hrs with different concentrations of cannabinoid agonists for a total of 
96hrs of culture. The absorbance of the phospo-ERK1/2 assay (n=6) was measured at 
a wavelength of 450nm. Phospho-ERK1&2 from the untreated normal (21%O2; 
5%CO2) B50 cells was used as the control (Data presented as mean ±SD; *P<0.05 
versus untreated normal cells; #P<0.05 versus hypoxia untreated; Student’s t-test).  
 
 
 
 
Fig.3.44.The effect of cannabinoid agonist on phospho-ERK1/2 
levels in B50 cells in hypoxia as estimated by direct immunoassay
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2.10.2.    Quantitative determination of the effect of hypoxia on Phospho-ERK1 & 2 
in B50 cells treated with opioid agonists. 
The quantitative determination of the effect of hypoxia on phospho-ERK1&2 in 
hypoxic B50 cells treated with opioid receptor agonists is shown in Figure 3.45. There 
was a significant decrease (P<0.05) in the quantity of phospho-ERK1&2 in hypoxic 
untreated B50 cells (6units/ml), compared to the normal cultured B50 cells 
(87units/ml). There was also a decrease in phospho-ERK1&2 in B50 cells treated 
with opioid agonists as shown in Table 3.20. When the quantity of phospho-ERK1&2 
in the hypoxic untreated B50 cells was compared to the cells with different 
concentrations of opioid agonist treatments, the result showed a significant (P<0.05) 
increase in cells treated with 10µM DAMGO (22.0units/ml); 10µM DSLET 
(16units/ml) and 10µM ICI-199441 (23.5units/ml) (Table 3.21).  
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 B50 cells were cultured for 48hrs in hypoxia (5%O2;5%CO2), then treated for 48hrs 
with different concentrations of opioid agonists for a total of 96hrs of culture. The 
absorbance of the phospho-ERK1/2 assay (n=6) was measured at a wavelength of 
450nm. The phospho-ERK1&2 from the untreated normal (21%O2;5%CO2) B50 cells 
was used as the control (Data as mean ±SD; *P<0.05 versus untreated normal cells; 
#P<0.05 versus hypoxia untreated; Student’s t-test).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.45.The effect of opioid agonist on Phospho-ERK1/2 levels in 
B50 cells in hypoxia as estimated by direct immunoassay
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Table 3.21: Quantitative determination of phospho-ERK1&2 levels in B50 cells 
treated with opioid agonists 
 
Type of 
Treatment 
Net Optical 
Density 
(NoD)(450nm) 
PhospoERK1/2 
(Units/ml) 
 
Normal Cells    2.59±0.65 87.00 
Hypoxia no Drug     0.35±0.21 6.00* 
Hypoxia 10µM 
DAMGO   
  0.80±0.25 22.0*# 
Hypoxia/50µM 
DAMGO  
  0.40±0.62 7.50* 
Hypoxia100µM 
DAMGO  
  0.44±0.22 8.50* 
Hypoxia/10µM 
DSLET 
  0.65±0.51 16.00*# 
Hypoxia/50µM 
DSLET 
  0.42±0.33 8.00* 
Hypoxia/100µM 
DSLET 
 0.31±0.11 4.50* 
Hypoxia/10µM 
ICI-199441 
0.88±0.23 23.50*# 
Hypoxia/50µM 
ICI-199441 
0.52±0.13 11.00* 
Hypoxia/100µM 
ICI-199441 
0.34±0.12 6.00* 
Hypoxia/10µM 
DAMGO/10µM 
CTAP 
0.33±0.08 5.25* 
Hypoxia/10µM 
DSLET/10µM 
ICI-174864 
0.34±0.10 5.50* 
Quantitative phospho-ERK1&2 levels in B50 cells treated with opioid agonists in 
hypoxia as estimated by direct phospho-ERK1/2 immunoassay. The B50 cells were 
cultured for 48hrs in hypoxia (5%O2;5%CO2), then treated for 48hrs with different 
concentrations of opioid agonists for a total of 96hrs of culture. The absorbance of the 
phospho-ERK1&2 assay (n=6) was measured at a wavelength of 450nm. Phospho-
ERK1&2 from the untreated normal (21%O2;5% CO2) B50 cells was used as the 
control (Data presented as mean ±SD; *P<0.05 versus untreated normal cells; #P<0.05 
versus hypoxia untreated; Student’s t-test). 
 
 
 
 
 
 
 
 244
                                           CHAPTER FOUR  
4.                                       Discussion  
4.1         General  
The B50 neuronal cells used in this study were able to grow, proliferate and 
differentiate well in culture and were shown to be a very good model of adherent cells 
since they could attach themselves and grow very well in culture plates. They were 
shown to be a good experimental model for research in neuronal morphology and cell 
biology in culture as they were able to grow to confluency levels of about 90-95 % in 
culture (Table 3.1 and Plates 2 and 4). This is in agreement with Otey et al. (2003), 
who also showed that the B50 cells could grow, proliferate and differentiate well in 
culture. The B50 cells, showed a remarkable neuronal pattern in culture resembling 
very closely those patterns seen in neuronal cells in vivo (Plates 3, 4 and 5). These 
patterns could result in the formation of nerve fibre bundles that form the neural 
tracks and networks needed for normal and accurate neuronal signal generation, 
transduction, coordination, relay and interpretation that normally occur in the 
mammalian nervous system. The cells are easy to handle and maintain in the 
laboratory environment, provided that their nutritional and general needs are met, and 
the general aseptic conditions of the laboratory, the culture incubators and the 
Laminar flow fume chamber are maintained to the highest standard. The cells have 
also been shown to be a useful model in drug testing since the effects of the drugs on 
B50 cells can easily be visualised morphologically (Plates 6, 7 and 8). 
 
The result of the effect of hypoxia on neuronal morphology, showed masses of dead 
and degenerating neuronal cells as shown in Plates 6, 7 and 8. These groups of dead 
and degenerating cells could result in loss of neuronal mass and volume in vivo. This 
is in agreement with reduced neuronal mass and volume as seen in cases of 
neurodegenerative diseases like stroke, dementias, Alzheimer’s Disease and 
Parkinson’s Disease. However, when these neuronal losses are applied to the whole 
brain, the overall effect will depend on the part of the brain tissue that the cell loss 
occurred, which would determine the neurodegenerative disease outcome. 
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Rodrigo et al. (2005) have shown that a dramatic reduction of oxygen supply to the 
brain may provoke ischaemia in the whole brain (global ischaemia) or in defined 
cerebral territories (focal ischaemia). The effect of ischaemic/hypoxic damage to the 
brain varies according to the area of the brain affected. It has been shown that 
ischaemia results in severe focal and global damage of the brain tissues accompanied 
by biochemical and molecular alterations, while hypoxia results in the depletion of 
cellular and tissue energy and consequently the death of the cells involved (Rodrigo et 
al., 2005; Szatkowski and Attwell, 1994). 
 
The present results show that there were morphological changes in the B50 cells in 
hypoxia (Plates 6, 7 and 8), when compared with those B50 cells in hypoxia either 
treated or pre-treated with cannabinoid and opioid receptor agonists (Plates 10, 11,15, 
27, 28 and 29). This shows that the cannabinoid and opioid agonists could have some 
potential protective and therapeutic benefits in hypoxic conditions by rendering B50 
cells treated with cannabinoid and opioid receptor agonists healthier morphologically 
when compared with the untreated hypoxic B50 cells in culture. The B50 cells treated 
with cannabinoid and opioid agonists showed more robust morphology when 
compared to the untreated hypoxic B50 cells in culture as evidenced from their 
appearances under the microscope. Zhang et al. (2006), have shown that prolonged 
hypoxia may impair neuronal activities and functions, and thus causes neuronal 
injury. The activation of the opioid and cannabinoid receptors have been shown to 
protect cortical neurons from neuronal stress, hypoxia or glutamate induced injury, 
whereas the antagonism of the receptors, blocks such action (Zhang et al., 2002; 
Ugdyzhekova et al., 2002; van der Stelt et al., 2001). The present results have 
demonstrated the presence of cannabinoid (CB1) and opioid receptors in B50 cells of 
which their activation by the agonists could have resulted in the observed effects in 
B50 cells cultured in hypoxia. 
 
Two mechanisms can be proposed for the death and degeneration of B50 cells in 
hypoxia. It could be as a result of increased intracellular calcium ions and the 
generation of reactive oxygen species in the cells. The increase in intracellular 
calcium ions results in excitotoxicity leading to neuronal cell death (Bickler and 
Buck, 1998). When B50 cells are exposed to hypoxia, the hypoxia may cause an 
increased excitation of the cells leading to the opening of the ionotropic channels. The 
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opening of these ionic channels may facilitate calcium ions entry into the B50 cells 
and the greater the accumulation of the calcium ions, the more excited the cells 
become. It has been shown that in hypoxia, there is an increase in extracellular 
excitatory neurotransmitters and Ca2+ which causes excitotoxicity resulting in 
neuronal cell death. The activation of cannabinoid and opioid receptors may play a 
role in the feedback regulation induced by hyperpolarization and lowering of neuronal 
excitability by lowering the calcium ion entry into the cells, and consequently 
lowering the excitotoxic effects of hypoxia on the cells (Zhang et al., 2006; Buzas et 
al., 1998).  
The second mechanism of hypoxia induced cell death is the formation of reactive 
oxygen species (ROS) within the B50 cells. The ROS that could be generated during 
hypoxia include oxygen ions, free radicals and peroxides. The ROS are small 
molecules which are highly reactive due to the presence of unpaired electrons. These 
ROS are formed as a natural by-product of the normal metabolism of oxygen and 
have important roles in cell signalling. However, during times of cellular 
environmental stress such as hypoxia, resulting in oxidative stress, ROS levels can 
increase and may be responsible for damage to cell structures. This cellular damage 
resulting in death and degeneration of B50 cells could be as a consequence of  
apoptosis or programmed cell death and ischaemic injury. This is the situation seen in 
some neurodegenerative disorders such as stroke, dementias and heart attack. This 
ROS could result in damage to DNA, oxidation of polyunsaturated fatty acids in  
neuronal membrane lipids and oxidation of amino acids in the proteins of neuronal 
membranes (Bickler and Buck, 1998; Trushina and McMurray,  2007), which results 
in cellular death and degeneration as shown in the case of B50 cells in hypoxia. 
The action of opioid agonists could have resulted in the lowering of Ca2+ entry into 
the neuronal cells leading to the opioid receptor upstream regulation as an early 
response of neurons to hypoxia. Thus it is possible that the increase in opioid receptor 
density as shown by Gross (2003) and Buzas et al. (1998), was partially attributable to 
an increase in intracellular Ca2+ concentration through Ca2+ channels activated by 
channel depolarization. The result of the morphological changes as shown in Plates 
27-29 suggest that opioid receptors are important mediators of the protective 
response. Buzas et al. (1998) and Gross, (2003), have shown that opioid receptors 
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participate in ischaemic preconditioning-induced myocardial protection and as such 
may serve as a general protector against ischaemic/hypoxic stress in oxygen/energy-
sensitive organs like the brain and heart (Zhang et al., 2006; Peart et al., 2005; 
Berridge et al., 2000). The morphological changes presented in the result showed that 
cannabinoid and opioid receptor agonists may have some potential protective and 
therapeutic benefits in the treatment of hypoxia in neuronal B50 cells in culture and in 
other neurodegenerative diseases.  
 
An illustration of the mode of cell death through excitotoxicity caused by Ca2+ influx 
and accumulation of intracellular Ca2+ in hypoxic neuronal cell death is shown in 
Figure 4.1. 
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Fig 4.1. Model of cell death through excitotoxicity caused by Ca2+ influx (   ) and 
accumulation of intracellular Ca2+ in hypoxic neuronal cell death. During hypoxic 
stress neuronal cell membrane become depolarized triggering Ca2+ influx through the 
Ca2+channels, which results in Na+ influx and reversal of Na+ gradient and the 
flooding of extracellular space with excitatory neurotransmitters (    ), causing cell 
damage.  Adapted from Bickler and Buck (1998). 
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4.2     Hypoxia 
The results presented in Plates 6, 7 and 8; Table 3.2 and Figure 3.4, showed hypoxia-
induced changes in the neuronal B50 cell morphology, pattern, proliferation and 
differentiation. The results showed that hypoxia has an effect on neuronal pattern and 
pattern forming abilities of B50 neuronal cells when compared to normal B50 cells in 
culture (Plates 3, 4 and 5). The neuronal pattern is very important for an organised 
and integrated neuronal activity which could be disrupted if the pattern is disorganised  
or disoriented (Plates 6, 7 and 8). This is because the normal neuronal organisation 
involves the grouping of nerve fibres to form nerve bundles of which functionally 
related nerve bundles ultimately become grouped together and form specific nerve 
tracts. These linkages of neurons are possible through synapses where signals are 
passed between cells. The disruption of the neuronal patterns (as shown during 
hypoxia in this study), indicate that hypoxia could result in the alteration of signal 
transmission between neuronal cells since some of the neuronal cells are dead and 
degenerating. These changes in the pattern could also explain the changes in the 
morphology since the neuronal pattern of arrangement is a part of neuronal 
morphology.  
 
The effect of hypoxia on B50 neuronal cell proliferation (Table 3.2), showed a time- 
course effect of hypoxia on B50 cell proliferation in which at 24 and 48 hours of 
culture, there was no significant change in the cellular proliferation between the 
normal and hypoxic B50 cells. However, cellular proliferation increased from 72 and 
96 hours of culture and then gradually decreased at 120 and 144 hours of culture. The 
reason the effect of hypoxia on proliferation was not very different at 24 and 48 hours 
could be as a result of the B50 cells settling down and gradually attaching themselves 
on the culture plates, then starting to grow and proliferate with the effect of hypoxia 
becoming pronounced from 72 hours of culture. The results shown in Figure 3.3, 
indicate that the cellular proliferation in B50 cells increased gradually from 24 hours, 
reaching a peak at 72 hours and gradually decreasing thereafter. The results suggest 
that hypoxia may be responsible for the decrease in B50 neuronal cell proliferation 
when compared with the normal cell in culture. 
 
The result of the effect of hypoxia on cellular differentiation, showed that a higher 
number of normal B50 cells were differentiated compared to those cultured in 
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hypoxia only. Hypoxia induced the inhibition of neuronal differentiation by 
preventing more neurons from differentiating into proper functional neuronal 
components as possible. The DbcAMP functions by arresting cell division and 
inducing neuronal differentiation by extension of the neurites (the axon and 
dendrites), while those cells cultured in hypoxia have more undifferentiated and fewer 
differentiated B50 cells in culture. However, the effect was more pronounced in those 
B50 cells cultured initially for 48 hours in normal culture before transferring them to 
the hypoxic condition for another 48 hours (Figure 3.4). This effect could be due to 
the shock of transferring these cells suddenly from the normal culture environment 
(21%O2;5%CO2), to hypoxia (5%O2; 5%CO2) which could have resulted in more 
cellular death when compared to the normal and hypoxic groups. This may be due to 
the adaptation of B50 cells grown exclusively in hypoxic environment.  
  
The changes in morphology, neuronal pattern, proliferation and differentiation that 
occur during hypoxia in B50 cells in culture were in agreement with the study by 
Titus et al. (2007), which showed that simulated hypobaric hypoxia, resembling that 
found in high altitude hypoxia, severely affects the morphology of the central nervous 
system (CNS) and results in several physiological changes. They showed that these 
effects specifically within the hippocampus may closely be associated with learning 
and memory and proposed that insult to this region also affects cognition.  
 
The B50 neuronal cell degeneration in hypoxic cultures may be linked to the loss of 
neuronal cells and tissues which invariably would result in defects in neuronal 
activities. These B50 neuronal cell losses and loss of normal neuronal pattern results 
in loss of neuronal mass, which could lead to loss of nervous system coordination of 
activities and actions from the cellular level to the whole organism. The neuronal loss 
may affect cognition, behavioural activities, learning, memory and may even lead to 
physical defect depending on the area of the brain affected by the degeneration. 
Studies by Shukitt-Hale et al. (1994), had suggested that rapid or prolonged exposure 
to hypobaric hypoxia (HBH), is associated with psychomotor and cognitive 
impairments.  
 
The results presented in this study which showed changes in the characteristics of 
neuronal B50 cells in hypoxia compared to the normal B50 cells support the work of 
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Titus et al. (2007), and Shukitt-Hale et al. (1996). They showed that there were 
structural changes in the neuronal cells of both human and animal models exposed to 
hypoxia. These structural and morphological changes can lead to defects in memory, 
cognitive behaviour and loss of coordinated responses to stimuli. 
 
The result with the B50 neuronal cells showed that cell damage increases with the 
increase in the exposure time to hypoxia (Plates 23 and 29). Thus, the more time the 
cells are exposed to the hypoxic environment the greater the damage to the B50 cells. 
This is in agreement with the findings of Titus et al. (2007), which showed that the 
damage to cells increases with the level of exposure to an oxygen-deprived 
environment and that the number of damaged cells increases following increase in 
altitude. Clausen et al. (2005), correlated the hippocampal morphological changes and 
memory dysfunction, cortical lesion volume and regional hippocampal morphological 
changes after controlled cortical contusion (CCC) injury in rats, and showed 
morphological changes in CA1, CA3, and hilus of the dentate gyrus in severely 
injured rats.  
 
Sousa et al. (2000) have demonstrated that stress-induced cognitive deficits in rats do 
not correlate with hippocampal neuronal loss when they evaluated the effects of 
chronic stress on hippocampal dendrite morphology, volume of mossy fibre system, 
and number and morphology of synapses between the mossy fibres. They found 
profound changes in the morphology of the mossy fibre terminals and significant loss 
of synapses were detected in stress-induced cognitive conditions (Sousa et al., 2000). 
The study by Sousa et al. (2000), showed that stress-induced morphological changes 
in the hippocampus could not be correlated with cognitive changes in rat. 
 
The data presented here showed that hypoxia had an effect on B50 neuronal cell 
morphology, pattern, proliferation and differentiation which could have a deleterious 
effects on neuronal structure and morphology which would result in overall functional 
impairment of the nervous system in terms physical activities, cognitive abilities, 
learning and memory functions even though this may depend on the parts of  the brain 
that are affected.   
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4.2.1   Hypoxia tolerance 
The result presented in Plates 6-9, showed that some of the B50 cells in hypoxia did 
not degenerate and had normal structural features as evidenced from their 
morphology. This is an indication that different cells within the same environment 
have different ways of reacting to the same conditions. The result from investigation 
of B50 cells cultured under hypoxia showed that some B50 cells can react to hypoxic 
conditions differently, while some would die and degenerate others may survive for a 
longer period of time even when other cells within the same environment have died 
and degenerated (Plates 6 and 7). This situation may be as a result of these neuronal 
B50 cells that survived being hypoxia tolerant. Lipton (1999) and Vornov et al. 
(1998), have shown that distinct neuronal populations have very different 
vulnerabilities to ischaemia and showed that at 5-minutes, global ischaemia caused 
delayed death in almost all CA1 pyramidal cell neurons with no effects on other 
populations, whereas at 20 minutes, ischaemia caused cell death in CA3 neurons but 
had almost no effect on dentate granule cells in the hippocampus or on interneurons in 
CA1 (Vornov et al., 1998). Wenger, (2002), observed that some cells were able to 
adapt to hypoxia by the use of oxygen sensing proteins such as hydroxylases, 
hypoxia-inducible transcription factors, and O2-regulated gene expression. 
 
In addition, Lipton (1999) have shown that the differences in presynaptic events may 
be responsible for apparent selective vulnerabilities of postsynaptic neurons. These 
large differences in selective vulnerabilities between neuronal cells are indicative of 
large differences in metabolism between different B50 cell types that presumably 
reflect their different physiological functions which may lead to differential 
vulnerabilities to ischaemia and hypoxia which may provide insight into mechanisms 
of cellular damage during hypoxia in B50 cells in culture. 
The reason why some of the B50 cells did not degenerate during hypoxia could be 
because hypoxia decreases metabolic demands and energy production of these B50 
cells, which may potentially lead to tolerance of these B50 cells to hypoxia. This 
hypothesis suggests that energy conservation leads to metabolic and ion channel 
arrests which must have accompanied decreased energy production to maintain 
energy charge, substrate stores, and ionic homeostasis during hypoxia in B50 cells 
thus leading to some of the cells surviving during the hypoxic condition in the culture 
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environment. With respect to ion homeostasis, the B50 cells that survived prevented 
the collapse of transcellular ion gradients, and may generally decrease the activity of 
ion pumps more than ion leaks. Ion channels responsible for ionic leakage, potassium 
channels, became relatively insensitive to the hypoxic changes in the B50 cells, 
whereas ion-motive pumps such as the Na+/K+ pump are more strongly inhibited by 
temperature changes in some cases (Boutilier, 2001). The disparity between ion 
pumping and ion channel leakage rates leads to a redistribution of ions, depolarization 
of transcellular electrical potentials, and water accumulation in hypoxia-intolerant 
B50 cells, leading to the death and degeneration of these B50 cells while the hypoxia-
tolerant would survive in such adverse conditions (Boutilier, 2001). 
It has been shown that oxygen depletion is relatively common in some environments 
and represents both a challenge and an opportunity for organisms that survive there 
(Buck and Pamenter, 2006). A commonly observed survival strategy to this kind of 
stress environment by cells is to lower metabolic rate known as metabolic depression. 
Whether metabolic rate is at a normal or a depressed level, the most important thing is 
that the supply of ATP from glycolysis and oxidative phosphorylation must match the 
cellular demand for ATP  for protein synthesis and ion pumping, a condition that must 
be met for long-term survival in hypoxic and anoxic environments (Buck and 
Pamenter, 2006).   
The above could be the situation for the survival of some of the B50 cells shown in 
the hypoxic condition as presented (Plates 6 and 7), while other B50 cells died and  
degenerated. The survival of some B50 cells could actively be regulated by second 
messenger pathways but it is less clear if they are regulated differentially or 
sequentially with the onset of hypoxia. The vertebrate brain is extremely sensitive to 
low oxygen levels yet some species survive in oxygen depleted environments for 
extended periods. Hypoxia/ischaemia tolerance mechanisms in liver and heart have 
been shown to offer clues to how the brain can tolerate anoxia (Buck and Pamenter, 
2006). Furthermore, it has been shown that mitochondria are ideally situated to serve 
as cellular oxygen sensors and mediator of protective mechanisms such as ion channel 
arrest (Buck and Pamenter 2006). 
Hypoxia has been shown to kill neurons because anaerobic energy production could 
not keep pace with demands (Bickler and Donohoe, 2002). Many types of hypoxia-
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tolerant neurons solve this risk of energy failure not by increasing anaerobic 
metabolism, but by decreasing the demand for energy sufficiently to prevent the loss 
of high-energy metabolic intermediates such as ATP and phosphocreatine (Hochachka 
,1986). When oxygen flow to the mammalian brain decreases to critical levels, energy 
failure occurs, with a decline in ATP and when half of the ATP is lost, depolarization 
of the membrane and subsequent uptake of sodium and water occurs (Knickerbocker 
and Lutz, 2001; Erecinska et al., 2005). Depolarization causes Ca2+ influx through 
voltage-gated Ca2+ channels. The Na+ gradient collapse causes the sodium-glutamate 
co-transporters to eject glutamate into the extracellular space (Rossi et al., 2000). 
Glutamate triggers vigorous activation of glutamate receptors, initiating a process of 
calcium influx and excitatory injury. Glutamate receptors have been primary targets 
for experimental treatment of ischaemic brain injury (Choi, 1995; Lee et al., 1999). 
The death of neurons from these insults could follow quickly from swelling and lysis 
(necrosis) or may be gradual over many days. This slower cell death is complex and, 
in some respects, resembles programmed cell death or apoptosis.  
A most fundamental adaptive response of hypoxia-tolerant cells to oxygen lack is the 
capacity to avoid a drastic decline in ATP levels at a time of absent aerobic ATP 
production. It is likely that similar responses to energetic stress are found in cells 
during hibernation and aestivation, although hypoxia does not characterize these 
states. A drastic, balanced, suppression of ATP demand and supply pathways must 
occur in all these conditions, this regulation allows ATP levels to remain relatively 
constant, even while ATP turnover rates greatly decline. In neurons, the ATP 
requirements of ion pumping (mainly Na+) are down regulated by channel arrest 
(Bickler et al., 2002). The ATP demands of protein synthesis also must be down 
regulated, and although rapid and global suppression of protein synthesis occurs in 
anoxia-adapted hepatocytes (Hochachka et al., 1996), Acker and Acker (2004) 
showed that it is likely that selective rather than global suppression of gene expression 
and protein synthesis occurs in neurons. This necessitates that a significant percentage 
of the neurons in the brain are functionally inactivated during anoxia, therefore cannot 
participate in vigilance or regulatory activities. Accordingly, metabolic arrest cannot 
be the only cellular response for vertebrate neurons, some neuron groups must remain 
vigilant and participate in regulation and eventual arousal from dormancy or inactivity 
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(Milton et al., 2007). Cellular adaptations essential for survival during hypoxia are 
illustrated in Figure 4.2. 
                     Hypoxia 
                      Signalling 
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig.4.2. Adaptations essential for surviving during hypoxia in cells depending on the 
species and tissues involved. Adapted from Bickler and Buck, (2007). 
 
 
     Metabolic Inhibition 
• Temperature Drop  
• Preservation of Substrates 
• Inhibition of Protein 
synthesis  
Ion Channel arrest 
• Viability of some cells 
and tissues. 
           Effects 
Changes in hydrogen ion, Ca2+ 
lactate enzymes, Loss in ATP, 
Cell death. 
 Addition of oxygen  
  Super Oxide, Free radical 
Cellular repair and regeneration 
 256
4.3       Morphological changes 
Hypoxia has been shown to result in depletion of cellular and tissue energy which 
consequently results in death of the cells and tissues involved. It is probable that many 
of the B50 cells in hypoxia underwent degeneration due to depletion of cellular 
energy which could have resulted in the death of these cells during hypoxia. It has 
been shown that oxygen delivery to the brain cells and tissues depends on the volume 
flow rate of blood and arterial oxygen content of which a reduction in any of these 
two parameters gravely affects vital brain functions (Rodrigo et al., 2005). In hypoxia 
and ischaemia, there is the tendency of production and accumulation of toxic 
substances, most especially carbon monoxide with concomitant deterioration and 
damage to neuronal cells and tissues (Bickler and Donohoe, 2002; Rodrigo et al., 
2005).  
Cerebral hypoxia/ischaemia results in a cascade of molecular events including rapid 
depletion of intracellular adenosine triphosphate (ATP) stores, anaerobic glycolysis, 
lactic acidosis and membrane depolarization, glutamate excitotoxicity, entry of 
calcium, sodium and water into the cells, resulting in cell swelling, activation of 
calcium-stimulated enzymes, mitochondrial dysfunction, free radical production, 
activation of the immune system, over expression of particular genes and 
consequently increased neuronal death (Agar et al., 2000; Acker and Acker, 2004). 
Hypoxia has been implicated in central nervous system pathology in a number of 
disorders including stroke, head trauma, neoplasia and other neurodegenerative 
diseases.  
Hypoxia/ischaemia compromises membrane functions and cellular enzymes like 
xanthine dehydrogenase which catalyses the reduction of molecular oxygen to form 
both superoxide anion radicals (O2-) and hydrogen peroxide (H2O2). Hypoxia/ 
ischaemia in the brain leads to extensive neuronal damage and subsequent 
neurological impairment. Some mechanisms could be proposed for the death of the 
B50 cells during hypoxia which include oxidative stress and glutamate toxicity. 
Cellular death of the B50 cells by hypoxia/ischaemia could be as a result of apoptosis 
or direct necrosis induced by oxygen and glucose lack and may also be by cytotoxic 
agents like  carbon monoxide (CO), carbon dioxide (CO2) and nitric oxide (NO) and 
proinflammatory cytokines. The role of free radical, NO produced by nitric oxide 
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synthase (NOS), has been shown to occur in acute cerebral ischaemia and chronic 
neurodegenerative diseases like schizophrenia, Alzheimer’s disease and Parkinson’s 
disease and aging dementia (Giannakopoulos et al., 2003; Mazarakis et al., 2005, 
Jellinger, 2007).  
It has been shown that the neuronal NOS isoform (nNOS) occurs in the brain neurons 
and generates NO which acts as a neurotransmitter (Rodrigo et al., 2007). Also 
inducible NOS (iNOS), a Ca2+/calmodulin-independent enzyme, is responsible for a 
high output of NO and is induced by the exposure to cytokines and 
lipopolysaccharide, and has been characterised in many cell types as a consequence of 
the inflammatory processes that follow infection, disease or tissue damage (Rodrigo et 
al., 2007). The iNOS is expressed by macrophages, neutrophils, vascular smooth 
muscles, endothelial cells, microglia, astrocytes and neurons of the cortical areas and 
cerebellum (Rodrigo et al., 2005; Rodrigo et al., 2007). Inducible NOS expression has 
been shown to form NO in many tissues of the body in response to diverse cell 
stresses, following injury, opiate dependence, trauma and cerebral ischaemia and 
several pathologies including demyelinating diseases, AIDS, dementia, amyotrophic 
lateral sclerosis, Alzheimer’s disease and epilepsy (Rodrigo et at., 2005; Yahyavi-
Firouz-Abadia et al., 2004).  
NO is associated with neuronal cell death (Hewett et al., 1994; Kolker et al., 2001). 
The adverse effects of NO in eukaryotic cells is related to the mitochondria of which 
the alteration of mitochondrial function seriously affects cell viability which can lead 
to necrosis through irreversible mitochondrial damage and collapse of the energetic 
capacity of the cell (Cramer and Sur, 1999; Andersen, 2004). Alternatively NO can 
induce apoptosis when proteins released from the mitochondria initiate caspase 
activation and the formation of a complex with apoptotic protease-activating factor 
(Weinmann et al., 2004a). The release of cytochrome c from mitochondria during 
hypoxia has been shown to be controlled by members of the Bcl-2 family which 
inhibit cell death and prevent the release of cytochrome c while other proteins such as 
Bax and Bak promote cell death and induce cytochrome c release (Weinmann et al., 
2004a Weinmann et al., 2004b). Also the product of the reaction between superoxide 
O2- and NO called peroxynitrite (ONOO-) inhibits mitochondrial respiration and 
stimulates apoptosis (Rodrigo et al., 2005; Mishra et al., 2006). Xu et al. (2001), have 
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observed that amyloid beta peptide-induced cerebral endothelial cell death involved 
mitochondrial dysfunction and caspase activation. Also ischaemia and severe hypoxia 
results in release of cytochrome c from mitochondria (Zhu and Bunn, 2001). Thus the 
mitochondrial swelling associated with ischaemia or glutamate excitotoxicity could be 
due to the mitochondrial permeability transition (MPT) induction by NO which 
reflects the formation of proteinaceous pores in the mitochondrial membrane that 
allows free diffusion of small molecules (Mishra et al., 2006; Rodrigo et al., 2005). 
Figure 4.3, illustrates the effect of oxidative stress in cells, leading to generation of 
reactive oxygen species and the consequent oxidative damage. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.3. Oxidative stress such as hypoxia is imposed on cells as a result of increase in 
oxidant generation, a decrease in antioxidant protection, or a failure to repair 
oxidative damage. Cell damage is induced by reactive oxygen species. The main 
damage to cells results from the ROS-induced alteration of polyunsaturated fatty acids 
in membrane lipids, essential proteins, and DNA. Adapted from Sigma (2006). 
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4.4.      Cell viability  
Since the B50 cell line was developed from neonatal neuronal cells, it means that 
these cells could grow, proliferate, and differentiate into mature neuronal tissues 
(Plates 1-5). However during development, most developing neural systems undergo a 
period of heightened neuronal cell death during which about 30-80% of their 
constituent neurons are lost during the time of their initial contact with innervation 
targets (Carr et al., 2005; Lobner et al., 2000). Middleton et al. (2001), showed that 
cranial sensory and parasympathetic ganglia revealed losses of about 30% in the 
mouse nodose ganglion, 35-55% in the mouse trigeminal ganglion and 50% in the rat 
vestibular ganglion and chick ciliary ganglion. There is elevated cell death in the 
geniculate ganglion neuronal population with a degeneration pattern similar to those 
seen in the vestibular, spinal and trigeminal ganglia (Nikolic et al., 2000; Lobner et 
al., 2000). However, the elevated cell death of geniculate neurons was not 
accompanied by a major reduction in the neuronal population which suggested an 
overlapping occurrence of neuronal death and neuronal generation in different 
neuronal subpopulations (Nikolic et al., 2000; Kim et al., 2006a; Lobner, 2000).  
 
The results from the proliferation, differentiation and morphological studies indicated 
that the B50 neuronal cell degeneration showed a pattern of neuronal cell death. The 
B50 neuronal degenerative activity level was significantly higher in hypoxic cultures 
without treatment than those in hypoxia but with various drug treatments (Figure 
3.32). It was seen from the result of this study that the major degenerative peak was 
found to be at 144 hours of culture in both normal and hypoxic cultured B50 cells 
(Tables 3.1 and 3.2). This shows that neuronal degeneration increases as the duration 
the cells stay in the culture increases. The presence of a greater density of dead and 
degenerating cells in the various experimental models in untreated hypoxic, hypoxic 
treated and pre-treated B50 cells revealed areas of heightened cell death which may 
represent cellular death due to developmental or tissue activities (morphogenetic or 
histogenetic cell death) (Carr et al., 2005) (Plates 6-9 and 24-26). Similar patterns of 
early degeneration with a later peak, rather than a sharp onset of degeneration 
corresponding with the time of target innervations was seen in neurons in the 
vestibular, spiral and trigeminal ganglia (Nikolic et al., 2000). The overall pattern of 
degenerating neuronal cell count in this study may reflect temporal aspects of 
responses of neuronal cells to noxious environmental conditions as in hypoxia within 
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different neuronal subpopulations as demonstrated by Carr et al. (2005) in trigeminal 
ganglion with different degenerative patterns occurring in some knockout mice. 
  
The neuronal counts (Figures 3.1 and 3.2), made in the course of this study were not 
intended to provide an absolute total neuronal cell count, because the numbers 
obtained clearly underestimated the actual number of dead and degenerating B50 
neurons in these experimental models. This is because the B50 neuronal cells are 
adherent or attached cells of which some of the dead and degenerating B50 cells 
become detached from the culture plate and float in the culture media. Hence when 
the media was removed, some of these cells are lost with the media. While the 
numbers obtained may underestimate the number of dead and degenerating B50 
neuronal cells, they provide a reliable indication of the pattern of the B50 neuronal 
cell population dynamics as evidenced from the results in control groups, and in both 
treated and untreated hypoxic B50 cells in culture.  
 
The data presented in Plates 3 and 4, and Figures 3.1 and 3.2, shows a striking feature 
of B50 cells in that they do not show any period of major neuronal loss in the control 
group when compared with the experimental or hypoxic groups. The control B50 cells 
showed a continual rise in neuronal cell numbers from 48 hours through 144 hours of 
culture with only slight decrease between 0 hours and 12 hours of culture in which the 
cells are trying to settle down to their new environment and start a new life after being 
disturbed by the harvesting and splitting of the cells. Some of the cells may be lost 
due to stress from the processes they pass through during splitting and sub-culturing. 
This is in contrast to the pattern seen in many developing neural systems in which not 
only are large numbers of neurons lost following initial target contact but this loss 
occurs over a limited period of time (Carr et al., 2005). Carr et al. (2005), showed that 
different subpopulations differed slightly in their temporal patterns of precursor 
proliferation and neuronal cell death and that accretion of neuronal cell numbers via 
proliferation and differentiation in one population could mask the degree of neuronal 
loss occurring simultaneously. The generation of free radicals which occurs in most 
oxidative stress conditions, causes free-radical signalling, defence, and injury which 
may result in the loss of cell viability and damage, and consequent death in neuronal 
cells as illustrated in Figure 4.4. 
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Fig.4.4. Oxidative stress in tissues experiencing cycles of oxygen presence, showing 
cyclic nature of free-radical generation during oxygen and hypoxia transitions. 
Adapted from Bickler and Buck (2007). 
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4.4.1.    LDH assay of cell viability  
Lactate dehydrogenase (LDH) leakage into the culture supernatant of untreated B50 
cells exposed to hypoxia showed more cellular death which may be as a result of the 
B50 neuronal cell membrane disintegration (Koh and Choi, 1987) (Table 3.3). The 
neuronal cell membrane disintegration allows the leakage and release of the 
cytoplasmic bound LDH enzymes into the culture medium, thus causing more 
neuronal cellular death. This additional cellular death could be corroborated by more 
groups of dead and degenerating B50 cells in hypoxia (Plates 6, 7, 23 and 26), when 
compared with the normal B50 cells (Plates 16, 22 and 24) and hypoxic treated and 
pre-treated B50 cells (Plates 15, 18, 27 and 33). The results from Table 3.3 and Figure 
3.5 show a time course comparative LDH release from both the normal and hypoxic 
B50 cells in culture. The results showed that there was a time course in the leakage of 
LDH from the B50 cells in both normal and hypoxic environments. The results 
showed that the length of time the cells stay in culture determines the amount of LDH 
they released into the media in both normal and hypoxic cells though the cells 
cultured in hypoxia had a significant increase in the LDH released into the cellular 
media when compared with those in normal culture. 
 
The question that arises is, if the normal cells were under optimal conditions, why 
were they releasing or leaking LDH into their media? The release of LDH by the 
normal B50 cells may be that since the B50 cells are neonatal cells, they are subject to 
normal developmental processes of which death and regeneration of cells are very 
common, especially in the neural system in which cells are subjected to continual 
death and renewal at early stages of their development. This is in agreement with 
Middleton et al. (2001), who showed that cranial sensory and parasympathetic ganglia 
losses about 30% of neurons in the mouse nodose ganglion and 35-55% of neurons in 
the mouse trigeminal ganglion. There was elevated cell death in the geniculate 
ganglion neuronal population but, the elevated cell death of geniculate neurons was 
not accompanied by a major reduction in the neuronal population which showed 
overlapping occurrence of neuronal death and neuronal generation in different 
neuronal subpopulations (Nikolic et al., 2000; Lobner, 2000). These B50 cellular 
death and degeneration, resulting in the release of LDH, could also result from either 
cell necrosis or programmed cell death (apoptosis) that occur as part of the normal 
cellular developmental processes. 
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 The second reason to account for the LDH leakage from normal cells could be the 
result of cellular injury and damage during the process of splitting the B50 cells as 
part of the culturing process. These effects could either be mechanical or chemical in 
nature. The mechanical injuries and damage could be the result of  frictional forces 
during the shaking and centrifugation process as one of the techniques involved in the 
splitting of the cells. Since the B50 cells are neuronal in nature, they are highly 
sensitive and could easily be injured and damaged by such processes leading to LDH 
leakage from the cell membranes. The chemical injuries and damages could occur due 
to the use of trypsin-EDTA solution to detach the cells from the base of the culture 
plate. Since this proteolytic enzyme is an oxidizing agent it could easily injure or 
damage the membrane resulting in LDH leakage from the cells.  
 
However, LDH release was reduced by cannabinoid and opioid treatment and pre-
treatment in B50 cells, which show that these drugs may have potential for protection 
and therapy in hypoxic conditions. The results presented in Tables 3.9, 3.10, A1, and 
A2, show the changes in LDH leakage in B50 cells administered with different 
concentrations of cannabinoid and opioid agonists. The more LDH leaked into the 
media, the more injurious the cells become and hence the cells are prone to die and 
degenerate more easily in hypoxic conditions than those in the normoxic conditions 
and those treated with some of the agonists in hypoxic conditions. The LDH release 
from the B50 cells could have been as a result of disintegration of the B50 cells due to 
oxidative stress caused by the hypoxic condition. The results presented in this study 
showed a concentration-dependent effect of cannabinoid agonists on LDH release 
from B50 cells. The results showed that the LDH release was increased with 
increasing concentration of Win agonist in that 10nM Win had LDH release lower 
that those from the 50nM Win and 100nM Win treated cells in hypoxia, while those 
treated with AEA and 2-AG had LDH release decreased as the concentration of the 
agonist increases. Hence the cells treated with 100nM AEA and 100nM 2-AG had 
LDH release lower than those treated with 50nM AEA, 50nM 2-AG,10nM AEA and 
10nM 2-AG. The results showed that different agonist has different trends in LDH 
release in B50 cells depending on the specific agonists. While Win was better in 
reducing the LDH release in lower concentration in B50 cells in hypoxia, AEA and 2-
AG were most useful at higher concentrations. This is in agreement with the findings 
of Shivachar (2007), which showed that cannabinoid agonists inhibited sodium-
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dependent, high-affinity excitatory amino acid transport in cultured rat cortical 
astrocytes in concentration-dependent manner.  
 
The results show that the selective cannabinoid (CB1) antagonist AM251 and the 
competitive cannabinoid antagonist, AM630 were able to reverse some of the effects 
of the cannabinoid agonists on LDH release in a concentration-dependent manner. 
The treatment with 10nM AM251/10nM Win (840%), was able to completely reverse 
the activity of the agonist 10nM Win (217%) against LDH release in B50 cells in 
hypoxia (Table 3.11 and Fig.3.16a), while at a higher concentration of both the 
agonist and the antagonist (50nM Win/50nM AM251; 100nM Win/100nM AM251), 
the LDH release from the B50 cells in hypoxia was about the same. The LDH release 
from the treatment with different concentrations of anandamide (AEA) was 
completely blocked with the equivalent concentrations of the competitive cannabinoid 
antagonist (AM630) (Table 3.11 and Figure 3.16b). The results also show that the 
selective cannabinoid (CB1) antagonist AM251 and the competitive cannabinoid 
antagonist AM630 were able to completely reverse the effects of the agonists on LDH 
release in B50 cells pre-treated against hypoxia in culture (Table 3.14 and Figure 
3.19). The results showed that the cannabinoid agonist-induced inhibition of LDH 
release from B50 cells in hypoxia was blocked by the cannabinoid receptor 
antagonists (AM251 and AM630). The results suggest that the inhibition of LDH 
release from B50 cells in hypoxia by cannabinoid agonists is mediated through 
cannabinoid (CB1) receptors since AM251 and AM630 have been shown to be potent 
CB1 antagonists in the brain (Gholizadeh et al., 2007; Werner and Koch, 2003). This 
is because AM630 though sold as CB2 antagonist, behaves as a competitive antagonist 
of Win 55,212-2 and anandemide and as such exerts cannabinoid receptor antagonism 
in the brain (Pertwee et al., 1995; Hosohata et al., 1997). 
 
The results of the opioid agonist and antagonist treatment on LDH release in B50 
cells, showed that the treatment of cells with different concentrations of opioid 
antagonists were able to reverse the inhibition of LDH release provided by the 
different opioid agonists in B50 cells in hypoxia. The results suggest that the 
inhibition of LDH release from B50 cells by opioid agonists is mediated through the 
opioid (µ, δ and κ) receptors and as such the opioid antagonists act to block the 
activities of the agonists on the receptors involved, since it has been shown that both 
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cannabinoids and opioids exert a wide range of their effects through coupling to 
inhibitory Gi/o proteins (Williams et al., 2001). It has also been shown that very low 
doses of opioids can selectively activate an excitatory Gs protein-coupled signalling 
pathway (Crain and Shen, 2000), and as such it was suggested that ultra-low doses of 
an opioid receptor antagonist can block this sensitive excitatory mechanisms and 
unmask a potent inhibition that is induced by opioids at concentrations lower than 
their minimal effective doses in some tests such as antinociception (Gholizadeh et al., 
2007). Manzanares et al. (1999), have shown that a number of functional interactions 
exist between cannabinoid and opioid systems which might be a result of shared 
signal transduction mechanisms (Childers et al., 1992), as well as the release of 
endogenous opioids by cannabinoid agonists (Valverde et al., 2001). 
 
Mitochondrial dysfunction has been shown to be involved in neuronal damage 
associated with hypoxic/ischaemic injury, aging and neurodegenerative diseases 
(Albers and Beal, 2000; Calabrese et al., 2001). Recent studies by Egea et al. (2007), 
and Weissman et al. (2007), have shown that mitochondrial membrane-potential was 
decreased during hypoxia/reoxygenation and subsequent Ca2+ overload, results in 
dysfunction of the mitochondria and ultimately cell death, resulting in higher LDH 
leakage as could be the case of B50 cells in hypoxia when compared with the normal 
B50 cells in culture. Mitochondrial dysfunction during hypoxia can be related to the 
depletion of ATP but also to the release of apoptotic proteins and various caspases 
during hypoxia resulting in cellular deaths (Jayalakshmi et al., 2005; Kreutz et al., 
2007). This explains why the hypoxic disturbance of the energy-producing system 
was likely to be one of the primary signals in hypoxia-induced cell death leading to 
increased LDH release from the cells in hypoxic cultures as in the case of B50 cells. 
The B50 cellular death and degeneration could be as a result of stress-induced cellular 
suicide (Steller, 1995), or some of the cells may undergo a process of dormancy or 
aestivation which may eventually result in death of these cells (Storey, 2002). 
 
Studies have shown that the increase in intracellular Ca2+-dependent signalling 
cascades contribute to further free radical formation, energy depletion which 
eventually leads to neuronal cell death (Choi, 1988; Burgoyne, 2007). Increased 
intracellular Ca2+ levels activate a group of serine proteases called caspases which in-
turn activate endonucleases resulting in DNA breaks (Jayalakshmi et al., 2005). The 
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significant damage to DNA resulting from endogenous free radical attack has already 
been suggested to contribute to the pathology of cancer and neurodegenerative disease 
processes (Zhang et al., 1999; Burgoyne, 2007). 
 
The results presented (Tables 3.12, 3.15, A5 and A6), show the LDH release from 
normal cultured B50 cells administered with different concentrations of cannabinoid 
and opioid agonists. They show some significant decreases and few insignificant 
increases in LDH leakage from the treated and pre-treated normal B50 cells when 
compared to the untreated normal B50 cells. There were decreases in LDH release 
from the normal B50 cells administered with cannabinoid agonists. The decreases in 
LDH release could be as a result of these agonists acting as a protective agent to the 
cells thereby limiting the amount of damage to the cells and hence the quantity of 
LDH released by these cells into the media. Abood et al. (2001), had shown that the 
activation of the cannabinoid (CB1) receptor protects cultured mouse spinal neurons 
against excitotoxicity induced by kainate. These neuroprotective effects of the 
cannabinoid agonists were blocked with the administration of CB1 receptor 
antagonist, AM251 indicating a receptor-mediated effect. Cannabinoid receptor 
agonists were neuroprotective in excitotoxic cell death in cultured cerebellar neurons 
(Skaper et al., 1996). Anandamide had been shown to decrease hippocampal neuronal 
loss after transient global cerebral ischaemia and reduce infarct volume after 
permanent focal cerebral ischaemia induced by middle cerebral artery occlusion in 
rats (Nagayama et al., 1999). Cannabinoid agonists were also shown to be protective 
in cultured cortical neurons from hypoxia and glucose deprivation though the effect 
was non-stereo selective and was insensitive to CB1 and CB2 receptor antagonists. In 
this way cannabinoids may have therapeutic potential in disorders resulting from 
cerebral ischaemia, including stroke, and may protect neurons from injury through a 
variety of mechanisms (Nagayama et al., 1999; Abood et al., 2001). Cannabinoid 
receptor agonists have been found to possess antioxidant properties, which may 
contribute to the reduction of excitotoxicity in neuronal cultures (Eshhar et al., 1995; 
Hampson et al., 1998). 
 
Some of the cells administered with opioid agonists showed increased levels of LDH 
release as in those normal cells pre-treated with 50µM DAMGO and 100µM 
DAMGO and  treated B50 cells with 50µM DAMGO, 100µM DAMGO and 10µM 
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ICI-199441. These increases in LDH release in the treated and pre-treated normal B50 
cells could be as a result of concentration-dependent toxicity of that particular drug 
thereby leading to damage to some of the cells administered with these drugs in the 
normal condition resulting in the release of higher LDH levels more than those 
untreated normal cells in culture. Though the opioid receptors have many similarities, 
one possible explanation for the differences in their neuroprotective capabilities is that 
the individual opioid receptors regulate different effectors, thereby eliciting different 
responses (Zhang et al., 2002), and the selectivity of these receptors for eliciting 
specific pathways does not lie in differences between each opioid receptor subtype but 
in their association with divergent types of G proteins (Connor and Christie, 1999). 
The µ, δ and κ-opioid receptors are all capable of interacting with the pertussis toxin-
sensitive G-protein α-subunits such as Gi1, Gi2, Gi3, Go1, Go2 and the pertussis toxin-
insensitive Gz and G16 (Connor and Christie, 1999). It has also been shown that each 
opioid receptor subtype preferentially couples to specific G proteins, example, the 
delta opioid receptor (DOR) is more efficiently coupled to the Gα16 protein than either 
mu or kappa-opioid receptors (Lee et al., 1998), which may apparently yield 
specialized differences between the opioid receptor subtypes and the regulation of the 
effectors. Zhang et al. (2002), had shown that the modulation of DOR plays a major 
role in neuroprotection in both normoxic and hypoxic environments even though the 
mechanisms of this action is not yet known, it could be speculated that this 
phenomenon may be linked to the role of DOR in selective regulation of G proteins, 
excitatory neurotransmitter release, glutamate receptor stimulation, and Ca2+ 
homeostasis (Howlett et al., 2004; Abood et al., 2001).  
 
The cellular damage that occurs in hypoxia leading to LDH leakage could result due 
to loss of ion gradient in the B50 cells. This is because neuronal function is dependent 
on maintenance of Na+, K+, Cl- and Ca2+ transmembrane distributions and the loss of 
ion gradients is considered to be an important event in the pathophysiology of brain 
ischaemia and reperfusion injuries (LoPachin et al., 2001). The onset of intraneuronal 
ion disturbance can be correlated to the development of cellular morphologic 
alterations and deficits (Taylor et al., 1999; LoPachin et al., 2001), which suggests 
that loss of ion homeostasis during ischaemia is linked to ischaemia-induced 
structural and functional changes as shown by degenerative changes in B50 cellular 
morphology and LDH leakage. The early sign of oxygen-glucose deprivation 
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associated with brain ischaemia is the reduction in neuronal aerobic metabolism and 
ATP production. This reduction in energy production leads to loss of active ion 
transport and subsequent dissipation of transmembrane gradients and membrane 
depolarization (Vornov, 1998; LoPachin et al., 2001; Kim et al., 2006b). Future 
studies in this B50 cell model could measure ATP production and normalized to total 
number of viable cells, hence determine whether ATP production is reduced in 
hypoxic conditions and the effects of the cannabinoid and opioid agonists. 
 
 
4.5. Hypoxia-induced cell damage and cell death 
The results from this study with B50 cells suggest that hypoxia could have led to B50 
neuronal cell death and degeneration in hypoxic condition as shown from the 
morphological observation and the results from total cell count and viability study, 
and cellular proliferation (Tables 3.1 and 3.2). The reduction in total cell count, viable 
cell count and percentage viability could be as a result of oxidative stress and 
generation of reactive oxygen species during hypoxia and as such resulting in cellular 
damage of the B50 cells which eventually leads to cellular death and degeneration. 
The result presented also demonstrated a reduction in the cellular proliferation in 
hypoxic B50 cells when compared to the normal B50 cells in culture. These 
reductions may be linked to the exposure of the B50 cells to hypoxia in the culture 
environment. 
 
These changes are possible because hypoxia has been known to generate reactive 
oxygen species (ROS) which are by-products of cellular oxidative metabolism 
(Jayalakshmi et al., 2005). The ROS include superoxide anion (O2-), hydrogen 
peroxide (H2O2), hydroxyl radicals (OH-) and nitric oxide (NO). However, enhanced 
production of ROS as seen in hypoxia, overwhelms the antioxidant scavenging 
capacity of the cells, thus causing oxidative damage to the DNA, lipids and proteins 
and leads to the development of cellular damage as the case with B50 cells (Lievre et 
al., 2001). Of all the cells in the body, neurons are highly susceptible to ROS damage 
and this susceptibility has been implicated in the development of neurodegenerative 
diseases like Parkinson’s disease, Huntington’s disease and Alzheimer’s disease. 
There are suggestions that ROS may play an important role in the processes leading to 
neuronal cell damage due to hypoxia, while Bossenmeyer et al. (1998), had shown 
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that cultured rat brain neurons on exposure to hypoxia/reoxygenation could induce 
apoptosis. Lievre et al. (2001), also showed that increased production of free radicals 
and modification in detoxifying enzymes leads to apoptosis in cultured rat forebrain 
neurons on exposure to transient hypoxia which can be prevented by antioxidants.  
 
Brain cells have been shown to be specially sensitive to oxidative stress due to the 
lipid composition of the cell membranes and low level of antioxidant enzymes 
(Marttila et al., 1988, Jayalakshmi, et al., 2005). Response to oxidative stress in the 
CNS has been shown to vary according to the various cell types and it was reported 
that the antioxidant capacity of neurons is lower than that of glia and as such neurons 
are more susceptible than glial cells to oxidative damage (Maker et al., 1994, Café et 
al., 1994; Jayalakshmi et al., 2005). Mishra and Delivoria-Papadopoulos (1999), have 
shown in their study that neurons from rat hippocampus exposed to transient hypoxia 
showed an increased oxidative stress and decreased antioxidant enzyme system of 
which the administration of N-acetyl cysteine (NAC), resulted in significant 
neuroprotection against oxidative stress. NAC has been reported to scavenge free 
radicals and to augment intracellular levels of glutathione (Jayalakshmi et al., 2005).   
 
4.6. Cellular proliferation and differentiation.  
The data presented in Table 3.2 and Figure 3.4 showed that hypoxia affected the B50 
neuronal cell proliferation and differentiation when compared with the normal B50 
cells while the treatment and pre-treatment of the cells against hypoxia with 
cannabinoid and opioid agonists improved and increased the rate of proliferation and 
differentiation of B50 cells in culture (Figures 3.11, 3.13, 3.30 and 3.32). The results 
also show that cell proliferation was higher in hypoxic B50 cells treated with 100nM 
Win than those treated with 10nM Win, while those treated with 100nM 2-AG had 
cell proliferation more that those treated with 10nM 2-AG. These differences in cell 
proliferation pattern may suggest a concentration dependent effect of the agonists in 
cell proliferation of B50 cells in culture. The result showed that 100nM Win and 2-
AG were more potent and efficacious in increasing cellular proliferation in B50 cells 
in hypoxia than 10nM Win and 2-AG. In contrast, 100nM Win was more potent than 
100nM AEA, while 10nM Win was more efficacious in cellular proliferation in B50 
cells treated in hypoxia than 10nM AEA and 2-AG. The results showed that there was 
a concentration dependent effect in those cells pre-treated against hypoxia with the 
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agonists. The result showed that 10nM Win was more potent in increasing cellular 
proliferation in B50 cells pre-treated against hypoxia than 100nM Win, 10nM AEA 
and 10nM 2-AG, while 100nM Win was more effective in cell proliferation in pre-
treatment against hypoxia than 100nM AEA and 100nM 2-AG. These are in support 
of Lauckner et al. (2005), who had shown a concentration dependent activity of 
cannabinoid agonists on intracellular calcium concentration in human embryonic 
kidney (HEK) 293 cells and in cultured hippocampal neurons. There was also a 
concentration dependent effect on the B50 cells treated and pre-treated with opioid 
agonists. The results showed that the cells treated with 100µM DAMGO had a higher 
proliferation than those treated with 10µM DAMGO and 100µM DSLET but had 
lower proliferation than those treated with 100µM ICI-199441. The result also 
showed that the cells treated with 10µM DSLET had higher cell proliferation than 
those treated with 10µM DAMGO and 10µM ICI-199441. The results of pre-
treatment of opioid agonists against hypoxia, showed that those pre-treated with 
50µM DSLET had higher cellular proliferation than 50µM DAMGO and 50µM ICI-
199441 while 50µM DAMGO cell proliferation was higher than those of 10µM 
DAMGO and 100µM DAMGO in B50 cells in culture. These differences in 
proliferation could be as a result of differences in the concentration and the mode of 
action of the different agonists used in the study.  
 
Arimura and Kaibuchi, (2007) have shown that at origin, nerve cells proliferate and 
differentiate which dramatically changes their shape and establishes two structurally 
and functionally distinct compartments namely axons and dendrites within a cell. The 
development of these morphologically and molecularly distinct compartments have 
recently been shown to be initiated by several signalling pathways (Ciani et al., 2006; 
Contestabile and Ciani, 2004). These pathways are evoked by extracellular signals 
which have essential roles in a number of aspects of neuronal polarization and 
functions (Arimura and Kaibuchi, 2007; Krymskaya et al., 2000). Most cells 
especially those undergoing differentiation, communicate through extracellular 
proteins. It has been shown that during embryogenesis, a cascade of signalling 
molecules are initiated between and among cells which instructs cells on their future 
course of differentiation. Much of this signalling occurs through growth factors, 
peptide hormones and cytokines, mostly directed by proteins on the cell surface and 
extracellular matrix (Gen, 2007; Weinstein, 2005). The results presented in this study, 
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showed that cannabinoid and opioid receptor agonists could have influence over the 
B50 cell proliferation and differentiation pathway which resulted in the increase in the 
rate of  proliferation and differentiation in B50 cells cultured in hypoxia (Figures 3.13 
and 3.32). 
 
Silverman et al. (2001) have shown that hippocampal neurons in culture developed 
morphological polarity in a sequential pattern in which axons form before dendrites 
and that molecular differences underlie the functional polarity of these areas especially 
the relationship between membrane protein polarization and morphological 
polarization. They showed that in neurons with morphologically distinguishable 
axons, even on the first day in culture, both axonal and dendritic proteins were 
polarized. The degree of polarization at these early stages was somewhat less than in 
mature cells and varied from cell to cell (Villalobo, 2006). This is in support of the 
results presented in this study which showed that there were differences in cell 
proliferation and differentiation in B50 cells treated and pre-treated with the different 
types of agonists which may be due to differences in the concentration and actions of 
the agonists or differences in the individual cells involved. 
 
The acquisition of a distinct morphological properties by neurons, called polarization, 
is a critical step in neuronal differentiation. Kinases have been shown to provide entry 
points for the signalling mechanisms that polarize neurons during the course of their 
proliferation and differentiation (Kishi et al., 2005; Aguado et al., 2007). A possible 
explanation why the normal B50 cells have higher rate of cellular proliferation and 
differentiation when compared with the untreated B50 cells in hypoxia with lower 
values could be as a result of higher value of phosphorylated kinases present in 
normal B50 cells as demonstrated from the results of phospho-ERK1/2 assays (Tables 
3.19 and 3.20), which promoted more cellular differentiation and proliferation in 
normal B50 cells than the untreated hypoxic B50 cells in culture. These phospho-
ERK1/2 was relatively higher in hypoxic B50 cells treated with cannabinoid and 
opioid receptor agonists when compared with untreated hypoxic cells except for those 
treated with 100µM DSLET and 100µM ICI-199441, which could explain why there 
was a higher rate of cellular proliferation and differentiation in treated cells than in 
untreated hypoxic B50 cells. The cells treated with opioid agonist showed 
concentration-dependent effects in that cells treated with lower concentration of the 
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agonists had a higher level of phospho-ERK1/2 when compared with those treated 
with higher doses. The cells treated with 10µM DAMGO had higher levels of 
phospho-ERK1/2 than cells treated with 50µM DAMGO and 100µM DAMGO, while 
cells treated with 10µM DSLET had higher levels of phosph-ERK1/2 than cells 
treated with 50µM DSLET and 100µM DSLET.  The cells treated with 10µM ICI-
199441 had higher levels of phospho-ERK1/2 than cells treated with 50µM and 
100µM ICI-199441 respectively. Hence the results revealed a concentration-
dependent effects of opioid agonists on the levels of phospho-ERK1/2 in B50 cells 
cultured in hypoxia. The present findings support the work of Moore and Potter 
(2001), who have shown a concentration-dependent effects of kappa opioid agonist on 
intraocular pressure. Hanks and Reid, (2005), had shown that individual opioids may 
manifest variability in their clinical responses and tolerance and they may induce 
receptor internalization which are known processes of highly addictive opiate agonists 
(Kreek, 2000; Compton and Volkow, 2005). The results presented in this study 
provide a probable explanation for the concentration-dependent action of opioid 
agonists on phospho-ERK1/2 in B50 cells in culture. The results showed that opioid 
agonists at low concentrations (10µM) induced a higher level of phospho-ERK1/2 in 
treated cells in hypoxia and this effect was reduced as the concentration increased 
(100µM). This may be the situation in which some opiate drugs may be effective at 
low concentration but at higher concentrations lead to opioid-induced plasticity 
causing opiate addiction and tolerance (Liao et al., 2007). This is because opioid 
drugs can be addictive in clinical usage and the dosage to be administered depends on 
the type of the opioid and situation of the individual involved (Kreek, 2000; Compton 
and Volkow, 2005). Hence the results presented showed that there were more 
signalling mechanisms occurring through the proliferation and differentiation 
pathways in the normal, followed by the treated hypoxic and the untreated hypoxic 
B50 cells showed the least proliferation and differentiation in culture.   
 
Yoshimura et al. (2006), have shown that neuronal polarity is essential for both 
structurally and functionally unidirectional signal flow from dendrites to axons. The 
initial event in establishing a polarized neuron is the specification of a single axon and 
early in neuronal development, one small neurite becomes differentiated from other 
neurites to form an axon. The ability of neuronal cells to proliferate, differentiate and 
polarize is essential for organization of the nervous system and cultured hippocampal 
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neurons which develop a single long axon and several shorter dendrites that maintain 
their structural characteristics at the molecular level have been used as a model for 
neuronal polarization (Yoshimura et al., 2006). During maturation, hippocampal 
neurons dramatically change their morphology and differentiate into a single axon and 
many dendrites which form synaptic contacts and establish a neuronal network 
(Yoshimura et al 2006; Dotti et al., 1988). It is these neuronal networks that finally 
joined together into a specific pattern to form neuronal bundles that ultimately form 
neural tracts.  
 
The result as presented in Plates 6-9 showed that hypoxia affected neuronal pattern 
and pattern formation in B50 cells in hypoxia when compared with the normal B50 
cells in culture in Plates 3-5. This disorganisation of the neuronal pattern could be as a 
result of the reduction and disorientation of the proteins necessary for cellular 
signalling through neuronal cell proliferation and differentiation. Of relevance are the 
findings of Zhong et al. (2007), who showed that Raf serine/threonine kinases play 
important role in nervous system development and when these molecules were 
conditionally eliminated, the result showed markedly reduced phosphorylation of 
ERK in neural tissues which led to growth retardation. This supports the finding in 
this present study. Reduced proliferation and differentiation in hypoxic B50 cells 
could be a result of attenuation in phospho-ERK1/2 in hypoxic B50 cells when 
compared with normal B50 cells in culture. The importance of this finding is that the 
reduction in proliferation and differentiation could be corroborated with the reduction 
in the phospho-ERK1/2 which plays a significant role in the B50 cell signalling 
mechanisms. Hence, this shows there is a direct relationship between the cellular 
induced activities like proliferation and differentiation with phospho-ERK1/2 
activities, even though Zhang and Fenton (2002), have shown that the proliferation of 
IL-6-independent multiple myeloma cells does not require the activity of extracellular 
signal-regulated kinases. This may suggest that the proliferation and growth of  IL-6-
independent multiple myeloma cells may be independent of ERK activities and as 
such, other signal transduction pathways may be involved. 
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4.7    Neuroprotection by cannabinoid receptor agonists 
The effect of cannabinoid receptor agonist treatment on the morphology of B50 cells 
(Plates 9-20), showed a drug-induced changes in the morphology of the B50 cells 
cultured in hypoxia when compared to the untreated hypoxic B50 cells (Plates 6-8), 
The hypoxic B50 cells treated with different concentrations of cannabinoid agonists 
had healthier morphology which is concentration-dependent (Plates 17-19) when 
compared with untreated hypoxic B50 cells (Plates 6-8). The changes in the 
morphology could be correlated with changes in proliferation, differentiation and 
LDH leakage from the B50 cells. The effect of cannabinoid treatment and pre-
treatment on proliferation in hypoxia (Tables 3.6 and 3.8), show a concentration-
dependent increase in cellular proliferation in cells treated and pre-treated with 
cannabinoid agonists when compared with untreated hypoxic B50 cells. The effect of 
cannabinoid agonists treatment and pre-treatment on proliferation in normal B50 cells 
(Tables 3.5 and 3.7), show a concentration-dependent increases in cellular 
proliferation. The results also revealed differences in cell proliferation from the 
different cannabinoid agonists used. The cells treated with Win and AEA, showed a 
concentration-dependent increase in cell proliferation in which cells treated with 
100nM of the agonists had higher cellular proliferation compared to those of lower 
concentration of the agonist (Table 3.6) in hypoxia, while the cells treated with 2-AG 
had a concentration-dependent decrease in cellular proliferation whereby the low 
concentration of the agonist produced higher cellular proliferation in B50 cells 
cultured in normal (Table 3.5). The result also showed that the proliferative effects of 
the cannabinoid agonists was not completely abolished by the cannabinoid antagonists 
(AM251) since some of the effects still show significant increases in cell proliferation 
in the presence of the antagonist, suggesting that the actions of the agonists may be 
mediated through both receptor- and  non-receptor-mediated pathways in the same 
cell. The mediation through the cannabinoid (CB1) receptors in this process occurs via 
the activation of Gαi/o proteins. Aguado et al. (2007) have shown that the CB1 
receptors mediate excitotoxicity-induced neural progenitor proliferation and 
neurogenesis. It has been shown that the endocannabinoid system exerts an important 
neuromodulatory function in different brain tissues and is known to be involved in the 
regulation of neural cell fate (Galve-Roperh et al., 2007). There is the presence of a 
functional endocannabinoid system in neural progenitor cells that participates in the 
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regulation of cell proliferation and differentiation which play a regulatory role in 
neurogenesis (Galve-Roperh, et al., 2007). 
The endocannabinoid system has been shown to affect early progenitors and this 
extends to the regulation of neuronal migration and the attainment of the 
morphological, physiological and molecular characteristics that occur during terminal 
neuronal differentiation (Harkany et al., 2007). It has also been shown that AEA and 
Win, with brain-derived neurotrophic factor, a pro-differentiating neurotrophin, 
induce the migration of GABA-containing interneurons that undergo migration to 
populate the embryonic cortex (Harkany et al., 2007). The activation of the CB1 
receptors in which downstream signalling events such as proliferation and 
differentiation occur, exert profound effects on neurite outgrowth and synaptogenesis 
(Harkany et al., 2007). AEA and Win have been shown to strongly inhibit neurite 
formation and elongation in GABA-containing interneurons (Berghuis et al., 2004; 
Berghuis et al., 2005). In N1E-115 neuroblastoma cells, AEA and HU210 reduce the 
rates of neurogenic differentiation by inducing cell rounding, and neurite remodelling 
and retraction through the recruitment of the Rho family of small guanosine 
triphosphatases (Jaffe and Hall, 2005). The cannabinoid agonist, HU210 promotes 
neurite outgrowth in Neuro 2A cells by the Gαo/i-mediated degradation of Rap–GAPII 
and the subsequent activation of Rap1 (Jordan et al., 2005). 
The results of the present study showed some consistency with other studies showing 
that the different cannabinoid receptor agonists used acted through the G protein 
coupled receptors (GPCRs) to mediate cellular activities, functions and alterations via 
the intracellular second messenger pathway. These cellular activities such as 
proliferation and differentiation were shown to increase in the cells treated with the 
cannabinoid agonists when compared with the untreated hypoxic B50 cells in culture. 
The most striking and important aspect of the cannabinoid-induced action was the fact 
that they could be diluted to lower concentrations in the medium during treatment and  
they still provided protection and increased cellular activities over extended periods of 
time (Zhuang et al., 2001).  
 
The effect of cannabinoid treatment on LDH release from B50 cells (Table 3.10), 
showed a change when compared to the untreated hypoxic cells and the change in 
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LDH release was concentration-dependent. The results also showed differences in 
LDH release between the cannabinoid agonists (Win and AEA) used, in which there 
was increase in LDH release from B50 cells with increase in the concentration of Win 
while there was a decrease in the LDH leakage with increase in the concentration of 
AEA. Hence there was an inverse relationship between the LDH leakage in B50 cells 
in hypoxia in which the LDH release was increasing with increase in Win 
concentration while decreasing with increase in AEA concentration. This difference 
in LDH release could be as a result of the difference in the concentrations of the 
agonists used, because these agonist though mediating their effects through CB1 
receptors, may have other systems involved in the overall protective effects of the 
cannabinoid agonist system. Kim et al. (2005) have shown there was a reduction in 
LDH release from primary cortical cell culture in the presence of increasing 
concentrations of the Win with 50% inhibition of the effect of FeCl2 at 100nM Win, 
while AEA also decreased FeCl2 toxicity by producing half-maximal inhibition at 
300nM AEA. The involvement of CB1 receptors in cannabinoid neuroprotective 
effects of Win and AEA, was because of the ability of the cannabinoid antagonists to 
inhibit the protection from the agonists, thus pointing to a Gi/o-mediated mechanism. 
The reduction in LDH release could be due to the protection afforded the cells by the 
cannabinoid from the oxidative stress caused by the hypoxia. This is because 
exogenous cannabinoids have been shown to protect against neurotoxicity in a 
number of different cellular, animal and human experimental models (Pryce et al., 
2003; Davies et al., 2002; Wang et al., 2007b). Zhang et al. (2005) have demonstrated 
that cultured rat hippocampal neurons were protected from excitotoxic insults by pre-
treatment with either ∆9-THC or Win and these compounds were effective in 
preventing cell death even if administered prior to the neurotoxic exposure. 
Cannabinoid protection has been demonstrated in vivo with respect to 
neurodegenerative changes resulting from experimental ischaemia (Sánchez et al., 
1998; Leker et al., 2003). In the present study, cannabinoid agonist treatment with 
Win, AEA and 2-AG was shown to be neuroprotective by the reduction of LDH 
leakage from the B50 cells. This is because LDH leakage has been shown to be a 
reliable method of accessing neuronal injury and damage in culture model (Zhang et 
al., 2006), and when the LDH leakage from the cells is reduced, cells were improved 
morphologically and functionally.  
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However, the results presented show some disparities in the concentration-dependent 
agonist response to hypoxia in that it was expected that the drugs would have more 
beneficial effects at higher concentrations which was not seen to be so as shown in the 
results (Table 3.10), with 100nM Win treatment having 527% of LDH release which 
is even more that of the hypoxic untreated cells with 440% when compared with the 
normal cells with 100% LDH leakage. The effect of cannabinoid receptor agonist pre-
treatment on LDH release (Table 3.13), of which the B50 cells pre-treated with had 
10nM Win (99%), 50nM Win (404%) and 100nM Win (447%) had LDH release. 
 
Three mechanisms could be attributable to the reactions of the these drugs used in the 
study. The G protein coupled receptors involved could be over activated, desensitized 
or saturated. Thus at higher concentrations of cannabinoid administration, the 
receptors could either become over-activated, desensitized or become saturated and 
hence leading to the higher concentrations of the drugs not resulting in higher or 
elevated response to the drug action. It could also be that at higher concentrations of 
the drugs, the receptors become highly activated and hence cell death could result 
from that leading to elevated LDH release from the B50 cells in culture. The 
mechanism involved could also be that the receptor stimulation by higher 
concentrations of the agonists evoke Ca2+ release from the endoplasmic reticular 
stores followed by Ca2+ influx through store-operated Ca2+ channels in the plasma 
membrane. Chang et al. (2007) had shown that at a single cell level, Ca2+ influx was 
related to agonist concentration in an all-or-none manner in mast cells and that 
increasing the agonist concentration, recruited more mast cells but each cell responded 
by generating all-or-none Ca2+ influx. This effect could also be an example of a 
specialized functional homologous or heterologous desensitization of the CB1 
receptors in higher concentrations of the agonists which induces interference on the 
receptor-induced activities. This is because Itzhaki Van-Ham and Oron (2005), have 
shown that Gαo G-proteins mediate both homologous and heterologous rapid 
desensitization of responses mediated by G-protein-coupled receptors coupled to the 
phosphoinositide phospholipase C-inositol trisphosphate-Ca2+ pathway in Xenopus 
oocytes.  Also the higher concentrations of these drugs could actually be toxic and 
hence result in toxic death of the cells involved leading to increased LDH leakage 
from the B50 cells in such media (Downer et al., 2003; Sarne and Mechoulam, 2005).  
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Zhang et al. (2001) have demonstrated that cannabinoid receptor mediated 
neuroprotection is sensitive to intracellular calcium levels, hence cannabinoids may 
act by reducing or blocking the release of intracellular calcium (Ca2+)i under 
neurotoxic conditions such as hypoxia. This intracellular calcium mechanism is 
possible in the case of B50 cells in hypoxia treated and pre-treated with different 
concentrations of cannabinoid agonists. This is because during hypoxia in B50 cells, 
there may be an increase in (Ca2+)i influx into the cells through the ionotropic 
channels in the cell membrane leading to increased Ca2+ accumulation that 
consequently results in the death of the cells. This cellular damage leads to increased 
LDH leakage from the cells into the media. Hence cannabinoid agonists could act by 
blocking the ionotropic channels which blocks the influx of the calcium ions into the 
intracellular surfaces thereby preventing the cells from calcium ion intoxication and 
consequent death of the cells. When this protection is proffered, it leads to the 
reduction of cell death in hypoxia which is correlated by the reduction of LDH 
leakage from the B50 cells into the culture media. 
 
One of the factors underlying the cannabinoid induced changes is the increase in 
cAMP levels in the cannabinoid treated hypoxic groups when compared to the 
hypoxic untreated B50 cell groups. This may be due to the cannabinoid agonist-
induced stimulation of CB1 receptors leading to cannabinoid receptor-mediated 
stimulatory effect on cAMP accumulation in the cells through Gαs (Glass and Felder, 
1997). The cannabinoid-induced increase in cAMP accumulation in B50 cells when 
compared to untreated hypoxic cells, may lead to the increased down-stream 
signalling activities such as proliferation and differentiation in cannabinoid-treated 
cells, through a combination of molecular signalling pathways in B50 cells (Yao et 
al., 2006). Guo and Ikeda (2004) have shown that cannabinoid mediate alterations in 
intracellular calcium (Ca2+)i levels via an intracellular second messenger pathway 
which provides a basis for cannabinoid effects on intracellular calcium ion mediating 
the neuroprotection. The significant feature of this finding is that protection for the 
B50 cells can be triggered by relatively low concentrations of cannabinoids acting on 
the CB1 receptors like 10nM Win. Neuroprotection from reduced (Ca2+)i can persist 
for relatively longer periods due to the extended recovery time of protein kinase A to 
constitutive levels (Zhuang et al., 2005).  
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It is shown in the results (Table 3.13), that since the cannabinoid pre-treatment effects 
were concentration-dependent with respect to the magnitude of the excitotoxic insult 
(LDH release), there exists considerable potential for adjustment of these 
concentrations with respect to the possible potential therapeutic application of  these 
potent synthetic cannabinoid compounds in hypoxia-related conditions (Zhuang et al., 
2005). Cannabinoid have been shown to protect neurons from toxic insults such as 
glutamatergic excitotoxicity, ischaemic stroke, hypoxia, trauma, oxidative stress and 
ouabain-induced secondary excitotoxicity (Zhang, et al., 2005; Smit and Iyengar, 
1998). Most of these protectant effects appear to be mediated by the activation of the 
cannabinoid (CB1) receptors (Grundy, 2002; Machoulam, et al., 2002; Biegon, 2004). 
 
The effect of cannabinoid agonists was reversed by the action of the antagonists 
(Table 3.11), using LDH release from the cortical B50 cells in culture. The result 
showed that the cannabinoid agonists (10nM Win, 50nM Win, 50nM AEA and 
100nM AEA), were able to reduce the levels of LDH release from the B50 cells in 
hypoxia. These effects were blocked by the cannabinoid receptor antagonists AM251 
and AM630, suggesting both cannabinoid receptor- and non-receptor-mediated 
mechanism. The cannabinoid agonist Win was shown to reduce neuronal cell death in 
murine cortical cultures treated with 20µM NMDA and its protective effect was 
attenuated by the CB1 receptor antagonist SR141716A (Kim et al., 2005), even 
though the results presented (Table 3.11) for the action of antagonists against the 
agonists may show some disparities in the LDH leakage in the treatment with the 
agonists and antagonists during hypoxia in B50 cells. One of the most promising 
potential medical applications of cannabinoids involves their ability to protect cells 
from a variety of toxic events (Guzman et al., 2001). Cannabinoids have been 
reported to protect neurons from death caused by glutamatergic over-stimulation, 
ischaemia and oxidative damage (Hansen et al., 2002). These effects could have been 
due to the cannabinoids having multiple effects on the G proteins mediated responses 
(Slessareva et al., 2003). The differences between the effects observed in different 
models may be related to the cell type or model system used and the differences in the 
toxic events which have been employed (Chen, et al., 2005; Drysdale and Platt, 2003; 
Zhang et al., 2005).  
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The results show that some antagonists completely reversed the action of the agonists 
while others did not. This effect can be seen with the cells treated with 10nM 
AM251/10nMWin, in which the LDH released was lower than that released by the 
untreated hypoxic B50, while the cells pre-treated with 10nM AM251/10nM Win 
showed more LDH release. These disparities may be due to the antagonists not being 
in the right amount and concentration to counter the effect of the agonists or the 
reduction in LDH release by Win may not be entirely mediated through the CB1 
receptors. It was because of these differences that concentration-response experiment 
was conducted using a standard concentration of the cannabinoid agonist (10nM 
Win), with varied concentrations of the antagonist (AM251), in both treatment and 
pre-treatment groups (Tables 3.16 and 3.17). The result showed that the treatment of 
B50 cells in hypoxia with 10nM Win required 5nM concentrations of the antagonist 
(AM251) to bring about the complete inhibition of the agonist (10nM Win) activity in 
reducing the LDH release from B50 cells while pre-treatment with 10nM Win used 
1nM concentrations of the antagonist (AM251) to bring about complete blockage of 
the agonist (10nM Win) action of LDH inhibition of B50 cells cultured in hypoxia. 
This concentration-dependent response of the antagonist to the agonistic action may 
suggest that antagonists does not function on equivalent concentrations, and as such, 
could not function effectively on a one to one basis. It was for this reason that 
differences in the antagonist reaction to the agonist action regarding LDH release 
from B50 cells were evident. The result showed that different concentrations of the 
agonist require different and specific concentration of the antagonist to bring about 
effective antagonism. Also if the concentrations are at the right proportion, the 
condition of the system in which the agonists and the antagonists interact is important 
for effective activity of both the agonists and the antagonists. The results showed that 
less concentration of antagonist was required to reverse the action of the agonist 
during pre-treatment with the drugs when compared with the treatment with the 
agonist. This means that the smaller amount of a drug can produce an effective 
response when introduced as a preventive measure rather than during treatment. 
Hence drugs used for inoculation in cases of vaccinations are usually administered at 
very small quantity which would produce a maximal effect, but when the disease is 
present, larger concentration of the drug will be required to produce the desired 
treatment from the drug.  
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4.8   Neuroprotective effects of opioid receptor agonists  
Five independent approaches were used to determine neuronal injury and damage in 
this study namely, morphological-based same field assessment, LDH assay, live/dead  
staining using trypan blue exclusion method, neuronal differentiation using DbcAMP 
and neuronal proliferation assay method. The results of the study show groups of dead 
and degenerating B50 cells in hypoxia (Plates 23, 25 and 26), when compared with 
the normal cells (Plates 22 and 24). When the hypoxic B50 cells were treated with 
different concentrations of opioid (Mu, delta and kappa) agonists and compared to the 
hypoxic untreated B50 cells, the results showed healthier looking cells with fewer 
degenerating cells. The opioid receptor agonists (DAMGO, DSLET and ICI-199441), 
may have provided protection to the B50 cells against the hypoxic injury and damage 
(Plates 27-29). The results of the effect of hypoxia on total cell count and viability, 
cellular proliferation and the LDH release are shown in Tables 3.1 and 3.2. These 
studies draw a detailed time course effect of hypoxia on total cell count and viability, 
cellular proliferation and LDH release in cultured B50 neuronal cells based on 
neuronal age and hypoxic duration, which demonstrated that cultured B50 neuronal 
cells are more vulnerable to hypoxic stress with maturation. 
 
The result of opioid agonists treatment and pre-treatment on the proliferation of B50 
cells in hypoxia (Tables A14 and A16), showed an increase in neuronal proliferation 
when compared with untreated hypoxic cells. This increase could be as a result of the 
opioid agonists mediating cellular activities like proliferation and differentiation 
through increases in cAMP signalling activities leading to increased cellular 
signalling through proliferation and differentiation activities. Tencheva et al. (2005), 
had observed that opioid agonists acting via specific opioid receptors have been 
shown to influence neural cell proliferation, and Law et al. (1997), had shown that 
chinese hamster ovary (CHO) cells transfected with δ-opioid receptor cDNA resulted 
in an agonist concentration-dependent potentiation of foetal calf serum-stimulated cell 
proliferation. The effect of µ, δ and κ opioid agonists on proliferation was abolished 
by the selective mu, delta and kappa antagonists (Table A17), suggesting that these 
effects were mediated through the µ, δ and κ opioid receptors in B50 cells in culture. 
Since this potentiation of cellular proliferation by the opioid agonists (µ, δ and κ) was 
antagonized by the selective antagonists, thus indicating that Gi/o was involved in this 
action. However this opioid agonist potentiation of cellular growth and proliferation 
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apparently was dependent on the level of agonist concentrations used in that, Law et 
al. (1997), had suggested that δ- and µ-opioid receptors in CHO cells activate similar 
but divergent second messenger pathways, resulting in differential regulation of cell 
growth, proliferation and differentiation. This is in agreement with the findings from 
the present study which show that the increase in B50 cell proliferation induced by the 
opioid agonist was concentration-dependent. The results show that cells treated with 
the agonist DAMGO and ICI-199441, had increases in cell proliferation as the 
concentration of the agonists increases, while those treated with DSLET demonstrated 
cell proliferation decreases with increase in concentrations of the agonist. The effects 
of the opioid agonist pre-treatment against hypoxia in B50 cells show that the cell 
proliferation was decreased with increases in the concentration of DAMGO and 
DSLET while there was no change in cell proliferation in those pre-treated with ICI-
199441. The results show some differences in the overall activity of the agonists and 
the antagonists suggesting that multiple processes may be involved in the regulation 
of opioid receptors (Tencheva et al., 2005).  
 
 The effects of opioid agonists (DAMGO, DSLET and ICI-199441) administration on 
LDH release from B50 cells in hypoxia (Tables A1 and A3), showed significant 
reductions in LDH leakage in hypoxia-treated B50 cells in culture while the pre-
treated B50 cells with opioid agonists showed more LDH leakage when compared 
with the treatment group. The use of LDH assay has a unique advantage of using the 
same culture dish which provides relatively accurate time course data for hypoxic 
duration and opioid agonist treatment experiments. The release of intracellular LDH 
into the extracellular fluids has been documented as a reliable indicator of neuronal 
injury and damage (Zhang et al., 2006). The results showed that there was a 
concentration-dependent decrease in LDH release from treated B50 cells in hypoxia. 
The cells treated with DAMGO and DSLET had LDH release decreased with increase 
in the concentration of the agonists while ICI-199441, had LDH release increased as 
the concentration of the agonist increases. The effect of the agonists in lowering the 
LDH release from B50 cells was blocked by the selective mu, delta and kappa 
(CTAP, ICI-174864 and NOR) opioid antagonists suggesting that the effect of 
inhibiting the LDH release from B50 cells was mediated through the (µ, δ and κ) 
opioid receptors, indicating the involvement of Gi/o in the protective activities of the 
opioid receptor agonists. There was some relative differences in the actions of the 
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agonists and antagonists like in the pre-treatment with 100µM ICI-199441, in which 
the LDH release was lower than that of 10µM ICI-199441 (Table A3), treatment with 
100µM DSLET was higher than that of 50µM DSLET (Table A1), and antagonist pre-
treatment with 10µM DAMGO and 10µM DSLET had LDH release lower than those 
of the agonist involved (Table A4). Thus indicating that there may be other systems 
and processes involved in the regulation of opioid receptor activities in B50 cells in 
culture. These multiple processes could be as a result of interaction between the 
various opioid receptor subtypes involved, since it has been shown that the opioid 
receptor subtypes share a close homology in their sequences (Mayer et al., 2003). 
There may be the involvement of endogenous opioids in the system, which have been 
shown to be released during hypoxia (Zhang et al., 2000). Also there may be the 
involvement of interaction between the opioid agonists, the endogenous opioid and 
the endogenous cannabinoid system present in the cells   (Schoffelmeer et al., 2007). 
This is because Zani et al. (2007) have demonstrated that opioid agonist (AM 404) 
and cannabinoid agonist (∆9-THC), reduced neuronal damage caused by bilateral 
carotid occlusion in gerbils and that this protection was mediated through an 
interaction between CB1 and opioid receptors.   
Hong et al. (2004) have shown that although δ-opioid receptor inactivation reduces 
LDH activity in normoxic neurons, neither δ-opioid receptor activation nor 
inactivation induces any appreciable effect on LDH activity in the cortical neurons 
under hypoxia and as such, other signal transduction pathways such as the glycolytic 
pathway, may play an important role in neuroprotection. Zhang et al. (2002) had 
shown clearly that the modulation of δ-opioid receptor, but not µ- and κ-opioid 
receptors, plays a major role in neuroprotection in both normoxic and hypoxic 
environments. Though the mechanism involved in this neuroprotection is not well 
understood, Zhang et al. (2002), speculated that this phenomenon may be linked to the 
role of δ-opioid receptors in selective regulation of G proteins, excitatory 
neurotransmitter release, glutamate receptor stimulation, and Ca2+ homeostasis. The 
activation of opioid receptor subtypes may have a wide range of clinical applications 
in treating and preventing acute and chronic hypoxia-related impairments. Further 
research in this area is necessary to develop a better understanding of opioid receptor 
activities and the pathways involved in their neuroprotection.  
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The use of LDH release as an index of neuronal injury does not provide direct 
assessment of the percentage of neurons injured and/or dead in culture. Hence the use 
of additional experimental approaches which include morphological assessments, 
live/dead trypan staining for total cell count and viability and proliferation assay was 
used to assess neuronal injury more directly. It has been shown that during hypoxia, 
glutamate is expelled from neurons leading to over-stimulation of glutamate receptors 
and subsequent injury and death of the neurons (Figure 4.1) (Haddad and Jiang, 1993; 
Nyakas et al., 1996). Since Zhang et al. (2002), had shown that because glutamate 
receptor expression increases during development, and sensitivity to glutamate 
excitotoxicity increases with neuronal maturation, the observed differences in hypoxic 
susceptibility between the neuronal ages in this study may be associated with the 
developmental increase in glutamate toxicity (Choi and Rothman, 1990). 
This study has demonstrated that stimulation of opioid receptors, proffers some 
protection by reducing neuronal cell injuries and deaths after treatments in hypoxic 
conditions but the benefit is reduced substantially with prolonged exposure durations 
and higher concentrations of the drugs. This supports the finding that the longer the 
neurons stayed in the culture media both in the normal and in the experimental 
hypoxic groups, the greater the extent of the neuronal cell injuries and death. A  
possible explanation for this phenomenon is that prolonged hypoxia may cause a 
significant release and accumulation of endogenous glutamate which causes 
glutamate-induced toxicity and hence death of the cells (Nyakas et al., 1996). Another 
alternative explanation is that prolonged hypoxia causes the release and accumulation 
of endogenous opioids which saturates opioid receptors in these neurons. Hence the 
positive effect of the opioid agonists decreases with the increase in the time the cells 
stay in the medium which may result in desensitization of the receptors and the 
reduced effect of the action of the drugs (Mao et al., 2002; Wallace et al., 2006).  
 
It has been shown that in response to short-term hypoxia, the level of enkephalins, the 
endogenous agonists for opioid receptors sharply increases (Zhang et al., 2002; 
Khasabova et al., 2002). This showed that cortical neurons may release opioids during 
normal function and in response to hypoxic stress as a mechanism of self-protection 
against injury (Ma et al., 2005; Wallace, et al., 2006). Zhang et al. (2002), showed 
that because of high levels of endogenous opioids which may already be present in the 
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culture media after prolonged exposure to hypoxia, adding more agonist may not 
increase the protection. On the other hand, desensitization of  the receptors may have 
occurred due to prolonged treatment of the cells with the agonists in conjunction with 
the endogenous opioid release during chronic hypoxia. Zhang et al. (2006), have 
shown that cortical neurons are highly susceptible to opioid receptor inhibition, which 
causes serious neuronal injury especially during hypoxic stress. 
 
However, the greater injury was observed in 144 hours cultured B50 neurons than in 
48 hours cultured B50 neurons in both normoxic and hypoxic conditions which 
suggests that maturational differences exist between these age group of neurons. This 
supports the work of Zhang et al. (2000), which showed that opioid receptor 
expression increases significantly with development in both brain and cultured 
neurons. This is because the opioid receptor density increases with increase in the age 
of the neurons. The more mature neurons may have greater dependence on this 
pathway to maintain neuronal function and therefore may be more susceptible to 
neuronal injury with opioid receptor inhibition. This observation suggests that the 
increase in opioid receptor agonist may compete with opioid receptor antagonist in 
terms of opioid receptor binding and thus reduce neuronal injury induced by opioid 
receptor inhibition during prolonged hypoxia (Wallace et al., 2006). This is in support 
of the findings in this study in which at higher concentration of the agonists and 
antagonist DAMGO/CTAP (100µM), DSLET/ICI-174864 (50µM) and ICI-199441/ 
NOR (50µΜ) during the pre-treatment against hypoxia, which led to complete 
inhibition of the agonists activities, resulting in increased LDH release in cultured 
B50 cells in hypoxia.  
 
Another issue is whether the differences in expression levels of the various opioid 
receptors account for the observed phenomenon in cortical neurons. Past studies have 
demonstrated that µ-opioid receptors are present at similar or even higher densities 
than δ-opioid receptors in mammalian cortex, although κ-opioid receptor density is 
slightly lower (Zhang et al., 2006). This implies that the relative distribution and 
expression levels of opioid receptor subtypes within the cortex as a whole may not be 
a key factor in the observations shown in this work. This is because the results 
presented in this study show that there was no observed differences in the receptor 
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expression densities of µ-opioid receptors in normoxic, hypoxic and hypoxic treated 
B50 cells in culture. 
 
The mechanisms of opioid receptor neuroprotection activity may involve the 
regulation of specific G proteins, ion channels mainly Ca2+ and K+ channels and 
excitatory neurotransmitter release. It has been shown that intracellular Ca2+ levels are 
elevated during hypoxic exposure leading to irreversible cell injury while the 
inhibition of Ca2+ currents by opioid receptor stimulation by DAMGO, DSLET and 
ICI-199441, may serve as a neuroprotective mechanism in preventing Ca2+ overload 
(Andersen, 2004; Bossy-Wetzel et al., 2004). Also opioid receptor regulation of 
glutamate signalling may be involved in normal function and protection of neurons 
(Ma et al., 2002, Mao et al., 2005). It has also been shown that opioid receptor 
agonists have the ability to reduce neuronal over-stimulation by blocking glutamate 
excitation (Zhang et al., 2002), and this could be the situation with the protection 
proffered by the µ-, δ- and κ-opioid agonists used in this study. This mechanism of 
cellular regulation may be utilised during normal cell functioning and in response to 
environmental stress like hypoxia (Andersen, 2004). Zhang et al. (2006), have shown 
that the inhibition of opioid receptors in normal neurons may lead to substantial injury 
in the neurons by the loss of inhibitory regulation of the excitatory neurotransmitter 
release and/or receptor excitation. 
 
The δ-, µ- and κ-opioid receptors have many similarities such as seven 
transmembrane domains existing as 60% identical sequences and being coupled to 
Gi/o proteins. They are also similar in several of their regulatory targets including 
adenylyl cyclases, protein kinases and certain Ca2+ and K+ channels (Bickler et al., 
2004; Zhang et al., 2006). One possible explanation for the differences in 
neuroprotective abilities and actions of these three different opioid receptors is that 
the individual opioid receptors regulate different effectors thereby eliciting different 
responses (Tables A1 and A2). Connor and Christie (1999), had proposed that 
because of the common features of opioid receptors, the selectivity of these receptors 
for eliciting specific pathways does not lie in the differences between each opioid 
receptor subtype but in their association with other divergent types of G proteins. It 
was observed that each opioid receptor subtype also preferentially couples to specific 
G proteins apart from the Gi/o proteins that they generally couple (Zhang et al., 2002). 
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Examples of this preferential coupling include as seen in δ-opioid receptors which are 
more efficiently coupled to Gα16 protein than either µ- or κ-opioid receptors (Lee et 
al., 1998). Also µ-receptor agonist (DAMGO) has been reported to have a selective 
coupling to Gαi1 and GαoA opioid receptors than other opioid agonists (Saidak et al., 
2006). This shows that the opioid receptor agonists have selective activation of G-
proteins in response to opioid receptor activation. This preferential coupling to other 
G protein subtypes may be the reason for the observed differences in the effect of the 
opioid agonists on the B50 cells treated in hypoxia. The activation of µ-, δ- and κ-
opioid receptors by the agonists may have a wide range of clinical implications in the 
treatment of hypoxia-related impairments and may form the basis for the development 
of new neuroprotective and therapeutic drugs useful for the treatment of stroke and 
other neurodegenerative pathologies. 
 
4.9.        Intracellular cAMP 
The results presented (Table 3.18), showed that there was a decreased cAMP release in  
hypoxic B50 cells when compared with normal B50 cells, which is in agreement with the 
findings of Cooper and Crossthwaite (2006), which showed that as the concentration of 
intracellular cAMP increases, it leads to activation of cAMP-dependent protein kinases 
and phosphorylation of targets which could lead to coordinated activities of the B50 cells 
such as cellular growth, proliferation and differentiation. The intracellular concentration 
of cAMP could be increased or decreased by a variety of ligands and hormones and such 
fluctuations affect a variety of cellular processes and activities. One prominent and 
important effect of elevated concentrations of cAMP is activation of cAMP-dependent 
protein kinases (Cooper, 2005). The results presented in this study showed that treatment 
of B50 cells in hypoxia with cannabinoid receptor agonists increased cAMP release in 
B50 cells in culture when compared with untreated hypoxic B50 cells with the exception 
of the cells treated with 10nM AEA and 50nM AEA in which the cAMP release was the 
same or less than that released by the untreated hypoxic cells. The changes in cAMP 
release during cannabinoid agonist treatment show in the case of cells treated with the 
cannabinoid agonist (2-AG), that the level of cAMP release was decreased with increase 
in the concentration of the agonist, hence those treated with 10nM 2-AG had higher 
cAMP release than 50nM 2-AG while 100nM 2-AG had the least cAMP release from 
B50 cells treated in hypoxia. The results also showed that the cells treated with Win and 
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AEA agonists had cAMP release increased with increase in the concentration of the 
agonists hence, the cells treated with 100nM Win and AEA had higher cAMP release 
when compared with the low concentration of the agonists. The results (Table 3.19) of 
the opioid treatment on cAMP release, show increase in cAMP release when compared to 
untreated hypoxic B50 cells in culture. The results show in the case of ICI-199441 that 
the cAMP release was decreased with increase in the concentration of the agonist while 
in the case of DAMGO and DSLET, the cAMP release was also decreased with increase 
in the concentration of the agonists with some differences among the agonists. The results 
showed that the cannabinoid and opioid receptor agonists’ administration to B50 cells in 
hypoxia resulted in the increase in cAMP release when compared with untreated hypoxic 
cells in culture (Tables 3.18 and 3.19). 
 
The regulation of intracellular concentrations of cyclic AMP has been shown to be 
largely due to the controlling effect of adenylyl cyclase (Cooper et al., 1995; Houslay and 
Milligan, 1997). It has been shown that when adenylyl cyclase (AC) is activated, it 
catalyses the conversion of ATP to cAMP which leads to an increase in intracellular 
levels of cAMP (Cooper and Crossthwaite, 2006). Hence there is a special relationship 
between the intracellular levels of cAMP and AC, the higher the level of AC that is 
activated, the higher the level of intracellular cAMP released into the cytoplasm for 
signalling activities of the cells assuming availability of ATP is constant. Thus the results 
presented in this study, showed that the higher the amount of cAMP released by the B50 
cells in culture, the higher the signalling activities exhibited by the cells. These signalling 
activities such as proliferation and differentiation were more in the normal cells followed 
by the hypoxic treated cells while the untreated hypoxic B50 cells had the least signalling 
activities, which correlated with the cAMP release from the cells in this study. The AC 
enzymes differ considerably in regulatory properties and have a very complex model of 
interactions that regulate cAMP production which affect the physiological state of the 
cells (Cooper, 2005; Cooper and Crossthwaite 2006).  
 
Cannabinoids have been shown to exert many of their effects through activation of Gi-
protein-coupled receptors and functional coupling of CB1 receptors have been 
demonstrated in the inhibition of adenylate cyclase and voltage-dependent calcium 
channels via pertussis toxin-sensitive G-proteins (Felder et al., 1992). Both dopamine (D1 
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and D2) receptors have also been shown to couple adenylate cyclase via G-proteins. 
Dopamine (D1) receptors stimulate adenylate cyclase via Gs-proteins, whereas dopamine 
(D2) receptors inhibit adenylate cyclase via Gi-proteins and there have been associations 
between the actions of cannabinoids and dopamine (Glass et al., 1997). It has been 
reported that concurrent activation of CB1 and D2 receptors results in an increase in 
cAMP accumulation in contrast to the inhibition of cAMP accumulation normally 
observed with activation of either of the receptors alone (Glass and Felder, 1997). The 
CB1 receptor couples to a Gs-protein indicating that cannabinoid receptor function may be 
more complex than the simple Gi linkage that is generally known (Howlett, 2004). The 
CB1 receptor interaction with Gs has been demonstrated in Chinese hamster ovary cells 
stably expressing recombinant human CB1 receptors (Bonhaus et al., 1998).  
 
The increase in the cAMP release in response to the treatment with cannabinoid agonists 
presented in this study may be caused by the coupling of the CB1 receptors to both Gi 
which mediates the inhibition of adenylate cyclase, and to a stimulatory component Gs, 
resulting in increases in cAMP accumulation in cannabinoid-treated B50 cells in hypoxia. 
In the study with primary striatal cells, Glass and Felder (1997), showed that the 
inhibitory effect on cAMP accumulation appear to dominate over the stimulatory 
component because the stimulatory component can only be observed when the inhibitory 
component was reduced. However, some of the treated cells (50nM AEA), showed 
reduced cAMP levels when compared with hypoxic untreated cells. This reduction in 
cAMP accumulation could be due to the direct effect of the drug thereby promoting the 
inhibition of adenylate cyclase release from the B50 cells through the Gi causing a 
reduction in cAMP release. Another explanation could be that since the cortical neurons 
are found in association with the striatal dopamine neurons that concurrent activation of 
CB1 and D2 receptors could result in an increase in cAMP accumulation as shown with 
the B50 cortical neurons treated with cannabinoid agonists in hypoxia. However, the 
increase in the accumulation of cAMP occurred only at higher concentrations of the 
cannabinoids (Win and AEA), and was likely attributable to the membrane-perturbing 
effects of these hydrophobic compounds (Felder et al., 1992). It has been shown that 
treatment of striatal neurons with pertussis toxins prevented the inhibition of cAMP 
accumulation by D2 receptors but unmasked a cannabinoid receptor-mediated stimulatory 
effect on cAMP accumulation (Felder et al., 2006). Similar augmentation of cAMP 
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accumulation was also observed by Glass and Felder (1997), in Chinese hamster ovary 
cells transfected with, and stably expressing, the CB1 receptors and this stimulation of 
cAMP was not Ca2+-sensitive, since the treatment of the pertussis toxin-treated cells with 
cholera toxin before CB1 receptor activation amplified the stimulatory pathway, 
suggesting that this response was mediated through a Gs-type G-protein.  
 
The results presented in this study which showed an increase in cAMP release as a result 
of cannabinoid agonist treatment, resulting in the activation of the CB1 receptors leading 
to the stimulation of cAMP accumulation, may be mediated through the stimulatory Gαs 
proteins. This is because Gαs and forskolin have been shown to be synergistic in their 
activation of adenylate cyclase (Barovsky and Brooker, 1985). Also the increased cAMP 
accumulation was observed when cannabinoid agonist, HU210, and forskolin were added 
together, compared with the level of stimulation observed when each agent was added 
alone (Glass and Felder, 1997). The mechanism involved in this could be that the Gαs 
subunits only become available as a substrate as they are released from the heterotrimeric 
G-proteins after receptor stimulation, resulting in the amplification of agonist-dependent 
increases in cAMP accumulation. This shows that at higher concentrations of the 
cannabinoid agonists (Win and AEA), there was a reversal of the inhibition of cAMP 
accumulation observed at lower concentrations, suggesting an underlying stimulatory 
component. It has been shown that dopamine (D2) agonists through Gi/o oppose the action 
of low concentrations of CB1 agonists acting through Gαs to modulate cone cell 
membrane currents, suggesting a role in shaping the cone light response and/or sensitivity 
to changes in ambient light conditions in cone cells of goldfish (Fan and Yazulla, 2004). 
It has been shown that cannabinoid receptors couple to both Gs and Gi proteins and can 
consequently stimulate or inhibit the formation of cAMP. Bonhaus et al. (1998), had 
shown that the cannabinoid agonists (anandamide and CP-55,940) were markedly less 
efficacious in stimulating the accumulation of cAMP than in inhibiting its formation. This 
receptor mediated stimulation of adenylyl cyclase revealed differences among agonists 
which support the finding from the present study that AEA has the least stimulatory 
effect on cAMP accumulation in B50 cells treated in hypoxia. Hence taken together, the 
findings from this study demonstrate differences among cannabinoid receptor agonists in 
their activation of intracellular cAMP release and as such the transduction pathways of 
cAMP in B50 neuronal cells may differ with these agonists. Another mechanism 
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resulting in the cannabinoid receptors couple to both Gs and Gi proteins and can stimulate 
or inhibit the formation of cAMP, is the differences in the relative and intrinsic activities 
of CB1 receptor agonists. The cannabinoid receptor agonists may have different affinities 
for Gs- and Gi-coupled CB1 receptors in B50 cells in which a  higher affinity towards Gs 
proteins will result in stimulatory cAMP effects but an affinity towards Gi proteins will 
lead to inhibitory cAMP effects as in the results of this study. This is because CB1 
receptors have been shown to predominantly couple Gi receptors but cannabinoid-induced 
tolerance is associated with a G protein coupling switch from the inhibitory Gi protein to 
the excitatory Gs protein (Paquette et al., 2007). 
 
The results presented showed increase in cAMP release following treatment with µ, δ and 
κ opioid receptor agonists in B50 cells cultured in hypoxia. This is in agreement with the 
findings of Russell and Potter (2001), which showed the stimulation of cAMP levels in 
the iris-ciliary body by bremazocine suggest that a κ-agonist has dual effects in inhibiting 
isoproterenol-stimulated cAMP production at high concentrations and in the absence of 
isoproterenol, enhancing cAMP levels at low concentrations of bremazocine. Dziedzicka-
Wasylewska and Przewlocki (1995), have shown that the κ-opioid receptor agonist 
(U50,488H) and µ-opioid receptor agonist (morphine), affected opioid receptor activation 
in vitro by increasing the cAMP level on the slices of hippocampus obtained from kainic 
acid-treated rats. The increase in cAMP level in B50 cells treated with opioid agonists 
may be as a result of direct coupling of receptors to adenylyl cyclase via a stimulatory G 
protein (Gs) (Russell and Potter, 2001). There was evidence to suggest that a subset of 
opioid receptors may be linked directly to Gs and thereby mediating stimulation by 
adenylyl cyclase (Cruciani et al., 1993). Thus, it is possible that the opioid receptors 
couple to both Gi and Gs in B50 cells and the stimulation of adenylyl cyclase by opioid 
agonists could occur as a result of µ-, δ- and κ-receptors linked to multiple G protein-
subunit mediated pathways. The stimulation of adenylyl cyclase resulting in the increase 
in cAMP has been shown to occur through βγ-subunits of Gi/o (Federman et al., 1992), 
which synergize with Gs to elevate cAMP levels (Mhaouty-Kodja et al., 1997). Newton 
and Klee, (1990), had observed that the -subunits of two molecular species of Gi,(Gi-1 
and Gi-2A), cause stimulation rather than inhibition of adenylyl cyclase in a bovine brain. 
Taken together, the results presented from the cAMP experiments in this study suggest 
that µ-, δ- and κ-opioid receptors can evoke both stimulatory and inhibitory processes on 
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B50 neuronal cells in culture.  
 
Opioids have been known to modulate cAMP formation in various cells and tissues and 
their main effect is to inhibit adenylyl cyclase activity and attenuate cAMP formation 
which is mediated by pertussis toxin-sensitive, Gi-GTP binding proteins. However, some 
studies have demonstrated stimulatory effects in which opioids induced either inhibition 
or stimulation depending on the concentration of the drug, the duration of incubation or 
the presence of forskolin (Rubovitch et al., 2003). In their study Fields and Sarne, (1997), 
and Sarne et al. (1998), had reported dual effects of opioids on cAMP formation in SK-
N-SH neuroblastoma cells in which they showed that at a low concentration, DAMGO 
stimulated cAMP production, while a higher concentration, inhibited cAMP production. 
This may be true as in the results presented here in which DAMGO at lower (10µM) 
concentrations, produced higher cAMP (2.5pmol/ml) accumulation in B50 cells while at 
higher (100µM) concentrations produced lower cAMP (1.5pmol/ml) accumulation. This 
is also true in the case of treatment in this study with the kappa opioid agonist (ICI-
199441) in which the cAMP release decreased with increase in the concentration of the 
agonist. Rubovitch et al. (2003), had observed that low concentrations of opioids 
stimulated cAMP production, while a high concentrations of opioids exert an inhibitory 
effect, which overcomes and masks the stimulatory pathway. There were similar 
concentration-dependent dual modulation by opioids in which low concentrations of 
opioids potentiated, while high concentrations suppressed, the calcium component of the 
action potential in dorsal root ganglion and visceral neurons (Shen and Crain 1989; 
Makman et al., 1988). Rubovitch et al. (2003) had shown that the stimulatory effect of 
DAMGO was mediated by phospholipase C (PLC), and since the most common activator 
of PLC is Gq-GTP binding protein, it is reasonable to assume the involvement of Gq in 
the opioid stimulatory pathway. This assumption was supported by the finding that opioid 
receptors were associated with the stimulatory Gq-GTP binding protein in transfected 
cells (Kramer and Simon, 1999). Hence there may be two parallel pathways operating 
within the cells, namely an inhibitory process which is mediated by Gi-GTP binding 
proteins, and a stimulatory process which is not mediated by PTX-sensitive GTP (Gs and 
Gq) binding proteins (Rubovitch et al., 2003; Sidhu and Niznik 2000), resulting in 
elevation of cAMP accumulation in B50 cells treated with opioid agonist in culture. The 
overall outcome either stimulation or inhibition of cAMP production is dependent on the 
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balance between the two overlapping pathways. Figure 4.5 show the activation of cAMP 
pathway leading to cellular induced changes. 
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Fig 4.5. Illustration of activation of cAMP pathway leading to cellular induced changes 
and effects. Adapted from Biocarta (2007). 
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4.11   Extracellular signal-regulated kinase (ERK) Signalling 
The cell based ELISA was used to quantify phospho-ERK1/2 in the study of the 
effects of hypoxia on ERK pathway activation in the B50 cell line and determine the 
effect of various cannabinoid and opioid agonist treatments on this pathway. The 
effects of hypoxia and the treatment with cannabinoid and opioid agonists on 
phospho-ERK1/2 in B50 cells in culture (Tables 3.20 and 3.21), show that the 
phospho-ERK1/2 was decreased in untreated hypoxic cells when compared with the 
normoxic cells. When compared with the hypoxic treated B50 cells, the result show 
increase in phospho-ERK1/2 in the cells treated with cannabinoid agonists while 
those treated with opioid agonists showed minor increases which were reversed by the 
selective cannabinoid and opioid antagonists. The effect of cannabinoid agonist 
treatment was concentration-dependent. The treatment with Win agonist show that the 
amount of phospho-ERK1/2 in the treated cells was decreasing with increasing 
concentration of Win, hence 10nM Win had the highest amount of phospho-ERK1/2 
followed by 50nM Win and then 100nM Win had the least amount. The results 
showed that the treatment of  B50 cells with cannabinoid agonists could have affected 
the cellular production of phospho-ERK1/2 resulting in increased intracellular 
concentration of phospho-ERK 1/2 when compared with the untreated hypoxic B50 
cells in culture. This increase could have resulted in increased downstream cellular 
activities such as cellular growth, proliferation, differentiation, morphological 
integrity and activities, and cell death. This is because cannabinoids have been shown 
to modulate the extracellular signal-regulated kinase (ERK), leading to various forms 
of plasticity in the brain (Moranta et al., 2007; Daigle et al., 2008). Cannabinoid 
agonist (Win), increased the immunodensities of phosphorylated ERK1 by 24% and 
ERK2 by 28% in the rat cerebral frontal cortex and these effects were antagonized by 
a selective CB1 antagonist, SR141716A, while pre-treatment with SL327, a MEK1/2 
inhibitor, increased the basal phosphorylation of MEK1/2 by 74% and prevented the 
up-regulation of ERK1/2 by 23-31% induced by Win, which demonstrated that the 
acute stimulation of CB1 receptors in the frontal cortex results in the sequential 
phosphorylation of Raf-MEK-ERK cascade (Moranta et al., 2007). The activation of 
the phospho-ERK1/2 cascade by cannabinoid agonists involved CB1 receptors 
coupled to Gi/o GTP-binding proteins since this was blocked by selective cannabinoid 
antagonists (AM251 and AM630). 
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ERK1 and ERK2 are serine and threonine kinases expressed broadly in normal tissues 
and various cell lines. They are activated through the phosphorylation of a threonine 
and a tyrosine residue and activate a signalling cascade, the downstream effects of 
which have been linked to the regulation of cell growth and differentiation as well as 
regulation of the cytoskeleton (Chan et al., 2005). The extracellular signal-regulated 
kinase (ERK) also known as mitogen activated protein kinase (MAPK) has two 
isoforms namely, ERK1 known as MAP Kinase1 or P44 MAP kinase and ERK2 
known as MAP kinase 2 or P42 kinase. They are activated upon treatment of cells 
with mitogens, hormones, growth factors, cytokines and bioactive peptides (Chan et 
al., 2005; Zhuang and Schnellmann, 2006). The results presented here, show that 
there was an increase in phospho-ERK1/2 in the cannabinoid treated B50 cell groups 
when compared with the untreated hypoxic groups which potentially could have 
resulted in increased cellular activities like proliferation and differentiation. This is 
because the MAP kinases, known as extracellular signal-regulated kinases (ERKs), 
act as an integration point for multiple biochemical signals, and are involved in a wide 
variety of cellular processes such as proliferation, differentiation, transcription 
regulation and development (Zhuang and Schnellmann, 2006). The activation of this 
kinase requires its phosphorylation by upstream kinases such as protein kinase A and 
protein kinase C. Upon activation, this kinase translocates into the nucleus of the 
stimulated cells, where it phosphorylates nuclear targets necessary for cellular growth, 
proliferation, differentiation and normal development (Robinson and Cobb, 1997; 
Belcheva and Coscia, 2002; Demuth and Molleman, 2006). The increase in phospho-
ERK1/2 in cannabinoid agonist treated B50 cells in hypoxia is in agreement with the 
findings of Derkinderen et al. (2003) and Valjent et al. (2001), in which acute ∆9-THC 
administration increased CB1 receptor-mediated ERK1/2 activation in the dorsal 
striatum, nucleus accumbens, and hippocampus, while chronic ∆9-THC treatment has 
been shown to increase ERK1/2 protein levels in the prefrontal cortex and 
hippocampus in vivo (Rubino et al., 2004). 
Ras proteins are small G proteins that are embedded on the inner surface of the plasma 
membrane (Sebolt-Leopold and Herrera, 2004; Ui, 1994). They are activated by a 
variety of transmembrane receptors, a process that involves the exchange of GTP for 
GDP. Ras proteins represent an important signalling branch point because they 
activate several signalling pathways through a number of effectors such as the protein 
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kinases of the Raf family (Jo et al., 1997). These cytosolic protein kinases are the first 
components of a three-tiered protein kinase cascade, which includes two other 
cytosolic protein kinases namely, MEK and ERK (Dumaz and Marais, 2005; Jo et al., 
1997). ERK phosphorylates many substrates, thereby regulating numerous cellular 
functions, such as gene expression, metabolism and cellular morphology. 
Consequently ERK signalling plays an important role in determining cell fate, 
choosing between diverse responses such as proliferation, differentiation, senescence 
or survival and it also regulates specialist functions such as those in neurons and 
immune cells (Sebolt-Leopold and Herrera, 2004; Baillie et al., 2000; van Biesen et 
al., 1996).  
The effect of opioid agonist treatment on phospho-ERK1/2 (Table 3.21), shows a 
slight increase in the quantity of phospho-ERK1/2 in the opioid agonist treated group 
of hypoxic cells when compared to the untreated hypoxic B50 cells. Additionally, 
phospho-ERK1/2 was decreased with increasing concentration of the agonist hence, 
the treatment of B50 cells in hypoxia with the opioid agonist (ICI-199441 and 
DSLET), 10µM had the highest amount of phospho-ERK1/2 followed by 50µM and 
100µM had the least phospho-ERK1/2. The reduction of phospho-ERK1/2 in some 
treatment groups may be due to high concentration of the agonists which may result in 
decreased cellular activities and functions as a result of receptor desensitization since 
increases in the ERK1/2 cascade following chronic drug treatment in vivo are most 
likely to be regulated by receptor desensitization at the cellular level (Derkinderen 
et al., 2003; Valjent et al., 2001). The results show that since B50 cells are neuronal in 
origin, the phospho-ERK1/2 activities are more in normal B50 cells when compared 
to the untreated hypoxic B50 cells which give an indication of normal proliferation, 
differentiation and growth. These normal neuronal activities was disrupted during 
hypoxic exposure of the B50 cells resulting in the reduction of the phospho-ERK1/2 
activities and the treatment of the hypoxic B50 cells with the agonists brought the 
phospho-ERK1/2 activities towards the normal levels. Dumaz and Marais (2005), 
have shown that in neuronal precursor cells, transient ERK signalling stimulates 
proliferation whereas sustained signalling induces differentiation while in fibroblasts, 
ERK signalling is essential for proliferation, but high intensity signals induce cell 
cycle arrest or senescence (Kolch, 2000). Thus ERK has been shown to be a key 
regulator of cellular behaviour and ERK signalling has long been associated with 
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cancer where its signalling is disrupted in approximately 30% of cases (Sebolt-
Leopold and Herrera, 2004; Dumaz and Marais, 2005, Davis and Laroche, 2006; 
Davis et al., 2000).  
The main mechanism for coupling opioid receptors with the ERK pathway was shown 
to involve the activation of Ras via Gβγ subunits that are associated with Gi/o protein 
activity (Audet et al., 2005). Other mechanisms by which opioid receptors could 
regulate the ERK pathway involve the modulation of protein kinase A and C 
signalling systems (Luttrell and Luttrell, 2003; Belcheva et al., 2005). Acute µ and κ 
opioid agonists activate the ERK/MAPK phosphorylation cascade that represents an 
integral part of the signalling pathway of growth factors in astrocytes and by this 
means, opioids may impact neural development and plasticity among other basic 
neurobiological processes in vivo (Asensio et al., 2005). The µ agonist, (DAMGO), 
induces a transient stimulation of ERK phosphorylation, whereas κ agonist, 
(U69,593), engenders sustained ERK activation (Belcheva et al., 2005). There is 
evidence to demonstrate that acute U69,593 and DAMGO can stimulate ERK 
phosphorylation by utilizing different secondary messengers and protein kinase C 
(PKC) isoforms upstream of the growth factor pathway (Belcheva et al., 2005; Yoon 
and Seger, 2006). The findings relating to the effects of cannabinoid and opioid 
agonists on phospho-ERK1/2 suggest that differences in their mechanism of signalling 
may contribute to the outcomes on ERK modulation induced by cannabinoid and 
opioid agonists as in the differences in cell proliferation and differentiation. 
The result showed that the higher the amount of phospho-ERK1/2 in B50 cells, the 
higher the cellular based activities such as proliferation, differentiation and 
morphological activities as in pattern formation. The extracellular signal-regulated 
protein kinases (ERK1/2) have been shown to be essential for normal development 
and functional plasticity of the central nervous system (Chu et al., 2004; Davis, 1993). 
The MAPK/ERK kinases-1/2 is emerging as an important regulator of neuronal 
responses to both functional (in terms of learning and memory) and pathologic (in 
case of regulated cell death) stimuli. It has been shown that ERK signalling plays a 
beneficial and neuroprotective role in many systems (Cavanaugh et al., 2001; Ji et al., 
2007; Molina-Holgado et al., 2005).  Aberrant neuronal expression of phosphorylated 
form of both ERK1/2 and other MAPKs have been shown in Alzheimer’s disease 
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patients’ brain in association with markers of oxidative stress (Chu et al., 2004; 
Colucci-D’Amato et al., 2003; DeGracia et al., 2007). 
 The results showed that the treatment of B50 cells in hypoxia with cannabinoid and 
opioid antagonists (Tables 3.20 and 3.21) were able to bring the level of phospho-
ERK1/2  back to untreated hypoxic levels which showed that the antagonist was able 
to abolish the agonist-induced stimulation of phospho-ERK1/2 production. The result 
showed that the treatment with the selective cannabinoid (CB1) and opioid antagonists 
in hypoxia resulted in the attenuation of the phospho-ERK1/2 signalling resulting in 
the inhibition of the agonist-induced activation by the antagonists suggesting the 
involvement of the cannabinoid (CB1) and opioid receptors. The results also suggest a 
mechanism involving Ras and beta gamma subunits of G proteins are involved in 
opioid agonist activation of ERK1/2 as well as opioid modulation of phospho-
ERK1/2-induced activity (Belcheva et al., 2005). 
The results presented show the quantification of cellular differentiation, proliferation 
and phospho-ERK1/2 in normal, hypoxic and hypoxic treated B50 cells and the data 
show that the higher level of phospho-ERK1/2 in B50 cells, correlated with increased 
cellular differentiation and proliferation indicating the significant involvement of 
phospho-ERK1/2 in these cellular processes. The results also showed a significant 
decrease in phospho-ERK1/2 from the normoxic to the hypoxic untreated groups and 
the treated hypoxic groups, which suggest an improvement in cellular activities in 
treated hypoxic groups when compared to untreated hypoxic groups. 
 
The results presented (Figures 3.40, 3.42, 3.44 and 3.45), show that the level of cAMP 
and phospho-ERK1/2 were decreased in the hypoxic untreated B50 cells when 
compared with the control and those treated with cannabinoid and opioid receptor 
agonists which may provide a link between the decreased level in cellular 
proliferation, differentiation and growth and morphological changes in the 
experimental groups when compared with the control and the hypoxic treated groups. 
The increased levels of cAMP and phospho-ERK1/2 in the normal B50 may suggest 
the increased signalling potential in these cells when compared with the hypoxic 
untreated cells while the treated B50 cells showed increased signalling potential when 
compared with the hypoxic untreated B50 cells. These signalling activities are in the 
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form of cellular growth, proliferation and differentiation which are more in the normal 
B50 cells when compared with the hypoxic untreated and hypoxic treated B50 cells.  
Dikic and Giordano (2003) had shown that binding of external factors like 
cannabinoid and opioid agonists to cell membrane receptors, triggers intracellular 
signalling pathways that ultimately determine if the cell proliferates, differentiates or 
undergoes apoptosis. Activated receptors also initiate a cascade of events, called 
negative receptor signalling, that decreases the amplitude of positive signals and 
modulates the level of cell stimulation. Dikic and Blaukat (1999) had shown that 
protein tyrosine kinases (PTKs) convey signals from G protein-coupled receptors 
(GPCRs) to regulate cell proliferation, migration, adhesion, and potentially cellular 
transformation and death (Subramaniam and Unsicker, 2006). Molecular mechanisms 
by which PTKs regulate such diverse effects in GPCR signalling are not well 
understood. It has been shown that both growth factors and GPCRs utilize protein 
tyrosine kinase activity and the Ras/MAP kinase pathway to control mitogenic signals 
and activities (Dikic and Blaukat, 1999). Many G protein-coupled receptors (GPCRs) 
generate signals that control cellular differentiation and growth, including stimulation 
of Ras family GTPases and activation of MAP kinase pathways (Luttrell and Luttrell, 
2003). The mechanisms that these GPCRs use to control the activity of MAP kinases 
vary between receptor and cell types and these receptors are coupled to the activation 
of the ERK cascade (Figure 4.6). 
The CB1 receptor has been shown to regulate different members of the MAPK 
(Bouaboula et al., 1995). Several mechanisms could be responsible for mediating 
ERK activation by G protein coupled receptors. In PC12 neuronal-like cells, short-
term ERK activation promotes proliferation, while sustained ERK activation results in 
cell cycle arrest and neuronal differentiation (Galve-Roperh et al., 2002). The G 
protein coupled receptors have been shown to be functionally coupled to inhibition of 
adenylate cyclase, modulation of ion channels and activation of extracellular-signal-
regulated kinase (Galve-Roperh et al., 2002; Cadwallader et al., 1997; Kelly et al., 
2003). This kinase plays a pivotal role in the regulation of basic cell functions such as 
cellular energy metabolism, cellular proliferation and migration (Gomez del Pulgar et 
al., 2000; Kolch, 2000; Chan et al., 2005). The actions of cannabinoids have been 
shown to control cell growth and induce proliferative effects in a number of cultured 
cell models. The ERK/MAPK cascade plays a central role in regulating cellular 
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proliferation and differentiation. For example, the ability of growth factors to promote 
and regulate cell growth depends on the activation of receptor tyrosine kinases, which 
recruit Ras family of small G proteins and leads to sequential activation of Raf family 
of Kinases. The sequential nature of ERK/MAPK cascade provides multiple points at 
which the response can be regulated by phosphorylation and dephosphorylation and 
allows for amplification of extracellular signals (Impey et al., 1999; Bohn et al., 2000; 
Kolch, 2000). Zhu et al. (2002), have observed cytoplasmic aggregates of 
phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. 
Dumaz and Marais (2005), have shown that there is an interaction between the cyclic 
adenosine monophosphate (cAMP) and RAS/RAF/mitogen-activated protein kinase 
(MAPK) and extracellular signal-regulated kinase (ERK) pathways and showed that 
these two important signalling pathways regulates a large number of cellular functions 
(Sweatt, 2001). ERK phosphorylation inactivates the enzyme resulting in an increase 
in the basal levels of cAMP (Hoffmann et al., 1999; Kelly et al., 2003). The results 
presented in this study suggest an interaction between the cAMP and ERK pathways 
in the B50 cells in which the effects of the agonists in one pathway may influence the 
effect in another pathway. This may be the situation in which the cannabinoid agonist 
(Win) treatment in B50 cells in culture led to increase in both cAMP and phospho-
ERK1/2. The mechanisms involved could either be due to the interaction between the 
cAMP and ERK pathways or the interaction between the endogenous cannabinoid and 
opioid systems in the cells. Figure 4.6 shows the interaction between the cAMP and 
ERK signalling pathways. 
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Fig. 4.6.  The cAMP and ERK signalling pathways are activated when agonists bind 
to GPCRs coupled to heterotrimeric G proteins and RTK leading to the activation of 
small G protein RAS through which ERK is activated. Adapted from Dumaz and 
Marais (2005). 
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                                          CHAPTER FIVE 
5.                                   Summary and Conclusion  
5.1     Summary and Conclusion 
The effects of hypoxia on neuronal cell signalling and the neuroprotectant effects of 
cannabinoid and opioid agonists against hypoxia were investigated using rat cortical 
neuronal B50 cells in culture. The effects were investigated using different study 
methods to assess the extent of damage to the cells in hypoxia and if the cell damage 
could be treated or protected against using cannabinoid and opioid receptor agonists. 
The methods used include the same field morphological assessment, live cell and 
death studies using the trypan blue exclusion method, cellular proliferation studies 
using Promega proliferation assay method, cellular differentiation using DbcAMP and 
neuronal counting method, cellular death and viability using the lactate 
dehydrogenase (LDH) assay method and neuronal physiological assessment was done 
using a quantitative second messenger assessment with cAMP assay and extracellular 
signal-regulated receptor kinases 1 and 2 (ERK1/2) using enzyme-linked 
Immunosorbent (ELISA) phospho-ERK1/2 assay methods. 
 
The results from morphological studies showed masses of dead and degenerating 
neuronal cells resulting from exposure of the B50 cells to hypoxia which could lead to 
loss of neuronal cell mass and volume. This agrees with the reduced neuronal mass 
and volume seen in cases of neurodegenerative diseases like stroke, dementias, 
Alzheimer’s and Parkinson’s diseases, of which the behavioural effects of these 
changes depend on the part of the brain tissue where these changes occur. The B50 
neuronal cells were derived from the rat cortical neurons, and as a result resemble the 
cortical neuronal cells in their morphological, biochemical, physiological and 
behavioural activities and functions as shown from their activities such as 
differentiation, neurite formation and neurite extension in culture.  
 
These morphological changes are the result of the death and degeneration of the 
neuronal cells which may result in defects in neuronal functions such as neuronal 
signal transmission and coordinated response to stimuli through the neuronal synapses 
due to the loss of neuronal cells in hypoxia. The results presented on the cellular 
viability, proliferation and differentiation showed that hypoxia affected the functional 
abilities of these B50 cells in performing their basic cellular and neuronal functions, 
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and this is consistent with the view that the morphological alterations have led to 
functional disadvantages in these B50 cells in culture. These cellular losses could 
account for the cellular and morphological basis of decline in memory function, 
cognitive and behavioural dysfunction and physical disabilities that accompany 
different forms of dementias, stroke, Alzheimer’s and  Parkinson’s diseases and other 
neurodegenerative disorders.  
 
The results on morphological alterations and changes in B50 cells during hypoxia was 
correlated with the changes observed in the estimated total neuronal cell numbers and 
density as well as viability, which suggested that the degeneration of the B50 cells in 
hypoxia has affected the total neuronal numbers and density, and viability of these 
B50 cells in culture. These morphological and structural changes also resulted in 
changes in enzyme functions and activities as shown by the changes in lactate 
dehydrogenase (LDH) enzyme activity, which could have led to the exacerbation of 
the hypoxic condition and hence may play a role in contributing to the pathologic 
mechanisms of brain dysfunction in some neurodegenerative disease processes. 
 
The data presented in this study suggest that the selective cannabinoid agonists (Win, 
AEA and 2-AG) and opioid receptor agonists (DAMGO, DSLET and ICI-199441) 
may possess some potential therapeutic and protective benefits which could be 
concentration-dependent in hypoxic situations by rendering B50 cells treated and pre-
treated with the cannabinoid and opioid agonists, morphologically healthier when 
compared with the untreated hypoxic cells. The actions of the cannabinoid agonists 
were abolished by the treatment with the cannabinoid antagonists (AM251 and 
AM630), suggesting that the actions of the agonists may be through the cannabinoid 
receptor and non-receptor mediated. The effects of the opioid agonists were inhibited 
by the treatment with the selective µ-, δ- and κ-opioid antagonists suggesting the 
involvement of µ-, δ- and κ-opioid receptors in mediation of these effects in B50 cells 
in culture. 
 
The morphological and structural alterations were accompanied by significantly 
elevated mean values of LDH in the B50 cells cultured in hypoxia when compared 
with the normal and hypoxic treated cells. Hypoxia results in cellular damage and, as 
such, LDH leaked out of the cells through the membrane into the culture media 
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leading to the accumulation of the LDH in the media. These alteration in morphology 
and LDH levels was affected by the treatment with cannabinoid and opioid agonists, 
which was shown to be concentration-dependent even though that the B50 cells did 
not seem to react to hypoxic and treatment conditions in the same way. This was 
shown to be true in the case of the B50 cells in hypoxia but showed normal 
morphology and consequently normal function. These observations showed a variable 
vulnerability between the B50 cells during hypoxia and during treatment leading to 
some of the cells having normal morphology during hypoxia while some even 
degenerated during the therapeutic treatment which may be as a result of higher 
concentrations of the cannabinoid and opioid agonists administration.  
 
Two mechanisms acting simultaneously could be responsible for the hypoxic induced 
cell death and degeneration in B50 cells in culture. These include ATP depletion from 
the B50 cells in hypoxia and Ca2+ excitotoxicity of B50 cells. Since brain cells are 
extremely sensitive to changes in oxygen and glucose supply, lowering of oxygen 
supply, as in the hypoxic conditions of the B50 cells in culture, leads to decreased 
ATP synthesis resulting in depletion of cellular ATP and energy with subsequent 
death of the neuronal cells. As a result, hypoxia initiates neuronal cell death by 
removal of the substrate oxygen from cytochrome oxidase making it sensitive to 
levels of hypoxia. Hypoxic conditions in the brain can be as a result of ischaemia, 
strokes, trauma or atherosclerosis which could result in the death and degeneration of 
the neuronal cells. 
Neuronal cell death and neurodegenerative processes may also be due to increases in 
intracellular Ca2+ which may subsequently provoke abnormal activation of Ca2+-
dependent enzymes such as neuronal nitric oxide synthase (nNOS). In hypoxia, there 
are increases in extracellular excitatory neurotransmitters and Ca2+ which causes 
excitotoxicity resulting in neuronal cell death. The activation of opioid and 
cannabinoid receptors may play a role in feedback regulation by hyperpolarization 
and lowering of the neuronal excitability. It is possible that Ca2+ entry may be 
involved in opioid and cannabinoid receptor upregulation as an early response of 
neurons to hypoxia. During hypoxia, the cell membrane becomes excited leading to 
the opening of the ionotropic Ca2+ channels resulting in the influx of calcium ions into 
 305
the cells. This entry of calcium ions into the cells results in excitotoxicity of the cells 
and the consequent death and degeneration as the case in hypoxic B50 cells in culture.  
The data presented in this study suggest that cannabinoid and opioid receptor agonists 
are important triggers and mediators of protective and therapeutic response while 
selective pharmacological antagonists of the cannabinoid and opioid receptor agonists 
have been shown to block such reactions. The effects of the cannabinoid agonists 
(Win, AEA and 2-AG), were blocked by the selective cannabinoid antagonists 
(AM251 and AM630) which suggest that the actions of these cannabinoid agonists 
were mediated through the CB1 receptors, through the Gi/o proteins and also through a 
non-receptor mechanism  such as ran and ras. while the actions of the opioid agonists 
(DMAGO, DSLET and ICI-199441), were inhibited by the selective µ-, δ- and κ-
opioid antagonists (CTAP, ICI-174864 and NOR), suggesting the involvement of the 
µ-, δ- and κ-opioid receptors through the inhibitory Gi/o proteins in the mediation of 
the effects of the opioid agonists in B50 cells in culture though there was evidence of 
some involvement of the stimulatory Gs protein pathway. This stimulatory pathway 
was observed at some high concentrations of both cannabinoid and opioid agonists 
resulting in the opposite effects of the inhibitory pathway. The actions of the agonists 
and antagonists were shown to be concentration-dependent since different levels of 
antagonists were required to counter the action of the agonists.  
The results show that there were some differences in the action of the agonists used in 
this study which could be due to the effects of the interaction between the agonists 
and other endogenous agonists, and between the agonists and the other receptor types 
present in the B50 cells. This is because the cannabinoid agonists (Win, AEA and 2-
AG), used in this study could be interacting with other endogenous cannabinoids that 
are normally present in the cells thus leading to the augmentation or exacerbation of 
the effects in this experimental model. Cannabinoid agonists could also be interacting 
with other non-cannabinoid (CB1/2) receptor targets such as opioid receptors, orphan 
G protein-coupled receptors (GPR55 and GPR119), vanilloid receptors (TRPV1) and 
peroxisome proliferator-activated receptors (PPARs). These non-CB1/2 receptors have 
been shown to contribute to behavioural, vascular, and immunological actions of ∆9-
THC and endogenous cannabinoids (Lauckner et al., 2008). The GPR55 is a 
cannabinoid receptor that is highly expressed in large dorsal root ganglion neurons 
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and upon activation by various synthetic and endogenous cannabinoids, increases 
intracellular calcium in these neurons through Gq, G12, G13, GTPγS binding, 
phospholipase C and calcium release from IP3R-gated stores, indicating that GPR55 
as a cannabinoid receptor with signalling distinct from the CB1/2 (Lauckner et al., 
2008; Pertwee, 2007, Ryberg et al., 2007). The TRPV1 receptor is activated by 
noxious stimuli including heat, hydrogen ions and capsaicin and can be found on 
sensory neurons, where TRPV1 channel opening causes Ca2+ influx and 
neurotransmitter release (Demuth and Molleman, 2006). It has been shown that 
anandamide can activate the TRPV1 receptor, although it is thought to do so by 
binding to sites on the cytosolic side of the receptor indicating that anandamide could 
activate TRPV1 channels in physiological conditions. Anandamide has also been 
shown to activate TRPV1 receptors in rat hippocampal slices and have dual effects on 
inhibitory CB1 and excitatory TRPV1 receptors (Demuth and Molleman, 2006). The 
PPARs are a group of nuclear receptor proteins that function as transcription factors 
regulating gene expression and they play essential roles in the regulation of cellular 
differentiation, development and metabolism (Michalik et al., 2006). The PPARs can 
be identified as α, γ or δ(β) and are expressed in different tissues but δ(β) are 
markedly expressed in the brain and skin (Balakumar et al., 2007). These non-
cannabinoid (CB1/2) receptors could be activated in B50 neuronal cells cultured in 
hypoxia, resulting in some of the observed effects. 
Some of the effects observed in this study could result from the pharmacological 
interactions between the cannabinoid and opioid systems because, it has been 
suggested that the antinociceptive effects of morphine mediated by µ-opioid receptors, 
might be enhanced by ∆9-THC through activation of κ- and δ-opioid receptors (Pugh 
et al., 1996). Cannabinoids and opioids might interact at the level of their signal-
transduction mechanisms (Manzanares et al., 1999), since opioid and cannabinoid 
receptors are coupled to similar intracellular signalling systems such as the inhibition 
of adenylyl cyclase activity and Ca2+ currents through the activation of Gi/o proteins. 
In vitro or in vivo exposure to opioid and/or cannabinoid agonists may cause a 
desensitisation and cross-desensitisation in the ability of the drugs to inhibit forskolin-
induced cAMP production (Demuth and Molleman, 2006). Cannabinoids may have a 
direct effect on the synthesis and release of endogenous opioids. Valverde et al. 
(2001), showed that acute administration of ∆9-THC increased the release of 
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enkephalin-like material in the nucleus accumbens of awake and freely moving rats 
suggesting cannabinoids can increase opioid release.  
Since cannabinoid and opioid receptor agonists may serve as a general protector 
against ischaemic and hypoxic stress in oxygen and energy-sensitive organs like the 
brain and heart, their effects on the B50 cells could be due to the anti-inflammatory 
properties of cannabinoids. This is because cannabinoids have been shown to possess 
anti-inflammatory properties, which may be relevant in neuroprotection in which 
cannabinoid agonists could have down-regulated inflammatory cytokines and up-
regulated anti-inflammatory ones in neuronal B50 cells cultured in hypoxia. 
The study have shown that B50 cells are good model cell line to study the effects of 
hypoxia on neuronal cell signalling using such downstream signalling activities as 
cellular morphology, viability, growth, proliferation, differentiation and second 
messenger cAMP and ERK1/2 activities and showed that these cells could be used to 
study neuronal cellular signalling in culture since they are derived from cortical 
neuronal cells. The results presented showed that cannabinoid and opioid receptor 
agonists have some positive effects on the B50 neuronal cells cultured in hypoxia by 
making the cells treated with cannabinoid and opioid agonists have healthier 
morphology, down regulation of LDH release, upregulation of intracellular cAMP and 
phospho-ERK1/2 when compared with the hypoxic untreated B50 cells in culture and 
as such, the signalling activities like cellular proliferation, differentiation, second 
messenger cAMP and ERK1/2 activities are shown to improve in the hypoxic treated 
B50 cells than in untreated hypoxic cells. The summary diagram showing the CB1 and 
opioid receptors through the signalling pathways involved in cell survival, growth, 
proliferation and differentiation is shown in Figure 5.1. Thus the study have shown 
that cannabinoid and opioid receptor agonists could have some positive potential 
benefits in the treatment and protection of hypoxia-related neurodegenerative 
disorders and diseases such as stroke, dementias, ageing, Alzheimer’s and Parkinson’s 
diseases and cognitive decline. 
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Fig.5.1.Summary diagram of the CB1 and µ, δ and κ opioid receptor activation and the 
signalling pathways involved in cell survival, growth, proliferation and differentiation 
in B50 cells cultured in hypoxia. The CB1 and µ-, δ- and κ-opioid receptors are 
activated by the binding of the agonists to their receptors, leading to the dissociation 
of G-protein Gαβγ complex into Gα and Gβγ proteins and the activation of adenylyl 
cyclase which results in the phosphorylation of ADP to ATP and the subsequent 
conversion of ATP to cAMP, the secondary messenger which act through many 
effectors to produce cellular effects through the inhibitory pathway of Gαi/o leading to 
the inhibition of cAMP accumulation within the B50 cells resulting in decrease in 
cAMP, while some can act through the stimulatory pathway of Gαs to stimulate 
cAMP accumulation within the cells leading to increase in cAMP accumulation. 
These agonists through their receptors activate receptor tyrosine kinase, an enzyme 
found around these receptors, resulting in the activation of small G proteins RAS and 
RAC which subsequently activate the RAF/MEK/ERK signal transduction pathway 
which is a conserved pathway that regulates cell growth, proliferation and 
differentiation. These activated proteins stimulate constitutive signalling through the 
pathway in the B50 cells to stimulate growth, proliferation and differentiation of the 
cells and protect them from cell death. Essentially these kinases are normally trapped 
in inactive forms but through the intramolecular interaction of the agonists and the 
receptors, are released into the active form. The activation of the receptors by the 
agonists resulting in the activation of the stimulatory pathway can also lead to the 
reduction of calcium influx into the cells and reduce ATP consumption leading to the 
conservation of cellular energy needed for other activities within the cells such as 
growth and differentiation. 
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5.2     Limitations of the study 
There were some limitations encountered during the study of the effect of hypoxia on 
neuronal cell signalling in B50 cells in culture. Since the B50 cells are adherent cells 
and are detached from the floor of the culture plate using trypsin-EDTA solution, this 
may result in the death of some of the cells due to the oxidizing action of the trypsin-
EDTA reagent. Some of the dead cells may be floating in the culture medium and 
may be lost during the process of decanting the media before the trypan blue 
exclusion method of estimation of the number of viable and dead cells in culture thus 
the number of dead cells may be under-estimated. The use of manual counting method 
may also present with some errors in the overall number of cells counted in that some 
cells may be missed during counting as in total cell count, total viable cells and 
number of differentiated cells in culture. There was also the tendency that the use of a 
colorimetric method as in CellTitre Aqueous cell proliferation assays for the 
determination of viable cells in proliferation in B50 cells may be prone to some 
errors. The use of a small amount of culture medium and the CellTitre Aqueous cell 
proliferation assay reagent may not give the overall effect on cellular proliferation on 
B50 cells in culture. This is because the factors that affect the metabolic activity of the 
cells may affect the relationship between cell numbers and absorbance and since B50 
cells are adherent, cells may undergo contact inhibition which may show a change in 
metabolic activity at high densities, resulting in a nonlinear relationship between cell 
numbers and absorbance since the factors that affect the cytoplasmic physiology of 
the cells will affect metabolic activity.  
 
The study on LDH release may be subjected to some limitations in that the culture 
medium contained serum, though heat-inactivated which may have some level of 
LDH activity since the use of medium containing serum could result in some levels of 
LDH to decrease the sensitivity of the assay or obscure the detection of cellular LDH 
completely. This was corrected by the measurement of the optical density of the 
culture medium. Also the reduced nicotinamide adenine dinucleotide (NADH) formed 
in the process of the assay is subject to photo degradation and as such any accidental 
exposure of the reaction to light may reduce the sensitivity and accuracy of the LDH 
assay results in this study. The culture medium may be subjected to uneven 
evaporation from the multiwells which may cause erroneous results. The reconstituted 
cofactor preparation and storage at higher temperatures may result in loss of activity 
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and yield erroneous results. The cAMP concentration assays were measured from B50 
cell culture media and were diluted with 0.1M HCl which may tend to dilute the 
cAMP concentrations and also there may be high levels of endogenous cAMP which 
may interfere with the results. Limitations to the procedure of cAMP assay method 
may result in variations in cAMP assay data in that there may be fluctuations in 
optical density readings during the shelf-life of the assay kit, even though the results 
are still comparable. 
 
The possibility that the phospho-ERK1/2 present in B50 cells in this study may be 
degraded by the cell extraction buffer used, presents a limitation of this procedure 
although it has not been described before. The phospho-ERK1/2 assay showed that 
only phosphopeptides containing the phosphorylated threonine 185 and tyrosine 187 
blocked the ELISA signal but the same sequence containing non-phosphorylated 
threonine and tyrosine at position 185/187 or mono-phosphopeptides may also 
produce a small blockage of the ELISA signal which may be a limitation to the study.  
Above all, funding and unavailability of some research equipments also had been a 
source of limitations to this study in that this research did not have any special 
funding on its own but rely mainly on the departmental funds and donation of 
reagents from companies. Some equipments were not available to enable some 
specific investigations such as calcium ion capture to measure intracellular calcium 
contents in the cells in culture and the agonists and membrane binding assay 
equipment for comparative receptor binding analyses of cannabinoid and opioid 
agonists and antagonists. 
 
 
5.3      Research Applications 
The findings of this research have several implications and potential applications 
which could be of interest to government and agencies, research institutes and 
research charities that are involved in neurodegenerative changes, their treatment, 
prevention and protection. The findings can be of interest and applied in the following 
ways: 
• The B50 neuronal cells which were derived from neonatal cortical cells have 
been shown to grow very well in both normoxic and hypoxic environments 
and also have been shown to develop, proliferate and differentiate very well in 
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culture environment and as such a good research model for the study of 
neuronal cells in culture.  
• Since the B50 cells are neonatal cells that can grow and develop well into 
normal neuronal patterns in culture, they could be a good source of  research 
cells for stem cell therapy research against neurodegenerative diseases and 
disorders.    
• Also since the B50 cells showed evidence of the presence of G protein 
coupled receptor most especially the cannabinoid (CB1) and µ-opioid 
receptors, it could be a good material for research in areas of agonists-induced 
and activated effects. 
• In the treatment of neurodegenerative diseases and disorders such as stroke, 
various dementias, Parkinson’s and Alzheimer’s diseases, the cannabinoid and 
opioid agonists have shown to have the potential to improve the brain 
morphology, chemistry and functions and by so doing improve the overall 
brain activity like learning, memory and cognitive functions and abilities. 
• In cases of pre-treatment against hypoxia with cannabinoid and opioid 
agonists for the prevention and protection against vascular dementia caused by 
decreased oxygen and nutrient supply due to the occlusion of blood vessels to 
the brain. 
• The cannabinoid and opioid agonists could be useful in the prevention and 
protection against respiratory distress syndrome in children caused by limiting 
oxygen supply to the brain in which they could have the potential to improve 
brain morphology and activities. 
• The cannabinoid and opioid agonists could be used for the treatment and 
protection against sleep apnea-induced brain hypoxia in both adults and 
children in which these drugs could have the potential to improve the effects 
on the brain cells. 
• The cannabinoid and opioid agonists could have the potential for the 
prevention and protection of individuals with high stroke risk especially those 
with prior minor or primary stroke with the possibility of secondary normally 
massive attack in order to prevent and protect against the secondary massive 
attack. 
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• The cannabinoid and opioid agonists could have the potential for the 
prevention and protection for individuals involved in high altitude activity to 
prevent and protect them against the effects of low oxygen level exposure. 
Examples include space travellers, mountain climbers and military personals. 
 
 
5.4.       Future directions 
In future studies, it would be worthy to measure and quantify ATP production in B50 
cells and normalized to the total number of viable cells, hence be able to determine 
whether ATP production is affected by hypoxia and the subsequent effect by the 
cannabinoid and opioid agonists used in the study. It would be necessary in the future 
to quantify the intracellular calcium ions using fluorescent calcium-sensitive dye, to 
monitor and measure calcium influx and efflux from B50 cells in normal, hypoxic and 
hypoxic treated B50 cells in culture. It would be good in the future to measure and 
quantify the level of oxidative stress in B50 cells using thiobarbituric acid reactive 
substances (TBARS) or glutathione assays in hypoxic cells and those treated with the 
agonists. 
 
Since the ultimate goal of any basic laboratory research is to help in alleviating human 
suffering caused by diseases and illnesses which will lead to successful treatment or 
prevention of these diseases and illnesses. This research was intended to identify the 
effects of hypoxia on neuronal cell signalling using cellular based activities as 
proliferation, differentiation, cell growth and viability, and cell death study using 
LDH release and the effects produced by the administration of cannabinoid and opioid 
agonists in the treatment and protection against the effects produced by hypoxia in 
cortical B50 neuronal cells in culture. In the future, effort would also be made to use 
animal models, most especially rodents (rats and mice), to conduct a whole animal 
study using an animal model of hypoxic diseases or animals induced with hypoxia to 
study the actions of these agonists in the reversal of the effects of hypoxia and the 
neuroprotective abilities of these agonists in these animal models against hypoxia, 
which would eventually lead in the testing of these agents in humans to see how these 
therapeutic and protective potentials could be harnessed for immense medical benefit.  
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                                            APPENDICES 
 
Table A1: The effect of opioid agonist treatment on LDH release in cultured  
                  B50 cells in hypoxia 
 
Type of Treatment Measured optical 
density(OD) 
Percent of control 
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 1.214±0.511 587±51.1* 
DAMGO(µ)10µM 0.699±0.421 338±42.1*# 
DAMGO(µ)50µM 0.344±0.210 167±21.0# 
DAMGO(µ)100µM 0.296±0.112 143±11.2# 
DSLET(δ) 10µM 0.346±0.201 167±20.1# 
DSLET(δ) 50µM 0.290±0.112 140±11.2# 
DSLET(δ) 100µM 0.296±0.221 143±22.1# 
ICI-199441(κ) 10µM  0.234±0.221 113±22.1# 
ICI-199441(κ) 50µM 0.224±0.223 109±22.3# 
ICI-99441(κ)100µM 0.666±0.251 322±25.1*# 
(Data presented as means ±SD; n=6; *P<0.05 versus normal B50 cells;  
#P<0.05 versus hypoxia untreated cells; Student’s t-test). 
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Table A2: The effect of opioid agonist/antagonist treatment on LDH release 
                  from cultured B50 cell in hypoxia 
 
Type of Treatment Measured optical 
density(OD)  
Percent of control 
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 1.214±0.511 587±51.1* 
DAMGO(µ)10µM 0.699±0.421 338±42.1* 
DAMGO/CTAP10µM 0.726±0.335 351±33.5* 
DAMGO(µ)50µM 0.344±0.210 167±21.0 
DAMGO/CTAP50µM 0.535±0.252 259±25.2*# 
DAMGO(µ)100µM 0.296±0.112 143±11.2 
DAMGO/CTAP100µM 0.752±0.305 364±30.5*# 
DSLET(δ) 10µM 0.346±0.201 167±20.1 
DSLET/ICI-174864   
10 µM 
0.530±0.256 256±25.6*# 
DSLET(δ) 50µM 0.290±0.112 140±11.2 
DSLET/ICI-174864   
50 µM 
0.859±0.345 416±34.5*# 
DSLET(δ) 100µM 0.296±0.221 143±22.1 
DSLET/ICI-174864 
100 µM 
0.644±0.225 312±22.5*# 
ICI-199441(κ) 10µM  0.234±0.221 113±22.1 
ICI-199441/NOR 
10µM 
1.698±0.501 821±50.1*# 
ICI-199441(κ) 50µM 0.224±0.223 109±22.3 
ICI-199441/NOR       
50 µM 
1.093±0.552 529±55.2*# 
ICI-99441(κ)100µM 0.666±0.251 322±25.1 
ICI-199441/NOR  
100 µM 
1.375±0.446 665±44.6*# 
(Data presented as means ±SD; n=6; *P<0.05 versus normal B50 cells;  
#P<0.05 versus agonist treated hypoxic cells; Student’s t-test). 
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Table A3: The effect of opioid agonist pre-treatment on LDH release in  
                   cultured B50 cells in hypoxia 
 
Type of Treatment Measured optical 
density(OD)  
Percent of Control  
(% of Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 1.214±0.511 587±51.1* 
DAMGO(µ)10µM 0.878±0.354 425±35.4*# 
DAMGO(µ)50µM 0.728±0.321 352±32.1*# 
DAMGO(µ)100µM 0.733±0.331 355±33.1*# 
DSLET(δ) 10µM 1.076±0.511 520±51.1* 
DSLET(δ) 50µM 0.700±0.433 339±43.3*# 
DSLET(δ) 100µM 0.930±0.322 450±32.2*# 
ICI-199441(κ) 10µM  0.716±0.442 346±44.2*# 
ICI-199441(κ) 50µM 0.866±0.544 419±54.4*# 
ICI-99441(κ)100µM 0.657±0.342 318±34.2*# 
(Data presented as means ±SD; n=6; *P<0.05 versus normal B50 cells; 
#P<0.05 versus hypoxia untreated cells; Student’s t-test). 
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Table A4: The effect of opioid agonist/antagonist pre-treatment on LDH release 
in cultured B50 cell in hypoxia. 
 
Type of Treatment Measured optical 
density(OD)  
Percent of Control
(% of  Control) 
Normal Culture 0.207±0.101 100±10.1 
Hypoxia no Drug 1.214±0.511 587±51.1* 
DAMGO(µ)10µM 
DAMGO/CTAP 
10µM 
DAMGO(µ)50µM  
  
0.878±0.354 
0.486±0.312 
0.728±0.321 
425±35.4* 
235±31.2* 
352±32.1* 
DAMGO/CTAP 
50µM 
 
DAMGO(µ)100µM  
 
1.427±0.445 
 
0.733±0.331 
690±44.5*# 
 
355±33.1* 
DAMGO/CTAP 
100µM 
1.268±0.502 613±50.2*# 
DSLET(δ) 10µM 
DSLET/ICI-174864 
10µM 
 
DSLET(δ) 50µM 
1.076±0.511 
0.800±0.445 
 
 
0.700±0.433 
520±51.1* 
387±44.5* 
 
 
339±43.3* 
 
DSLET/ICI-174864 
50µM 
 
DSLET(δ) 100µM 
1.264±0.421 
 
0.930±0.322 
611±42.1*# 
 
450±32.2* 
DSLET/ICI-174864 
100µM 
0.607±0.352 294±35.2* 
ICI-199441(κ) 
10µM 
ICI-199441/NOR 
10µM 
ICI-199441(κ) 
50µM 
0.716±0.442 
 
0.342±0.252 
 
0.866±0.544 
 
346±44.2* 
 
165±25.2* 
 
419±54.4* 
ICI-199441/NOR 
50µM 
ICI-199441(κ) 
50µM 
1.279±0.511 
 
0.657±0.342 
 
619±51.1*# 
 
318±34.2* 
ICI-199441/NOR 
100µM 
0.738±0.462 357±46.2*# 
(Data presented as means ±SD; n=6; *P<0.05 versus normal B50 cells;  
#P<0.05 versus agonist treated hypoxic cells; Student’s t-test). 
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Table A5:  The effect of opioid agonist treatment on LDH release from normal 
cultured B50 cells 
Type of Treatment Measured optical 
density(OD)  
Percent of Control
(% of  Control) 
Normal no Drug 0.172±0.122    100±12.2 
DAMGO(µ)10µM 0.165±0.108    96±10.8 
DAMGO(µ)50µM 0.215±0.191    125±19.1* 
DAMGO(µ)100µM 0.183±0.178    107±17.8 
DSLET(δ) 10µM 0.137±0.133    80±13.3* 
DSLET(δ) 50µM 0.138±0.115    80±11.5* 
DSLET(δ) 100µM 0.149±0.121    87±12.1* 
ICI-199441(κ)10µM   0.176±0.119    103±11.9 
ICI-199441(κ) 50µM 0.139±0.111    81±11.1* 
ICI-199441(κ)100µM 0.158±0.122    92±12.2 
(Data presented as means ±SD; n=6;*P<0.05 versus untreated normal B50 cells 
  Student’s t-test). 
 
Table A6:The effect of opioid pre-treatment on LDH release in normal B50 cells. 
Type of Treatment Measured optical 
density(OD)  
Percent of Control
(% of  Control) 
Normal no Drug 0.172±0.122    100±12.2 
DAMGO(µ)10µM 0.165±0.125    96±12.5 
DAMGO(µ)50µM 0.183±0.221    107±22.1 
DAMGO(µ)100µM 0.224±0.121    131±12.1* 
DSLET(δ) 10µM 0.146±0.111    85±11.1* 
DSLET(δ) 50µM 0.128±0.101    75±10.1* 
DSLET(δ) 100µM 0.120±0.110    70±11.0* 
ICI-199441(κ) 10µM  0.099±0.091    58±9.1* 
ICI-199441(κ) 50µM 0.116±0.104    68±10.4* 
ICI-199441(κ)100µM 0.140±0.115    82±11.5* 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal B50 cells; 
Student’s t-test). 
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Table A7: The effect of DbcAMP and cannabinoid agonist treatment on LDH 
release in normal cultured B50 cells. 
 
Type of Treatment Measured optical 
density(OD)  
Percent of Control
(% of  Control) 
Normal Culture no 
drug treatment 
0.108±0.105 100±10.5 
Cells with DbcAMP 
only 
0.120±0.100 110±10.0 
DbcAMP/10nM 
Win 
0.117±0.101 108±10.1 
DbcAMP/50nM 
Win  
0.128±0.110 118±11.0 
DbcAMP/100nM 
Win 
0.146±0.121 134±12.1 
(Data presented as means ±SD; n=6; Student’s t-test). 
 
 
 
 
Table A8: The effect of DbcAMP and cannabinoid agonist pre-treatment on 
LDH release in normal cultured B50 cells. 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of Control
(% of  Control) 
Normal Culture no 
drug treatment 
0.108±0.105 100±10.5 
Cells with DbcAMP 
only 
0.120±0.100 110±10.0 
DbcAMP/10nM 
Win 
0.118±0.101 109±10.1 
DbcAMP/50nM 
Win  
0.190±0.121 175±12.1*# 
DbcAMP/100nM 
Win 
0.203±0.225 188±22.5*# 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal; #P<0.05 
versus cells with DbcAMP only; Student’s t-test). 
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Table A9: The effect of DbcAMP and cannabinoid agonist ± antagonist on LDH 
release in normal B50 cells. 
 
Type of Treatment Measured optical 
density(OD)  
Percent of Control
(% of  Control) 
Normal cells no 
drug treatment 
0.108±0.105 100±10.5 
DbcAMP only 
DbcAMP/10nM 
Win 
 
0.120±0.100 
0.118±0.101 
110±10.0 
109±10.1 
AM251/10nM Win 0.116±0.102 107±10.2 
AM251/50nM Win 0.141±0.121 130±12.1* 
AM251/100nM Win 0.207±0.181 191±18.1*# 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal; 
 #P<0.05 versus cells with DbcAMP only; Student’s t-test). 
 
 
Table A10: The effect of DbcAMP and cannabinoid agonist treatment on LDH 
release in B50 cells in hypoxia. 
 
Type of Treatment Measured optical 
density(OD)  
Percent of Control 
(% of  Control) 
Normal Culture no 
drug treatment 
0.108±0.105 100±10.5 
Hypoxia no Drug 0.172±0.107 158±10.7* 
Hypoxia/DbcAMP 0.206±0.166 190±16.6*# 
DbcAMP/10nM 
Win 
 
0.144±0.122 133±12.2 
DbcAMP/50nM 
Win 
 
0.148±0.119 136±11.9 
DbcAMP/100nM 
Win 
0.153±0.131 141±13.1*# 
(Data presented as means ±SD; n=6;*P<0.05 versus untreated normal cells;  
#P<0.05 versus hypoxia untreated cells; Student’s t-test). 
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Table A11: The effect of DbcAMP and cannabinoid agonist pre-treatment on 
LDH release in B50 cells in hypoxia. 
Type of Treatment Measured optical 
density(OD)  
Percent of control 
(% of  Control) 
Normal Culture no 
drug treatment 
0.108±0.105 100±10.5 
Hypoxia no Drug 0.172±0.107 158±10.7* 
Hypoxia/DbcAMP 0.206±0.166 190±16.6*# 
DbcAMP/10nM 
Win 
 
0.158±0.122 146±12.2* 
DbcAMP/50nM 
Win 
 
0.198±0.151 183±15.1*# 
DbcAMP/100nM 
Win 
0.207±0.156 191±15.6*# 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal cells;  
#P<0.05 versus untreated hypoxic cells; Student’s t-test). 
 
 
Table A12: The effect of DbcAMP and cannabinoid agonist/antagonist treatment 
in B50 cells in hypoxia 
 
Type of Treatment Measured Optical 
Density(OD)  
Percent of control
(% of  Control) 
Normal Culture no 
drug treatment 
0.108±0.105 100±10.5 
Hypoxia no Drug 0.172±0.107 158±10.7* 
Hypoxia/DbcAMP 0.206±0.166 190±16.6*# 
DbcAMP/10nMWin 0.158±0.122 146±12.2* 
AM251/10nM Win 0.197±0.131 182±13.1*# 
DbcAMP/50nMWin 0.198±0.151 183±15.1*# 
AM251/50nM Win 0.142±0.122 131±12.2 
DbcAMP/100nMWin 
AM251/100nM Win  
0.207±0.156 
0.231±0.125 
191±15.6*# 
213±12.5*# 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal cells; #P<0.05 
versus hypoxia untreated cells; Student’s t-test). 
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Table A13: The effect of opioid agonist treatment on cellular proliferation in  
normal cultured B50 cells. 
 
Type of Treatment  Measured optical  
density 
Calculated Value 
   (x106)/ml 
 Normal Cells no Drug 1.5 20.00±0.47 
10uM DAMGO 1.0 15.00±0.30* 
100uM DAMGO 1.3 17.50±0.11 
10uM DSLET 1.3 17.50±0.53 
100uM DSLET 0.88 13.75±0.10* 
10uM ICI-199441  1.19 16.88±0.10 
100uM ICI-199441 1.56 20.20±0.15 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal cells; Student’s 
t-test). 
 
Table A14: The effect of opioid agonist treatment on cellular proliferation in  
B50 cells in hypoxia. 
 
Type of Treatment  Measured optical  
density 
Calculated Value 
   (x106)/ml 
 Normal Cells no Drug 1.5 20.00±0.47# 
 Hypoxic cells no drug 0.35 7.00±0.12* 
10uM DAMGO 1.06 16.25±0.53 
100uM DAMGO 1.51 20.00±0.54# 
10uM DSLET 1.52 20.00±0.70# 
100uM DSLET 1.32 17.60±0.27# 
10uM ICI-199441 1.36 17.70±0.34# 
100uM ICI-199441 1.6 21.52±0.45# 
(Data presented as means ±SD; n=6;*P<0.05 versus untreated normal cells; #P<0.05 
versus untreated hypoxic cells; Student’s t-test). 
 
Table A15: The effect of opioid agonist pre-treatment on cellular proliferation in 
normal B50 cells. 
 
Type of Treatment  Measured optical  
density 
Calculated Value 
     (x106)/ml 
Normal Cells no Drug 1.50 20.00±0.47 
10uM DAMGO 1.51 20.00±0.06 
50uM DAMGO 1.57 20.80±0.64 
100uM DAMGO 2.00 24.75±0.47 
10uM DSLET  1.30 17.50±0.93 
50uM DSLET 1.68 15.70±0.77 
100uM DSLET 1.47 19.80±0.35 
10uM ICI-199441 1.20 17.10±0.51 
50uM ICI-199441 1.60 22.40±0.65 
100uM ICI-199441 0.90 14.50±0.66* 
(Data presented as means ±SD; n=6; *P<0.05 versus untreated normal cells; Student’s 
t-test). 
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Table A16: The effect of opioid agonist pre-treatment on cellular proliferation in 
B50 cells in hypoxia. 
 
Type of Treatment  Measured optical  
density 
Calculated Value 
      (x106)/ml 
 Normal Cells no Drug 1.5 20.00±0.47 
 Hypoxic cells no drug 0.35 07.00±0.12* 
10uM DAMGO 0.64 11.25±0.02*# 
50uM DAMGO 0.70 12.00±0.53*# 
100uM DAMGO 0.49 09.75±0.17*# 
10uM DSLET  0.37 07.40±0.12* 
50uM DSLET 0.89 13.75±0.21*# 
100uM DSLET 0.74 12.50±0.37*# 
10uM ICI-199441 0.44 09.45±0.15* 
50uM ICI-199441 0.45 09.50±0.02* 
100uM ICI-199441 0.42 09.40±0.26* 
(Data presented as means ±SD; n=6;*P<0.05 versus normal cells; #P<0.05 versus 
untreated hypoxic cells; Student’s t-test). 
 
Table A17: The effect of opioid agonist/antagonist treatment on cellular  
proliferation in B50 cells in hypoxia. 
Type of Treatment  Measured optical  
density 
Calculated Value 
   (x106)/ml 
Normal Cells no Drug 1.5 20.00±0.47 
Hypoxic cells no drug 0.35 07.00±0.12 
50uM DAMGO 
DAMGO/CTAP 50µM 
100uM DAMGO 
0.70 
1.43 
0.49 
12.00±0.53* 
18.50±0.63*# 
09.75±0.17 
DAMGO/CTAP 100µM 1.56 20.10±0.83*# 
50uM DSLET 
DSLET/ICI-174864 
50µM 
100uM DSLET 
0.37 
1.12 
 
0.74 
07.40±0.12 
16.25±0.37*# 
 
12.50±0.37* 
DSLET/ICI-178464 
100µM 
0.96 14.90±0.10* 
50uM ICI-199441 
ICI-199441/NOR 50µM 
100uM ICI-199441 
0.45 
1.38 
0.42 
09.50±0.02 
18.75±0.68*# 
09.40±0.26 
ICI-199441/NOR 100µM 1.28 17.50±0.42*# 
 (Data presented as means ±SD; n=6;*P<0.05 versus untreated hypoxic cells; #P<0.05 
versus agonist treated hypoxic cells; Student’s t-test). 
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Table A18:The effect of hypoxia on B50 cell differentiation using DbcAMP and 
random field assessment method. 
Type of treatment  Mean number of 
differentiated cells 
Normal 56.44±13.50 
Hypoxia 28.17±10.70* 
Normal/Hypoxia 19.72±7.27*# 
(Data presented as means ±SD; n=6;*P<0.05 versus normal cells;  
#P<0.05 versus untreated hypoxic cells; Student’s t-test). 
 
Table A19: Standard table of absorbance versus cell concentration used in 
standard curve in cell proliferation assay in time-course effect of hypoxia. 
Dilution Absorbance (490nm) Cell concentration  
        (106)/ml 
 0 3.73±0.57 46.5 
1:2 (50%) 1.67±0.30 23.25 
1:4 (25%) 0.52±0.18 11.63 
1:5 (20%) 0.38±0.26 9.30 
1:10(10%) 0.20±0.16 4.65 
                                    (Data presented as mean ±SD; n=5) 
 
Table A20: Standard table of absorbance versus cell concentration used in 
standard curve in cell proliferation assay in agonist treated cells in hypoxia.  
Dilution Absorbance (490nm) Cell concentration    
    (106)/ml 
0 2.71±0.76 42.50 
1:2 (50%) 1.29±0.92 21.25 
1:4 (25%) 0.50±0.77 10.63 
1:5 (20%) 0.37±0.56 8.50 
1:10 (10%) 0.13±0.64 4.25 
                                    (Data presented as mean ±SD; n=5) 
 
 
 
